{
  "callto": {
    "callto:": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/november/viiv-healthcare-announces-start-of-phase-iii-study-of-long-actin/",
      "status": "new",
      "txt": "+1 919 605 4521"
    }
  },
  "errors": [],
  "external": {},
  "homePage": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/",
  "linksProcessed": 0,
  "mailto": {
    "mailto:abattistella@unive.it": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/hiv-behind-bars-supporting-hiv-research-education-and-testing-in-italian-prisons/",
      "status": "new",
      "txt": "abattistella@unive.it"
    },
    "mailto:abonetti@buchanwe.com.au": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/october/viiv-healthcare-awards-new-grants-to-accelerate-community-led-so/",
      "status": "new",
      "txt": "abonetti@buchanwe.com.au"
    },
    "mailto:antoinette.x.lee@gsk.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2016/grassroots-hiv-organisations-receive-140-000-funding-boost/",
      "status": "new",
      "txt": "antoinette.x.lee@gsk.com"
    },
    "mailto:audrey.x.abernathy@viivhealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/november/viiv-healthcare-announces-start-of-phase-iii-study-of-long-actin/",
      "status": "new",
      "txt": "audrey.x.abernathy@viivhealthcare.com"
    },
    "mailto:Australia.medinfo@viivhealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/ziagen-/",
      "status": "new",
      "txt": "Australia.medinfo@viivhealthcare.com"
    },
    "mailto:cara.m.vivarelli-o'neill@viivhealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/more-press-releases-from-viiv-healthcare/",
      "status": "new",
      "txt": "cara.m.vivarelli-o'neill@viivhealthcare.com"
    },
    "mailto:chldel@tin.it": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/hiv-behind-bars-supporting-hiv-research-education-and-testing-in-italian-prisons/",
      "status": "new",
      "txt": "chldel@tin.it"
    },
    "mailto:cub.barrett@amfar.org": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/june/viiv-healthcare-and-amfar-partner-to-optimize-hiv-treatment-for-infants-and-children-in-asia/",
      "status": "new",
      "txt": "cub.barrett@amfar.org"
    },
    "mailto:DE.Datenschutz-ViiVHealthcare@viivhealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/datenschutzerklaerung/",
      "status": "new",
      "txt": "DE.Datenschutz-ViiVHealthcare@viivhealthcare.com"
    },
    "mailto:dolutegravir-eap@parexel.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/dolutegravir-expanded-access-program/",
      "status": "new",
      "txt": "dolutegravir-eap@parexel.com"
    },
    "mailto:fabio.perocco@unive.it": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/hiv-behind-bars-supporting-hiv-research-education-and-testing-in-italian-prisons/",
      "status": "new",
      "txt": "fabio.perocco@unive.it"
    },
    "mailto:Globalcomms@viivhealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/ias-paris-2017/",
      "status": "new",
      "txt": "Sébastien Desprez"
    },
    "mailto:ir@aurobindo.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/may/press-release/",
      "status": "new",
      "txt": "ir@aurobindo.com"
    },
    "mailto:Isabelle.x.scali@viivealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/november/fast-track-cities-survey-data-provide-insights-into-quality-of-life-of-people-living-with-hiv/",
      "status": "new",
      "txt": "Isabelle.x.scali@viivealthcare.com"
    },
    "mailto:isabelle.x.scali@viivhealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-to-progress-collaboration-with-janssen-to-develo/",
      "status": "new",
      "txt": "isabelle.x.scali@viivhealthcare.com"
    },
    "mailto:katy.j.hayward@viivhealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/spark-igniting-change/",
      "status": "new",
      "txt": "katy.j.hayward@viivhealthcare.com"
    },
    "mailto:lhebditch@buchanwe.com.au": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/october/viiv-healthcare-awards-new-grants-to-accelerate-community-led-so/",
      "status": "new",
      "txt": "lhebditch@buchanwe.com.au"
    },
    "mailto:marc.s.meachem@viivhealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-sword-100-week-data-for-juluca-dolute/",
      "status": "new",
      "txt": "marc.s.meachem@viivhealthcare.com"
    },
    "mailto:Marc.s.meachem@Viivhealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/june/viiv-healthcare-and-elizabeth-glaser-pediatric-aids-foundation-partner-to-expedite-access-to-arv-treatment-for-infants-and-children/",
      "status": "new",
      "txt": "Marc.s.meachem@Viivhealthcare.com"
    },
    "mailto:Medical.Education@viivhealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals/independent-grants-and-support-programs/",
      "status": "new",
      "txt": "Medical.Education@viivhealthcare.com"
    },
    "mailto:menosesmas.proyectosong@viivhealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/spanish-articles/sumate-a-conmenosesposiblemas/",
      "status": "new",
      "txt": "menosesmas.proyectosong@viivhealthcare.com"
    },
    "mailto:nazionale@npsitalia.net": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/hiv-behind-bars-supporting-hiv-research-education-and-testing-in-italian-prisons/",
      "status": "new",
      "txt": "nazionale@npsitalia.net"
    },
    "mailto:positiveaction.europe@viivhealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/",
      "status": "new",
      "txt": "positiveaction.europe@viivhealthcare.com"
    },
    "mailto:positiveaction.msmt@viivhealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-msm-transgender-people/",
      "status": "new",
      "txt": "positiveaction.msmt@viivhealthcare.com"
    },
    "mailto:positiveaction@viivhealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/february/viiv-healthcare-expands-positive-action-southern-initiative-to-fight-hivaids-and-support-community-action/",
      "status": "new",
      "txt": "positiveaction@viivhealthcare.com"
    },
    "mailto:positiveactionforchildren@viivhealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/march/viiv-healthcare-calls-for-initial-grant-proposals-to-the-positive-action-for-children-fund/",
      "status": "new",
      "txt": "positiveactionforchildren@viivhealthcare.com"
    },
    "mailto:positiveactionforchildrenfund@viivhealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/october/media-alert-viiv-healthcare-s-positive-action-for-children-fund-announces-16-new-grantees-for-the-year-20112012/",
      "status": "new",
      "txt": "register their interest"
    },
    "mailto:press@clintonhealthaccess.org": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/may/press-release/",
      "status": "new",
      "txt": "press@clintonhealthac-cess.org"
    },
    "mailto:sbowen@pedaids.org": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/june/viiv-healthcare-and-elizabeth-glaser-pediatric-aids-foundation-partner-to-expedite-access-to-arv-treatment-for-infants-and-children/",
      "status": "new",
      "txt": "sbowen@pedaids.org"
    },
    "mailto:Scott.d.purdon@Viivhealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/june/viiv-healthcare-and-elizabeth-glaser-pediatric-aids-foundation-partner-to-expedite-access-to-arv-treatment-for-infants-and-children/",
      "status": "new",
      "txt": "Scott.d.purdon@Viivhealthcare.com"
    },
    "mailto:swiss.cpa@gsk.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/privacy-notice/",
      "status": "new",
      "txt": "swiss.cpa@gsk.com"
    },
    "mailto:UK.EFPIA-Disclosure-Customer@gsk.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-kingdom/viiv-healthcare-disclosure-of-payments-to-uk-based-healthcare-professionals-and-healthcare-organisations-and-patient-organisations/",
      "status": "new",
      "txt": "UK.EFPIA-Disclosure-Customer@gsk.com"
    },
    "mailto:usgrants@viivhealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/july/viiv-healthcare-announces-positive-action-us-southern-initiative-an-innovative-community-support-program-to-fight-hivaids/",
      "status": "new",
      "txt": "usgrants@viivhealthcare.com"
    },
    "mailto:viiv.med.info@viivhealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/datenschutzerklaerung/",
      "status": "new",
      "txt": "viiv.med.info@viivhealthcare.com"
    },
    "mailto:viiv.partnering@viivhealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/our-approach-to-rd/",
      "status": "new",
      "txt": "viiv.partnering@viivhealthcare.com"
    },
    "mailto:viiv.unsubscibe@viivhealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/unsubscribe/",
      "status": "new",
      "txt": "viiv.unsubscibe@viivhealthcare.com"
    },
    "mailto:viiv@tccgrp.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/local-partnerships/",
      "status": "new",
      "txt": "viiv@tccgrp.com"
    },
    "mailto:viivhc.globalcomms@viivhealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/november/viiv-healthcare-announces-start-of-phase-iii-study-of-long-actin/",
      "status": "new",
      "txt": "Isabelle Scali"
    },
    "mailto:viivhc.globalcoms@viivhealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/committed-to-data-transparency/",
      "status": "new",
      "txt": "ViiV Healthcare Global Communications"
    }
  },
  "origin": {
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/": {
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,302"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/about-us.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "About us"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/about-us/corporate-ethics-and-compliance.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/who-we-are/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Corporate ethics and compliance  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "The NGOs & patient advocacy groups we fund"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/about-us/corporate-ethics-and-compliance/united-kingdom/viiv-healthcare-disclosure-of-payments-to-uk-based-healthcare-professionals-and-healthcare-organisations-and-patient-organisations.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-kingdom/viiv-healthcare-disclosure-of-payments-to-uk-based-healthcare-professionals-and-healthcare-organisations-and-patient-organisations/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare - Disclosure of payments to UK based healthcare professionals and healthcare organisations and patient organisations"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/about-us/corporate-ethics-and-compliance/united-states/research-and-development-payments-in-the-us.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-states/research-and-development-payments-in-the-us/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Research and Development payments in the US"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/about-us/corporate-ethics-and-compliance/united-states/us-healthcare-professional-fee-disclosures.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-states/us-healthcare-professional-fee-disclosures/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "US healthcare professional fee disclosures"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/about-us/our-board.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/who-we-are/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/our-board/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Our Board  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/about-us/our-culture-and-values.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/who-we-are/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/our-culture-and-values/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Our culture and values  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/about-us/our-executive-team.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/who-we-are/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/our-executive-team/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Our Executive Team  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/about-us/where-we-work.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/where-we-work/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Where we work"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/about-us/who-we-are.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/who-we-are/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Who we are"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/accessibility.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/accessibility/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Accessibility"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/advancing-hiv-science-and-rd.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Advancing Science and R&D"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/advancing-hiv-science-and-rd/we-are-committed-to-data-transparency.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-are-committed-to-data-transparency/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "We are committed to data transparency"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/advancing-hiv-science-and-rd/we-collaborate-to-innovate.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-collaborate-to-innovate/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "We collaborate to innovate"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/advancing-hiv-science-and-rd/we-research-and-develop-new-hiv-medicines.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-research-and-develop-new-hiv-medicines/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "We research and develop new HIV medicines"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "AIDS 2018 Amsterdam"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/100-dedicated-to-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/100-dedicated-to-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "100% Dedicated to HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Advancing HIV Treatment and Science"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/accelerating-the-pace-of-innovation.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/accelerating-the-pace-of-innovation/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Accelerating the pace of innovation"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/ageing-with-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/ageing-with-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Ageing with HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/branford-the-world-s-only-hiv-dedicated-research-facility.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/branford-the-world-s-only-hiv-dedicated-research-facility/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Branford: the world’s only HIV-dedicated research facility"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/committed-to-data-transparency.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/committed-to-data-transparency/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Committed to Data Transparency"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/data-release-1-sword.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/data-release-1-sword/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Data Release #1 (SWORD)"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/data-release-2-gemini.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/data-release-2-gemini/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Data Release #2 (GEMINI)"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/events-at-aids-2018.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/events-at-aids-2018/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Events at AIDS 2018"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/exploring-cure-and-remission-in-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/exploring-cure-and-remission-in-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Exploring cure and remission in HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/medicines-in-development.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/medicines-in-development/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Medicines in Development"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/more-press-releases-from-viiv-healthcare.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/more-press-releases-from-viiv-healthcare/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "More press releases from ViiV Healthcare"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-approach-to-rd.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-approach-to-rd/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Our approach to R&D"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Our Medicines"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/combivir.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/combivir/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Combivir®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/epivir-3tc.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/epivir-3tc/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Epivir/ 3TC®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/epzicom-kivexa.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/epzicom-kivexa/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Epzicom/ Kivexa®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/juluca.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/juluca/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Juluca®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/lexiva-telzir.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/lexiva-telzir/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Lexiva/ Telzir®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/medicines-in-development.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/medicines-in-development/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/report-a-side-effect.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/juluca/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/report-a-side-effect/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Report a side effect"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/rescriptor.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/rescriptor/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Rescriptor®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/retrovir-azt.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/retrovir-azt/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Retrovir/ AZT®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/selzentry-celsentri.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/selzentry-celsentri/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Selzentry/ Celsentri®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/tivicay.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/tivicay/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Tivicay®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/triumeq.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/triumeq/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Triumeq®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/trizivir.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/trizivir/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Trizivir®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/viracept.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/viracept/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Viracept®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/ziagen.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/ziagen/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Ziagen®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Championing 360 degree HIV Care"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/events-at-aids-2018.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/events-at-aids-2018/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " Events at AIDS18"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/explore-part-one-of-our-positive-perspectives-survey.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/explore-part-one-of-our-positive-perspectives-survey/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Explore part one of our Positive Perspectives Survey"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/helping-botswana-treat-all-people-living-with-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/helping-botswana-treat-all-people-living-with-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Helping Botswana 'Treat All' people living with HIV."
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/hiv-behind-bars-improving-hiv-testing-in-italian-prisons.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/hiv-behind-bars-improving-hiv-testing-in-italian-prisons/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " HIV Behind Bars: improving HIV testing in Italian prisons"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/hiv-is-a-global-issue-that-needs-an-ongoing-collaborative-response.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/hiv-is-a-global-issue-that-needs-an-ongoing-collaborative-response/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "HIV is a global issue that needs an ongoing, collaborative response."
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/metrics-matter-measuring-impact-in-hiv-implementation.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/metrics-matter-measuring-impact-in-hiv-implementation/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " Metrics matter: measuring impact in HIV implementation"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/our-approach-to-improving-access-to-medicines.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/our-approach-to-improving-access-to-medicines/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Our approach to improving access to medicines"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/positive-perspectives-partner-data.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/positive-perspectives-partner-data/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " Positive Perspectives Partner Data"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/striking-the-balance-through-flexible-pricing.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/striking-the-balance-through-flexible-pricing/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Striking the balance through flexible pricing."
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/the-state-of-hiv-implementation-science-carlos-del-rio.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/the-state-of-hiv-implementation-science-carlos-del-rio/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " The State of HIV Implementation Science – Carlos Del Rio"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/u-u-undetectable-equals-untransmittable.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/u-u-undetectable-equals-untransmittable/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "U=U: Undetectable equals Untransmittable"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/understanding-the-concerns-of-people-living-with-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/understanding-the-concerns-of-people-living-with-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Understanding the concerns of people living with HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/viiv-healthcare-s-commitment-to-implementation-science.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/viiv-healthcare-s-commitment-to-implementation-science/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " ViiV Healthcare’s commitment to implementation science"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/working-towards-unaids-90-90-90-targets.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/working-towards-unaids-90-90-90-targets/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " Working towards UNAIDS 90-90-90 targets."
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/fighting-hiv-together.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/fighting-hiv-together/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Fighting HIV Together"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/fighting-hiv-together/hiv-a-virus-that-thrives-on-inequality.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/fighting-hiv-together/hiv-a-virus-that-thrives-on-inequality/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "HIV: A virus that thrives on inequality"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/fighting-hiv-together/inspiring-the-next-generation-of-hiv-leaders.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/spark-igniting-change/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Inspiring the next generation of HIV leaders"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/fighting-hiv-together/million-positive-faces.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/fighting-hiv-together/million-positive-faces/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Million Positive Faces"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/fighting-hiv-together/mtv-shuga.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-shuga/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "MTV Shuga"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/fighting-hiv-together/positive-action-at-aids-2018.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/fighting-hiv-together/positive-action-at-aids-2018/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Positive Action at AIDS 2018"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/fighting-hiv-together/positive-action-challenges.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/fighting-hiv-together/positive-action-challenges/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Positive Action Challenges"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/fighting-hiv-together/positive-action-programmes.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/fighting-hiv-together/positive-action-programmes/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Positive Action Programmes"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/fighting-hiv-together/stigma-action-network.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Stigma Action Network"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/fighting-hiv-together/the-fight-to-end-mother-to-child-transmission-of-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/fighting-hiv-together/the-fight-to-end-mother-to-child-transmission-of-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "The fight to end Mother-to-Child Transmission of HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/careers.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/careers/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Careers"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/careers/frequently-asked-questions.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/careers/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/careers/frequently-asked-questions/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " \n      \n      Frequently asked questions  \n      Read more \n      "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/careers/how-to-apply.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/careers/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/careers/how-to-apply/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " \n      \n      How to apply \n      A step-by-step guide to our recruitment process and how to set up an email notification of vacancies that match your requirements. \n      Read more \n      "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/careers/job-search.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/careers/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/careers/job-search/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " \n      \n      Job search \n      Find out about current vacancies in the ViiV Healthcare team \n      Read more \n      "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/careers/why-join-us.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/careers/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/careers/why-join-us/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " \n      \n      Why join us? \n      If you are passionate about making a difference to people living with HIV we'd love to meet you. \n      Read more \n      "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/contact-us.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/accessibility/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/contact-us/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "contact us"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/contact-us/social-media-at-viiv-healthcare.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/contact-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/contact-us/social-media-at-viiv-healthcare/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Social media at ViiV Healthcare"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/content/cf-viiv/viiv-healthcare/en_CH/home/latest-news/2017/september/flashcards": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/latest-news/2017/september/flashcards/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,302",
      "txt": " \n              \n               HIV Flashcards Learn the most important facts about HIV in an entertaining way  \n               "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/content/cf-viiv/viiv-healthcare/en_GB/home/mapping-an-hiv-free-future/paediatric-hiv-care": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/paediatric-hiv-care/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,302",
      "txt": " \n        \n         ViiV Healthcare  \n        INNOVATORS AND DISRUPTORS IN HIV RESEARCH AND TREATMENT \n        "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/content/cf-viiv/viiv-healthcare/en_GB/home/our-stories/advancing-hiv-treatment-and-care/championing-effective-hiv-care-for-plhiv": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/championing-effective-hiv-care-for-plhiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,302",
      "txt": " \n        \n         ViiV Healthcare  \n        INNOVATORS AND DISRUPTORS IN HIV RESEARCH AND TREATMENT \n        "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/content/cf-viiv/viiv-healthcare/en_GB/home/our-stories/innovation---hiv-science/welcome-to-branford--the-worlds-only-hiv-dedicated-research-faci": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/welcome-to-branford-the-world-s-only-hiv-dedicated-research-facility/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,302",
      "txt": " \n        \n         ViiV Healthcare  \n        INNOVATORS AND DISRUPTORS IN HIV RESEARCH AND TREATMENT \n        "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/content/cf-viiv/viiv-healthcare/en_US/home/as-much-as-i-can-received-with-open-arms-in-new-york-city": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,302",
      "txt": " \n           \n            \"As Much as I Can\" Received With Open Arms    \n           The immersive theater experience captivated sold-out crowds during its run in NYC. \n            "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/content/cf-viiv/viiv-healthcare/home/welcome-switzerland.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "results": {},
      "status": "done",
      "statusCode": 404,
      "txt": "ch"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/content/cf-viiv/viiv-healthcare/master/sitemap.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/",
      "results": {},
      "status": "done",
      "statusCode": 404,
      "txt": "Sitemap"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/cookie-policy.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/cookie-policy/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Cookie policy"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/croi-2018.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/croi-2018/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "CROI 2018"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/croi-2018/addressing-hiv-in-adolescents.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/croi-2018/addressing-hiv-in-adolescents/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Addressing HIV in Adolescents"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/croi-2018/advancing-hiv-science-through-collaboration.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/croi-2018/advancing-hiv-science-through-collaboration/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Advancing HIV science through collaboration"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/croi-2018/building-on-30-years-of-innovation-ingenuity-and-passion.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/croi-2018/building-on-30-years-of-innovation-ingenuity-and-passion/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Building on 30 years of innovation, ingenuity and passion"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/croi-2018/leading-the-way-in-hiv-on-international-women-s-day.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/croi-2018/leading-the-way-in-hiv-on-international-women-s-day/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Leading the way in HIV on International Women’s Day"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/croi-2018/understanding-hiv-in-women.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/croi-2018/understanding-hiv-in-women/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Understanding HIV in women"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/croi-2018/working-towards-90-90-90.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/croi-2018/working-towards-90-90-90/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Working towards 90-90-90"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "results": {},
      "status": "done",
      "statusCode": 200,
      "txt": "Germany"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/90-90-90.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/90-90-90/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "90-90-90  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/90-90-90/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/90-90-90.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Aktuelles  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/antiretrovirale-kombinationstherapie-eine-erfolgsgeschichte.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/antiretrovirale-kombinationstherapie-eine-erfolgsgeschichte/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Antiretrovirale Kombinationstherapie – eine Erfolgsgeschichte  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/antiretrovirale-kombinationstherapie-eine-erfolgsgeschichte/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/antiretrovirale-kombinationstherapie-eine-erfolgsgeschichte.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/auf-dem-weg-zu-90-90-90-wie-sieht-es-in-europa-aus.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/auf-dem-weg-zu-90-90-90-wie-sieht-es-in-europa-aus/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Auf dem Weg zu 90-90-90: Wie sieht es in Europa aus?  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/auf-dem-weg-zu-90-90-90-wie-sieht-es-in-europa-aus/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/auf-dem-weg-zu-90-90-90-wie-sieht-es-in-europa-aus.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/bundesweites-treffen-fuer-hiv-positive-jugendliche.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/bundesweites-treffen-fuer-hiv-positive-jugendliche/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Bundesweites Treffen für HIV-positive Jugendliche  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/bundesweites-treffen-fuer-hiv-positive-jugendliche/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/bundesweites-treffen-fuer-hiv-positive-jugendliche.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/bundesweites-treffen-fuer-hiv-positive-jugendliche/$NewsURL_01": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/bundesweites-treffen-fuer-hiv-positive-jugendliche/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/bundesweites-treffen-fuer-hiv-positive-jugendliche/$NewsURL_01/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "  Mai 25  \n       \n        \n       "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/bundesweites-treffen-fuer-hiv-positive-jugendliche/$NewsURL_01/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/bundesweites-treffen-fuer-hiv-positive-jugendliche/$NewsURL_01"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/deutsch-oesterreichischer-aids-kongress.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/deutsch-oesterreichischer-aids-kongress/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Deutsch-Österreichischer AIDS-Kongress  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/deutsch-oesterreichischer-aids-kongress/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/deutsch-oesterreichischer-aids-kongress.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/deutsche-aids-hilfe-startet-die-informationskampagne-zum-welt-ai.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/deutsche-aids-hilfe-startet-die-informationskampagne-zum-welt-ai/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Deutsche AIDS-Hilfe startet die Informationskampagne zum Welt-AIDS-Tag  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/deutsche-aids-hilfe-startet-die-informationskampagne-zum-welt-ai/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/deutsche-aids-hilfe-startet-die-informationskampagne-zum-welt-ai.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/schulung-und-selbstmanagement-koennen-die-adhaerenz-verbessern.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/schulung-und-selbstmanagement-koennen-die-adhaerenz-verbessern/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Schulung und Selbstmanagement können die Adhärenz verbessern  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/schulung-und-selbstmanagement-koennen-die-adhaerenz-verbessern/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/schulung-und-selbstmanagement-koennen-die-adhaerenz-verbessern.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/art-erreicht-mehr-als-20-mio-menschen.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/art-erreicht-mehr-als-20-mio-menschen/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ART erreicht mehr als 20 Mio Menschen  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/art-erreicht-mehr-als-20-mio-menschen/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/art-erreicht-mehr-als-20-mio-menschen.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/begleiterkrankungen-bei-hiv-patienten-daten-aus-den-usa.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/begleiterkrankungen-bei-hiv-patienten-daten-aus-den-usa/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Begleiterkrankungen bei HIV-Patienten – Daten aus den USA  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/begleiterkrankungen-bei-hiv-patienten-daten-aus-den-usa/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/begleiterkrankungen-bei-hiv-patienten-daten-aus-den-usa.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/frueher-therapiebeginn-kann-resistenzentwicklung-verhindern.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/frueher-therapiebeginn-kann-resistenzentwicklung-verhindern/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Früher Therapiebeginn kann Resistenzentwicklung verhindern  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/frueher-therapiebeginn-kann-resistenzentwicklung-verhindern/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/frueher-therapiebeginn-kann-resistenzentwicklung-verhindern.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/geringes-resistenzrisiko-auch-bei-sofortigem-art-beginn.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/geringes-resistenzrisiko-auch-bei-sofortigem-art-beginn/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Geringes Resistenzrisiko auch bei sofortigem ART-Beginn  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/geringes-resistenzrisiko-auch-bei-sofortigem-art-beginn/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/geringes-resistenzrisiko-auch-bei-sofortigem-art-beginn.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/patienten-mit-hohen-cd4-zellzahlen-wer-profitiert-am-meisten-von.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/patienten-mit-hohen-cd4-zellzahlen-wer-profitiert-am-meisten-von/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Patienten mit hohen CD4-Zellzahlen: wer profitiert am meisten von sofortigem Therapiebeginn?  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/patienten-mit-hohen-cd4-zellzahlen-wer-profitiert-am-meisten-von/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/patienten-mit-hohen-cd4-zellzahlen-wer-profitiert-am-meisten-von.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/rote-hand-brief-zu-dolutegravir.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/rote-hand-brief-zu-dolutegravir/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "  Jun 01  \n       \n        \n       \n       \n       Rote-Hand-Brief zu Tivicay (Dolutegravir), Triumeq (Dolutegravir/Abacavir/Lamivudin), Juluca (Dolutegravir/Rilpivirin): Berichte über Neuralrohrdefekte bei Neugeborenen von Frauen, die zur Zeit der Konzeption Dolutegravir eingenommen haben  \n       "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/rote-hand-brief-zu-dolutegravir/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/rote-hand-brief-zu-dolutegravir.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/solidaritaet-mit-hivplus-frauen-zeigen-undsichtbar.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/solidaritaet-mit-hivplus-frauen-zeigen-undsichtbar/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "  Mrz 08  \n       \n        \n       \n       \n       Solidarität mit HIV+ Frauen zeigen #UNDSICHTBAR  \n       "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/solidaritaet-mit-hivplus-frauen-zeigen-undsichtbar/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/solidaritaet-mit-hivplus-frauen-zeigen-undsichtbar.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/test-auf-hiv-und-geschlechtskrankheiten-per-post.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/test-auf-hiv-und-geschlechtskrankheiten-per-post/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "  Jul 19  \n       \n        \n       \n       \n       Pilotprojekt in Bayern: Per Abo soll der diskrete und regelmäßige Check einfacher werden.  \n       "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/test-auf-hiv-und-geschlechtskrankheiten-per-post/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/test-auf-hiv-und-geschlechtskrankheiten-per-post.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/therapie-als-praevention-tasp-wie-gross-ist-das-wissen-bei-msm.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/therapie-als-praevention-tasp-wie-gross-ist-das-wissen-bei-msm/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Therapie als Prävention (TasP): wie groß ist das Wissen bei MSM?  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/therapie-als-praevention-tasp-wie-gross-ist-das-wissen-bei-msm/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/therapie-als-praevention-tasp-wie-gross-ist-das-wissen-bei-msm.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/uebertragene-hiv-resistenzen-seltener.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/uebertragene-hiv-resistenzen-seltener/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Übertragene HIV-Resistenzen seltener  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/uebertragene-hiv-resistenzen-seltener/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/uebertragene-hiv-resistenzen-seltener.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " \n              \n                \n               "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/viiv-ist-1-im-patientview-report.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/viiv-ist-1-im-patientview-report/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "  Mai 16  \n       \n        \n       \n       \n       In dem von PatientView kürzlich veröffentlichten Bericht über „Das Ansehen von Pharmaunternehmen für das Jahr 2017“ belegt ViiV Healthcare erneut den ersten Platz. Es ist das fünfte Jahr in Folge, dass ViiV Healthcare bei der Umfrage das Feld anführt, diesmal in 11 der 12 Kategorien.  \n       "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/viiv-ist-1-im-patientview-report/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/viiv-ist-1-im-patientview-report.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/cookie-richtlinie.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/cookie-richtlinie/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Cookie-Richtlinie"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/cookie-richtlinie/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/cookie-richtlinie.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/datenschutzerklaerung.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/datenschutzerklaerung/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Datenschutzerklärung"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/datenschutzerklaerung/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/datenschutzerklaerung.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/forschung-und-innovation.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/forschung-und-innovation/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Forschung und Innovation  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/forschung-und-innovation/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/forschung-und-innovation.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/fuer-eine-hiv-freie-zukunft.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/fuer-eine-hiv-freie-zukunft/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Für eine HIV-freie Zukunft  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/fuer-eine-hiv-freie-zukunft/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/fuer-eine-hiv-freie-zukunft.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/herzlich-willkommen.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/herzlich-willkommen/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Herzlich Willkommen  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/herzlich-willkommen/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/herzlich-willkommen.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Kalender  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/nutzungsbedingungen.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/nutzungsbedingungen/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Nutzungsbedingungen"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/nutzungsbedingungen/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/nutzungsbedingungen.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Unser Engagement in Deutschland  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/das-innovative-zentrum-fuer-sexuelle-gesundheit-und-medizin-wir-.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/das-innovative-zentrum-fuer-sexuelle-gesundheit-und-medizin-wir-/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/das-innovative-zentrum-fuer-sexuelle-gesundheit-und-medizin-wir-/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/das-innovative-zentrum-fuer-sexuelle-gesundheit-und-medizin-wir-.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/hiv-und-sti-test-leicht-er-gemacht-self-sampling-in-muenchen.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/hiv-und-sti-test-leicht-er-gemacht-self-sampling-in-muenchen/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/hiv-und-sti-test-leicht-er-gemacht-self-sampling-in-muenchen/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/hiv-und-sti-test-leicht-er-gemacht-self-sampling-in-muenchen.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/let-s-talk-about-sex-and-drugs-in-berlin.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/let-s-talk-about-sex-and-drugs-in-berlin/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/let-s-talk-about-sex-and-drugs-in-berlin/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/let-s-talk-about-sex-and-drugs-in-berlin.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/let-s-talk-about-sex.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/let-s-talk-about-sex/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/let-s-talk-about-sex/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/let-s-talk-about-sex.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/spickzettel-unterstuetzung-bei-der-fruehen-diagnose-informatione.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/spickzettel-unterstuetzung-bei-der-fruehen-diagnose-informatione/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/spickzettel-unterstuetzung-bei-der-fruehen-diagnose-informatione/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/spickzettel-unterstuetzung-bei-der-fruehen-diagnose-informatione.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-weltweit.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Unser Engagement weltweit  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-weltweit.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/artikel/kinder-und-jugendliche-im-fokus.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/artikel/kinder-und-jugendliche-im-fokus/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/artikel/kinder-und-jugendliche-im-fokus/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/artikel/kinder-und-jugendliche-im-fokus.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/artikel/positive-action.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/artikel/positive-action/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/artikel/positive-action/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/artikel/positive-action.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/artikel/weltweiter-zugang-zu-medikamenten.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/artikel/weltweiter-zugang-zu-medikamenten/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/artikel/weltweiter-zugang-zu-medikamenten/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/artikel/weltweiter-zugang-zu-medikamenten.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/viiv-foerderpreis.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/viiv-foerderpreis/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Förderpreis  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/viiv-foerderpreis/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/viiv-foerderpreis.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "results": {},
      "status": "done",
      "statusCode": 200,
      "txt": "Australia"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Community Partnerships"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/what-we-do/partnerships-with-the-hiv-community.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/about-positive-action.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/about-positive-action/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "  \n    \n      About Positive Action \n     "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/about-positive-action/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/about-positive-action.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/acon-healthy-ageing-with-hiv---self-management-groups.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/community-partnerships-grants/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/acon-healthy-ageing-with-hiv---self-management-groups/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ACON- Healthy Ageing with HIV - Self Management Groups  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/acon-healthy-ageing-with-hiv---self-management-groups/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/acon-healthy-ageing-with-hiv---self-management-groups.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/acon-start-making-sense--online-workshops.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/positive-action-grant-projects/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/acon-start-making-sense--online-workshops/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Healthy Ageing with HIV - Self Management Groups"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/acon-start-making-sense--online-workshops/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/acon-start-making-sense--online-workshops.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/afao-national-african-australian-hiv-network.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/positive-action-grant-projects/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/afao-national-african-australian-hiv-network/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "National African Australian HIV Network (2015)"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/afao-national-african-australian-hiv-network/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/afao-national-african-australian-hiv-network.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/bgf-online-group-counselling-for-isolated-people-living-with-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/community-partnerships-grants/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/bgf-online-group-counselling-for-isolated-people-living-with-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "BGF - Online Group Counselling for Isolated People Living with HIV  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/bgf-online-group-counselling-for-isolated-people-living-with-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/bgf-online-group-counselling-for-isolated-people-living-with-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/community-partnerships-grants.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/community-partnerships-grants/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/community-partnerships-grants/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/community-partnerships-grants.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/global-community-partnerships.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "  \n    \n      Global Community Partnerships \n     "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/inside-hiv-the-podcast-for-positive-people.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/positive-action-grant-projects/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/inside-hiv-the-podcast-for-positive-people/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Inside HIV – The Podcast for Positive People"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/inside-hiv-the-podcast-for-positive-people/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/inside-hiv-the-podcast-for-positive-people.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/napwha-linkage-to-care-project-lkcp-identifying-the-barriers-and.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/community-partnerships-grants/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/napwha-linkage-to-care-project-lkcp-identifying-the-barriers-and/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "NAPWHA - Linkage to Care Project (LKCP): Identifying the Barriers and Facilitators for Maintaining Linkage to HIV Care  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/napwha-linkage-to-care-project-lkcp-identifying-the-barriers-and/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/napwha-linkage-to-care-project-lkcp-identifying-the-barriers-and.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/other-community-partnership-projects.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/other-community-partnership-projects/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "  \n    \n      Other Community Partnership Projects \n     "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/other-community-partnership-projects/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/other-community-partnership-projects.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/positive-action-grant-projects.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/positive-action-grant-projects/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "  \n    \n      Positive Action Grant Projects \n     "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/positive-action-grant-projects/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/positive-action-grant-projects.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/positive-life-nsw-hiv-work-ready.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/positive-action-grant-projects/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/positive-life-nsw-hiv-work-ready/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "HIV Work Ready"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/positive-life-nsw-hiv-work-ready/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/positive-life-nsw-hiv-work-ready.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/positive-women-victoria-community-camp.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/positive-action-grant-projects/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/positive-women-victoria-community-camp/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Community Camp"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/positive-women-victoria-community-camp/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/positive-women-victoria-community-camp.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/positive-women-victoria-needs-of-women-from-african-diaspora-com.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/community-partnerships-grants/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/positive-women-victoria-needs-of-women-from-african-diaspora-com/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Positive women Victoria needs of women from African diaspora communities in Victoria Australia who are living with HIV  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/positive-women-victoria-needs-of-women-from-african-diaspora-com/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/positive-women-victoria-needs-of-women-from-african-diaspora-com.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/qpp-peer-navigation-program--education-modules.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/positive-action-grant-projects/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/qpp-peer-navigation-program--education-modules/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Peer Navigation Program: Education Modules"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/qpp-peer-navigation-program--education-modules/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/qpp-peer-navigation-program--education-modules.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/qpp-plhiv-peer-testernavigator-pilot-project-townsville-queensla.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/community-partnerships-grants/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/qpp-plhiv-peer-testernavigator-pilot-project-townsville-queensla/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "QPP - PLHIV Peer Tester/Navigator Pilot Project (Townsville, Queensland)  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/qpp-plhiv-peer-testernavigator-pilot-project-townsville-queensla/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/qpp-plhiv-peer-testernavigator-pilot-project-townsville-queensla.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/qpp-queensland-positive-speakers-bureau-neutralising-the-health-.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/community-partnerships-grants/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/qpp-queensland-positive-speakers-bureau-neutralising-the-health-/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "QPP - Queensland Positive Speakers Bureau. Neutralising the health impact of HIV related stigma  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/qpp-queensland-positive-speakers-bureau-neutralising-the-health-/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/qpp-queensland-positive-speakers-bureau-neutralising-the-health-.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/tascahrd-rural-tasmanian-council-on-aids-hepatitis-and-related-d.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/community-partnerships-grants/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/tascahrd-rural-tasmanian-council-on-aids-hepatitis-and-related-d/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "TasCAHRD Rural - Tasmanian Council on AIDS, Hepatitis and Related Diseases  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/tascahrd-rural-tasmanian-council-on-aids-hepatitis-and-related-d/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/tascahrd-rural-tasmanian-council-on-aids-hepatitis-and-related-d.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/the-western-suburbs-haven-young-and-moving-forward.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/community-partnerships-grants/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/the-western-suburbs-haven-young-and-moving-forward/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "The Western Suburbs Haven - Young and Moving Forward  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/the-western-suburbs-haven-young-and-moving-forward/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/the-western-suburbs-haven-young-and-moving-forward.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/wa-aids-council-ageing-and-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/positive-action-grant-projects/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/wa-aids-council-ageing-and-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Ageing and HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/wa-aids-council-ageing-and-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/wa-aids-council-ageing-and-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/contact-us.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/contact-us/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Contact us"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/contact-us/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/contact-us.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/external/au-viivexchange-com--utmcampaign-viivcorporate-utmsource-whatwed.html": {
      "redirectedTo": "https://au.viivexchange.com/?utm_campaign=viivcorporate&utm_source=whatwedo&utm_medium=web&utm_content=vxbtn",
      "status": "redirected"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/external/viivhealthcare-com-au-media-124190-critical-steps-towards-addres.html": {
      "redirectedTo": "https://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/en-au/critical-steps-towards-addressing-hiv-in-australia_viiv-australia-report.pdf",
      "status": "redirected"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Our medicines"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/3tc-.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/3tc-/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "3TC®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/3tc-/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/3tc-.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/celsentri-.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/celsentri-/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Celsentri®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/celsentri-/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/celsentri-.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/combivir-.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/combivir-/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Combivir®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/combivir-/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/combivir-.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/juluca-.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/juluca-/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Juluca®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/juluca-/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/juluca-.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/kivexa-.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/kivexa-/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Kivexa®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/kivexa-/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/kivexa-.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/retrovir-.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/retrovir-/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Retrovir®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/retrovir-/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/retrovir-.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/telzir-.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/telzir-/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Telzir®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/telzir-/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/telzir-.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/tivicay-.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/tivicay-/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Tivicay®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/tivicay-/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/tivicay-.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/triumeq-.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/triumeq-/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Triumeq®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/triumeq-/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/triumeq-.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/trizivir-.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/trizivir-/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Trizivir®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/trizivir-/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/trizivir-.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/ziagen-.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/ziagen-/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Ziagen®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/ziagen-/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/ziagen-.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/privacy-policy.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/privacy-policy/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Privacy policy"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/privacy-policy/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/site-services/privacy.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/report-an-adverse-event.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/report-an-adverse-event/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Report an adverse event"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/report-an-adverse-event/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/report-an-adverse-event.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/site-services/privacy.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/website-terms-of-use/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/privacy-policy/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "VHCA Privacy Policy"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/transparency-reporting.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/transparency-reporting/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Transparency Reporting"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/transparency-reporting/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/transparency-reporting.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV News"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2016.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2016/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "2016"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2016/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2016.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2016/grassroots-hiv-organisations-receive-140-000-funding-boost.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2016/grassroots-hiv-organisations-receive-140-000-funding-boost/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Grassroots HIV organisations receive 140 000 funding boost"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2016/grassroots-hiv-organisations-receive-140-000-funding-boost/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2016/grassroots-hiv-organisations-receive-140-000-funding-boost.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2016/viiv-healthcare-to-progress-collaboration-with-janssen-to-develo.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2016/viiv-healthcare-to-progress-collaboration-with-janssen-to-develo/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare to progress collaboration with Janssen to develop the first long-acting two drug injectable regimen for treatment of HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2016/viiv-healthcare-to-progress-collaboration-with-janssen-to-develo/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2016/viiv-healthcare-to-progress-collaboration-with-janssen-to-develo.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "2017"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/march.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/march/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "March"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/march/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/march.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/march/oonagh-makes-a-difference-for-people-affected-by-hiv-through-pos.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/march/oonagh-makes-a-difference-for-people-affected-by-hiv-through-pos/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Oonagh makes a difference for people affected by HIV through Positive Action programmes"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/march/oonagh-makes-a-difference-for-people-affected-by-hiv-through-pos/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/march/oonagh-makes-a-difference-for-people-affected-by-hiv-through-pos.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/october.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/october/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "October"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/october/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/october.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/october/viiv-healthcare-awards-new-grants-to-accelerate-community-led-so.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/october/viiv-healthcare-awards-new-grants-to-accelerate-community-led-so/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare awards new grants to accelerate community led solutions to HIV challenges"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/october/viiv-healthcare-awards-new-grants-to-accelerate-community-led-so/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/october/viiv-healthcare-awards-new-grants-to-accelerate-community-led-so.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/september.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/september/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "September"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/september/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/september.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/september/critical-steps-towards-addressing-hiv-in-australia-a-report-from.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/september/critical-steps-towards-addressing-hiv-in-australia-a-report-from/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Critical Steps Towards Addressing HIV in Australia a report from ViiV Healthcare Australia"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/september/critical-steps-towards-addressing-hiv-in-australia-a-report-from/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/september/critical-steps-towards-addressing-hiv-in-australia-a-report-from.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/first-two-drug-single-pill-for-hiv-now-approved-for-use-in-austr.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/first-two-drug-single-pill-for-hiv-now-approved-for-use-in-austr/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "First two drug single pill for HIV now approved for use in Australia"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/first-two-drug-single-pill-for-hiv-now-approved-for-use-in-austr/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/first-two-drug-single-pill-for-hiv-now-approved-for-use-in-austr.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/website-terms-of-use.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/website-terms-of-use/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Website Terms of Use"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/website-terms-of-use/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/website-terms-of-use.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/what-we-do.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/what-we-do/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "What we do"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/what-we-do/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/what-we-do.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/what-we-do/partnerships-with-the-hiv-community.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/what-we-do/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " \n      \n      Partnerships with the HIV community  \n      Partnership is at the very core of who we are. As a company established through an innovative collaboration, we know we can achieve better outcomes when working together.  \n      Read more \n      "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "results": {},
      "status": "done",
      "statusCode": 200,
      "txt": "Canada"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-hivaids.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-hivaids/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "About HIV/AIDS"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-hivaids/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-hivaids.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-hivaids/about-hivaids-in-canada.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-hivaids/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-hivaids/about-hivaids-in-canada/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " \n      \n      About HIV/Aids in Canada \n      Find out more about HIV/AIDS in Canada. \n      Read more \n      "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-hivaids/about-hivaids-in-canada/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-hivaids/about-hivaids-in-canada.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-hivaids/canadian-resources.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-hivaids/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-hivaids/canadian-resources/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " \n      \n      Canadian resources  Find out what ViiV Healthcare in Canada is doing to support populations at risk, people living with HIV/AIDS, their caregivers and healthcare providers  \n      Read more \n      "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-hivaids/canadian-resources/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-hivaids/canadian-resources.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-us.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-us/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "About us"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-us/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-us.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-us/our-mission.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-us/our-mission/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-us/our-mission/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-us/our-mission.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-us/our-team.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-us/our-team/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " \n      \n      Our team  \n      Find out more about ViiV Healthcare's leadership team who work closely with our CEO to set our strategy and run the company according to our values of innovation, passion, trust, resilience and integrity.  \n      Read more \n      "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-us/our-team/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-us/our-team.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-us/our-values.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-us/our-values/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " \n           \n            Our core values run deep    \n           Our values lead to action. See what drives our commitment to deliver innovative new options for the care and treatment of people living with HIV/AIDS. \n            "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-us/our-values/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-us/our-values.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-us/who-we-are.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-us/who-we-are/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " \n      \n      Who we are  \n      ViiV Healthcare Canada works to provide treatment, research and support to people affected by HIV/AIDS.  \n      Read more \n      "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-us/who-we-are/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-us/who-we-are.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/accessibility.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/accessibility/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Accessibility"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/accessibility/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/accessibility.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/careers.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/careers/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Careers"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/careers/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/careers.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Community Partnerships"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "  \n       \n         Community grants \n        "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/in-the-community.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/in-the-community/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " \n      \n      In the community  \n      Our companies are committed not only to improve access to treatment, but also to support those communities most affected by the disease.  \n      Read more \n      "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/in-the-community/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/in-the-community.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/positive-action.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/positive-action/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/positive-action/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/positive-action.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/the-viiv-healthcare-effect.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/the-viiv-healthcare-effect/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "  \n       \n         The ViiV Healthcare Effect \n        "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/the-viiv-healthcare-effect/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/the-viiv-healthcare-effect.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/contact-us.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/contact-us/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Contact us"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/contact-us/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/contact-us.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/cookie-policy.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/cookie-policy/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Cookie Policy"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/cookie-policy/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/cookie-policy.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Healthcare professionals"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals/independent-grants-and-support-programs.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals/independent-grants-and-support-programs/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals/independent-grants-and-support-programs/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals/independent-grants-and-support-programs.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals/research-development.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals/research-development/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals/research-development/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals/research-development.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals/viiv-healthcare-clinical-study-register.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals/viiv-healthcare-clinical-study-register/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals/viiv-healthcare-clinical-study-register/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals/viiv-healthcare-clinical-study-register.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals/voluntary-disclosure-of-viiv-healthcare-canada-payments-to-hcps-.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals/voluntary-disclosure-of-viiv-healthcare-canada-payments-to-hcps-/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals/voluntary-disclosure-of-viiv-healthcare-canada-payments-to-hcps-/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals/voluntary-disclosure-of-viiv-healthcare-canada-payments-to-hcps-.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Media"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/press-releases/2013/january.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/press-releases/2013/january/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "January"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/press-releases/2013/january/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/press-releases/2013/january.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/press-releases/2017/inspiring-voices-in-hiv-lead-the-way-on-international-women-s-day-2017.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/press-releases/2017/inspiring-voices-in-hiv-lead-the-way-on-international-women-s-day-2017/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Inspiring voices in HIV lead the way on International Women’s Day 2017"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/press-releases/2017/inspiring-voices-in-hiv-lead-the-way-on-international-women-s-day-2017/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/press-releases/2017/inspiring-voices-in-hiv-lead-the-way-on-international-women-s-day-2017.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/press-releases/2017/viiv-healthcare-ranks-1-in-patientview-corporate-reputation-survey.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/press-releases/2017/viiv-healthcare-ranks-1-in-patientview-corporate-reputation-survey/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " ViiV Healthcare ranks #1 in PatientView corporate reputation survey"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/press-releases/2017/viiv-healthcare-ranks-1-in-patientview-corporate-reputation-survey/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/press-releases/2017/viiv-healthcare-ranks-1-in-patientview-corporate-reputation-survey.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/press-releases/2018.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/press-releases/2018/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "2018"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/press-releases/2018/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/press-releases/2018.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Our medicines"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/3tc.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/3tc/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "3TC®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/3tc/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/3tc.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/celsentri.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/celsentri/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Celsentri®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/celsentri/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/celsentri.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/combivir.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/combivir/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Combivir®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/combivir/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/combivir.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/juluca.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/juluca/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare is proud to announce that Juluca is now available in Canada!"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/juluca/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/juluca.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/kivexa.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/kivexa/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Kivexa®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/kivexa/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/kivexa.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/medicines-in-development.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/medicines-in-development/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/medicines-in-development/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/medicines-in-development.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/rescriptor.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/rescriptor/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Rescriptor®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/rescriptor/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/rescriptor.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/retrovirazt.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/retrovirazt/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Retrovir/AZT®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/retrovirazt/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/retrovirazt.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/telzir.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/telzir/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Telzir®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/telzir/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/telzir.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/tivicay.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/tivicay/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Tivicay®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/tivicay/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/tivicay.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/triumeq.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/triumeq/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Triumeq®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/triumeq/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/triumeq.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/trizivir.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/trizivir/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Trizivir®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/trizivir/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/trizivir.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/viracept.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/viracept/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Viracept®*"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/viracept/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/viracept.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/ziagen.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/ziagen/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Ziagen®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/ziagen/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/ziagen.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/privacy-code.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/privacy-code/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/privacy-code/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/privacy-code.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/privacy-statement.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/privacy-statement/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Privacy Code"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/privacy-statement/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/privacy-statement.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/terms-and-conditions.html": {
      "redirectedTo": "https://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/en-ca/purchase_order_viiv.pdf",
      "status": "redirected"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/terms-of-use.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/terms-of-use/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Terms of Use"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/terms-of-use/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/terms-of-use.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "results": {},
      "status": "done",
      "statusCode": 200,
      "txt": "Switzerland"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/latest-news/2017/september/flashcards.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/privacy-notice/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/latest-news/2017/september/flashcards/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Flashcards  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/latest-news/2017/september/flashcards/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/latest-news/2017/september/flashcards.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/latest-news/2018/june-1/hiv-knowledge-builds-trust.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/latest-news/2018/june-1/hiv-knowledge-builds-trust/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "  Jun 30  \n       \n        \n       \n       \n       YES! Let's talk about sex!  \n       "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/latest-news/2018/june-1/hiv-knowledge-builds-trust/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/latest-news/2018/june-1/hiv-knowledge-builds-trust.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/privacy-notice.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/privacy-notice/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Privacy notice"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/privacy-notice/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/privacy-notice.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/swiss-viiv-team.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/swiss-viiv-team/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/swiss-viiv-team/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/swiss-viiv-team.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/welcome-switzerland.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/welcome-switzerland/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Welcome Switzerland  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/welcome-switzerland/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/welcome-switzerland.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/about-us.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/about-us/corporate-ethics-and-compliance.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-kingdom/viiv-healthcare-disclosure-of-payments-to-uk-based-healthcare-professionals-and-healthcare-organisations-and-patient-organisations/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/about-us/corporate-ethics-and-compliance/united-kingdom/viiv-healthcare-disclosure-of-payments-to-uk-based-healthcare-professionals-and-healthcare-organisations-and-patient-organisations.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-states/research-and-development-payments-in-the-us/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/about-us/corporate-ethics-and-compliance/united-states/research-and-development-payments-in-the-us.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-states/us-healthcare-professional-fee-disclosures/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/about-us/corporate-ethics-and-compliance/united-states/us-healthcare-professional-fee-disclosures.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/our-board/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/about-us/our-board.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/our-culture-and-values/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/about-us/our-culture-and-values.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/our-executive-team/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/about-us/our-executive-team.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/where-we-work/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/about-us/where-we-work.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/who-we-are/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/about-us/who-we-are.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/accessibility/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/accessibility.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/advancing-hiv-science-and-rd.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-are-committed-to-data-transparency/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/advancing-hiv-science-and-rd/we-are-committed-to-data-transparency.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-collaborate-to-innovate/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/advancing-hiv-science-and-rd/we-collaborate-to-innovate.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-research-and-develop-new-hiv-medicines/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/advancing-hiv-science-and-rd/we-research-and-develop-new-hiv-medicines.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/100-dedicated-to-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/100-dedicated-to-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/accelerating-the-pace-of-innovation/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/accelerating-the-pace-of-innovation.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/ageing-with-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/ageing-with-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/branford-the-world-s-only-hiv-dedicated-research-facility/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/branford-the-world-s-only-hiv-dedicated-research-facility.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/committed-to-data-transparency/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/committed-to-data-transparency.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/data-release-1-sword/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/data-release-1-sword.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/data-release-2-gemini/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/data-release-2-gemini.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/events-at-aids-2018/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/events-at-aids-2018.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/exploring-cure-and-remission-in-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/exploring-cure-and-remission-in-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/medicines-in-development/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/medicines-in-development.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/more-press-releases-from-viiv-healthcare/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/more-press-releases-from-viiv-healthcare.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-approach-to-rd/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-approach-to-rd.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/combivir/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/combivir.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/epivir-3tc/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/epivir-3tc.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/epzicom-kivexa/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/epzicom-kivexa.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/juluca/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/juluca.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/lexiva-telzir/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/lexiva-telzir.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/medicines-in-development/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/medicines-in-development.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/report-a-side-effect/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/report-a-side-effect.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/rescriptor/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/rescriptor.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/retrovir-azt/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/retrovir-azt.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/selzentry-celsentri/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/selzentry-celsentri.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/tivicay/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/tivicay.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/triumeq/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/triumeq.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/trizivir/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/trizivir.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/viracept/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/viracept.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/ziagen/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/ziagen.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/events-at-aids-2018/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/events-at-aids-2018.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/explore-part-one-of-our-positive-perspectives-survey/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/explore-part-one-of-our-positive-perspectives-survey.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/helping-botswana-treat-all-people-living-with-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/helping-botswana-treat-all-people-living-with-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/hiv-behind-bars-improving-hiv-testing-in-italian-prisons/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/hiv-behind-bars-improving-hiv-testing-in-italian-prisons.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/hiv-is-a-global-issue-that-needs-an-ongoing-collaborative-response/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/hiv-is-a-global-issue-that-needs-an-ongoing-collaborative-response.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/metrics-matter-measuring-impact-in-hiv-implementation/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/metrics-matter-measuring-impact-in-hiv-implementation.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/our-approach-to-improving-access-to-medicines/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/our-approach-to-improving-access-to-medicines.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/positive-perspectives-partner-data/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/positive-perspectives-partner-data.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/striking-the-balance-through-flexible-pricing/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/striking-the-balance-through-flexible-pricing.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/the-state-of-hiv-implementation-science-carlos-del-rio/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/the-state-of-hiv-implementation-science-carlos-del-rio.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/u-u-undetectable-equals-untransmittable/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/u-u-undetectable-equals-untransmittable.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/understanding-the-concerns-of-people-living-with-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/understanding-the-concerns-of-people-living-with-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/viiv-healthcare-s-commitment-to-implementation-science/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/viiv-healthcare-s-commitment-to-implementation-science.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/working-towards-unaids-90-90-90-targets/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/championing-360-degree-hiv-care/working-towards-unaids-90-90-90-targets.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/fighting-hiv-together/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/fighting-hiv-together.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/fighting-hiv-together/hiv-a-virus-that-thrives-on-inequality/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/fighting-hiv-together/hiv-a-virus-that-thrives-on-inequality.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/fighting-hiv-together/million-positive-faces/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/fighting-hiv-together/million-positive-faces.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/fighting-hiv-together/positive-action-at-aids-2018/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/fighting-hiv-together/positive-action-at-aids-2018.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/fighting-hiv-together/positive-action-challenges/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/fighting-hiv-together/positive-action-challenges.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/fighting-hiv-together/positive-action-programmes/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/fighting-hiv-together/positive-action-programmes.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/fighting-hiv-together/the-fight-to-end-mother-to-child-transmission-of-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/fighting-hiv-together/the-fight-to-end-mother-to-child-transmission-of-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/careers/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/careers.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/careers/frequently-asked-questions/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/careers/frequently-asked-questions.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/careers/how-to-apply/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/careers/how-to-apply.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/careers/job-search/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/careers/job-search.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/careers/why-join-us/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/careers/why-join-us.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/contact-us/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/contact-us.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/contact-us/social-media-at-viiv-healthcare/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/contact-us/social-media-at-viiv-healthcare.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/cookie-policy/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/cookie-policy.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/croi-2018/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/croi-2018.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/croi-2018/addressing-hiv-in-adolescents/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/croi-2018/addressing-hiv-in-adolescents.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/croi-2018/advancing-hiv-science-through-collaboration/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/croi-2018/advancing-hiv-science-through-collaboration.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/croi-2018/building-on-30-years-of-innovation-ingenuity-and-passion/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/croi-2018/building-on-30-years-of-innovation-ingenuity-and-passion.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/croi-2018/leading-the-way-in-hiv-on-international-women-s-day/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/croi-2018/leading-the-way-in-hiv-on-international-women-s-day.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/croi-2018/understanding-hiv-in-women/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/croi-2018/understanding-hiv-in-women.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/croi-2018/working-towards-90-90-90/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/croi-2018/working-towards-90-90-90.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/es/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/global/global-medical-education-events/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/global/global-medical-education-events.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/hiv-treatment-and-care/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/hiv-treatment-and-care.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/hiv-treatment-and-care/european-network-of-young-hiv-experts/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/hiv-treatment-and-care/european-network-of-young-hiv-experts.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/hiv-treatment-and-care/the-positive-perspectives-survey/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/hiv-treatment-and-care/the-positive-perspectives-survey.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/ias-paris-2017/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/ias-paris-2017.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/accelerating-the-pace-of-innovation/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/accelerating-the-pace-of-innovation.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/ageing-with-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/ageing-with-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/branford-the-world-s-only-hiv-dedicated-research-facility/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/branford-the-world-s-only-hiv-dedicated-research-facility.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/committed-to-data-transparency/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/committed-to-data-transparency.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/medicines-in-development/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/medicines-in-development.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/more-press-releases-from-viiv-healthcare/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/more-press-releases-from-viiv-healthcare.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/our-approach-to-rd/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/our-approach-to-rd.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/our-medicines/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/our-medicines.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/positive-perspectives-looking-into-the-lives-of-people-living-with-hiv-and-their-partners/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/positive-perspectives-looking-into-the-lives-of-people-living-with-hiv-and-their-partners.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/towards-a-cure-exploring-cure-and-remission-in-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/towards-a-cure-exploring-cure-and-remission-in-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-at-hiv-glasgow/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/viiv-healthcare-at-hiv-glasgow.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/case-studies.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/argentina/hiv-environment-in-buenos-aires/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/case-studies/argentina/hiv-environment-in-buenos-aires.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/brazil/hiv-environment-in-brazil/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/case-studies/brazil/hiv-environment-in-brazil.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/canada/hiv-environment-in-saskatchewan/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/case-studies/canada/hiv-environment-in-saskatchewan.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/estonia/hiv-environment-in-estonia/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/case-studies/estonia/hiv-environment-in-estonia.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/germany-ii/hiv-environment-in-berlin/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/case-studies/germany-ii/hiv-environment-in-berlin.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/germany/hiv-environment-in-bochum/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/case-studies/germany/hiv-environment-in-bochum.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/italy/hiv-environment-in-italy/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/case-studies/italy/hiv-environment-in-italy.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/spain/hiv-environment-in-spain/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/case-studies/spain/hiv-environment-in-spain.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/switzerland/hiv-environment-in-switzerland/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/case-studies/switzerland/hiv-environment-in-switzerland.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/uk/hiv-environment-in-london/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/case-studies/uk/hiv-environment-in-london.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/uruguay/hiv-environment-in-montevideo/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/case-studies/uruguay/hiv-environment-in-montevideo.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/dolutegravir-expanded-access-program/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/dolutegravir-expanded-access-program.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/hiv-health-outcomes/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/hiv-health-outcomes.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/implementation-science/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/implementation-science.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/paediatric-hiv-care/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/content/cf-viiv/viiv-healthcare/en_GB/home/mapping-an-hiv-free-future/paediatric-hiv-care"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/policy-papers/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/policy-papers.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/we-improve-access-to-our-medicines/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/we-improve-access-to-our-medicines.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/working-towards-90-90-90/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/working-towards-90-90-90.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/working-towards-90-90-90/fast-track-cities/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/working-towards-90-90-90/fast-track-cities.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/working-towards-90-90-90/positive-partnerships/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/working-towards-90-90-90/positive-partnerships.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/working-towards-90-90-90/positive-pathways/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/working-towards-90-90-90/positive-pathways.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/oonagh-makes-a-difference-for-people-affected-by-hiv-through-positive-action-programmes/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/oonagh-makes-a-difference-for-people-affected-by-hiv-through-positive-action-programmes.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2009/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2009.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2009/april/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2009/april.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2009/april/glaxosmithkline-and-pfizer-announce-innovative-agreement-to-create-a-new-world-leading-specialist-hiv-company/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2009/april/glaxosmithkline-and-pfizer-announce-innovative-agreement-to-create-a-new-world-leading-specialist-hiv-company.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2009/november/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2009/november.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2009/november/fda-approves-expanded-use-of-selzentry-for-appropriate-patients-starting-hiv-antiretroviral-therapy-for-the-first-time/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2009/november/fda-approves-expanded-use-of-selzentry-for-appropriate-patients-starting-hiv-antiretroviral-therapy-for-the-first-time.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2009/november/viiv-healthcare-launches/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2009/november/viiv-healthcare-launches.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/december/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/december.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/december/global-agenda-for-elimination-of-mother-to-child-transmission-of-hiv-positive-action-for-children-fund-calls-for-proposals-to-fill-the-gaps/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/december/global-agenda-for-elimination-of-mother-to-child-transmission-of-hiv-positive-action-for-children-fund-calls-for-proposals-to-fill-the-gaps.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/july/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/july.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/july/positive-phase-iib-data-on-investigational-once-daily-integrase-inhibitor-572-presented-at-international-aids-conference/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/july/positive-phase-iib-data-on-investigational-once-daily-integrase-inhibitor-572-presented-at-international-aids-conference.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/july/shionogi-viiv-healthcare-announces-commitment-to-phase-iii-development-programme-for-investigational-once-daily-hiv-integrase-inhibitor/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/july/shionogi-viiv-healthcare-announces-commitment-to-phase-iii-development-programme-for-investigational-once-daily-hiv-integrase-inhibitor.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/july/viiv-healthcare-announces-further-initiatives-to-improve-access-to-hiv-medications-for-people-living-in-the-least-developed-countries/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/july/viiv-healthcare-announces-further-initiatives-to-improve-access-to-hiv-medications-for-people-living-in-the-least-developed-countries.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/july/viiv-healthcare-announces-positive-action-us-southern-initiative-an-innovative-community-support-program-to-fight-hivaids/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/july/viiv-healthcare-announces-positive-action-us-southern-initiative-an-innovative-community-support-program-to-fight-hivaids.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/june/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/june.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/june/viiv-healthcare-and-amfar-partner-to-optimize-hiv-treatment-for-infants-and-children-in-asia/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/june/viiv-healthcare-and-amfar-partner-to-optimize-hiv-treatment-for-infants-and-children-in-asia.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/june/viiv-healthcare-and-elizabeth-glaser-pediatric-aids-foundation-partner-to-expedite-access-to-arv-treatment-for-infants-and-children/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/june/viiv-healthcare-and-elizabeth-glaser-pediatric-aids-foundation-partner-to-expedite-access-to-arv-treatment-for-infants-and-children.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/june/viiv-healthcare-awards-grants-from-the-positive-action-for-children-fund-of-36m/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/june/viiv-healthcare-awards-grants-from-the-positive-action-for-children-fund-of-36m.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/march/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/march.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/march/viiv-healthcare-calls-for-initial-grant-proposals-to-the-positive-action-for-children-fund/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/march/viiv-healthcare-calls-for-initial-grant-proposals-to-the-positive-action-for-children-fund.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/october/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/october.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/october/shionogi-viiv-healthcare-llc-initiates-phase-iii-clinical-programme-for-investigational-once-daily-hiv-integrase-inhibitor/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/october/shionogi-viiv-healthcare-llc-initiates-phase-iii-clinical-programme-for-investigational-once-daily-hiv-integrase-inhibitor.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/october/viiv-healthcare-acts-to-improve-access-to-hiv-medicines-in-united-states-for-those-most-in-need/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/october/viiv-healthcare-acts-to-improve-access-to-hiv-medicines-in-united-states-for-those-most-in-need.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/september/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/september.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/september/viiv-healthcare-awards-southern-initiative-grants-to-reduce-hiv-disparities-among-african-americans-and-latinos/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/september/viiv-healthcare-awards-southern-initiative-grants-to-reduce-hiv-disparities-among-african-americans-and-latinos.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/april/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/april.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/april/viiv-healthcare-expands-positive-action-us-southern-initiative-to-fight-hivaids-in-hard-hit-region/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/april/viiv-healthcare-expands-positive-action-us-southern-initiative-to-fight-hivaids-in-hard-hit-region.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/february/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/february.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/february/david-redfern-appointed-as-chairman-of-the-board-for-viiv-healthcare/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/february/david-redfern-appointed-as-chairman-of-the-board-for-viiv-healthcare.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/february/positive-action-and-vida-digna-further-information/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/february/positive-action-and-vida-digna-further-information.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/february/viiv-healthcare-s-positive-action-and-the-international-hivaids-alliance-tackle-hiv-stigma-in-six-central-american-countries/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/february/viiv-healthcare-s-positive-action-and-the-international-hivaids-alliance-tackle-hiv-stigma-in-six-central-american-countries.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/june/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/june.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/june/viiv-healthcare-awards-small-grants-from-positive-action-for-children-fund-to-82-charitable-organisations-globally/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/june/viiv-healthcare-awards-small-grants-from-positive-action-for-children-fund-to-82-charitable-organisations-globally.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/march/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/march.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/march/regulatory-update-celsentriselzentry-maraviroc/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/march/regulatory-update-celsentriselzentry-maraviroc.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/october/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/october.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/october/media-alert-viiv-healthcare-s-positive-action-for-children-fund-announces-16-new-grantees-for-the-year-20112012/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/october/media-alert-viiv-healthcare-s-positive-action-for-children-fund-announces-16-new-grantees-for-the-year-20112012.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/october/viiv-healthcare-starts-phase-iii-programme-of-celsentri-selzentry-versus-truvada-in-combination-with-a-protease-inhibitor-in-people-living-with-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/october/viiv-healthcare-starts-phase-iii-programme-of-celsentri-selzentry-versus-truvada-in-combination-with-a-protease-inhibitor-in-people-living-with-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/september/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/september.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/september/regulatory-update-celsentriselzentry-maraviroc/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/september/regulatory-update-celsentriselzentry-maraviroc.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/september/viiv-healthcare-reaffirms-commitment-to-us-regions-hardest-hit-by-hivaids/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/september/viiv-healthcare-reaffirms-commitment-to-us-regions-hardest-hit-by-hivaids.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/april/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/april.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/april/shionogi-viiv-healthcare-announces-initial-data-from-pivotal-phase-iii-study-of-dolutegravir-in-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/april/shionogi-viiv-healthcare-announces-initial-data-from-pivotal-phase-iii-study-of-dolutegravir-in-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/december/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/december.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/december/viiv-healthcare-announces-regulatory-submissions-for-dolutegravir-in-the-eu-us-and-canada/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/december/viiv-healthcare-announces-regulatory-submissions-for-dolutegravir-in-the-eu-us-and-canada.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/july/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/july.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/july/once-daily-dolutegravir-is-non-inferior-to-twice-daily-raltegravir-in-treatment-na%c3%afve-adults-with-hiv-1/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/july/once-daily-dolutegravir-is-non-inferior-to-twice-daily-raltegravir-in-treatment-na%C3%AFve-adults-with-hiv-1.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/july/shionogi-viiv-healthcare-announces-positive-initial-data-from-phase-iii-study-of-dolutegravir-based-regimen-vs-atripla-in-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/july/shionogi-viiv-healthcare-announces-positive-initial-data-from-phase-iii-study-of-dolutegravir-based-regimen-vs-atripla-in-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/july/viiv-healthcare-expands-commitment-to-addressing-gaps-in-paediatric-hiv-research-care-and-treatment/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/july/viiv-healthcare-expands-commitment-to-addressing-gaps-in-paediatric-hiv-research-care-and-treatment.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/july/viiv-healthcare-expands-support-for-hiv-prevention-and-education-in-hard-hit-us-region/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/july/viiv-healthcare-expands-support-for-hiv-prevention-and-education-in-hard-hit-us-region.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/november/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/november.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/november/viiv-healthcare-commits-nearly-4m-in-positive-action-for-children-fund-grants-for-programmes-focused-on-alleviating-burden-of-hiv-on-women-and-children/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/november/viiv-healthcare-commits-nearly-4m-in-positive-action-for-children-fund-grants-for-programmes-focused-on-alleviating-burden-of-hiv-on-women-and-children.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/november/viiv-healthcare-presents-phase-iii-data-from-viking-3-study-of-dolutegravir-in-hiv-1-infected-integrase-inhibitor-resistant-adults/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/november/viiv-healthcare-presents-phase-iii-data-from-viking-3-study-of-dolutegravir-in-hiv-1-infected-integrase-inhibitor-resistant-adults.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/october/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/october.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/october/shionogi-and-viiv-healthcare-announce-new-agreement-to-commercialise-and-develop-integrase-inhibitor-portfolio/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/october/shionogi-and-viiv-healthcare-announce-new-agreement-to-commercialise-and-develop-integrase-inhibitor-portfolio.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/october/shionogi-viiv-healthcare-announces-completion-of-initial-clinical-registration-package-for-dolutegravir-in-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/october/shionogi-viiv-healthcare-announces-completion-of-initial-clinical-registration-package-for-dolutegravir-in-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/august/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/august.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/august/viiv-healthcare-announces-us-approval-of-tivicay-dolutegravir-for-the-treatment-of-hiv-1/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/august/viiv-healthcare-announces-us-approval-of-tivicay-dolutegravir-for-the-treatment-of-hiv-1.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/december/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/december.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/december/update-on-patent-ruling-on-viiv-healthcare-s-epzicom-and-trizivir/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/december/update-on-patent-ruling-on-viiv-healthcare-s-epzicom-and-trizivir.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/december/viiv-healthcare-commits-34m-in-positive-action-for-children-fund-grants-for-programmes-focused-on-prevention-of-mother-to-child-transmission-of-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/december/viiv-healthcare-commits-34m-in-positive-action-for-children-fund-grants-for-programmes-focused-on-prevention-of-mother-to-child-transmission-of-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/february/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/february.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/february/viiv-healthcare-announces-a-voluntary-licence-agreement-with-the-medicines-patent-pool-to-increase-access-to-hiv-medicines-for-children/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/february/viiv-healthcare-announces-a-voluntary-licence-agreement-with-the-medicines-patent-pool-to-increase-access-to-hiv-medicines-for-children.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/february/viiv-healthcare-announces-fda-priority-review-designation-for-dolutegravir-as-a-potential-treatment-for-hiv-infection/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/february/viiv-healthcare-announces-fda-priority-review-designation-for-dolutegravir-as-a-potential-treatment-for-hiv-infection.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/february/viiv-healthcare-expands-positive-action-southern-initiative-to-fight-hivaids-and-support-community-action/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/february/viiv-healthcare-expands-positive-action-southern-initiative-to-fight-hivaids-and-support-community-action.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/february0/viiv-healthcare-expands-positive-action-southern-initiative-to-f/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/february0/viiv-healthcare-expands-positive-action-southern-initiative-to-f.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/march/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/march.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/march/viiv-healthcare-presents-data-from-phase-iii-study-of-dolutegravir-vs-raltegravir-in-treatment-experienced-adults-with-hiv-1/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/march/viiv-healthcare-presents-data-from-phase-iii-study-of-dolutegravir-vs-raltegravir-in-treatment-experienced-adults-with-hiv-1.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/november/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/november.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/october/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/october.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/october/viiv-healthcare-announces-european-regulatory-submission-for-single-tablet-regimen/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/october/viiv-healthcare-announces-european-regulatory-submission-for-single-tablet-regimen.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/october/viiv-healthcare-announces-us-regulatory-submission-for-a-single-tablet-regimen-combining-dolutegravir-with-abacavir-and-lamivudine-for-people-living-with-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/october/viiv-healthcare-announces-us-regulatory-submission-for-a-single-tablet-regimen-combining-dolutegravir-with-abacavir-and-lamivudine-for-people-living-with-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/september/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/september.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/september/viiv-healthcare-expands-hivaids-community-support-in-hard-hit-southern-us/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/september/viiv-healthcare-expands-hivaids-community-support-in-hard-hit-southern-us.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/september/viiv-healthcare-presents-positive-data-from-phase-iiibiv-study-of-dolutegravir-vs-darunavir-in-treatment-na%c3%afve-adults-with-hiv-1/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/september/viiv-healthcare-presents-positive-data-from-phase-iiibiv-study-of-dolutegravir-vs-darunavir-in-treatment-na%C3%AFve-adults-with-hiv-1.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/april/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/april.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/april/viiv-healthcare-announces-new-initiatives-to-improve-access-to-dolutegravir-licence-to-the-medicines-patent-pool/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/april/viiv-healthcare-announces-new-initiatives-to-improve-access-to-dolutegravir-licence-to-the-medicines-patent-pool.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/august/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/august.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/august/viiv-healthcare-receives-fda-approval-for-triumeq/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/august/viiv-healthcare-receives-fda-approval-for-triumeq.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/december/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/december.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/december/mylans-tentative-fda-approval-for-paeds-formulations-of-abacavirlamivudine-through-innovative-collaboration-with-viiv-healthcare-and-chai/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/december/mylans-tentative-fda-approval-for-paeds-formulations-of-abacavirlamivudine-through-innovative-collaboration-with-viiv-healthcare-and-chai.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/december/viiv-healthcare-announces-regulatory-submission-in-japan-for-single-pill-regimen-combining-dolutegravir-abacavir-and-lamivudine-for-the-treatment-of-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/december/viiv-healthcare-announces-regulatory-submission-in-japan-for-single-pill-regimen-combining-dolutegravir-abacavir-and-lamivudine-for-the-treatment-of-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/january/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/january.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/january/viiv-healthcare-s-new-hiv-medicine-tivicay-dolutegravir-is-approved-in-europe/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/january/viiv-healthcare-s-new-hiv-medicine-tivicay-dolutegravir-is-approved-in-europe.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/january/viiv-healthcare-to-make-available-anonymised-patient-level-data-from-its-clinical-trials/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/january/viiv-healthcare-to-make-available-anonymised-patient-level-data-from-its-clinical-trials.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/july/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/july.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/july/viiv-healthcare-presents-phase-iii-data-comparing-once-daily-maraviroc/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/july/viiv-healthcare-presents-phase-iii-data-comparing-once-daily-maraviroc.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/june/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/june.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/june/viiv-healthcare-announces-new-collaboration-with-janssen/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/june/viiv-healthcare-announces-new-collaboration-with-janssen.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/march/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/march.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/march/viiv-healthcare-announces-next-round-of-the-positive-action-southern-initiative-to-support-linkages-to-hivaids-care-and-treatment-adherence/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/march/viiv-healthcare-announces-next-round-of-the-positive-action-southern-initiative-to-support-linkages-to-hivaids-care-and-treatment-adherence.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/november/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/november.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/november/gsk-ranked-top-of-the-2014-access-to-medicines-atm-index-for-the-fourth-consecutive-time/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/november/gsk-ranked-top-of-the-2014-access-to-medicines-atm-index-for-the-fourth-consecutive-time.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/november/hiv-testing-week/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/november/hiv-testing-week.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/november/viiv-healthcare-announces-new-grants-in-support-of-ending-mother-to-child-transmission-of-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/november/viiv-healthcare-announces-new-grants-in-support-of-ending-mother-to-child-transmission-of-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/october/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/october.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/october/viiv-healthcare-expands-program-to-reduce-hiv-disparities-in-southern-us/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/october/viiv-healthcare-expands-program-to-reduce-hiv-disparities-in-southern-us.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/december/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/december.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/december/viiv-healthcare-to-acquire-bristol-myers-squibb-hiv-rd-assets/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/december/viiv-healthcare-to-acquire-bristol-myers-squibb-hiv-rd-assets.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/february/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/february.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/february/viiv-healthcare-announces-10-million-initiative-to-accelerate-response-to-hivaids-among-black-gay-and-bisexual-men/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/february/viiv-healthcare-announces-10-million-initiative-to-accelerate-response-to-hivaids-among-black-gay-and-bisexual-men.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/july/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/july.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/july/viiv-healthcare-and-desano-pharmaceuticals-manufacturing-agreement-will-allow-competitive-supply-of-dolutegravir-in-china-and-several-developing-countries/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/july/viiv-healthcare-and-desano-pharmaceuticals-manufacturing-agreement-will-allow-competitive-supply-of-dolutegravir-in-china-and-several-developing-countries.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/june/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/june.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/june/viiv-healthcare-announces-new-positive-action-project-in-us-for-msm-youth-calls-for-proposals/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/june/viiv-healthcare-announces-new-positive-action-project-in-us-for-msm-youth-calls-for-proposals.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/march/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/march.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/march/viiv-healthcare-announces-the-approval-in-japan-of-triumeq-dolutegravir-abacavir-and-lamivudine-a-new-single-pill-regimen-for-the-treatment-of-hiv-infection/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/march/viiv-healthcare-announces-the-approval-in-japan-of-triumeq-dolutegravir-abacavir-and-lamivudine-a-new-single-pill-regimen-for-the-treatment-of-hiv-infection.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/march/viiv-healthcare-launches-new-global-positive-action-programme-focused-on-msm-and-transgender-populations/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/march/viiv-healthcare-launches-new-global-positive-action-programme-focused-on-msm-and-transgender-populations.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/may/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/may.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/may/european-patient-advocacy-groups-awarded-grants-from-positive-action-europe/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/may/european-patient-advocacy-groups-awarded-grants-from-positive-action-europe.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/may/press-release/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/may/press-release.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/may/viiv-healthcare-begins-phase-iii-programme-with-dolutegravirrilpivirine-combination-for-hiv-maintenance-therapy/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/may/viiv-healthcare-begins-phase-iii-programme-with-dolutegravirrilpivirine-combination-for-hiv-maintenance-therapy.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/november/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/november.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/november/viiv-healthcare-announces-positive-headline-results-from-a-study-of-two-drug-injectable-regimen-for-hiv-maintenance-therapy/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/november/viiv-healthcare-announces-positive-headline-results-from-a-study-of-two-drug-injectable-regimen-for-hiv-maintenance-therapy.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/november/viiv-healthcare-at-icasa-improving-access-to-hiv-treatment-and-care-for-people-everywhere/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/november/viiv-healthcare-at-icasa-improving-access-to-hiv-treatment-and-care-for-people-everywhere.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/november/viiv-healthcare-awards-additional-round-of-grants-to-support-innovative-hiv-programs-aimed-at-reducing-disparities-in-the-southern-us/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/november/viiv-healthcare-awards-additional-round-of-grants-to-support-innovative-hiv-programs-aimed-at-reducing-disparities-in-the-southern-us.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/november/viiv-healthcare-gets-ready-for-africa-s-largest-hiv-aids-conference/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/november/viiv-healthcare-gets-ready-for-africa-s-largest-hiv-aids-conference.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/november/viiv-healthcare-highlights-its-continued-commitment-to-end-mother-to-child-transmission-of-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/november/viiv-healthcare-highlights-its-continued-commitment-to-end-mother-to-child-transmission-of-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/october/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/october.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/october/viiv-healthcare-awards-23-small-grants-to-help-alleviate-the-stigma-of-hiv-and-aids-in-the-msm-and-transgender-community-globally/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/october/viiv-healthcare-awards-23-small-grants-to-help-alleviate-the-stigma-of-hiv-and-aids-in-the-msm-and-transgender-community-globally.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/october/viiv-healthcare-employee-named-top-marketer-in-healthcare-industry-by-medical-marketing-media/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/october/viiv-healthcare-employee-named-top-marketer-in-healthcare-industry-by-medical-marketing-media.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/september/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/september.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/september/new-phase-iiibiv-data-show-switching-to-once-daily-triumeq-maintains-hiv-viral-suppression/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/september/new-phase-iiibiv-data-show-switching-to-once-daily-triumeq-maintains-hiv-viral-suppression.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/april/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/april.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/april/global-partnership-launches-new-programme-with-goal-to-save-the-lives-of-thousands-of-children-affected-by-hiv-in-lesotho/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/april/global-partnership-launches-new-programme-with-goal-to-save-the-lives-of-thousands-of-children-affected-by-hiv-in-lesotho.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/april/viiv-healthcare-extends-medicines-patent-pool-licence-agreement-for-dolutegravir-to-cover-all-lower-middle-income-countries/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/april/viiv-healthcare-extends-medicines-patent-pool-licence-agreement-for-dolutegravir-to-cover-all-lower-middle-income-countries.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/august/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/august.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/august/viiv-healthcare-launches-phase-iii-programme-evaluating-a-two-drug-regimen-combining-dolutegravir-and-lamivudine-for-hiv-1-treatment/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/august/viiv-healthcare-launches-phase-iii-programme-evaluating-a-two-drug-regimen-combining-dolutegravir-and-lamivudine-for-hiv-1-treatment.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/december/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/december.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/december/dominique-limet-to-step-down-as-ceo-of-viiv-healthcare-deborah-waterhouse-to-succeed-him/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/december/dominique-limet-to-step-down-as-ceo-of-viiv-healthcare-deborah-waterhouse-to-succeed-him.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/december/new-agreement-with-ministry-of-health-will-enable-access-to-dolutegravir-for-the-treatment-of-hiv-under-the-national-health-programme-in-brazil/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/december/new-agreement-with-ministry-of-health-will-enable-access-to-dolutegravir-for-the-treatment-of-hiv-under-the-national-health-programme-in-brazil.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/december/viiv-healthcare-announces-chmp-positive-opinion-to-lower-the-age-and-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv-in-europe/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/december/viiv-healthcare-announces-chmp-positive-opinion-to-lower-the-age-and-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv-in-europe.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/december/viiv-healthcare-announces-positive-results-from-first-phase-iii-studies-of-two-drug-hiv-treatment-regimen/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/december/viiv-healthcare-announces-positive-results-from-first-phase-iii-studies-of-two-drug-hiv-treatment-regimen.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/december/viiv-healthcare-announces-start-of-phase-iii-study-evaluating-long-acting-cabotegravir-for-hiv-prevention/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/december/viiv-healthcare-announces-start-of-phase-iii-study-evaluating-long-acting-cabotegravir-for-hiv-prevention.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/february/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/february.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/february/viiv-healthcare-announces-first-phase-ii-hiv-prevention-study-results-for-investigational-long-acting-injectable-cabotegravir/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/february/viiv-healthcare-announces-first-phase-ii-hiv-prevention-study-results-for-investigational-long-acting-injectable-cabotegravir.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/february/viiv-healthcare-announces-phase-ii-study-results-for-first-two-drug-long-acting-injectable-regimen-for-hiv-1-treatment/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/february/viiv-healthcare-announces-phase-ii-study-results-for-first-two-drug-long-acting-injectable-regimen-for-hiv-1-treatment.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/january/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/january.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/january/viiv-healthcare-to-progress-collaboration-with-janssen-to-develop-the-first-long-acting-two-drug-injectable-regimen-for-treatment-of-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/january/viiv-healthcare-to-progress-collaboration-with-janssen-to-develop-the-first-long-acting-two-drug-injectable-regimen-for-treatment-of-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/july/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/july.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/july/aria-study-shows-superior-efficacy-of-triumeq-for-treatment-na%c3%afve-women-living-with-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/july/aria-study-shows-superior-efficacy-of-triumeq-for-treatment-na%C3%AFve-women-living-with-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/june/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/june.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/june/viiv-healthcare-announces-fda-approval-to-lower-the-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/june/viiv-healthcare-announces-fda-approval-to-lower-the-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/june/viiv-healthcare-announces-public-tender-agreement-with-botswana-ministry-of-health-for-dolutegravir/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/june/viiv-healthcare-announces-public-tender-agreement-with-botswana-ministry-of-health-for-dolutegravir.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/june/viiv-healthcare-joins-penta-foundation-in-search-for-strategies-to-achieve-remission-in-children-living-with-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/june/viiv-healthcare-joins-penta-foundation-in-search-for-strategies-to-achieve-remission-in-children-living-with-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/may/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/may.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/may/viiv-healthcare-and-the-international-association-of-providers-of-aids-care-to-collaborate-on-fast-track-cities/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/may/viiv-healthcare-and-the-international-association-of-providers-of-aids-care-to-collaborate-on-fast-track-cities.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/november/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/november.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/november/viiv-healthcare-launches-phase-iii-programme-to-evaluate-a-long-acting-injectable-hiv-treatment-regimen/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/november/viiv-healthcare-launches-phase-iii-programme-to-evaluate-a-long-acting-injectable-hiv-treatment-regimen.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/october/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/october.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/october/viiv-healthcare-announces-fda-approval-of-selzentry-maraviroc-for-use-in-children-and-adolescents-living-with-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/october/viiv-healthcare-announces-fda-approval-of-selzentry-maraviroc-for-use-in-children-and-adolescents-living-with-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/october/viiv-healthcare-s-positive-action-europe-invites-applications-for-2017-grants-scheme/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/october/viiv-healthcare-s-positive-action-europe-invites-applications-for-2017-grants-scheme.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/september/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/september.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/september/every-woman-every-child-and-viiv-healthcare-announce-the-winner-of-empowering-girls-in-emergency-settings-challenge-prize/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/september/every-woman-every-child-and-viiv-healthcare-announce-the-winner-of-empowering-girls-in-emergency-settings-challenge-prize.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/september/new-hiv-awareness-in-primary-care-campaign-launched-to-increase-primary-care-hiv-testing/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/september/new-hiv-awareness-in-primary-care-campaign-launched-to-increase-primary-care-hiv-testing.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/september/viiv-healthcare-welcomes-the-fda-s-tentative-approval-of-the-first-generic-dolutegravir-from-aurobindo-pharma/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/september/viiv-healthcare-welcomes-the-fda-s-tentative-approval-of-the-first-generic-dolutegravir-from-aurobindo-pharma.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/february/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/february.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/february/viiv-healthcare-announces-detailed-positive-phase-iii-results-for-investigational-two-drug-regimen-of-dolutegravir-and-rilpivirine-for-hiv-treatment/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/february/viiv-healthcare-announces-detailed-positive-phase-iii-results-for-investigational-two-drug-regimen-of-dolutegravir-and-rilpivirine-for-hiv-treatment.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/february/viiv-healthcare-welcomes-european-commission-approval-of-dolutegravir-paediatric-type-ii-variation-and-extension-applications/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/february/viiv-healthcare-welcomes-european-commission-approval-of-dolutegravir-paediatric-type-ii-variation-and-extension-applications.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/honoring-the-memory-of-dr-mark-wainberg/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/honoring-the-memory-of-dr-mark-wainberg.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/january/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/january.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/january/viiv-healthcare-awards-grants-to-msm-and-transgender-hiv-programmes-led-by-the-community-for-the-community/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/january/viiv-healthcare-awards-grants-to-msm-and-transgender-hiv-programmes-led-by-the-community-for-the-community.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/january/viiv-healthcare-re-affirms-its-continued-commitment-to-ending-mother-to-child-transmission-of-hiv-with-35-new-community-grants/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/january/viiv-healthcare-re-affirms-its-continued-commitment-to-ending-mother-to-child-transmission-of-hiv-with-35-new-community-grants.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/july/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/july.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/july/phase-ii-study-results-showed-comparable-viral-suppression-rates-at-96-weeks-for-a-two-drug-regimen/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/july/phase-ii-study-results-showed-comparable-viral-suppression-rates-at-96-weeks-for-a-two-drug-regimen.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/july/viiv-healthcare-and-neat-id-announce-results-from-the-neat-022-study-at-the-international-aids-society-meeting-in-paris/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/july/viiv-healthcare-and-neat-id-announce-results-from-the-neat-022-study-at-the-international-aids-society-meeting-in-paris.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/july/viiv-healthcare-announces-superior-efficacy-of-dolutegravir-versus-lopinavirritonavir-in-second-line-hiv-treatment-in-resource-limited-settings/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/july/viiv-healthcare-announces-superior-efficacy-of-dolutegravir-versus-lopinavirritonavir-in-second-line-hiv-treatment-in-resource-limited-settings.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/july/viiv-healthcare-shares-data-from-its-innovative-portfolio-with-hiv-community-at-ias-2017/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/july/viiv-healthcare-shares-data-from-its-innovative-portfolio-with-hiv-community-at-ias-2017.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/june/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/june.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/june/viiv-healthcare-s-positive-action-europe-programme-awards-grants-to-14-community-based-organisations/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/june/viiv-healthcare-s-positive-action-europe-programme-awards-grants-to-14-community-based-organisations.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/june/viiv-healthcare-submits-regulatory-applications-for-the-first-hiv-maintenance-regimen-comprising-only-two-medicines/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/june/viiv-healthcare-submits-regulatory-applications-for-the-first-hiv-maintenance-regimen-comprising-only-two-medicines.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/march/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/march.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/march/viiv-healthcare-ranks-1-in-patientview-corporate-reputation-surv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/march/viiv-healthcare-ranks-1-in-patientview-corporate-reputation-surv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/march/viiv-healthcare-ranks-1-in-patientview-corporate-reputation-survey/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/march/viiv-healthcare-ranks-1-in-patientview-corporate-reputation-survey.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/november/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/november.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/november/viiv-healthcare-announces-start-of-phase-iii-study-of-long-actin/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/november/viiv-healthcare-announces-start-of-phase-iii-study-of-long-actin.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/november/viiv-healthcare-announces-start-of-phase-iii-study-of-long-acting-cabotegravir-for-hiv-prevention-in-women/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/november/viiv-healthcare-announces-start-of-phase-iii-study-of-long-acting-cabotegravir-for-hiv-prevention-in-women.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/november/viiv-healthcare-announces-us-fda-approval-for-juluca/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/november/viiv-healthcare-announces-us-fda-approval-for-juluca.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/november/viiv-healthcare-starts-third-phase-iii-hiv-treatment-study-investigating-long-acting-two-drug-regimen-of-cabotegravir-plus-rilpivirine/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/november/viiv-healthcare-starts-third-phase-iii-hiv-treatment-study-investigating-long-acting-two-drug-regimen-of-cabotegravir-plus-rilpivirine.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/october/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/october.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/october/new-results-from-the-positive-perspectives-global-survey-provide-insights-into-the-attitudes-and-perceptions-of-people-living-with-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/october/new-results-from-the-positive-perspectives-global-survey-provide-insights-into-the-attitudes-and-perceptions-of-people-living-with-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/october/tivicay-and-celsentri-now-included-in-the-essential-drug-list-in-russia/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/october/tivicay-and-celsentri-now-included-in-the-essential-drug-list-in-russia.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/october/viiv-healthcare-announces-positive-phase-3-results-from-the-brig/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/october/viiv-healthcare-announces-positive-phase-3-results-from-the-brig.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/october/viiv-healthcare-announces-positive-phase-3-results-from-the-brighte-study-of-fostemsavir-in-heavily-treatment-experienced-patients-with-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/october/viiv-healthcare-announces-positive-phase-3-results-from-the-brighte-study-of-fostemsavir-in-heavily-treatment-experienced-patients-with-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/december/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/december.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/december/viiv-healthcare-update-on-commitments-regarding-the-clinical-development-and-registration-of-age-appropriate-formulations-of-dolutegravir-for-the-treatment-of-hiv-in-infant-and-children/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/december/viiv-healthcare-update-on-commitments-regarding-the-clinical-development-and-registration-of-age-appropriate-formulations-of-dolutegravir-for-the-treatment-of-hiv-in-infant-and-children.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/february/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/february.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/february/viiv-healthcare-files-patent-infringement-litigation-against-gilead-sciences-inc-over-bictegravir/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/february/viiv-healthcare-files-patent-infringement-litigation-against-gilead-sciences-inc-over-bictegravir.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/february/viiv-healthcare-launches-eighth-phase-iii-study-in-two-drug-regi/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/february/viiv-healthcare-launches-eighth-phase-iii-study-in-two-drug-regi.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/february/viiv-healthcare-launches-eighth-phase-iii-study-in-two-drug-regimen-programme-for-hiv-1-treatment/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/february/viiv-healthcare-launches-eighth-phase-iii-study-in-two-drug-regimen-programme-for-hiv-1-treatment.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/july/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/july.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/july/innovative-public-private-partnership-initiative-to-accelerate-development-of-optimal-pediatric-formulations-of-dolutegravir-to-improve-the-lives-of-clhiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/july/innovative-public-private-partnership-initiative-to-accelerate-development-of-optimal-pediatric-formulations-of-dolutegravir-to-improve-the-lives-of-clhiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/july/viiv-healthcare-announces-sword-100-week-data-for-juluca-dolutegravirrilpivirine-at-aids-2018/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/july/viiv-healthcare-announces-sword-100-week-data-for-juluca-dolutegravirrilpivirine-at-aids-2018.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/july/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen-has-similar-efficacy-to-a-three-drug-regimen-in-treatment-naive-hiv-patients-with-no-resistance/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/july/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen-has-similar-efficacy-to-a-three-drug-regimen-in-treatment-naive-hiv-patients-with-no-resistance.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/july/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/july/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/july/viiv-healthcare-s-commitments-to-accelerate-the-availability-of-dolutegravir-for-the-treatment-of-hiv-in-children/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/july/viiv-healthcare-s-commitments-to-accelerate-the-availability-of-dolutegravir-for-the-treatment-of-hiv-in-children.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/july/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-at-aids-2018/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/july/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-at-aids-2018.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/june/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/june.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/june/viiv-healthcare-reports-positive-results-for-landmark-phase-iii-/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/june/viiv-healthcare-reports-positive-results-for-landmark-phase-iii-.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/june/viiv-healthcare-reports-positive-results-for-landmark-phase-iii-studies-for-dolutegravir-and-lamivudine/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/june/viiv-healthcare-reports-positive-results-for-landmark-phase-iii-studies-for-dolutegravir-and-lamivudine.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/march/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/march.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/march/viiv-healthcare-announces-positive-new-dolutegravir-data-for-the-treatment-of-people-living-with-hiv-co-infected-with-tuberculosis/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/march/viiv-healthcare-announces-positive-new-dolutegravir-data-for-the-treatment-of-people-living-with-hiv-co-infected-with-tuberculosis.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/march/viiv-healthcare-gains-chmp-positive-opinion-for-juluca-dolutegra/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/march/viiv-healthcare-gains-chmp-positive-opinion-for-juluca-dolutegra.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/march/viiv-healthcare-gains-chmp-positive-opinion-for-juluca-dolutegravirrilpivirine-in-europe/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/march/viiv-healthcare-gains-chmp-positive-opinion-for-juluca-dolutegravirrilpivirine-in-europe.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/may/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/may.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/may/viiv-healthcare-receives-eu-marketing-authorisation-for-juluca-dolutegravirrilpivirine-the-first-2-drug-regimen-once-daily-single-pill-for-the-treatment-of-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/may/viiv-healthcare-receives-eu-marketing-authorisation-for-juluca-dolutegravirrilpivirine-the-first-2-drug-regimen-once-daily-single-pill-for-the-treatment-of-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/may/viiv-healthcare-reports-positive-results-for-landmark-phase-iii-/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/may/viiv-healthcare-reports-positive-results-for-landmark-phase-iii-.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/november/fast-track-cities-survey-data-provide-insights-into-quality-of-life-of-people-living-with-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/november/fast-track-cities-survey-data-provide-insights-into-quality-of-life-of-people-living-with-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/october/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/october.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/viiv-healthcare-reports-positive-48-week-results-for-first-pivot/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/viiv-healthcare-reports-positive-48-week-results-for-first-pivot.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/viiv-healthcare-reports-positive-48-week-results-for-first-pivotal-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/viiv-healthcare-reports-positive-48-week-results-for-first-pivotal-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/viiv-healthcare-submits-regulatory-application-to-european-medicines-agency-for-single-tablet-two-drug-regimen-of-dolutegravir-and-lamivudine-for-treatment-of-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/viiv-healthcare-submits-regulatory-application-to-european-medicines-agency-for-single-tablet-two-drug-regimen-of-dolutegravir-and-lamivudine-for-treatment-of-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/viiv-healthcare-update-on-how-we-work-with-healthcare-professionals/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/viiv-healthcare-update-on-how-we-work-with-healthcare-professionals.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/juluca-the-first-single-pill-2-drug-regimen-for-the-maintenance-treatment-of-hiv-granted-marketing-approval-by-japan-ministry-of-health-labour-and-welfare/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/juluca-the-first-single-pill-2-drug-regimen-for-the-maintenance-treatment-of-hiv-granted-marketing-approval-by-japan-ministry-of-health-labour-and-welfare.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-phase-3-results-from-the-brighte-study-of-fostemsavir-in-heavily-treatment-experienced-patients-with-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/viiv-healthcare-announces-positive-phase-3-results-from-the-brighte-study-of-fostemsavir-in-heavily-treatment-experienced-patients-with-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/viiv-healthcare-presents-three-year-data-for-investigational-lon/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/viiv-healthcare-presents-three-year-data-for-investigational-lon.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/viiv-healthcare-presents-three-year-data-for-investigational-long-acting-injectable-two-drug-hiv-regimen/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/viiv-healthcare-presents-three-year-data-for-investigational-long-acting-injectable-two-drug-hiv-regimen-1.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/viiv-healthcare-receives-chmp-positive-opinion-for-tivicay-eu-label-update-with-gemini-study-data-for-the-2-drug-regimen-of-tivicay-plus-lamivudine/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/viiv-healthcare-receives-chmp-positive-opinion-for-tivicay-eu-label-update-with-gemini-study-data-for-the-2-drug-regimen-of-tivicay-plus-lamivudine.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/viiv-healthcare-submits-new-drug-application-to-us-fda-for-single-tablet-two-drug-regimen-of-dolutegravir-and-lamivudine-for-treatment-of-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/viiv-healthcare-submits-new-drug-application-to-us-fda-for-single-tablet-two-drug-regimen-of-dolutegravir-and-lamivudine-for-treatment-of-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/viiv-healthcare-s-innovation-unit-offers-fresh-approach-to-solving-important-challenges-in-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/viiv-healthcare-s-innovation-unit-offers-fresh-approach-to-solving-important-challenges-in-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/viiv-healthcare-s-the-hive-and-positive-action-community-challenge-seek-outside-collaborations-in-order-to-innovate-for-people-living-with-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/viiv-healthcare-s-the-hive-and-positive-action-community-challenge-seek-outside-collaborations-in-order-to-innovate-for-people-living-with-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/medical-education-events/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/medical-education-events.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/combivir/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/combivir.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/epivir-3tc/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/epivir-3tc.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/epzicom-kivexa/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/epzicom-kivexa.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/juluca/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/juluca.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/lexiva-telzir/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/lexiva-telzir.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/medicines-in-development/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/medicines-in-development.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/report-a-side-effect/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/report-a-side-effect.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/rescriptor/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/rescriptor.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/retrovir-azt/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/retrovir-azt.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/selzentry-celsentri/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/selzentry-celsentri.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/tivicay/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/tivicay.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/triumeq/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/triumeq.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/trizivir/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/trizivir.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/viracept/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/viracept.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/ziagen/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/ziagen.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/accelerating-city-hivaids-responses-through-collaboration/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/accelerating-city-hivaids-responses-through-collaboration.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/addressing-the-challenges-of-the-hiv-epidemic-in-africa/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/addressing-the-challenges-of-the-hiv-epidemic-in-africa.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/championing-effective-hiv-care-for-plhiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/championing-effective-hiv-care-for-plhiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/driving-change-through-implementation-science/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/driving-change-through-implementation-science.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/fighting-hiv-together-collaboration-is-driving-progress-with-the-launch-of-new-fast-track-city-dashboards/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/fighting-hiv-together-collaboration-is-driving-progress-with-the-launch-of-new-fast-track-city-dashboards.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/helping-botswana-treat-all-people-living-with-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/helping-botswana-treat-all-people-living-with-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/hiv-is-a-global-issue-that-needs-an-ongoing-collaborative-response/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/hiv-is-a-global-issue-that-needs-an-ongoing-collaborative-response.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/how-the-unity-tool-can-help-conversations-between-plhiv-and-their-hcp/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/how-the-unity-tool-can-help-conversations-between-plhiv-and-their-hcp.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/metrics-matter-measuring-impact-in-hiv-implementation/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/metrics-matter-measuring-impact-in-hiv-implementation.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/overcoming-the-challenges-for-partners-of-people-living-with-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/overcoming-the-challenges-for-partners-of-people-living-with-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/positive-partnerships-initiative-launches-in-estonia/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/positive-partnerships-initiative-launches-in-estonia.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/preliminary-positive-perspectives-survey-data-released-at-9th-international-aids-society-conference/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/preliminary-positive-perspectives-survey-data-released-at-9th-international-aids-society-conference.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/striking-the-right-balance/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/striking-the-right-balance.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/the-state-of-hiv-implementation-science-do-we-need-more-science-or-more-implementation/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/the-state-of-hiv-implementation-science-do-we-need-more-science-or-more-implementation.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/towards-a-cure-exploring-cure-and-remission-in-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/towards-a-cure-exploring-cure-and-remission-in-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/understanding-the-concerns-of-people-living-with-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/understanding-the-concerns-of-people-living-with-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/viiv-healthcare-s-commitment-to-implementation-science/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/viiv-healthcare-s-commitment-to-implementation-science.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/viiv-healthcare-s-positive-partnerships-accelerates-progress-towards-90-90-90-goals-in-estonia/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/viiv-healthcare-s-positive-partnerships-accelerates-progress-towards-90-90-90-goals-in-estonia.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/a-look-back-at-aids-2016/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/a-look-back-at-aids-2016.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/accelerating-the-pace-of-innovation/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/accelerating-the-pace-of-innovation.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/addressing-hiv-in-adolescents/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/addressing-hiv-in-adolescents.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/advancing-hiv-science-through-collaboration/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/advancing-hiv-science-through-collaboration.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/collaboration-is-driving-progress-with-the-launch-of-new-fast-track-city-dashboards/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/collaboration-is-driving-progress-with-the-launch-of-new-fast-track-city-dashboards.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/croi-2017-what-s-in-store-for-viiv-healthcare-in-seattle/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/croi-2017-what-s-in-store-for-viiv-healthcare-in-seattle.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/facing-the-challenges-of-getting-old-with-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/facing-the-challenges-of-getting-old-with-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/fighting-hiv-together/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/fighting-hiv-together.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/find-out-about-industrial-placement-opportunities-at-viiv-healthcare/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/find-out-about-industrial-placement-opportunities-at-viiv-healthcare.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/hiv-research-a-panoramic-view-using-science-to-improve-lives-from-all-angles/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/hiv-research-a-panoramic-view-using-science-to-improve-lives-from-all-angles.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/how-our-innovation-unit-is-addressing-new-areas-of-need-in-hiv-care/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/how-our-innovation-unit-is-addressing-new-areas-of-need-in-hiv-care.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/how-viiv-healthcare-is-helping-to-accelerate-city-hivaids-responses-through-our-collaboration/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/how-viiv-healthcare-is-helping-to-accelerate-city-hivaids-responses-through-our-collaboration.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/how-we-re-addressing-the-challenges-of-the-hiv-epidemic-in-africa/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/how-we-re-addressing-the-challenges-of-the-hiv-epidemic-in-africa.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/improving-retention-of-breastfeeding-wlhiv-on-art-challenge-winner/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/improving-retention-of-breastfeeding-wlhiv-on-art-challenge-winner.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/industrial-placement-opportunities-at-viiv-healthcare/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/industrial-placement-opportunities-at-viiv-healthcare.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/inspiring-voices-in-hiv-lead-the-way-on-international-women-s-day/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/inspiring-voices-in-hiv-lead-the-way-on-international-women-s-day.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/new-online-platform-for-positive-action-challenges-launched/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/new-online-platform-for-positive-action-challenges-launched.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/positive-partnerships-da%c3%ad-galera-brazil/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/positive-partnerships-da%C3%AD-galera-brazil.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/positive-partnerships-hiv-digital-grand-final-estonia/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/positive-partnerships-hiv-digital-grand-final-estonia.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/positive-partnerships-initiative-launches-in-estonia/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/positive-partnerships-initiative-launches-in-estonia.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/preliminary-positive-perspectives-survey-data-released-at-9th-international-aids-society-conference/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/preliminary-positive-perspectives-survey-data-released-at-9th-international-aids-society-conference.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/pride-around-the-world/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/pride-around-the-world.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/putting-people-living-with-hiv-at-the-heart-of-everything-we-do/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/putting-people-living-with-hiv-at-the-heart-of-everything-we-do.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/qa-with-angelina-namiba-on-viiv-healthcare-s-skills-workshop/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/qa-with-angelina-namiba-on-viiv-healthcare-s-skills-workshop.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/qa-with-every-footstep-counts-judge-amaya-gillespie-from-unicef/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/qa-with-every-footstep-counts-judge-amaya-gillespie-from-unicef.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/qa-with-heather-brogan-piloting-a-new-mentoring-app-for-hiv-patients/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/qa-with-heather-brogan-piloting-a-new-mentoring-app-for-hiv-patients.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/sabena-solomon-pursues-diverse-career-opportunities-at-viiv-healthcare/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/sabena-solomon-pursues-diverse-career-opportunities-at-viiv-healthcare.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/see-you-in-paris-viiv-healthcare-the-international-aids-society-conference/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/see-you-in-paris-viiv-healthcare-the-international-aids-society-conference.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/tackling-hiv-challenges-in-europe/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/tackling-hiv-challenges-in-europe.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/towards-a-cure-exploring-cure-and-remission-in-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/towards-a-cure-exploring-cure-and-remission-in-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/treating-hiv-building-on-30-years-of-innovation-ingenuity-and-passion/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/treating-hiv-building-on-30-years-of-innovation-ingenuity-and-passion.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/understanding-hiv-in-women-spotlight-on-the-gender-gap-in-hiv-research/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/understanding-hiv-in-women-spotlight-on-the-gender-gap-in-hiv-research.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-aids-2016/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/viiv-healthcare-aids-2016.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-hiv-glasgow/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/viiv-healthcare-hiv-glasgow.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-host-the-inaugural-implementation-science-network-meeting-in-paris/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/viiv-healthcare-host-the-inaugural-implementation-science-network-meeting-in-paris.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-presents-phase-iii-data-comparing-once-daily-maraviroc-in-combination/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/viiv-healthcare-presents-phase-iii-data-comparing-once-daily-maraviroc-in-combination.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-s-commitment-to-implementation-science/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/viiv-healthcare-s-commitment-to-implementation-science.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-s-positive-partnerships-accelerates-progress-towards-90-90-90-goals-in-estonia/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/viiv-healthcare-s-positive-partnerships-accelerates-progress-towards-90-90-90-goals-in-estonia.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-to-host-inaugural-implementation-science-network-meeting-in-paris/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/viiv-healthcare-to-host-inaugural-implementation-science-network-meeting-in-paris.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/we-re-allies-the-power-of-partnership/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/we-re-allies-the-power-of-partnership.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/welcome-to-branford-the-world-s-only-hiv-dedicated-research-facility/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/welcome-to-branford-the-world-s-only-hiv-dedicated-research-facility.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/young-britons-break-down-hiv-stigma-isolation-to-be-the-genendit/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/young-britons-break-down-hiv-stigma-isolation-to-be-the-genendit.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/our-people/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/our-people.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/our-people/find-out-about-industrial-placement-opportunities-at-viiv-healthcare/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/our-people/find-out-about-industrial-placement-opportunities-at-viiv-healthcare.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/our-people/from-classroom-to-congress-hall-my-year-at-viiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/our-people/from-classroom-to-congress-hall-my-year-at-viiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/our-people/one-million-positive-faces/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/our-people/one-million-positive-faces.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/our-people/sabena-solomon-pursues-diverse-career-opportunities-at-viiv-healthcare/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/our-people/sabena-solomon-pursues-diverse-career-opportunities-at-viiv-healthcare.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/our-people/treating-hiv-building-on-30-years-of-innovation-ingenuity-and-passion/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/our-people/treating-hiv-building-on-30-years-of-innovation-ingenuity-and-passion.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/addressing-hiv-in-adolescents/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/addressing-hiv-in-adolescents.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/facing-the-challenges-of-getting-old-with-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/facing-the-challenges-of-getting-old-with-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/hiv-a-virus-that-thrives-on-inequality/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/hiv-a-virus-that-thrives-on-inequality.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/hiv-behind-bars-supporting-hiv-research-education-and-testing-in-italian-prisons/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/hiv-behind-bars-supporting-hiv-research-education-and-testing-in-italian-prisons.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/how-we-are-collaborating-to-seek-remission-strategies-in-paediatric-hiv-research/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/how-we-are-collaborating-to-seek-remission-strategies-in-paediatric-hiv-research.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/international-day-against-homophobia-transphobia-biphobia/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/international-day-against-homophobia-transphobia-biphobia.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/new-online-platform-for-positive-action-challenges-launched/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/new-online-platform-for-positive-action-challenges-launched.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/pride-around-the-world/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/pride-around-the-world.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/spark-igniting-change/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/fighting-hiv-together/inspiring-the-next-generation-of-hiv-leaders.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/the-fight-to-end-mother-to-child-transmission-of-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/the-fight-to-end-mother-to-child-transmission-of-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/u-u-undetectable-equals-untransmittable/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/u-u-undetectable-equals-untransmittable.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/understanding-hiv-in-women-spotlight-on-the-gender-gap-in-hiv-research/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/understanding-hiv-in-women-spotlight-on-the-gender-gap-in-hiv-research.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/understanding-hiv-stigma-and-discrimination/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/understanding-hiv-stigma-and-discrimination.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/young-britons-break-down-hiv-stigma-isolation-to-be-the-genendit/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/young-britons-break-down-hiv-stigma-isolation-to-be-the-genendit.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/positive-perspectives/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/positive-perspectives.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/privacy-notice/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/privacy-notice.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/search/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/search.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/sitemap.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/global-community-partnerships.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/case-studies.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/case-studies/amfar-treat-asia.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amplifychange/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/case-studies/amplifychange.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/elizabeth-glaser-pediatric-aids-foundation-partnership/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/case-studies/elizabeth-glaser-pediatric-aids-foundation-partnership.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kaiser-family-foundation/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/case-studies/kaiser-family-foundation.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kenya-council-of-imams-and-ulamaa-kcui/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/case-studies/kenya-council-of-imams-and-ulamaa-kcui.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-shuga/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/fighting-hiv-together/mtv-shuga.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-aidsmap/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/case-studies/nam-aidsmap.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/aids-2018-amsterdam/fighting-hiv-together/stigma-action-network.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-centre-for-sexual-health-and-hivaids-research-ceshhar-zimbabwe/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/case-studies/the-centre-for-sexual-health-and-hivaids-research-ceshhar-zimbabwe.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-community-led-hivaids-prevention-project-kenya/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/case-studies/the-community-led-hivaids-prevention-project-kenya.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/our-approach/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/our-approach.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/announcing-the-2016-every-footsteps-counts-winners/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/announcing-the-2016-every-footsteps-counts-winners.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/hiv-a-virus-that-thrives-on-inequality/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/hiv-a-virus-that-thrives-on-inequality.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/local-partnerships/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/local-partnerships.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/paediatric-innovation-seed-fund/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/paediatric-innovation-seed-fund.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-challenges/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/positive-action-challenges.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-adolescents/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/positive-action-for-adolescents.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-collaborathon-grants-announced/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/positive-action-for-children-collaborathon-grants-announced.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund-french/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/positive-action-for-children-fund-french.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/positive-action-for-children-fund.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/positive-action-for-europe.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-girls-women/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/positive-action-for-girls-women.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-msm-transgender-people/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/positive-action-for-msm-transgender-people.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-southern-initiative/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/positive-action-southern-initiative.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/positive-action.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/we-partner-with-the-hiv-community/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/we-partner-with-the-hiv-community.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/terms-and-conditions/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/terms-and-conditions.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/terms-of-use/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/terms-of-use.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/unsubscribe/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/unsubscribe.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/what-we-do/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/what-we-do.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/world-aids-day-2017-fighting-hiv-together.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/driving-change-through-implementation-science/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/world-aids-day-2017-fighting-hiv-together/driving-change-through-implementation-science.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/hiv-is-a-global-issue-that-needs-an-ongoing-collaborative-response/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/world-aids-day-2017-fighting-hiv-together/hiv-is-a-global-issue-that-needs-an-ongoing-collaborative-response.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/research-in-hiv-science/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/world-aids-day-2017-fighting-hiv-together/research-in-hiv-science.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "results": {},
      "status": "done",
      "statusCode": 200,
      "txt": "United States"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/about-us.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/about-us/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "About us"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/about-us/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/about-us.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accelerate--initiative-resources.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-community-grants/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ACCELERATE! Initiative Resources  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accelerate--initiative-resources.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accelerate--initiative.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accelerate--initiative/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ACCELERATE! Initiative"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accelerate--initiative/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accelerate--initiative.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accessibility.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accessibility/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Accessibility"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accessibility/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accessibility.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/articles-sidebar-navigation/other-local-stories.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-positive-phase-3-results-from-the-brig0/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/articles-sidebar-navigation/other-local-stories/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Other Local Stories  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/articles-sidebar-navigation/other-local-stories/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/articles-sidebar-navigation/other-local-stories.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Read More About  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can-wins-excellence-in-patient-engagement-award.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can-wins-excellence-in-patient-engagement-award/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " \n           \n            \"As Much as I Can\" Wins Excellence in Patient Engagement Award    \n           Click here to learn more. \n            "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can-wins-excellence-in-patient-engagement-award/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can-wins-excellence-in-patient-engagement-award.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can-wins-excellence-in-patient-engagement-award/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "\"As Much as I Can\"  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/cierre-de-la-brecha-en-la-comunidad-latina.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/our-commitment-to-latinx-communities-living-with-hiv/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/cierre-de-la-brecha-en-la-comunidad-latina/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "working to close the gap"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/cierre-de-la-brecha-en-la-comunidad-latina/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/cierre-de-la-brecha-en-la-comunidad-latina.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/closing-the-gap-in-the-latinx-community.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/our-commitment-to-latinx-communities-living-with-hiv/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/closing-the-gap-in-the-latinx-community/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Closing the Gap in the Latinx Community  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/closing-the-gap-in-the-latinx-community/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/closing-the-gap-in-the-latinx-community.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/community-giving.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/community-giving/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Community Giving"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/community-giving/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/community-giving.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/community-youth-summits.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/community-youth-summits/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Community & Youth Summits"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/community-youth-summits/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/community-youth-summits.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/contact-us.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/contact-us/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Contact Us"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/contact-us/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/contact-us.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/cookie-policy.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/terms-of-use/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/cookie-policy/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Other Local Stories  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/cookie-policy/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/cookie-policy.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/educating-healthcare-professionals.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/terms-of-use/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/educating-healthcare-professionals/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Educating Healthcare Professionals  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/educating-healthcare-professionals/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/educating-healthcare-professionals.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/es.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/nuestro-compromiso-con-la-poblacion-hispana-y-latina-que-vive-co/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/es/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Read More About  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/es/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/es.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/how-we-work.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/how-we-work/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "How We Work"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/how-we-work/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/how-we-work.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/nuestro-compromiso-con-la-poblacion-hispana-y-latina-que-vive-co.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/our-commitment-to-latinx-communities-living-with-hiv/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/nuestro-compromiso-con-la-poblacion-hispana-y-latina-que-vive-co/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Nuestro compromiso con la población hispana y latina que vive con VIH  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/nuestro-compromiso-con-la-poblacion-hispana-y-latina-que-vive-co/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/nuestro-compromiso-con-la-poblacion-hispana-y-latina-que-vive-co.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/our-commitment-to-latinx-communities-living-with-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/terms-of-use/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/our-commitment-to-latinx-communities-living-with-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Our commitment to Latinx communities living with HIV  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/our-commitment-to-latinx-communities-living-with-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/our-commitment-to-latinx-communities-living-with-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-community-grants.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-community-grants/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Positive Action Community Grants"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-community-grants/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-community-grants.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-for-women.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-for-women/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Positive Action for Women"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-for-women/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-for-women.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-for-youth.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-for-youth/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Positive Action for Youth"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-for-youth/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-for-youth.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative-resources.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative-resources/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Positive Action Southern Initiative Resources  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative-resources/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative-resources.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Positive Action Southern Initiative"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/privacy-policy.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/privacy-policy/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Privacy policy"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/privacy-policy/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/privacy-policy.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/redirects/accelerate-research-fact-sheet-pdf.html": {
      "redirectedTo": "https://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/en-us/accelerate-research-fact-sheet.pdf",
      "status": "redirected"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/redirects/report-a-possible-side-effect.html": {
      "redirectedTo": "https://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect",
      "status": "redirected"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/redirects/viiv_healthcare-narrativespanish.html": {
      "redirectedTo": "https://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/en-us/viiv_healthcare-narrative_spanish.pdf",
      "status": "redirected"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/search-results.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/search-results/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Our Medicines"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/search-results/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/search-results.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/standing-together.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/standing-together/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Standing Together"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/standing-together/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/standing-together.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/terms-and-conditions.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/terms-and-conditions/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Terms and conditions"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/terms-and-conditions/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/terms-and-conditions.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/terms-of-use.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/terms-of-use/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Terms of use"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/terms-of-use/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/terms-of-use.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "News"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/isabelle.x.scali@viivhealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/",
      "results": {},
      "status": "done",
      "statusCode": 404,
      "txt": "isabelle.x.scali@viivhealthcare.com"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/iiv-healthcare-starts-third-phase-iii-hiv-treatment-study-invest.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/iiv-healthcare-starts-third-phase-iii-hiv-treatment-study-invest/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ATLAS-2M Study: Phase III Study Investigating Long-Acting 2-Drug Regimen"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/iiv-healthcare-starts-third-phase-iii-hiv-treatment-study-invest/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/iiv-healthcare-starts-third-phase-iii-hiv-treatment-study-invest.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/new-results-from-the-positive-perspectives-global-survey-provide.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/new-results-from-the-positive-perspectives-global-survey-provide/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "New Results From Positive Perspectives Survey"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/new-results-from-the-positive-perspectives-global-survey-provide/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/new-results-from-the-positive-perspectives-global-survey-provide.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/phase-ii-study-results-showed-comparable-viral-suppression-rates.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/phase-ii-study-results-showed-comparable-viral-suppression-rates/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "LATTE-2 Study Results Announced At Paris IAS Meeting"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/phase-ii-study-results-showed-comparable-viral-suppression-rates/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/phase-ii-study-results-showed-comparable-viral-suppression-rates.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-and-neat-id-announce-results-from-the-neat-022-s.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-and-neat-id-announce-results-from-the-neat-022-s/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "NEAT-022 Study Results Announced At Paris IAS Meeting"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-and-neat-id-announce-results-from-the-neat-022-s/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-and-neat-id-announce-results-from-the-neat-022-s.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-fda-approval-of-selzentry-maraviroc.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-fda-approval-of-selzentry-maraviroc/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "FDA Drug Approval Of SELZENTRY® For CCR5-tropic HIV in Pediatric Patients"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-fda-approval-of-selzentry-maraviroc/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-fda-approval-of-selzentry-maraviroc.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-first-phase-ii-hiv-prevention-study-re.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-first-phase-ii-hiv-prevention-study-re/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ECLAIR HIV Prevention Study Results"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-first-phase-ii-hiv-prevention-study-re/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-first-phase-ii-hiv-prevention-study-re.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-phase-ii-study-results-for-first-two-d.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-phase-ii-study-results-for-first-two-d/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "LATTE-2 Study Announcement Results: Investigational 2-Drug Long-Acting Injectable Regimen For HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-phase-ii-study-results-for-first-two-d/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-phase-ii-study-results-for-first-two-d.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-positive-new-dolutegravir-data-for-the.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-positive-new-dolutegravir-data-for-the/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Announcement of INSPIRING Study Results: Safety Efficacy Of Dolutegravir in HIV Patients Co-Infected With Tuberculosis"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-positive-new-dolutegravir-data-for-the/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-positive-new-dolutegravir-data-for-the.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-positive-phase-3-results-from-the-brig.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-positive-phase-3-results-from-the-brig/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Announcement of BRIGHTE Study Results: HTE Patients With HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-positive-phase-3-results-from-the-brig/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-positive-phase-3-results-from-the-brig.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-positive-phase-3-results-from-the-brig0.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-positive-phase-3-results-from-the-brig0/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-positive-phase-3-results-from-the-brig0/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-positive-phase-3-results-from-the-brig0.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-start-of-phase-iii-study-of-long-actin.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-start-of-phase-iii-study-of-long-actin/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare US Announces Start of HPTN-084 Study Results: For HIV Prevention in Women"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-start-of-phase-iii-study-of-long-actin/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-start-of-phase-iii-study-of-long-actin.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-superior-efficacy-of-dolutegravir-vers.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-superior-efficacy-of-dolutegravir-vers/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "DAWNING HIV Study In Adults With HIV: Studying Efficacy Of Dolutegravir"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-superior-efficacy-of-dolutegravir-vers/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-superior-efficacy-of-dolutegravir-vers.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-sword-100-week-data-for-juluca-dolute.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-sword-100-week-data-for-juluca-dolute/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "SWORD 100-week Data Presented at AIDS 2018 For Juluca HIV Treatment"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-sword-100-week-data-for-juluca-dolute/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-sword-100-week-data-for-juluca-dolute.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-us-fda-approval-for-juluca.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-us-fda-approval-for-juluca/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "US FDA Approval For Juluca® HIV Medication"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-us-fda-approval-for-juluca/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-us-fda-approval-for-juluca.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-expands-u-s--commitment-to-youth-living-with-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-for-youth/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-expands-u-s--commitment-to-youth-living-with-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "click here"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-expands-u-s--commitment-to-youth-living-with-hiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-expands-u-s--commitment-to-youth-living-with-hiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-extends-medicines-patent-pool-licence-agreement.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-extends-medicines-patent-pool-licence-agreement/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Medicines Patent Pool Licence Agreement For Dolutegravir Extended"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-extends-medicines-patent-pool-licence-agreement/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-extends-medicines-patent-pool-licence-agreement.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-files-patent-infringement-litigation-against-gil.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-files-patent-infringement-litigation-against-gil/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Patent Litigation Suit Filed Against Gilead Over Bictegravir Competitor"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-files-patent-infringement-litigation-against-gil/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-files-patent-infringement-litigation-against-gil.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-launches-eighth-phase-iii-study-in-two--drug-reg.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-launches-eighth-phase-iii-study-in-two--drug-reg/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "TANGO Study To Evaluate Efficacy of Investigational Results: 2-Drug HIV Regimen"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-launches-eighth-phase-iii-study-in-two--drug-reg/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-launches-eighth-phase-iii-study-in-two--drug-reg.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare US Presents Abstracts On Trials Studying 2-Drug HIV Regimens Trials At AIDS 2018"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen/ref": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen/ref/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "[1]"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen/ref/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen/ref"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-presents-three-year-data-for-investigational-lon.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-presents-three-year-data-for-investigational-lon/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare presents three-year data for investigational long-acting injectable, two-drug HIV regimen"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-presents-three-year-data-for-investigational-lon/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-presents-three-year-data-for-investigational-lon.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-reports-positive-48-week-results-for-first-pivot.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-reports-positive-48-week-results-for-first-pivot/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ATLAS HIV Study: Report of 48-Week Results"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-reports-positive-48-week-results-for-first-pivot/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-reports-positive-48-week-results-for-first-pivot.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-shares-data-from-its-innovative-portfolio-with-h.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-shares-data-from-its-innovative-portfolio-with-h/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "22 Abstracts Shared At IAS HIV Conference"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-shares-data-from-its-innovative-portfolio-with-h/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-shares-data-from-its-innovative-portfolio-with-h.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare shares data from landmark 2-drug regimen trials at AIDS 2018"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-submits-regulatory-applications-for-the-first-hi.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-submits-regulatory-applications-for-the-first-hi/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "First HIV Maintenance Regimen Of Two Medicines"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-submits-regulatory-applications-for-the-first-hi/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-submits-regulatory-applications-for-the-first-hi.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-to-progress-collaboration-with-janssen-to-develo.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-to-progress-collaboration-with-janssen-to-develo/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Collaboration With Janssen: Investigate Long-Acting Injectable 2-Drug HIV Regimen"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-to-progress-collaboration-with-janssen-to-develo/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-to-progress-collaboration-with-janssen-to-develo.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/where-we-work.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/where-we-work/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Where we work"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/where-we-work/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/where-we-work.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/who-we-are.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/who-we-are/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Who We Are"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/who-we-are/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/who-we-are.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "results": {},
      "status": "done",
      "statusCode": 200,
      "txt": "Spain"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/bienvenido.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/bienvenido/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Bienvenido  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/bienvenido/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/bienvenido.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " \n           \n            Descubre los consejos de expertos \"Menos es Más\"  \n           #conMenosEsposibleMas \n            "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/consigue-mas-salud-con-menos-esfuerzo-en-10-pasos.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/consigue-mas-salud-con-menos-esfuerzo-en-10-pasos/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/consigue-mas-salud-con-menos-esfuerzo-en-10-pasos/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/consigue-mas-salud-con-menos-esfuerzo-en-10-pasos.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/en-el-deporte-como-en-la-vida-menos-es-mas.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/en-el-deporte-como-en-la-vida-menos-es-mas/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "En el deporte, como en la vida, “Menos es Más”"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/en-el-deporte-como-en-la-vida-menos-es-mas/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/en-el-deporte-como-en-la-vida-menos-es-mas.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/imagina-mas.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/imagina-mas/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Imagina Más"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/imagina-mas/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/imagina-mas.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/menos-es-mas-en-nuestra-cocina-y-en-nuestro-paladar.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/menos-es-mas-en-nuestra-cocina-y-en-nuestro-paladar/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Menos es más, en nuestra cocina y en nuestro paladar"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/menos-es-mas-en-nuestra-cocina-y-en-nuestro-paladar/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/menos-es-mas-en-nuestra-cocina-y-en-nuestro-paladar.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/trabajando-en-positivo.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/trabajando-en-positivo/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Trabajando en Positivo"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/trabajando-en-positivo/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/trabajando-en-positivo.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mes/consigue-mas-salud-con-menos-esfuerzo-en-10-pasos.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mes/consigue-mas-salud-con-menos-esfuerzo-en-10-pasos/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "Consigue más salud con menos esfuerzo en 10 pasos"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mes/consigue-mas-salud-con-menos-esfuerzo-en-10-pasos/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mes/consigue-mas-salud-con-menos-esfuerzo-en-10-pasos.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/quienes-somos.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/quienes-somos/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Quiénes somos  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/quienes-somos/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/quienes-somos.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/spanish-articles/conoce-a-los-protagonistas.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/spanish-articles/conoce-a-los-protagonistas/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " \n           \n            Victor, Graciela y Jorge nos cuentan cómo #conMenosEsposibleMas Conoce a los protagonistas  \n            "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/spanish-articles/conoce-a-los-protagonistas/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/spanish-articles/conoce-a-los-protagonistas.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/spanish-articles/por-que-menos-es-mas.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/spanish-articles/por-que-menos-es-mas/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " \n           \n            En ViiV Healthcare lo aplicamos en todas nuestras areas ¿Por qué Menos es Más?  \n            "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/spanish-articles/por-que-menos-es-mas/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/spanish-articles/por-que-menos-es-mas.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/spanish-articles/sumate-a-conmenosesposiblemas.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/spanish-articles/sumate-a-conmenosesposiblemas/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " - SÚMATE a #conMenosEsposibleMas  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/spanish-articles/sumate-a-conmenosesposiblemas/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/spanish-articles/sumate-a-conmenosesposiblemas.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/es/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "es"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/external/everyfootstepcounts-com-.html": {
      "redirectedTo": "https://everyfootstepcounts.com/",
      "status": "redirected"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/external/gsk-com-en-gb-contact-us-report-a-possible-side-effect-.html": {
      "redirectedTo": "https://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect/",
      "status": "redirected"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/external/hivimplementationscience-com-.html": {
      "redirectedTo": "https://hivimplementationscience.com/",
      "status": "redirected"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/external/infographic.html": {
      "redirectedTo": "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/hiv-tb_infographic-final.pdf",
      "status": "redirected"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/external/www-positiveactionchallenges-com-.html": {
      "redirectedTo": "https://www.positiveactionchallenges.com/",
      "status": "redirected"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/external/www-viivexchange-com.html": {
      "redirectedTo": "https://gskpro.com/pl-pl/",
      "status": "redirected"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "results": {},
      "status": "done",
      "statusCode": 200,
      "txt": "France"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/bienvenue.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/bienvenue/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "fr"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/bienvenue/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/bienvenue.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/conditions-dutilisation.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/conditions-dutilisation/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Conditions d'utilisation"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/conditions-dutilisation/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/conditions-dutilisation.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Bienvenue  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/mieux-nous-connaitre.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/mieux-nous-connaitre/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Mieux nous connaître  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/mieux-nous-connaitre/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/mieux-nous-connaitre.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " \n              \n               Nos engagements, nos services en France  \n               "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Nos médicaments en France  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/politique-qualite-en-matiere-dinformation-promotionnelle.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/politique-qualite-en-matiere-dinformation-promotionnelle/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Politique qualité en matière d'information promotionnelle  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/politique-qualite-en-matiere-dinformation-promotionnelle/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/politique-qualite-en-matiere-dinformation-promotionnelle.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/viiv-healthcare-en-bref.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/viiv-healthcare-en-bref/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare en bref  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/viiv-healthcare-en-bref/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/viiv-healthcare-en-bref.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/viiv-healthcare-en-france.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/viiv-healthcare-en-france/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare en France  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/viiv-healthcare-en-france/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/viiv-healthcare-en-france.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/lactualite-en-direct.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/lactualite-en-direct/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " \n              \n               L'actualité en direct  \n              ViiV Healthcare communique ! Retrouvez nos dernières communications et actualités \n               "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/lactualite-en-direct/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/lactualite-en-direct.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/mentions-legales.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/mentions-legales/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Mentions Légales"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/mentions-legales/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/mentions-legales.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/politique-de-cookies.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/politique-de-cookies/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Politique de cookies"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/politique-de-cookies/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/politique-de-cookies.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Politique de protection des données personnelles"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/global/global-medical-education-events.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/global/global-medical-education-events/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Global Medical Education Events"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/hiv-treatment-and-care.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/hiv-treatment-and-care/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "HIV Treatment and Care"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/hiv-treatment-and-care/european-network-of-young-hiv-experts.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/medical-education-events/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/hiv-treatment-and-care/european-network-of-young-hiv-experts/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/hiv-treatment-and-care/the-positive-perspectives-survey.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/hiv-treatment-and-care/the-positive-perspectives-survey/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "The Positive Perspectives Survey"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/ias-paris-2017.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/ias-paris-2017/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "IAS Paris 2017"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-research-and-develop-new-hiv-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Explore our stories"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/accelerating-the-pace-of-innovation.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/accelerating-the-pace-of-innovation/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/ageing-with-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/ageing-with-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/branford-the-world-s-only-hiv-dedicated-research-facility.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/branford-the-world-s-only-hiv-dedicated-research-facility/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/committed-to-data-transparency.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/committed-to-data-transparency/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/iconographic.html": {
      "redirectedTo": "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/hiv-tb_infographic-final.pdf",
      "status": "redirected"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/medicines-in-development.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/medicines-in-development/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/more-press-releases-from-viiv-healthcare.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/more-press-releases-from-viiv-healthcare/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/our-approach-to-rd.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/our-approach-to-rd/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/our-medicines.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/our-medicines/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/positive-perspectives-looking-into-the-lives-of-people-living-with-hiv-and-their-partners.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/positive-perspectives-looking-into-the-lives-of-people-living-with-hiv-and-their-partners/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/towards-a-cure-exploring-cure-and-remission-in-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/towards-a-cure-exploring-cure-and-remission-in-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/viiv-exchange.html": {
      "redirectedTo": "https://www.viivexchange.com/routing",
      "status": "redirected"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/viiv-healthcare-at-hiv-glasgow.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-at-hiv-glasgow/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/viiv-healthcare-presents-three-year-data-for-investigational-long-acting-injectable-two-drug-hiv-regimen-1.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/viiv-healthcare-presents-three-year-data-for-investigational-long-acting-injectable-two-drug-hiv-regimen/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/innovators-and-disruptors-in-hiv/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "results": {},
      "status": "done",
      "statusCode": 200,
      "txt": "Italy"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/contenuti-ita.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/contenuti-ita/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Contenuti ITA"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/contenuti-ita/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/contenuti-ita.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/contenuti-ita/i-nostri-valori.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/contenuti-ita/i-nostri-valori/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "I \n              \n              \n                nostri \n               \n              Valori"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/contenuti-ita/i-nostri-valori/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/contenuti-ita/i-nostri-valori.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/contenuti-ita/il-nostro-essere-responsabili.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/contenuti-ita/il-nostro-essere-responsabili/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/contenuti-ita/il-nostro-essere-responsabili/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/contenuti-ita/il-nostro-essere-responsabili.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/contenuti-ita/il-nostro-obiettivo.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/contenuti-ita/il-nostro-obiettivo/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/contenuti-ita/il-nostro-obiettivo/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/contenuti-ita/il-nostro-obiettivo.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/contenuti-ita/la-nostra-ricerca.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/contenuti-ita/la-nostra-ricerca/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/contenuti-ita/la-nostra-ricerca/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/contenuti-ita/la-nostra-ricerca.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/informativa-sulla-privacy.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/informativa-sulla-privacy/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Informativa sulla Privacy"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/informativa-sulla-privacy/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/informativa-sulla-privacy.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/italia.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/italia/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "it"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/italia/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/italia.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Sala Stampa - l’area delle nostre news per i giornalisti e i media"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2017/giugno/sottoposta-la-richiesta-di-autorizzazione-regolatoria-per-il-pri.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2017/giugno/sottoposta-la-richiesta-di-autorizzazione-regolatoria-per-il-pri/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Sottoposta la richiesta di autorizzazione regolatoria per il primo regime di mantenimento per il trattamento dell’HIV con due soli farmaci  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2017/giugno/sottoposta-la-richiesta-di-autorizzazione-regolatoria-per-il-pri/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2017/giugno/sottoposta-la-richiesta-di-autorizzazione-regolatoria-per-il-pri.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2017/novembre/viiv-healthcare-annuncia-la-partenza-dello-studio-di-fase-iii-co.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2017/novembre/viiv-healthcare-annuncia-la-partenza-dello-studio-di-fase-iii-co/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare annuncia la partenza dello studio di fase III con cabotegravir a lunga durata d’azione per la prevenzione dell’HIV nella donna  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2017/novembre/viiv-healthcare-annuncia-la-partenza-dello-studio-di-fase-iii-co/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2017/novembre/viiv-healthcare-annuncia-la-partenza-dello-studio-di-fase-iii-co.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2017/ottobre/viiv-healthcare-annuncia-i-risultati-positivi-dello-studio-di-fa.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2017/ottobre/viiv-healthcare-annuncia-i-risultati-positivi-dello-studio-di-fa/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare annuncia i risultati positivi dello studio di fase 3 BRIGHTE su fostemsavir in pazienti con HIV multitrattati  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2017/ottobre/viiv-healthcare-annuncia-i-risultati-positivi-dello-studio-di-fa/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2017/ottobre/viiv-healthcare-annuncia-i-risultati-positivi-dello-studio-di-fa.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2017/settembre/l_hiv-in-carcere--un-progetto-svela-la-ricetta-per-combatterlo.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2017/settembre/l_hiv-in-carcere--un-progetto-svela-la-ricetta-per-combatterlo/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "L’HIV in carcere, un progetto svela la ricetta per combatterlo  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2017/settembre/l_hiv-in-carcere--un-progetto-svela-la-ricetta-per-combatterlo/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2017/settembre/l_hiv-in-carcere--un-progetto-svela-la-ricetta-per-combatterlo.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/febbraio/viiv-healthcare-annuncia-la-partenza-dellottavo-studio-di-fase-i.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/febbraio/viiv-healthcare-annuncia-la-partenza-dellottavo-studio-di-fase-i/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare annuncia la partenza dell’ottavo studio di fase III nell’ambito del programma di sviluppo di regimi a due farmaci per il trattamento dell’HIV-1  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/febbraio/viiv-healthcare-annuncia-la-partenza-dellottavo-studio-di-fase-i/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/febbraio/viiv-healthcare-annuncia-la-partenza-dellottavo-studio-di-fase-i.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/giugno/viiv-healthcare-annuncia-importanti-studi-di-fase-iii-per-dolute.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/giugno/viiv-healthcare-annuncia-importanti-studi-di-fase-iii-per-dolute/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare annuncia importanti studi di fase III per dolutegravir e lamivudina  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/giugno/viiv-healthcare-annuncia-importanti-studi-di-fase-iii-per-dolute/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/giugno/viiv-healthcare-annuncia-importanti-studi-di-fase-iii-per-dolute.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/luglio/viiv-healthcare-presenta-ad-aids-2018-i-dati-di-fase-iii-per-gli.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/luglio/viiv-healthcare-presenta-ad-aids-2018-i-dati-di-fase-iii-per-gli/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare presenta ad AIDS 2018 i dati di fase III per gli importanti studi GEMINI  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/luglio/viiv-healthcare-presenta-ad-aids-2018-i-dati-di-fase-iii-per-gli/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/luglio/viiv-healthcare-presenta-ad-aids-2018-i-dati-di-fase-iii-per-gli.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/maggio/viiv-healthcare-riceve-lapprovazione-in-europa-per-la-combinazio.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/maggio/viiv-healthcare-riceve-lapprovazione-in-europa-per-la-combinazio/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare riceve l’approvazione in Europa per la combinazione dolutegravir-rilpivirina  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/maggio/viiv-healthcare-riceve-lapprovazione-in-europa-per-la-combinazio/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/maggio/viiv-healthcare-riceve-lapprovazione-in-europa-per-la-combinazio.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/marzo/marzo.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/marzo/marzo/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare ha ricevuto l’opinione positiva del CHMP in Europa per la combinazione dolutegravir/rilpivirina  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/marzo/marzo/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/marzo/marzo.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/hiv--da-parma-innovazione--industria-e-cure-per-i-pazienti-di-tu.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/hiv--da-parma-innovazione--industria-e-cure-per-i-pazienti-di-tu/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "HIV: da Parma innovazione, industria e cure per i pazienti di tutto il mondo"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/hiv--da-parma-innovazione--industria-e-cure-per-i-pazienti-di-tu/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/hiv--da-parma-innovazione--industria-e-cure-per-i-pazienti-di-tu.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-annuncia-i-risultati-positivi-di-fase-3-dello-st.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-annuncia-i-risultati-positivi-di-fase-3-dello-st/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare annuncia i risultati positivi di Fase 3 dello studio Brighte su fostemsavir nei pazienti con HIV HTE (Heavily Treatment-Experienced)"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-annuncia-i-risultati-positivi-di-fase-3-dello-st/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-annuncia-i-risultati-positivi-di-fase-3-dello-st.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-presenta-i-dati-relativi-a-tre-anni-di-trattamen.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-presenta-i-dati-relativi-a-tre-anni-di-trattamen/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare presenta i dati relativi a tre anni di trattamento con il regime sperimentale iniettabile a due farmaci HIV a lunga durata di azione"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-presenta-i-dati-relativi-a-tre-anni-di-trattamen/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-presenta-i-dati-relativi-a-tre-anni-di-trattamen.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-presenta-i-risultati-positivi-a-48-settimane-del.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-presenta-i-risultati-positivi-a-48-settimane-del/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare presenta i risultati positivi a 48 settimane del secondo studio di fase III per un innovativo trattamento iniettabile"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-presenta-i-risultati-positivi-a-48-settimane-del/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-presenta-i-risultati-positivi-a-48-settimane-del.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Mapping an HIV Free Future"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/case-studies.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Mapping an Hiv Free Future Case Studies"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/case-studies/argentina/hiv-environment-in-buenos-aires.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/argentina/hiv-environment-in-buenos-aires/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/case-studies/brazil/hiv-environment-in-brazil.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/brazil/hiv-environment-in-brazil/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/case-studies/canada/hiv-environment-in-saskatchewan.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/canada/hiv-environment-in-saskatchewan/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/case-studies/estonia/hiv-environment-in-estonia.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/estonia/hiv-environment-in-estonia/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/case-studies/germany-ii/hiv-environment-in-berlin.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/germany-ii/hiv-environment-in-berlin/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/case-studies/germany/hiv-environment-in-bochum.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/germany/hiv-environment-in-bochum/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/case-studies/italy/hiv-environment-in-italy.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/italy/hiv-environment-in-italy/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/case-studies/spain/hiv-environment-in-spain.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/spain/hiv-environment-in-spain/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/case-studies/switzerland/hiv-environment-in-switzerland.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/switzerland/hiv-environment-in-switzerland/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/case-studies/uk/hiv-environment-in-london.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/uk/hiv-environment-in-london/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/case-studies/uruguay/hiv-environment-in-montevideo.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/case-studies/uruguay/hiv-environment-in-montevideo/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/dolutegravir-expanded-access-program.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/we-improve-access-to-our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/dolutegravir-expanded-access-program/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Dolutegravir Expanded Access Program  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/hiv-health-outcomes.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/hiv-health-outcomes/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "HIV Health Outcomes"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/implementation-science.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/we-improve-access-to-our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/implementation-science/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Implementation Science  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/implementation-science0.html": {
      "redirectedTo": "https://hivimplementationscience.com/",
      "status": "redirected"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/paediatric-hiv-care.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/paediatric-hiv-care/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Paediatric HIV Care"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/policy-papers.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/policy-papers/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Policy Papers"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/we-improve-access-to-our-medicines.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/we-improve-access-to-our-medicines/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Access to Medicines"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/working-towards-90-90-90.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/working-towards-90-90-90/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Working towards 90 90 90"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/working-towards-90-90-90/fast-track-cities.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/working-towards-90-90-90/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/working-towards-90-90-90/fast-track-cities/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/working-towards-90-90-90/positive-partnerships.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/working-towards-90-90-90/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/working-towards-90-90-90/positive-partnerships/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/mapping-an-hiv-free-future/working-towards-90-90-90/positive-pathways.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/working-towards-90-90-90/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/working-towards-90-90-90/positive-pathways/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Media"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/oonagh-makes-a-difference-for-people-affected-by-hiv-through-positive-action-programmes.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/inspiring-voices-in-hiv-lead-the-way-on-international-women-s-day/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/oonagh-makes-a-difference-for-people-affected-by-hiv-through-positive-action-programmes/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "here"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2009.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2009/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "2009"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2009/april.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2009/april/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "April"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2009/april/glaxosmithkline-and-pfizer-announce-innovative-agreement-to-create-a-new-world-leading-specialist-hiv-company.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2009/april/glaxosmithkline-and-pfizer-announce-innovative-agreement-to-create-a-new-world-leading-specialist-hiv-company/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "GlaxoSmithKline and Pfizer announce innovative agreement to create a new world-leading, specialist HIV company"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2009/november.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2009/november/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "November"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2009/november/fda-approves-expanded-use-of-selzentry-for-appropriate-patients-starting-hiv-antiretroviral-therapy-for-the-first-time.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2009/november/fda-approves-expanded-use-of-selzentry-for-appropriate-patients-starting-hiv-antiretroviral-therapy-for-the-first-time/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "FDA Approves Expanded Use of Selzentry® for Appropriate Patients Starting HIV Antiretroviral Therapy for the First Time"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2009/november/viiv-healthcare-launches.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2009/november/viiv-healthcare-launches/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare Launches"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "2010"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/december.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/december/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "December"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/december/global-agenda-for-elimination-of-mother-to-child-transmission-of-hiv-positive-action-for-children-fund-calls-for-proposals-to-fill-the-gaps.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/december/global-agenda-for-elimination-of-mother-to-child-transmission-of-hiv-positive-action-for-children-fund-calls-for-proposals-to-fill-the-gaps/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Global Agenda for Elimination of Mother to Child Transmission of HIV: Positive Action for Children Fund Calls for Proposals to Fill the Gaps"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/july.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/july/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "july"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/july/positive-phase-iib-data-on-investigational-once-daily-integrase-inhibitor-572-presented-at-international-aids-conference.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/july/positive-phase-iib-data-on-investigational-once-daily-integrase-inhibitor-572-presented-at-international-aids-conference/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Positive Phase IIb Data on Investigational Once-Daily Integrase Inhibitor, 572, presented at International AIDS Conference"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/july/shionogi-viiv-healthcare-announces-commitment-to-phase-iii-development-programme-for-investigational-once-daily-hiv-integrase-inhibitor.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/july/shionogi-viiv-healthcare-announces-commitment-to-phase-iii-development-programme-for-investigational-once-daily-hiv-integrase-inhibitor/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Shionogi - ViiV Healthcare Announces Commitment to Phase III Development Programme for Investigational Once-Daily HIV Integrase Inhibitor"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/july/viiv-healthcare-announces-further-initiatives-to-improve-access-to-hiv-medications-for-people-living-in-the-least-developed-countries.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/july/viiv-healthcare-announces-further-initiatives-to-improve-access-to-hiv-medications-for-people-living-in-the-least-developed-countries/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces further initiatives to improve access to HIV medications for people living in the least developed countries"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/july/viiv-healthcare-announces-positive-action-us-southern-initiative-an-innovative-community-support-program-to-fight-hivaids.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/july/viiv-healthcare-announces-positive-action-us-southern-initiative-an-innovative-community-support-program-to-fight-hivaids/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare Announces Positive Action US Southern Initiative, an Innovative Community Support Program to Fight HIV/AIDS"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/june.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/june/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "June"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/june/viiv-healthcare-and-amfar-partner-to-optimize-hiv-treatment-for-infants-and-children-in-asia.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/june/viiv-healthcare-and-amfar-partner-to-optimize-hiv-treatment-for-infants-and-children-in-asia/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare and amfAR Partner to Optimize HIV Treatment for Infants and Children in Asia"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/june/viiv-healthcare-and-elizabeth-glaser-pediatric-aids-foundation-partner-to-expedite-access-to-arv-treatment-for-infants-and-children.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/june/viiv-healthcare-and-elizabeth-glaser-pediatric-aids-foundation-partner-to-expedite-access-to-arv-treatment-for-infants-and-children/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare and Elizabeth Glaser Pediatric AIDS Foundation Partner to Expedite Access to ARV Treatment for Infants and Children"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/june/viiv-healthcare-awards-grants-from-the-positive-action-for-children-fund-of-36m.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/june/viiv-healthcare-awards-grants-from-the-positive-action-for-children-fund-of-36m/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare Awards Grants from the Positive Action for Children Fund of £3.6m"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/march.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/march/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "March"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/march/viiv-healthcare-calls-for-initial-grant-proposals-to-the-positive-action-for-children-fund.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/march/viiv-healthcare-calls-for-initial-grant-proposals-to-the-positive-action-for-children-fund/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare Calls for Initial Grant Proposals to the Positive Action for Children Fund"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/october.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/october/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "october"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/october/shionogi-viiv-healthcare-llc-initiates-phase-iii-clinical-programme-for-investigational-once-daily-hiv-integrase-inhibitor.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/october/shionogi-viiv-healthcare-llc-initiates-phase-iii-clinical-programme-for-investigational-once-daily-hiv-integrase-inhibitor/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Shionogi-ViiV Healthcare LLC Initiates Phase III Clinical Programme for Investigational Once-Daily HIV Integrase Inhibitor"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/october/viiv-healthcare-acts-to-improve-access-to-hiv-medicines-in-united-states-for-those-most-in-need.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/october/viiv-healthcare-acts-to-improve-access-to-hiv-medicines-in-united-states-for-those-most-in-need/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare acts to improve access to HIV Medicines in United States for those most in need"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/september.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/september/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "September"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2010/september/viiv-healthcare-awards-southern-initiative-grants-to-reduce-hiv-disparities-among-african-americans-and-latinos.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/september/viiv-healthcare-awards-southern-initiative-grants-to-reduce-hiv-disparities-among-african-americans-and-latinos/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare Awards Southern Initiative Grants to Reduce HIV Disparities Among African Americans and Latinos"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "2011"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/april.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/april/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "April"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/april/viiv-healthcare-expands-positive-action-us-southern-initiative-to-fight-hivaids-in-hard-hit-region.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/april/viiv-healthcare-expands-positive-action-us-southern-initiative-to-fight-hivaids-in-hard-hit-region/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare Expands Positive Action US Southern Initiative to Fight HIV/AIDS in Hard-hit Region"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/february.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/february/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "February"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/february/david-redfern-appointed-as-chairman-of-the-board-for-viiv-healthcare.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/february/david-redfern-appointed-as-chairman-of-the-board-for-viiv-healthcare/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "David Redfern appointed as Chairman of the Board for ViiV Healthcare"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/february/positive-action-and-vida-digna-further-information.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/february/positive-action-and-vida-digna-further-information/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Positive Action and Vida Digna - further information"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/february/viiv-healthcare-s-positive-action-and-the-international-hivaids-alliance-tackle-hiv-stigma-in-six-central-american-countries.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/february/viiv-healthcare-s-positive-action-and-the-international-hivaids-alliance-tackle-hiv-stigma-in-six-central-american-countries/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare’s Positive Action and the International HIV/AIDS Alliance Tackle HIV Stigma in Six Central American Countries"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/june.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/june/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "June"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/june/viiv-healthcare-awards-small-grants-from-positive-action-for-children-fund-to-82-charitable-organisations-globally.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/june/viiv-healthcare-awards-small-grants-from-positive-action-for-children-fund-to-82-charitable-organisations-globally/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare Awards Small Grants from Positive Action for Children Fund to 82 Charitable Organisations Globally"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/march.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/march/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "March"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/march/regulatory-update-celsentriselzentry-maraviroc.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/march/regulatory-update-celsentriselzentry-maraviroc/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Regulatory Update – Celsentri/Selzentry® (maraviroc)"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/october.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/october/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "October"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/october/media-alert-viiv-healthcare-s-positive-action-for-children-fund-announces-16-new-grantees-for-the-year-20112012.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/october/media-alert-viiv-healthcare-s-positive-action-for-children-fund-announces-16-new-grantees-for-the-year-20112012/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Media Alert: ViiV Healthcare’s Positive Action for Children Fund announces 16 new grantees for the year 2011/2012"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/october/viiv-healthcare-starts-phase-iii-programme-of-celsentri-selzentry-versus-truvada-in-combination-with-a-protease-inhibitor-in-people-living-with-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/october/viiv-healthcare-starts-phase-iii-programme-of-celsentri-selzentry-versus-truvada-in-combination-with-a-protease-inhibitor-in-people-living-with-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare starts phase III programme of Celsentri-Selzentry versus Truvada in combination with a protease inhibitor in people living with HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/september.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/september/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "September"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/september/regulatory-update-celsentriselzentry-maraviroc.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/september/regulatory-update-celsentriselzentry-maraviroc/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Regulatory Update – Celsentri/Selzentry® (maraviroc)"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2011/september/viiv-healthcare-reaffirms-commitment-to-us-regions-hardest-hit-by-hivaids.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/september/viiv-healthcare-reaffirms-commitment-to-us-regions-hardest-hit-by-hivaids/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare Reaffirms Commitment to US Regions Hardest Hit by HIV/AIDS"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "2012"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/april.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/april/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "April"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/april/shionogi-viiv-healthcare-announces-initial-data-from-pivotal-phase-iii-study-of-dolutegravir-in-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/april/shionogi-viiv-healthcare-announces-initial-data-from-pivotal-phase-iii-study-of-dolutegravir-in-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Shionogi – ViiV Healthcare announces initial data from Pivotal Phase III study of dolutegravir in HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/december.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/december/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "December"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/december/viiv-healthcare-announces-regulatory-submissions-for-dolutegravir-in-the-eu-us-and-canada.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/december/viiv-healthcare-announces-regulatory-submissions-for-dolutegravir-in-the-eu-us-and-canada/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces regulatory submissions for dolutegravir in the EU, US and Canada"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/july.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/july/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "July"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/july/once-daily-dolutegravir-is-non-inferior-to-twice-daily-raltegravir-in-treatment-na%C3%AFve-adults-with-hiv-1.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/july/once-daily-dolutegravir-is-non-inferior-to-twice-daily-raltegravir-in-treatment-na%c3%afve-adults-with-hiv-1/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Once-Daily Dolutegravir is Non-Inferior to Twice-Daily Raltegravir in Treatment-Naïve Adults with HIV-1"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/july/shionogi-viiv-healthcare-announces-positive-initial-data-from-phase-iii-study-of-dolutegravir-based-regimen-vs-atripla-in-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/july/shionogi-viiv-healthcare-announces-positive-initial-data-from-phase-iii-study-of-dolutegravir-based-regimen-vs-atripla-in-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Shionogi – ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/july/viiv-healthcare-expands-commitment-to-addressing-gaps-in-paediatric-hiv-research-care-and-treatment.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/july/viiv-healthcare-expands-commitment-to-addressing-gaps-in-paediatric-hiv-research-care-and-treatment/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare Expands Commitment to Addressing Gaps in Paediatric HIV Research, Care and Treatment"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/july/viiv-healthcare-expands-support-for-hiv-prevention-and-education-in-hard-hit-us-region.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/july/viiv-healthcare-expands-support-for-hiv-prevention-and-education-in-hard-hit-us-region/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare Expands Support for HIV Prevention and Education in Hard-Hit US Region"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/november.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/november/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "November"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/november/viiv-healthcare-commits-nearly-4m-in-positive-action-for-children-fund-grants-for-programmes-focused-on-alleviating-burden-of-hiv-on-women-and-children.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/november/viiv-healthcare-commits-nearly-4m-in-positive-action-for-children-fund-grants-for-programmes-focused-on-alleviating-burden-of-hiv-on-women-and-children/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare commits nearly £4M in Positive Action for Children Fund grants for programmes focused on alleviating burden of HIV on women and children"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/november/viiv-healthcare-presents-phase-iii-data-from-viking-3-study-of-dolutegravir-in-hiv-1-infected-integrase-inhibitor-resistant-adults.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/november/viiv-healthcare-presents-phase-iii-data-from-viking-3-study-of-dolutegravir-in-hiv-1-infected-integrase-inhibitor-resistant-adults/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare presents phase III data from VIKING-3 study of dolutegravir in HIV-1 infected integrase inhibitor-resistant adults"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/october.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/october/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "October"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/october/shionogi-and-viiv-healthcare-announce-new-agreement-to-commercialise-and-develop-integrase-inhibitor-portfolio.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/october/shionogi-and-viiv-healthcare-announce-new-agreement-to-commercialise-and-develop-integrase-inhibitor-portfolio/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2012/october/shionogi-viiv-healthcare-announces-completion-of-initial-clinical-registration-package-for-dolutegravir-in-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/october/shionogi-viiv-healthcare-announces-completion-of-initial-clinical-registration-package-for-dolutegravir-in-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Shionogi-ViiV Healthcare announces completion of initial clinical registration package for dolutegravir in HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "2013"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/august.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/august/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "august"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/august/viiv-healthcare-announces-us-approval-of-tivicay-dolutegravir-for-the-treatment-of-hiv-1.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/august/viiv-healthcare-announces-us-approval-of-tivicay-dolutegravir-for-the-treatment-of-hiv-1/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces US approval of Tivicay® (dolutegravir) for the treatment of HIV-1"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/december.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/december/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "december"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/december/update-on-patent-ruling-on-viiv-healthcare-s-epzicom-and-trizivir.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/december/update-on-patent-ruling-on-viiv-healthcare-s-epzicom-and-trizivir/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Update on patent ruling on ViiV Healthcare’s Epzicom® and Trizivir®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/december/viiv-healthcare-commits-34m-in-positive-action-for-children-fund-grants-for-programmes-focused-on-prevention-of-mother-to-child-transmission-of-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/december/viiv-healthcare-commits-34m-in-positive-action-for-children-fund-grants-for-programmes-focused-on-prevention-of-mother-to-child-transmission-of-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare commits £3.4M in Positive Action for Children Fund grants for programmes focused on prevention of mother-to-child transmission of HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/february.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/february/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "february"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/february/viiv-healthcare-announces-a-voluntary-licence-agreement-with-the-medicines-patent-pool-to-increase-access-to-hiv-medicines-for-children.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/february/viiv-healthcare-announces-a-voluntary-licence-agreement-with-the-medicines-patent-pool-to-increase-access-to-hiv-medicines-for-children/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces a voluntary licence agreement with the Medicines Patent Pool to increase access to HIV medicines for children"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/february/viiv-healthcare-announces-fda-priority-review-designation-for-dolutegravir-as-a-potential-treatment-for-hiv-infection.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/february/viiv-healthcare-announces-fda-priority-review-designation-for-dolutegravir-as-a-potential-treatment-for-hiv-infection/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces FDA priority review designation for dolutegravir as a potential treatment for HIV infection"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/february/viiv-healthcare-expands-positive-action-southern-initiative-to-fight-hivaids-and-support-community-action.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/february/viiv-healthcare-expands-positive-action-southern-initiative-to-fight-hivaids-and-support-community-action/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare expands Positive Action Southern Initiative to fight HIV/AIDS and support community action"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/february0/viiv-healthcare-expands-positive-action-southern-initiative-to-f.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/february/viiv-healthcare-expands-positive-action-southern-initiative-to-fight-hivaids-and-support-community-action/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/february0/viiv-healthcare-expands-positive-action-southern-initiative-to-f/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "/community-partnerships/the-viiv-healthcare-effect/positive-action-southern-initiative.aspx."
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/march.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/march/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "march"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/march/viiv-healthcare-presents-data-from-phase-iii-study-of-dolutegravir-vs-raltegravir-in-treatment-experienced-adults-with-hiv-1.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/march/viiv-healthcare-presents-data-from-phase-iii-study-of-dolutegravir-vs-raltegravir-in-treatment-experienced-adults-with-hiv-1/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare presents data from Phase III study of dolutegravir vs raltegravir in treatment-experienced adults with HIV-1"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/november.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/november/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "november"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/october.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/october/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "october"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/october/viiv-healthcare-announces-european-regulatory-submission-for-single-tablet-regimen.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/october/viiv-healthcare-announces-european-regulatory-submission-for-single-tablet-regimen/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces European regulatory submission for single-tablet regimen"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/october/viiv-healthcare-announces-us-regulatory-submission-for-a-single-tablet-regimen-combining-dolutegravir-with-abacavir-and-lamivudine-for-people-living-with-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/october/viiv-healthcare-announces-us-regulatory-submission-for-a-single-tablet-regimen-combining-dolutegravir-with-abacavir-and-lamivudine-for-people-living-with-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces US regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine for people living with HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/september.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/september/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "september"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/september/viiv-healthcare-expands-hivaids-community-support-in-hard-hit-southern-us.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/september/viiv-healthcare-expands-hivaids-community-support-in-hard-hit-southern-us/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare Expands HIV/AIDS Community Support in Hard-Hit Southern US"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2013/september/viiv-healthcare-presents-positive-data-from-phase-iiibiv-study-of-dolutegravir-vs-darunavir-in-treatment-na%C3%AFve-adults-with-hiv-1.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/september/viiv-healthcare-presents-positive-data-from-phase-iiibiv-study-of-dolutegravir-vs-darunavir-in-treatment-na%c3%afve-adults-with-hiv-1/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare Presents Positive Data from Phase IIIb/IV Study of Dolutegravir vs Darunavir in Treatment-Naïve Adults with HIV-1"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "2014"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/april.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/april/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "April"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/april/viiv-healthcare-announces-new-initiatives-to-improve-access-to-dolutegravir-licence-to-the-medicines-patent-pool.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/april/viiv-healthcare-announces-new-initiatives-to-improve-access-to-dolutegravir-licence-to-the-medicines-patent-pool/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/august.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/august/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "August"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/august/viiv-healthcare-receives-fda-approval-for-triumeq.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/august/viiv-healthcare-receives-fda-approval-for-triumeq/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare receives FDA approval for Triumeq"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/december.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/december/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "December"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/december/mylans-tentative-fda-approval-for-paeds-formulations-of-abacavirlamivudine-through-innovative-collaboration-with-viiv-healthcare-and-chai.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/december/mylans-tentative-fda-approval-for-paeds-formulations-of-abacavirlamivudine-through-innovative-collaboration-with-viiv-healthcare-and-chai/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Mylan's tentative FDA approval for paeds formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and CHAI"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/december/viiv-healthcare-announces-regulatory-submission-in-japan-for-single-pill-regimen-combining-dolutegravir-abacavir-and-lamivudine-for-the-treatment-of-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/december/viiv-healthcare-announces-regulatory-submission-in-japan-for-single-pill-regimen-combining-dolutegravir-abacavir-and-lamivudine-for-the-treatment-of-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces regulatory submission in Japan for single-pill regimen combining dolutegravir, abacavir and lamivudine for the treatment of HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/january.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/january/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "January"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/january/viiv-healthcare-s-new-hiv-medicine-tivicay-dolutegravir-is-approved-in-europe.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/january/viiv-healthcare-s-new-hiv-medicine-tivicay-dolutegravir-is-approved-in-europe/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare’s new HIV medicine Tivicay™ (dolutegravir) is approved in Europe"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/january/viiv-healthcare-to-make-available-anonymised-patient-level-data-from-its-clinical-trials.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/january/viiv-healthcare-to-make-available-anonymised-patient-level-data-from-its-clinical-trials/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare to Make Available Anonymised Patient-Level Data from its Clinical Trials"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/july.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/july/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "July"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/july/viiv-healthcare-presents-phase-iii-data-comparing-once-daily-maraviroc.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/july/viiv-healthcare-presents-phase-iii-data-comparing-once-daily-maraviroc/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare presents phase III data comparing once-daily maraviroc"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/june.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/june/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "June"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/june/viiv-healthcare-announces-new-collaboration-with-janssen.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/june/viiv-healthcare-announces-new-collaboration-with-janssen/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces new collaboration with Janssen"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/march.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/march/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "March"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/march/viiv-healthcare-announces-next-round-of-the-positive-action-southern-initiative-to-support-linkages-to-hivaids-care-and-treatment-adherence.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/march/viiv-healthcare-announces-next-round-of-the-positive-action-southern-initiative-to-support-linkages-to-hivaids-care-and-treatment-adherence/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare Announces Next Round of the Positive Action Southern Initiative to Support Linkages to HIV/AIDS Care and Treatment Adherence"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/november.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/november/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "November"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/november/gsk-ranked-top-of-the-2014-access-to-medicines-atm-index-for-the-fourth-consecutive-time.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/november/gsk-ranked-top-of-the-2014-access-to-medicines-atm-index-for-the-fourth-consecutive-time/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "GSK ranked top of the 2014 Access to Medicines (ATM) Index for the fourth consecutive time"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/november/hiv-testing-week.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/november/hiv-testing-week/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "HIV Testing Week"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/november/viiv-healthcare-announces-new-grants-in-support-of-ending-mother-to-child-transmission-of-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/november/viiv-healthcare-announces-new-grants-in-support-of-ending-mother-to-child-transmission-of-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces new grants in support of ending mother to child transmission of HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/october.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/october/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "October"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2014/october/viiv-healthcare-expands-program-to-reduce-hiv-disparities-in-southern-us.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/october/viiv-healthcare-expands-program-to-reduce-hiv-disparities-in-southern-us/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare Expands Program to Reduce HIV Disparities in Southern US"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "2015"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/december.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/december/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "December"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/december/viiv-healthcare-to-acquire-bristol-myers-squibb-hiv-rd-assets.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/december/viiv-healthcare-to-acquire-bristol-myers-squibb-hiv-rd-assets/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare to acquire Bristol-Myers Squibb HIV R&D assets"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/february.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/february/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "February"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/february/viiv-healthcare-announces-10-million-initiative-to-accelerate-response-to-hivaids-among-black-gay-and-bisexual-men.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/february/viiv-healthcare-announces-10-million-initiative-to-accelerate-response-to-hivaids-among-black-gay-and-bisexual-men/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare Announces $10 Million Initiative to Accelerate Response to HIV/AIDS Among Black Gay and Bisexual Men"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/july.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/july/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "July"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/july/viiv-healthcare-and-desano-pharmaceuticals-manufacturing-agreement-will-allow-competitive-supply-of-dolutegravir-in-china-and-several-developing-countries.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/july/viiv-healthcare-and-desano-pharmaceuticals-manufacturing-agreement-will-allow-competitive-supply-of-dolutegravir-in-china-and-several-developing-countries/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare and Desano Pharmaceuticals’ manufacturing agreement will allow competitive supply of dolutegravir in China and several developing countries"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/june.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/june/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "June"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/june/viiv-healthcare-announces-new-positive-action-project-in-us-for-msm-youth-calls-for-proposals.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/june/viiv-healthcare-announces-new-positive-action-project-in-us-for-msm-youth-calls-for-proposals/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare Announces New Positive Action Project in US for MSM Youth, Calls for Proposals"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/march.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/march/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "March"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/march/viiv-healthcare-announces-the-approval-in-japan-of-triumeq-dolutegravir-abacavir-and-lamivudine-a-new-single-pill-regimen-for-the-treatment-of-hiv-infection.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/march/viiv-healthcare-announces-the-approval-in-japan-of-triumeq-dolutegravir-abacavir-and-lamivudine-a-new-single-pill-regimen-for-the-treatment-of-hiv-infection/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces the approval in Japan of Triumeq® (dolutegravir, abacavir and lamivudine), a new single-pill regimen for the treatment of HIV infection"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/march/viiv-healthcare-launches-new-global-positive-action-programme-focused-on-msm-and-transgender-populations.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/march/viiv-healthcare-launches-new-global-positive-action-programme-focused-on-msm-and-transgender-populations/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare Launches New Global Positive Action Programme Focused on MSM and Transgender Populations"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/may.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/may/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "May"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/may/european-patient-advocacy-groups-awarded-grants-from-positive-action-europe.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/may/european-patient-advocacy-groups-awarded-grants-from-positive-action-europe/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "European Patient Advocacy Groups Awarded Grants from Positive Action Europe"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/may/press-release.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/may/press-release/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Press Release"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/may/viiv-healthcare-begins-phase-iii-programme-with-dolutegravirrilpivirine-combination-for-hiv-maintenance-therapy.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/may/viiv-healthcare-begins-phase-iii-programme-with-dolutegravirrilpivirine-combination-for-hiv-maintenance-therapy/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare begins phase III programme with dolutegravir/rilpivirine combination for HIV maintenance therapy"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/november.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/november/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "November"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/november/viiv-healthcare-announces-positive-headline-results-from-a-study-of-two-drug-injectable-regimen-for-hiv-maintenance-therapy.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/november/viiv-healthcare-announces-positive-headline-results-from-a-study-of-two-drug-injectable-regimen-for-hiv-maintenance-therapy/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces positive headline results from a study of two drug injectable regimen for HIV maintenance therapy"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/november/viiv-healthcare-at-icasa-improving-access-to-hiv-treatment-and-care-for-people-everywhere.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/november/viiv-healthcare-at-icasa-improving-access-to-hiv-treatment-and-care-for-people-everywhere/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare at ICASA: Improving Access to HIV Treatment and Care for People Everywhere"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/november/viiv-healthcare-awards-additional-round-of-grants-to-support-innovative-hiv-programs-aimed-at-reducing-disparities-in-the-southern-us.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/november/viiv-healthcare-awards-additional-round-of-grants-to-support-innovative-hiv-programs-aimed-at-reducing-disparities-in-the-southern-us/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare Awards Additional Round of Grants to Support Innovative HIV Programs Aimed at Reducing Disparities in the Southern US"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/november/viiv-healthcare-gets-ready-for-africa-s-largest-hiv-aids-conference.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/november/viiv-healthcare-gets-ready-for-africa-s-largest-hiv-aids-conference/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare gets ready for Africa’s largest HIV-AIDS Conference"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/november/viiv-healthcare-highlights-its-continued-commitment-to-end-mother-to-child-transmission-of-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/november/viiv-healthcare-highlights-its-continued-commitment-to-end-mother-to-child-transmission-of-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare highlights its continued commitment to end mother to child transmission of HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/october.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/october/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "October"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/october/viiv-healthcare-awards-23-small-grants-to-help-alleviate-the-stigma-of-hiv-and-aids-in-the-msm-and-transgender-community-globally.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/october/viiv-healthcare-awards-23-small-grants-to-help-alleviate-the-stigma-of-hiv-and-aids-in-the-msm-and-transgender-community-globally/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare awards 23 small grants to help alleviate the stigma of HIV and AIDS in the MSM and transgender community globally"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/october/viiv-healthcare-employee-named-top-marketer-in-healthcare-industry-by-medical-marketing-media.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/october/viiv-healthcare-employee-named-top-marketer-in-healthcare-industry-by-medical-marketing-media/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare employee named top marketer in healthcare industry, by Medical Marketing & Media"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/september.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/september/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "September"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2015/september/new-phase-iiibiv-data-show-switching-to-once-daily-triumeq-maintains-hiv-viral-suppression.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/september/new-phase-iiibiv-data-show-switching-to-once-daily-triumeq-maintains-hiv-viral-suppression/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "New Phase IIIb/IV data show switching to once-daily Triumeq® maintains HIV viral suppression"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "2016"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/april.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/april/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "April"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/april/global-partnership-launches-new-programme-with-goal-to-save-the-lives-of-thousands-of-children-affected-by-hiv-in-lesotho.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/april/global-partnership-launches-new-programme-with-goal-to-save-the-lives-of-thousands-of-children-affected-by-hiv-in-lesotho/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Global partnership launches new programme with goal to save the lives of thousands of children affected by HIV in Lesotho"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/april/viiv-healthcare-extends-medicines-patent-pool-licence-agreement-for-dolutegravir-to-cover-all-lower-middle-income-countries.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/april/viiv-healthcare-extends-medicines-patent-pool-licence-agreement-for-dolutegravir-to-cover-all-lower-middle-income-countries/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare extends Medicines Patent Pool licence agreement for dolutegravir to cover all lower middle-income countries"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/august.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/august/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "August"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/august/viiv-healthcare-launches-phase-iii-programme-evaluating-a-two-drug-regimen-combining-dolutegravir-and-lamivudine-for-hiv-1-treatment.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/august/viiv-healthcare-launches-phase-iii-programme-evaluating-a-two-drug-regimen-combining-dolutegravir-and-lamivudine-for-hiv-1-treatment/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare launches phase III programme evaluating a two-drug regimen combining dolutegravir and lamivudine for HIV-1 treatment"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/december.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/december/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "December"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/december/dominique-limet-to-step-down-as-ceo-of-viiv-healthcare-deborah-waterhouse-to-succeed-him.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/december/dominique-limet-to-step-down-as-ceo-of-viiv-healthcare-deborah-waterhouse-to-succeed-him/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Dominique Limet to step down as CEO of ViiV Healthcare; Deborah Waterhouse to succeed him"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/december/new-agreement-with-ministry-of-health-will-enable-access-to-dolutegravir-for-the-treatment-of-hiv-under-the-national-health-programme-in-brazil.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/december/new-agreement-with-ministry-of-health-will-enable-access-to-dolutegravir-for-the-treatment-of-hiv-under-the-national-health-programme-in-brazil/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "New agreement with Ministry of Health will enable access to dolutegravir for the treatment of HIV under the national health programme in Brazil"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/december/viiv-healthcare-announces-chmp-positive-opinion-to-lower-the-age-and-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv-in-europe.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/december/viiv-healthcare-announces-chmp-positive-opinion-to-lower-the-age-and-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv-in-europe/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare Announces CHMP positive opinion to lower the age and weight limit for dolutegravir in children and adolescents living with HIV in Europe"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/december/viiv-healthcare-announces-positive-results-from-first-phase-iii-studies-of-two-drug-hiv-treatment-regimen.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/december/viiv-healthcare-announces-positive-results-from-first-phase-iii-studies-of-two-drug-hiv-treatment-regimen/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces positive results from first phase III studies of two-drug HIV treatment regimen"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/december/viiv-healthcare-announces-start-of-phase-iii-study-evaluating-long-acting-cabotegravir-for-hiv-prevention.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/december/viiv-healthcare-announces-start-of-phase-iii-study-evaluating-long-acting-cabotegravir-for-hiv-prevention/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces start of phase III study evaluating long-acting cabotegravir for HIV prevention"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/february.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/february/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "February"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/february/viiv-healthcare-announces-first-phase-ii-hiv-prevention-study-results-for-investigational-long-acting-injectable-cabotegravir.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/february/viiv-healthcare-announces-first-phase-ii-hiv-prevention-study-results-for-investigational-long-acting-injectable-cabotegravir/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces first phase II HIV prevention study results for investigational long-acting injectable cabotegravir"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/february/viiv-healthcare-announces-phase-ii-study-results-for-first-two-drug-long-acting-injectable-regimen-for-hiv-1-treatment.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/february/viiv-healthcare-announces-phase-ii-study-results-for-first-two-drug-long-acting-injectable-regimen-for-hiv-1-treatment/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/january.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/january/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "January"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/january/viiv-healthcare-to-progress-collaboration-with-janssen-to-develop-the-first-long-acting-two-drug-injectable-regimen-for-treatment-of-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/january/viiv-healthcare-to-progress-collaboration-with-janssen-to-develop-the-first-long-acting-two-drug-injectable-regimen-for-treatment-of-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare to progress collaboration with Janssen to develop the first long-acting, two drug injectable regimen for treatment of HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/july.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/july/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "July"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/july/aria-study-shows-superior-efficacy-of-triumeq-for-treatment-na%C3%AFve-women-living-with-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/july/aria-study-shows-superior-efficacy-of-triumeq-for-treatment-na%c3%afve-women-living-with-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ARIA study shows superior efficacy of Triumeq® for treatment-naïve women living with HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/june.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/june/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "June"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/june/viiv-healthcare-announces-fda-approval-to-lower-the-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/june/viiv-healthcare-announces-fda-approval-to-lower-the-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces FDA approval to lower the weight limit for dolutegravir in children and adolescents living with HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/june/viiv-healthcare-announces-public-tender-agreement-with-botswana-ministry-of-health-for-dolutegravir.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/june/viiv-healthcare-announces-public-tender-agreement-with-botswana-ministry-of-health-for-dolutegravir/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces public tender agreement with Botswana Ministry of Health for dolutegravir"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/june/viiv-healthcare-joins-penta-foundation-in-search-for-strategies-to-achieve-remission-in-children-living-with-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/june/viiv-healthcare-joins-penta-foundation-in-search-for-strategies-to-achieve-remission-in-children-living-with-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare joins PENTA Foundation in search for strategies to achieve remission in children living with HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/may.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/may/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "May"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/may/viiv-healthcare-and-the-international-association-of-providers-of-aids-care-to-collaborate-on-fast-track-cities.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/may/viiv-healthcare-and-the-international-association-of-providers-of-aids-care-to-collaborate-on-fast-track-cities/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare and the International Association of Providers of AIDS Care to Collaborate on Fast-Track Cities"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/november.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/november/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "November"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/november/viiv-healthcare-launches-phase-iii-programme-to-evaluate-a-long-acting-injectable-hiv-treatment-regimen.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/november/viiv-healthcare-launches-phase-iii-programme-to-evaluate-a-long-acting-injectable-hiv-treatment-regimen/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare launches phase III programme to evaluate a long-acting, injectable HIV treatment regimen"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/october.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/october/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "October"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/october/viiv-healthcare-announces-fda-approval-of-selzentry-maraviroc-for-use-in-children-and-adolescents-living-with-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/october/viiv-healthcare-announces-fda-approval-of-selzentry-maraviroc-for-use-in-children-and-adolescents-living-with-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare Announces FDA Approval of SELZENTRY® (maraviroc) for Use in Children and Adolescents Living With HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/october/viiv-healthcare-s-positive-action-europe-invites-applications-for-2017-grants-scheme.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/october/viiv-healthcare-s-positive-action-europe-invites-applications-for-2017-grants-scheme/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare’s Positive Action Europe Invites Applications for 2017 Grants Scheme"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/september.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/september/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "September"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/september/every-woman-every-child-and-viiv-healthcare-announce-the-winner-of-empowering-girls-in-emergency-settings-challenge-prize.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/september/every-woman-every-child-and-viiv-healthcare-announce-the-winner-of-empowering-girls-in-emergency-settings-challenge-prize/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Every Woman, Every Child and ViiV Healthcare Announce the Winner of ‘Empowering Girls in Emergency Settings’ Challenge Prize"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/september/new-hiv-awareness-in-primary-care-campaign-launched-to-increase-primary-care-hiv-testing.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/september/new-hiv-awareness-in-primary-care-campaign-launched-to-increase-primary-care-hiv-testing/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "New HIV Awareness in Primary Care campaign launched to increase primary care HIV testing"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2016/september/viiv-healthcare-welcomes-the-fda-s-tentative-approval-of-the-first-generic-dolutegravir-from-aurobindo-pharma.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/september/viiv-healthcare-welcomes-the-fda-s-tentative-approval-of-the-first-generic-dolutegravir-from-aurobindo-pharma/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare welcomes the FDA’s Tentative Approval of the first generic dolutegravir from Aurobindo Pharma"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "2017"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/february.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/february/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "February"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/february/viiv-healthcare-announces-detailed-positive-phase-iii-results-for-investigational-two-drug-regimen-of-dolutegravir-and-rilpivirine-for-hiv-treatment.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/february/viiv-healthcare-announces-detailed-positive-phase-iii-results-for-investigational-two-drug-regimen-of-dolutegravir-and-rilpivirine-for-hiv-treatment/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces detailed positive phase III results for investigational two-drug regimen of dolutegravir and rilpivirine for HIV treatment"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/february/viiv-healthcare-welcomes-european-commission-approval-of-dolutegravir-paediatric-type-ii-variation-and-extension-applications.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/february/viiv-healthcare-welcomes-european-commission-approval-of-dolutegravir-paediatric-type-ii-variation-and-extension-applications/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare welcomes European Commission approval of dolutegravir paediatric Type II variation and extension applications"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/honoring-the-memory-of-dr-mark-wainberg.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/honoring-the-memory-of-dr-mark-wainberg/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Honoring the memory of Dr Mark Wainberg"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/january.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/january/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "January"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/january/viiv-healthcare-awards-grants-to-msm-and-transgender-hiv-programmes-led-by-the-community-for-the-community.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/january/viiv-healthcare-awards-grants-to-msm-and-transgender-hiv-programmes-led-by-the-community-for-the-community/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare awards grants to MSM and Transgender HIV programmes led by the community for the community"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/january/viiv-healthcare-re-affirms-its-continued-commitment-to-ending-mother-to-child-transmission-of-hiv-with-35-new-community-grants.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/january/viiv-healthcare-re-affirms-its-continued-commitment-to-ending-mother-to-child-transmission-of-hiv-with-35-new-community-grants/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare re-affirms its continued commitment to ending mother- to- child transmission of HIV with 35 new community grants"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/july.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/july/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "July"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/july/phase-ii-study-results-showed-comparable-viral-suppression-rates-at-96-weeks-for-a-two-drug-regimen.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/july/phase-ii-study-results-showed-comparable-viral-suppression-rates-at-96-weeks-for-a-two-drug-regimen/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Phase II study results showed comparable viral suppression rates at 96 weeks for a two-drug regimen"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/july/viiv-healthcare-and-neat-id-announce-results-from-the-neat-022-study-at-the-international-aids-society-meeting-in-paris.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/july/viiv-healthcare-and-neat-id-announce-results-from-the-neat-022-study-at-the-international-aids-society-meeting-in-paris/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare and NEAT-ID announce results from the NEAT 022 study at the International AIDS Society meeting in Paris"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/july/viiv-healthcare-announces-superior-efficacy-of-dolutegravir-versus-lopinavirritonavir-in-second-line-hiv-treatment-in-resource-limited-settings.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/july/viiv-healthcare-announces-superior-efficacy-of-dolutegravir-versus-lopinavirritonavir-in-second-line-hiv-treatment-in-resource-limited-settings/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces superior efficacy of dolutegravir versus lopinavir/ritonavir in second-line HIV treatment in resource-limited settings"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/july/viiv-healthcare-shares-data-from-its-innovative-portfolio-with-hiv-community-at-ias-2017.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/july/viiv-healthcare-shares-data-from-its-innovative-portfolio-with-hiv-community-at-ias-2017/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare shares data from its innovative portfolio with HIV community at IAS 2017"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/june.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/june/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "June"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/june/viiv-healthcare-s-positive-action-europe-programme-awards-grants-to-14-community-based-organisations.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/june/viiv-healthcare-s-positive-action-europe-programme-awards-grants-to-14-community-based-organisations/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare’s Positive Action Europe Programme awards grants to 14 community-based organisations"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/june/viiv-healthcare-submits-regulatory-applications-for-the-first-hiv-maintenance-regimen-comprising-only-two-medicines.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/june/viiv-healthcare-submits-regulatory-applications-for-the-first-hiv-maintenance-regimen-comprising-only-two-medicines/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare submits regulatory applications for the first HIV maintenance regimen comprising only two medicines"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/march.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/march/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "March"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/march/viiv-healthcare-ranks-1-in-patientview-corporate-reputation-surv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/contenuti-ita/il-nostro-essere-responsabili/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/march/viiv-healthcare-ranks-1-in-patientview-corporate-reputation-surv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "indagine annuale PatientView"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/march/viiv-healthcare-ranks-1-in-patientview-corporate-reputation-survey.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/march/viiv-healthcare-ranks-1-in-patientview-corporate-reputation-survey/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare ranks #1 in PatientView corporate reputation survey"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/november.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/november/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "November"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/november/viiv-healthcare-announces-start-of-phase-iii-study-of-long-actin.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2017/novembre/viiv-healthcare-annuncia-la-partenza-dello-studio-di-fase-iii-co/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/november/viiv-healthcare-announces-start-of-phase-iii-study-of-long-actin/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "https://www.viivhealthcare.com/media/press-releases/2017/november/viiv-healthcare-announces-start-of-phase-iii-study-of-long-acting-cabotegravir-for-hiv-prevention-in-women.asp"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/november/viiv-healthcare-announces-start-of-phase-iii-study-of-long-acting-cabotegravir-for-hiv-prevention-in-women.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/november/viiv-healthcare-announces-start-of-phase-iii-study-of-long-acting-cabotegravir-for-hiv-prevention-in-women/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces start of phase III study of long-acting cabotegravir for HIV prevention in women"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/november/viiv-healthcare-announces-us-fda-approval-for-juluca.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/november/viiv-healthcare-announces-us-fda-approval-for-juluca/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces US FDA approval for Juluca®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/november/viiv-healthcare-starts-third-phase-iii-hiv-treatment-study-investigating-long-acting-two-drug-regimen-of-cabotegravir-plus-rilpivirine.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/november/viiv-healthcare-starts-third-phase-iii-hiv-treatment-study-investigating-long-acting-two-drug-regimen-of-cabotegravir-plus-rilpivirine/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare starts third phase III HIV treatment study investigating long-acting two-drug regimen of cabotegravir plus rilpivirine"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/october.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/october/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "October"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/october/new-results-from-the-positive-perspectives-global-survey-provide-insights-into-the-attitudes-and-perceptions-of-people-living-with-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/october/new-results-from-the-positive-perspectives-global-survey-provide-insights-into-the-attitudes-and-perceptions-of-people-living-with-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "New results from the Positive Perspectives global survey provide insights into the attitudes and perceptions of people living with HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/october/tivicay-and-celsentri-now-included-in-the-essential-drug-list-in-russia.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/october/tivicay-and-celsentri-now-included-in-the-essential-drug-list-in-russia/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Tivicay® and Celsentri® now included in the Essential Drug List in Russia"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/october/viiv-healthcare-announces-positive-phase-3-results-from-the-brig.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-annuncia-i-risultati-positivi-di-fase-3-dello-st/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/october/viiv-healthcare-announces-positive-phase-3-results-from-the-brig/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "qui"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2017/october/viiv-healthcare-announces-positive-phase-3-results-from-the-brighte-study-of-fostemsavir-in-heavily-treatment-experienced-patients-with-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/october/viiv-healthcare-announces-positive-phase-3-results-from-the-brighte-study-of-fostemsavir-in-heavily-treatment-experienced-patients-with-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "2018"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/december.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/december/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "december"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/december/viiv-healthcare-update-on-commitments-regarding-the-clinical-development-and-registration-of-age-appropriate-formulations-of-dolutegravir-for-the-treatment-of-hiv-in-infant-and-children.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/december/viiv-healthcare-update-on-commitments-regarding-the-clinical-development-and-registration-of-age-appropriate-formulations-of-dolutegravir-for-the-treatment-of-hiv-in-infant-and-children/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare update on commitments regarding the clinical development and registration of age-appropriate formulations of dolutegravir for the treatment of HIV in infant and children"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/february.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/february/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "February"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/february/viiv-healthcare-files-patent-infringement-litigation-against-gilead-sciences-inc-over-bictegravir.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/february/viiv-healthcare-files-patent-infringement-litigation-against-gilead-sciences-inc-over-bictegravir/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare files patent infringement litigation against Gilead Sciences Inc. over bictegravir"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/february/viiv-healthcare-launches-eighth-phase-iii-study-in-two-drug-regi.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/febbraio/viiv-healthcare-annuncia-la-partenza-dellottavo-studio-di-fase-i/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/february/viiv-healthcare-launches-eighth-phase-iii-study-in-two-drug-regi/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "qui"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/february/viiv-healthcare-launches-eighth-phase-iii-study-in-two-drug-regimen-programme-for-hiv-1-treatment.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/february/viiv-healthcare-launches-eighth-phase-iii-study-in-two-drug-regimen-programme-for-hiv-1-treatment/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare launches eighth phase III study in two-drug regimen programme for HIV-1 treatment"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/july.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/july/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "July"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/july/innovative-public-private-partnership-initiative-to-accelerate-development-of-optimal-pediatric-formulations-of-dolutegravir-to-improve-the-lives-of-clhiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/july/innovative-public-private-partnership-initiative-to-accelerate-development-of-optimal-pediatric-formulations-of-dolutegravir-to-improve-the-lives-of-clhiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Innovative public-private partnership initiative to accelerate development of optimal pediatric formulations of dolutegravir to improve the lives of CLHIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/july/viiv-healthcare-announces-sword-100-week-data-for-juluca-dolutegravirrilpivirine-at-aids-2018.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/july/viiv-healthcare-announces-sword-100-week-data-for-juluca-dolutegravirrilpivirine-at-aids-2018/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces SWORD 100-week data for Juluca (dolutegravir/rilpivirine) at AIDS 2018"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/july/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen-has-similar-efficacy-to-a-three-drug-regimen-in-treatment-naive-hiv-patients-with-no-resistance.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/july/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen-has-similar-efficacy-to-a-three-drug-regimen-in-treatment-naive-hiv-patients-with-no-resistance/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare presents phase III data showing two drug regimen has similar efficacy to a three-drug regimen in treatment naïve HIV patients, with no resistance"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/july/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/luglio/viiv-healthcare-presenta-ad-aids-2018-i-dati-di-fase-iii-per-gli/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/july/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "qui"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/july/viiv-healthcare-s-commitments-to-accelerate-the-availability-of-dolutegravir-for-the-treatment-of-hiv-in-children.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/july/viiv-healthcare-s-commitments-to-accelerate-the-availability-of-dolutegravir-for-the-treatment-of-hiv-in-children/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare’s commitments to accelerate the availability of dolutegravir for the treatment of HIV in children"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/july/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-at-aids-2018.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/july/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-at-aids-2018/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare shares data from landmark 2-drug regimen trials at AIDS 2018"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/june.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/june/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "June"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/june/viiv-healthcare-reports-positive-results-for-landmark-phase-iii-.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/giugno/viiv-healthcare-annuncia-importanti-studi-di-fase-iii-per-dolute/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/june/viiv-healthcare-reports-positive-results-for-landmark-phase-iii-/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "qui"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/june/viiv-healthcare-reports-positive-results-for-landmark-phase-iii-studies-for-dolutegravir-and-lamivudine.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/june/viiv-healthcare-reports-positive-results-for-landmark-phase-iii-studies-for-dolutegravir-and-lamivudine/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare reports positive results for landmark phase III studies for dolutegravir and lamivudine"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/march.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/march/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "March"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/march/viiv-healthcare-announces-positive-new-dolutegravir-data-for-the-treatment-of-people-living-with-hiv-co-infected-with-tuberculosis.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/march/viiv-healthcare-announces-positive-new-dolutegravir-data-for-the-treatment-of-people-living-with-hiv-co-infected-with-tuberculosis/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces positive new dolutegravir data for the treatment of people living with HIV co-infected with tuberculosis"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/march/viiv-healthcare-gains-chmp-positive-opinion-for-juluca-dolutegra.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/marzo/marzo/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/march/viiv-healthcare-gains-chmp-positive-opinion-for-juluca-dolutegra/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "qui"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/march/viiv-healthcare-gains-chmp-positive-opinion-for-juluca-dolutegravirrilpivirine-in-europe.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/march/viiv-healthcare-gains-chmp-positive-opinion-for-juluca-dolutegravirrilpivirine-in-europe/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/may.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/may/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "May"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/may/viiv-healthcare-receives-eu-marketing-authorisation-for-juluca-dolutegravirrilpivirine-the-first-2-drug-regimen-once-daily-single-pill-for-the-treatment-of-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/may/viiv-healthcare-receives-eu-marketing-authorisation-for-juluca-dolutegravirrilpivirine-the-first-2-drug-regimen-once-daily-single-pill-for-the-treatment-of-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare receives EU marketing authorisation for Juluca (dolutegravir/rilpivirine), the first 2-drug regimen, once-daily, single-pill for the treatment of HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/may/viiv-healthcare-reports-positive-results-for-landmark-phase-iii-.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/maggio/viiv-healthcare-riceve-lapprovazione-in-europa-per-la-combinazio/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/may/viiv-healthcare-reports-positive-results-for-landmark-phase-iii-/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "qui"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/november/fast-track-cities-survey-data-provide-insights-into-quality-of-life-of-people-living-with-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/november/fast-track-cities-survey-data-provide-insights-into-quality-of-life-of-people-living-with-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Fast-Track Cities Survey Data Provide Insights into Quality of Life of People Living with HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/october.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/october/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "October"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/viiv-healthcare-reports-positive-48-week-results-for-first-pivot.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-presenta-i-risultati-positivi-a-48-settimane-del/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/viiv-healthcare-reports-positive-48-week-results-for-first-pivot/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "qui"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/viiv-healthcare-reports-positive-48-week-results-for-first-pivotal-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/viiv-healthcare-reports-positive-48-week-results-for-first-pivotal-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare reports positive 48-week results for first pivotal, phase III study for novel, long-acting, injectable HIV-treatment regimen"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/viiv-healthcare-submits-regulatory-application-to-european-medicines-agency-for-single-tablet-two-drug-regimen-of-dolutegravir-and-lamivudine-for-treatment-of-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/viiv-healthcare-submits-regulatory-application-to-european-medicines-agency-for-single-tablet-two-drug-regimen-of-dolutegravir-and-lamivudine-for-treatment-of-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "viiv healthcare submits regulatory application to ema for single tablet two drug regimen of dolutegravir and lamivudine for treatment of hiv"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/2018/viiv-healthcare-update-on-how-we-work-with-healthcare-professionals.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/viiv-healthcare-update-on-how-we-work-with-healthcare-professionals/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare update on how we work with healthcare professionals"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/juluca-the-first-single-pill-2-drug-regimen-for-the-maintenance-treatment-of-hiv-granted-marketing-approval-by-japan-ministry-of-health-labour-and-welfare.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/juluca-the-first-single-pill-2-drug-regimen-for-the-maintenance-treatment-of-hiv-granted-marketing-approval-by-japan-ministry-of-health-labour-and-welfare/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Juluca, the first single pill, 2-drug regimen, for the maintenance treatment of HIV, granted marketing approval by Japan Ministry of Health, Labour and Welfare"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/viiv-healthcare-announces-positive-phase-3-results-from-the-brighte-study-of-fostemsavir-in-heavily-treatment-experienced-patients-with-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-phase-3-results-from-the-brighte-study-of-fostemsavir-in-heavily-treatment-experienced-patients-with-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare announces positive phase 3 results from the BRIGHTE study of fostemsavir in heavily treatment-experienced patients with HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/viiv-healthcare-presents-three-year-data-for-investigational-lon.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-presenta-i-dati-relativi-a-tre-anni-di-trattamen/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/viiv-healthcare-presents-three-year-data-for-investigational-lon/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "qui"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/viiv-healthcare-presents-three-year-data-for-investigational-long-acting-injectable-two-drug-hiv-regimen.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/viiv-healthcare-presents-three-year-data-for-investigational-long-acting-injectable-two-drug-hiv-regimen/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare presents three year data for investigational long acting injectable two drug HIV regimen (1)"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/viiv-healthcare-receives-chmp-positive-opinion-for-tivicay-eu-label-update-with-gemini-study-data-for-the-2-drug-regimen-of-tivicay-plus-lamivudine.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/viiv-healthcare-receives-chmp-positive-opinion-for-tivicay-eu-label-update-with-gemini-study-data-for-the-2-drug-regimen-of-tivicay-plus-lamivudine/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare receives CHMP Positive Opinion for Tivicay EU label update with GEMINI study data for the 2-drug regimen of Tivicay + lamivudine (1)"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare reports positive 48-week results for second phase III study for novel, long-acting, injectable HIV-treatment regimen"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/press-releases/viiv-healthcare-submits-new-drug-application-to-us-fda-for-single-tablet-two-drug-regimen-of-dolutegravir-and-lamivudine-for-treatment-of-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/viiv-healthcare-submits-new-drug-application-to-us-fda-for-single-tablet-two-drug-regimen-of-dolutegravir-and-lamivudine-for-treatment-of-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare submits New Drug Application to US FDA for single-tablet, two-drug regimen of dolutegravir and lamivudine for treatment of HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/viiv-healthcare-s-innovation-unit-offers-fresh-approach-to-solving-important-challenges-in-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/how-our-innovation-unit-is-addressing-new-areas-of-need-in-hiv-care/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/viiv-healthcare-s-innovation-unit-offers-fresh-approach-to-solving-important-challenges-in-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare's Innovation Unit offers fresh approach to solving important challenges in HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/media/viiv-healthcare-s-the-hive-and-positive-action-community-challenge-seek-outside-collaborations-in-order-to-innovate-for-people-living-with-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/how-our-innovation-unit-is-addressing-new-areas-of-need-in-hiv-care/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/viiv-healthcare-s-the-hive-and-positive-action-community-challenge-seek-outside-collaborations-in-order-to-innovate-for-people-living-with-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare's 'the hive' and Positive Action Community Challenge seek outside collaborations in order to innovate for people living with HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/medical-education-events.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/medical-education-events/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Medical Education Events"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "results": {},
      "status": "done",
      "statusCode": 200,
      "txt": "Netherlands"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/privacy-verklaring.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/privacy-verklaring/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Privacy Verklaring"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/privacy-verklaring/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/privacy-verklaring.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "RETHiNK+ verhalen  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/-ik-had-meer-last-van-het-leven-met-een-geheim-dan-van-hiv-zelf-.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/-ik-had-meer-last-van-het-leven-met-een-geheim-dan-van-hiv-zelf-/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "interview met Gino"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/-ik-had-meer-last-van-het-leven-met-een-geheim-dan-van-hiv-zelf-/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/-ik-had-meer-last-van-het-leven-met-een-geheim-dan-van-hiv-zelf-.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/als-een-kind-tegen-hiv-blijft-vechten--dan-wordt-het-een-groot-d.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/als-een-kind-tegen-hiv-blijft-vechten--dan-wordt-het-een-groot-d/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/als-een-kind-tegen-hiv-blijft-vechten--dan-wordt-het-een-groot-d/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/als-een-kind-tegen-hiv-blijft-vechten--dan-wordt-het-een-groot-d.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/amsterdam-op-weg-naar-een-toekomst-zonder-nieuwe-hiv-infecties.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/amsterdam-op-weg-naar-een-toekomst-zonder-nieuwe-hiv-infecties/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/amsterdam-op-weg-naar-een-toekomst-zonder-nieuwe-hiv-infecties/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/amsterdam-op-weg-naar-een-toekomst-zonder-nieuwe-hiv-infecties.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/brenda--leven-met-hiv-in-oeganda.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/brenda--leven-met-hiv-in-oeganda/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/brenda--leven-met-hiv-in-oeganda/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/brenda--leven-met-hiv-in-oeganda.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/de-leukste-dag-van-het-jaar-om-hiv-te-hebben.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/leven-met-het-hiv-label/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/de-leukste-dag-van-het-jaar-om-hiv-te-hebben/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "De leukste dag van het jaar om hiv te hebben  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/de-leukste-dag-van-het-jaar-om-hiv-te-hebben/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/de-leukste-dag-van-het-jaar-om-hiv-te-hebben.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/de-mensen-van-de-hiv-vereniging.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/-ik-had-meer-last-van-het-leven-met-een-geheim-dan-van-hiv-zelf-/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/de-mensen-van-de-hiv-vereniging/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "De mensen van de Hiv Vereniging  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/de-mensen-van-de-hiv-vereniging/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/de-mensen-van-de-hiv-vereniging.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/happi-app.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/happi-app/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Lees hier het artikel"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/happi-app/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/happi-app.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/hiv-uit-de-kast-campagne.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/hiv-uit-de-kast-campagne/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/hiv-uit-de-kast-campagne/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/hiv-uit-de-kast-campagne.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-corina.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-corina/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-corina/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-corina.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-eliane.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-eliane/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-eliane/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-eliane.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-jorgen--vrijwilliger-voor-poz-proud.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-jorgen--vrijwilliger-voor-poz-proud/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-jorgen--vrijwilliger-voor-poz-proud/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-jorgen--vrijwilliger-voor-poz-proud.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-pieter-brokx--directeur-hiv-vereniging.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-pieter-brokx--directeur-hiv-vereniging/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-pieter-brokx--directeur-hiv-vereniging/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-pieter-brokx--directeur-hiv-vereniging.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-reina.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-reina/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-reina/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-reina.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-tim.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-tim/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-tim/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-tim.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/jongvolwassenen-hebben-speciale-aandacht-nodig.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/jongvolwassenen-hebben-speciale-aandacht-nodig/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/jongvolwassenen-hebben-speciale-aandacht-nodig/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/jongvolwassenen-hebben-speciale-aandacht-nodig.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/knap-als-een-tiener-de-pillen-goed-slikt.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/leven-met-het-hiv-label/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/knap-als-een-tiener-de-pillen-goed-slikt/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Knap als een tiener de pillen goed slikt  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/knap-als-een-tiener-de-pillen-goed-slikt/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/knap-als-een-tiener-de-pillen-goed-slikt.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/leven-met-het-hiv-label.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/leven-met-het-hiv-label/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "hier"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/leven-met-het-hiv-label/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/leven-met-het-hiv-label.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/matchen-van-maatjes.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/matchen-van-maatjes/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/matchen-van-maatjes/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/matchen-van-maatjes.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/mijn-maatje-heeft-mijn-leven-gered.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/mijn-maatje-heeft-mijn-leven-gered/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/mijn-maatje-heeft-mijn-leven-gered/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/mijn-maatje-heeft-mijn-leven-gered.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/positieve-krachten-bundelen.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/positieve-krachten-bundelen/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/positieve-krachten-bundelen/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/positieve-krachten-bundelen.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/rethink--volgens-viiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/rethink--volgens-viiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/rethink--volgens-viiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/rethink--volgens-viiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/stigma-ervaring--john.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/leven-met-het-hiv-label/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/stigma-ervaring--john/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "John"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/stigma-ervaring--john/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/stigma-ervaring--john.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/therapietrouw-bij-migranten.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/therapietrouw-bij-migranten/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/therapietrouw-bij-migranten/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/therapietrouw-bij-migranten.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/veel-pubers-worstelen-met-het-aangaan-van-intieme-relaties.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/leven-met-het-hiv-label/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/veel-pubers-worstelen-met-het-aangaan-van-intieme-relaties/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Veel pubers worstelen met het aangaan van intieme relaties  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/veel-pubers-worstelen-met-het-aangaan-van-intieme-relaties/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/veel-pubers-worstelen-met-het-aangaan-van-intieme-relaties.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "RETHiNK+ verhalen"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/als-een-kind-tegen-hiv-blijft-vechten-dan-wordt-het-een-groot-ding.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/als-een-kind-tegen-hiv-blijft-vechten-dan-wordt-het-een-groot-ding/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "Als een kind tegen hiv blijft vechten, dan wordt het een groot ding"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/als-een-kind-tegen-hiv-blijft-vechten-dan-wordt-het-een-groot-ding/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/als-een-kind-tegen-hiv-blijft-vechten-dan-wordt-het-een-groot-ding.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/amsterdam-op-weg-naar-een-toekomst-zonder-nieuwe-hiv-infecties.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/amsterdam-op-weg-naar-een-toekomst-zonder-nieuwe-hiv-infecties/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "Amsterdam op weg naar een toekomst zonder nieuwe hiv-infecties"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/amsterdam-op-weg-naar-een-toekomst-zonder-nieuwe-hiv-infecties/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/amsterdam-op-weg-naar-een-toekomst-zonder-nieuwe-hiv-infecties.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/brenda-leven-met-hiv-in-oeganda.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/brenda-leven-met-hiv-in-oeganda/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "Brenda: Leven met hiv in Oeganda"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/brenda-leven-met-hiv-in-oeganda/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/brenda-leven-met-hiv-in-oeganda.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/de-leukste-dag-van-het-jaar-om-hiv-te-hebben.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/de-leukste-dag-van-het-jaar-om-hiv-te-hebben/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "De leukste dag van het jaar om hiv te hebben"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/de-leukste-dag-van-het-jaar-om-hiv-te-hebben/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/de-leukste-dag-van-het-jaar-om-hiv-te-hebben.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/de-mensen-van-de-hiv-vereniging.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/de-mensen-van-de-hiv-vereniging/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "De mensen van de Hiv Vereniging"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/de-mensen-van-de-hiv-vereniging/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/de-mensen-van-de-hiv-vereniging.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/happi-app.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/happi-app/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "Happi app"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/happi-app/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/happi-app.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/hiv-uit-de-kast-campagne.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/hiv-uit-de-kast-campagne/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "Hiv uit de kast campagne"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/hiv-uit-de-kast-campagne/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/hiv-uit-de-kast-campagne.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/ik-had-meer-last-van-het-leven-met-een-geheim-dan-van-hiv-zelf.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/ik-had-meer-last-van-het-leven-met-een-geheim-dan-van-hiv-zelf/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "'Ik had meer last van het leven met een geheim dan van hiv zelf'"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/ik-had-meer-last-van-het-leven-met-een-geheim-dan-van-hiv-zelf/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/ik-had-meer-last-van-het-leven-met-een-geheim-dan-van-hiv-zelf.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/interview-corina.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/interview-corina/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "Interview Corina"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/interview-corina/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/interview-corina.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/interview-jorgen-vrijwilliger-voor-pozproud.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/interview-jorgen-vrijwilliger-voor-pozproud/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "Interview Jorgen, vrijwilliger voor Poz&Proud"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/interview-jorgen-vrijwilliger-voor-pozproud/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/interview-jorgen-vrijwilliger-voor-pozproud.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/interview-pieter-brokx-directeur-hiv-vereniging.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/interview-pieter-brokx-directeur-hiv-vereniging/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "Interview Pieter Brokx, directeur Hiv Vereniging"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/interview-pieter-brokx-directeur-hiv-vereniging/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/interview-pieter-brokx-directeur-hiv-vereniging.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/interview-reina.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/interview-reina/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "Interview Reina"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/interview-reina/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/interview-reina.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/interview-tim.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/interview-tim/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "Interview Tim"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/interview-tim/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/interview-tim.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/jongvolwassenen-hebben-speciale-aandacht-nodig.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/jongvolwassenen-hebben-speciale-aandacht-nodig/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "Jongvolwassenen hebben speciale aandacht nodig"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/jongvolwassenen-hebben-speciale-aandacht-nodig/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/jongvolwassenen-hebben-speciale-aandacht-nodig.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/knap-als-een-tiener-de-pillen-goed-slikt.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/knap-als-een-tiener-de-pillen-goed-slikt/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "Knap als een tiener de pillen goed slikt"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/knap-als-een-tiener-de-pillen-goed-slikt/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/knap-als-een-tiener-de-pillen-goed-slikt.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/leven-met-het-hiv-label.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/leven-met-het-hiv-label/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "Leven met het hiv-label"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/leven-met-het-hiv-label/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/leven-met-het-hiv-label.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/matchen-van-maatjes.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/matchen-van-maatjes/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "Matchen van maatjes"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/matchen-van-maatjes/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/matchen-van-maatjes.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/mijn-maatje-heeft-mijn-leven-gered.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/mijn-maatje-heeft-mijn-leven-gered/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "Mijn maatje heeft mijn leven gered"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/mijn-maatje-heeft-mijn-leven-gered/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/mijn-maatje-heeft-mijn-leven-gered.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/positieve-krachten-bundelen.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/positieve-krachten-bundelen/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "Positieve Krachten Bundelen"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/positieve-krachten-bundelen/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/positieve-krachten-bundelen.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/rethinkplus-volgens-viiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/rethinkplus-volgens-viiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "RETHiNK+ volgens ViiV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/rethinkplus-volgens-viiv/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/rethinkplus-volgens-viiv.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/stigma-ervaring-john.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/stigma-ervaring-john/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "Stigma ervaring: John"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/stigma-ervaring-john/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/stigma-ervaring-john.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/therapietrouw-bij-migranten.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/therapietrouw-bij-migranten/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "Therapietrouw bij migranten"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/therapietrouw-bij-migranten/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/therapietrouw-bij-migranten.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/veel-pubers-worstelen-met-het-aangaan-van-intieme-relaties.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/veel-pubers-worstelen-met-het-aangaan-van-intieme-relaties/",
      "results": {},
      "status": "redirected",
      "statusCode": "404,301",
      "txt": "Veel pubers worstelen met het aangaan van intieme relaties"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/veel-pubers-worstelen-met-het-aangaan-van-intieme-relaties/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethinkplus-verhalen/veel-pubers-worstelen-met-het-aangaan-van-intieme-relaties.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/welkom.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/welkom/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Welkom  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/welkom/": {
      "redirectedFrom": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/welkom.html"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Our Medicines"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/combivir.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/combivir/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Combivir®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/epivir-3tc.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/epivir-3tc/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Epivir/ 3TC®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/epzicom-kivexa.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/epzicom-kivexa/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Epzicom/ Kivexa®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/juluca.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/juluca/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Juluca®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/lexiva-telzir.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/lexiva-telzir/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Lexiva/ Telzir®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/medicines-in-development.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/medicines-in-development/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Medicines in development"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/report-a-side-effect.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/juluca/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/report-a-side-effect/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Report a side effect"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/rescriptor.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/rescriptor/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Rescriptor®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/retrovir-azt.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/retrovir-azt/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Retrovir/ AZT®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/selzentry-celsentri.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/selzentry-celsentri/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Selzentry/ Celsentri®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/tivicay.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/tivicay/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Tivicay®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/triumeq.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/triumeq/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Triumeq®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/trizivir.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/trizivir/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Trizivir®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/viracept.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/viracept/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Viracept®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-medicines/ziagen.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/ziagen/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Ziagen®"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Our Stories"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/accelerating-city-hivaids-responses-through-collaboration.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/championing-effective-hiv-care-for-plhiv/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/accelerating-city-hivaids-responses-through-collaboration/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/addressing-the-challenges-of-the-hiv-epidemic-in-africa.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/addressing-the-challenges-of-the-hiv-epidemic-in-africa/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Addressing the challenges of the HIV epidemic in Africa"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/championing-effective-hiv-care-for-plhiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/championing-effective-hiv-care-for-plhiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Championing effective HIV care for PLHIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/driving-change-through-implementation-science.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/championing-effective-hiv-care-for-plhiv/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/driving-change-through-implementation-science/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/fighting-hiv-together-collaboration-is-driving-progress-with-the-launch-of-new-fast-track-city-dashboards.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/fighting-hiv-together-collaboration-is-driving-progress-with-the-launch-of-new-fast-track-city-dashboards/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Fighting HIV Together: Collaboration is driving progress with the launch of new Fast-Track City dashboards"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/helping-botswana-treat-all-people-living-with-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/we-improve-access-to-our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/helping-botswana-treat-all-people-living-with-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/hiv-is-a-global-issue-that-needs-an-ongoing-collaborative-response.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/hiv-is-a-global-issue-that-needs-an-ongoing-collaborative-response/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "HIV is a global issue that needs an ongoing, collaborative response."
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/how-the-unity-tool-can-help-conversations-between-plhiv-and-their-hcp.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/how-the-unity-tool-can-help-conversations-between-plhiv-and-their-hcp/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "How the Unity Tool can help conversations between PLHIV and their HCP"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/metrics-matter-measuring-impact-in-hiv-implementation.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/metrics-matter-measuring-impact-in-hiv-implementation/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Metrics matter: measuring impact in HIV implementation"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/overcoming-the-challenges-for-partners-of-people-living-with-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/overcoming-the-challenges-for-partners-of-people-living-with-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Overcoming the challenges for partners of people living with HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/positive-partnerships-initiative-launches-in-estonia.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/positive-partnerships-initiative-launches-in-estonia/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Positive Partnerships initiative launches in Estonia"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/preliminary-positive-perspectives-survey-data-released-at-9th-international-aids-society-conference.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/preliminary-positive-perspectives-survey-data-released-at-9th-international-aids-society-conference/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Preliminary Positive Perspectives Survey Data Released at 9th International AIDS Society Conference"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/striking-the-right-balance.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/we-improve-access-to-our-medicines/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/striking-the-right-balance/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/the-state-of-hiv-implementation-science-do-we-need-more-science-or-more-implementation.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/championing-effective-hiv-care-for-plhiv/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/the-state-of-hiv-implementation-science-do-we-need-more-science-or-more-implementation/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/towards-a-cure-exploring-cure-and-remission-in-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/towards-a-cure-exploring-cure-and-remission-in-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Towards a Cure: exploring cure and remission in HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/understanding-the-concerns-of-people-living-with-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/championing-effective-hiv-care-for-plhiv/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/understanding-the-concerns-of-people-living-with-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/viiv-healthcare-s-commitment-to-implementation-science.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/championing-effective-hiv-care-for-plhiv/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/viiv-healthcare-s-commitment-to-implementation-science/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/advancing-hiv-treatment-and-care/viiv-healthcare-s-positive-partnerships-accelerates-progress-towards-90-90-90-goals-in-estonia.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/viiv-healthcare-s-positive-partnerships-accelerates-progress-towards-90-90-90-goals-in-estonia/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare’s Positive Partnerships Accelerates Progress Towards 90-90-90 Goals in Estonia"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/a-look-back-at-aids-2016.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/a-look-back-at-aids-2016/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "A Look Back at AIDS 2016"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/accelerating-the-pace-of-innovation.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/welcome-to-branford-the-world-s-only-hiv-dedicated-research-facility/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/accelerating-the-pace-of-innovation/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/addressing-hiv-in-adolescents.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/addressing-hiv-in-adolescents/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Addressing HIV in Adolescents"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/advancing-hiv-science-through-collaboration.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/advancing-hiv-science-through-collaboration/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Advancing HIV science through collaboration"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/collaboration-is-driving-progress-with-the-launch-of-new-fast-track-city-dashboards.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/collaboration-is-driving-progress-with-the-launch-of-new-fast-track-city-dashboards/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Collaboration is driving progress with the launch of new Fast-Track City dashboards"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/croi-2017-what-s-in-store-for-viiv-healthcare-in-seattle.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/croi-2017-what-s-in-store-for-viiv-healthcare-in-seattle/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "CROI 2017: What’s in store for ViiV Healthcare in Seattle?"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/facing-the-challenges-of-getting-old-with-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-collaborate-to-innovate/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/facing-the-challenges-of-getting-old-with-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/fighting-hiv-together.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/fighting-hiv-together/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Fighting HIV Together"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/find-out-about-industrial-placement-opportunities-at-viiv-healthcare.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/find-out-about-industrial-placement-opportunities-at-viiv-healthcare/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Find out about Industrial Placement opportunities at ViiV Healthcare"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/hiv-research-a-panoramic-view-using-science-to-improve-lives-from-all-angles.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/hiv-research-a-panoramic-view-using-science-to-improve-lives-from-all-angles/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "HIV research – a panoramic view: using science to improve lives from all angles"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/how-our-innovation-unit-is-addressing-new-areas-of-need-in-hiv-care.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-collaborate-to-innovate/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/how-our-innovation-unit-is-addressing-new-areas-of-need-in-hiv-care/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/how-viiv-healthcare-is-helping-to-accelerate-city-hivaids-responses-through-our-collaboration.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/how-viiv-healthcare-is-helping-to-accelerate-city-hivaids-responses-through-our-collaboration/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "How ViiV Healthcare is helping to accelerate city HIV/AIDS responses through our collaboration"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/how-we-re-addressing-the-challenges-of-the-hiv-epidemic-in-africa.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/how-we-re-addressing-the-challenges-of-the-hiv-epidemic-in-africa/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "How we’re addressing the challenges of the HIV epidemic in Africa"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/improving-retention-of-breastfeeding-wlhiv-on-art-challenge-winner.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/improving-retention-of-breastfeeding-wlhiv-on-art-challenge-winner/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Improving Retention of Breastfeeding WLHIV on ART Challenge Winner"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/industrial-placement-opportunities-at-viiv-healthcare.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/industrial-placement-opportunities-at-viiv-healthcare/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Industrial Placement opportunities at ViiV Healthcare"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/inspiring-voices-in-hiv-lead-the-way-on-international-women-s-day.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/inspiring-voices-in-hiv-lead-the-way-on-international-women-s-day/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Inspiring voices in HIV lead the way on International Women’s Day"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/new-online-platform-for-positive-action-challenges-launched.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/new-online-platform-for-positive-action-challenges-launched/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "New Online Platform for Positive Action Challenges Launched"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/positive-partnerships-da%C3%AD-galera-brazil.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/positive-partnerships-da%c3%ad-galera-brazil/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Positive Partnerships: ‘Daí Galera’, Brazil"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/positive-partnerships-hiv-digital-grand-final-estonia.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/positive-partnerships-hiv-digital-grand-final-estonia/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Positive Partnerships: HIV Digital Grand Final (Estonia)"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/positive-partnerships-initiative-launches-in-estonia.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/positive-partnerships-initiative-launches-in-estonia/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Positive Partnerships initiative launches in Estonia"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/preliminary-positive-perspectives-survey-data-released-at-9th-international-aids-society-conference.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/preliminary-positive-perspectives-survey-data-released-at-9th-international-aids-society-conference/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Preliminary Positive Perspectives Survey Data Released at 9th International AIDS Society Conference"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/pride-around-the-world.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/pride-around-the-world/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Pride Around The World"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/putting-people-living-with-hiv-at-the-heart-of-everything-we-do.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/putting-people-living-with-hiv-at-the-heart-of-everything-we-do/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Putting people living with HIV at the heart of everything we do"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/qa-with-angelina-namiba-on-viiv-healthcare-s-skills-workshop.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/qa-with-angelina-namiba-on-viiv-healthcare-s-skills-workshop/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Q&A with Angelina Namiba on ViiV Healthcare’s Skills Workshop"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/qa-with-every-footstep-counts-judge-amaya-gillespie-from-unicef.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/qa-with-every-footstep-counts-judge-amaya-gillespie-from-unicef/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Q&A with Every Footstep Counts Judge Amaya Gillespie from UNICEF"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/qa-with-heather-brogan-piloting-a-new-mentoring-app-for-hiv-patients.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/qa-with-heather-brogan-piloting-a-new-mentoring-app-for-hiv-patients/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Q&A with Heather Brogan: piloting a new mentoring app for HIV patients"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/sabena-solomon-pursues-diverse-career-opportunities-at-viiv-healthcare.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/sabena-solomon-pursues-diverse-career-opportunities-at-viiv-healthcare/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Sabena Solomon pursues diverse career opportunities at ViiV Healthcare"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/see-you-in-paris-viiv-healthcare-the-international-aids-society-conference.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/see-you-in-paris-viiv-healthcare-the-international-aids-society-conference/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "See you in Paris! ViiV Healthcare @ the International AIDS Society conference"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/tackling-hiv-challenges-in-europe.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/tackling-hiv-challenges-in-europe/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Tackling HIV Challenges in Europe"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/towards-a-cure-exploring-cure-and-remission-in-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-collaborate-to-innovate/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/towards-a-cure-exploring-cure-and-remission-in-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/treating-hiv-building-on-30-years-of-innovation-ingenuity-and-passion.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/treating-hiv-building-on-30-years-of-innovation-ingenuity-and-passion/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Treating HIV: building on 30 years of innovation, ingenuity and passion"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/understanding-hiv-in-women-spotlight-on-the-gender-gap-in-hiv-research.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/understanding-hiv-in-women-spotlight-on-the-gender-gap-in-hiv-research/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Understanding HIV in women: Spotlight on the gender gap in HIV research"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/viiv-healthcare-aids-2016.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-aids-2016/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare @AIDS 2016"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/viiv-healthcare-hiv-glasgow.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-hiv-glasgow/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare @HIV Glasgow"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/viiv-healthcare-host-the-inaugural-implementation-science-network-meeting-in-paris.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-host-the-inaugural-implementation-science-network-meeting-in-paris/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare host the inaugural Implementation Science Network meeting in Paris"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/viiv-healthcare-presents-phase-iii-data-comparing-once-daily-maraviroc-in-combination.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-presents-phase-iii-data-comparing-once-daily-maraviroc-in-combination/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare presents phase III data comparing once-daily maraviroc in combination"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/viiv-healthcare-s-commitment-to-implementation-science.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-s-commitment-to-implementation-science/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare’s commitment to implementation science"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/viiv-healthcare-s-positive-partnerships-accelerates-progress-towards-90-90-90-goals-in-estonia.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-s-positive-partnerships-accelerates-progress-towards-90-90-90-goals-in-estonia/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare’s Positive Partnerships Accelerates Progress Towards 90-90-90 Goals in Estonia"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/viiv-healthcare-to-host-inaugural-implementation-science-network-meeting-in-paris.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-to-host-inaugural-implementation-science-network-meeting-in-paris/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "ViiV Healthcare to host inaugural Implementation Science Network Meeting in Paris"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/we-re-allies-the-power-of-partnership.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/we-re-allies-the-power-of-partnership/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "We’re allies: the power of partnership"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/welcome-to-branford-the-world-s-only-hiv-dedicated-research-facility.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/welcome-to-branford-the-world-s-only-hiv-dedicated-research-facility/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Welcome to Branford: the world’s only HIV-dedicated research facility"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/innovation-hiv-science/young-britons-break-down-hiv-stigma-isolation-to-be-the-genendit.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/young-britons-break-down-hiv-stigma-isolation-to-be-the-genendit/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Young Britons break down HIV stigma & isolation to be the #GenEndIt"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/our-people.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/our-people/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/our-people/find-out-about-industrial-placement-opportunities-at-viiv-healthcare.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/our-people/find-out-about-industrial-placement-opportunities-at-viiv-healthcare/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Find out about Industrial Placement opportunities at ViiV Healthcare"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/our-people/from-classroom-to-congress-hall-my-year-at-viiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/our-people/from-classroom-to-congress-hall-my-year-at-viiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "From classroom to congress hall: my year at ViiV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/our-people/one-million-positive-faces.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/our-people/one-million-positive-faces/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "One Million Positive Faces"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/our-people/sabena-solomon-pursues-diverse-career-opportunities-at-viiv-healthcare.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/our-people/sabena-solomon-pursues-diverse-career-opportunities-at-viiv-healthcare/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Sabena Solomon pursues diverse career opportunities at ViiV Healthcare"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/our-people/treating-hiv-building-on-30-years-of-innovation-ingenuity-and-passion.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/our-people/treating-hiv-building-on-30-years-of-innovation-ingenuity-and-passion/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Treating HIV: building on 30 years of innovation, ingenuity and passion"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/addressing-hiv-in-adolescents.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/addressing-hiv-in-adolescents/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Addressing HIV in Adolescents"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Celebrating the 25th year of community partnerships and collaborations through Positive Action"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/facing-the-challenges-of-getting-old-with-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/facing-the-challenges-of-getting-old-with-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Facing the Challenges of getting old with HIV"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/hiv-a-virus-that-thrives-on-inequality.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/hiv-a-virus-that-thrives-on-inequality/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/hiv-behind-bars-supporting-hiv-research-education-and-testing-in-italian-prisons.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/hiv-behind-bars-supporting-hiv-research-education-and-testing-in-italian-prisons/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "HIV Behind Bars: Supporting HIV research, education and testing in Italian prisons"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/how-we-are-collaborating-to-seek-remission-strategies-in-paediatric-hiv-research.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-collaborate-to-innovate/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/how-we-are-collaborating-to-seek-remission-strategies-in-paediatric-hiv-research/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/international-day-against-homophobia-transphobia-biphobia.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/international-day-against-homophobia-transphobia-biphobia/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "International Day Against Homophobia, Transphobia & Biphobia"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/new-online-platform-for-positive-action-challenges-launched.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/new-online-platform-for-positive-action-challenges-launched/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "New Online Platform for Positive Action Challenges Launched"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/pride-around-the-world.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/pride-around-the-world/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Pride Around The World"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/spark-igniting-change.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/paediatric-hiv-care/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/spark-igniting-change/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/the-fight-to-end-mother-to-child-transmission-of-hiv.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/paediatric-hiv-care/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/the-fight-to-end-mother-to-child-transmission-of-hiv/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/u-u-undetectable-equals-untransmittable.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/u-u-undetectable-equals-untransmittable/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "U=U: Undetectable equals Untransmittable"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/understanding-hiv-in-women-spotlight-on-the-gender-gap-in-hiv-research.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/understanding-hiv-in-women-spotlight-on-the-gender-gap-in-hiv-research/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Understanding HIV in women: Spotlight on the gender gap in HIV research"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/understanding-hiv-stigma-and-discrimination.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/understanding-hiv-stigma-and-discrimination/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Understanding HIV stigma and discrimination"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/our-stories/partnerships-key-populations/young-britons-break-down-hiv-stigma-isolation-to-be-the-genendit.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/young-britons-break-down-hiv-stigma-isolation-to-be-the-genendit/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Young Britons break down HIV stigma & isolation to be the #GenEndIt"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/positive-perspectives.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/overcoming-the-challenges-for-partners-of-people-living-with-hiv/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/positive-perspectives/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Positive Perspectives  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/privacy-notice.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/privacy-notice/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Privacy notice"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/search.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/search/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Search"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/sitemap.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Sitemap"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Supporting the community"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/case-studies.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Case Studies"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/case-studies/amfar-treat-asia.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/paediatric-hiv-care/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/case-studies/amplifychange.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amplifychange/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/case-studies/elizabeth-glaser-pediatric-aids-foundation-partnership.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/elizabeth-glaser-pediatric-aids-foundation-partnership/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/case-studies/kaiser-family-foundation.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kaiser-family-foundation/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/case-studies/kenya-council-of-imams-and-ulamaa-kcui.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kenya-council-of-imams-and-ulamaa-kcui/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/case-studies/mtv-shuga.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-shuga/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/case-studies/nam-aidsmap.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/nam-aidsmap/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/case-studies/the-centre-for-sexual-health-and-hivaids-research-ceshhar-zimbabwe.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-centre-for-sexual-health-and-hivaids-research-ceshhar-zimbabwe/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/case-studies/the-community-led-hivaids-prevention-project-kenya.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/we-partner-with-the-hiv-community/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-community-led-hivaids-prevention-project-kenya/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "support for the Community-led HIV/AIDS Prevention Project (CHAPP)"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/our-approach.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/our-approach/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Our Approach"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Positive Action Programmes"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/announcing-the-2016-every-footsteps-counts-winners.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/announcing-the-2016-every-footsteps-counts-winners/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Announcing the 2016 Every Footsteps Counts Winners"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/hiv-a-virus-that-thrives-on-inequality.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/our-approach/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/hiv-a-virus-that-thrives-on-inequality/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/local-partnerships.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/fighting-hiv-together/positive-action-programmes/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/local-partnerships/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/paediatric-innovation-seed-fund.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/november/gsk-ranked-top-of-the-2014-access-to-medicines-atm-index-for-the-fourth-consecutive-time/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/paediatric-innovation-seed-fund/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Paediatric Innovation Seed Fund"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/positive-action-challenges.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-challenges/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Positive Action Challenges"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/positive-action-for-adolescents.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/paediatric-hiv-care/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-adolescents/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Positive Action for Adolescents"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/positive-action-for-children-collaborathon-grants-announced.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-collaborathon-grants-announced/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Positive Action for Children Collaborathon Grants Announced"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/positive-action-for-children-fund-french.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund-french/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/positive-action-for-children-fund.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/paediatric-hiv-care/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Positive Action for Children Fund"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/positive-action-for-europe.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/positive-action-for-girls-women.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/paediatric-hiv-care/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-girls-women/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Positive Action for Girls & Women"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/positive-action-for-msm-transgender-people.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-msm-transgender-people/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/positive-action-southern-initiative.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-southern-initiative/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": " "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/positive-action-programmes/positive-action.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/our-approach/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Find out more"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/supporting-the-community/we-partner-with-the-hiv-community.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/we-partner-with-the-hiv-community/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "We partner with the HIV community  "
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/terms-and-conditions.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/terms-and-conditions/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Terms and conditions"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/terms-of-use.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/terms-of-use/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Terms of use"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/unsubscribe.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/unsubscribe/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Unsubscribe"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/what-we-do.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/what-we-do/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "What we do"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/world-aids-day-2017-fighting-hiv-together.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "World Aids Day 2017 - Fighting HIV Together"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Celebrating the 25th year of community partnerships and collaborations through Positive Action"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/world-aids-day-2017-fighting-hiv-together/driving-change-through-implementation-science.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/driving-change-through-implementation-science/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Driving change through Implementation Science"
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/world-aids-day-2017-fighting-hiv-together/hiv-is-a-global-issue-that-needs-an-ongoing-collaborative-response.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/hiv-is-a-global-issue-that-needs-an-ongoing-collaborative-response/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "HIV is a global issue that needs an ongoing, collaborative response."
    },
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/world-aids-day-2017-fighting-hiv-together/research-in-hiv-science.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/sitemap/",
      "redirectedTo": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/research-in-hiv-science/",
      "results": {},
      "status": "redirected",
      "statusCode": "200,301",
      "txt": "Research in HIV Science"
    }
  },
  "originMedia": {
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/content/dam/cf-viiv/viiv-healthcare/master/documents/18211_viiv_en.pdf": {},
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/content/dam/cf-viiv/viiv-healthcare/master/documents/18211_viiv_fr.pdf": {},
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/content/dam/cf-viiv/viiv-healthcare/master/documents/juluca_pm-2018-08-27.pdf": {},
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/content/dam/cf-viiv/viiv-healthcare/master/documents/juluca_pm-french-2018-08-27.pdf": {},
    "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/content/dam/cf-viiv/viiv-healthcare/master/table/adolescents.png": {}
  },
  "other": {
    "": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/es/",
      "status": "new",
      "txt": ""
    },
    "http://abacavirhsr.viivhealthcare.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/trizivir/",
      "status": "new",
      "txt": "Abacavir HSR Support -"
    },
    "http://afrisante.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/",
      "status": "new",
      "txt": "AFRISANTE"
    },
    "http://aids.sc.gov.br/dados.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/positive-partnerships-da%c3%ad-galera-brazil/",
      "status": "new",
      "txt": "http://aids.sc.gov.br/dados.html"
    },
    "http://aidsalabama.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-for-youth/",
      "status": "new",
      "txt": "AIDS Alabama"
    },
    "http://aidsinfo.unaids.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-extends-medicines-patent-pool-licence-agreement/",
      "status": "new",
      "txt": "http://aidsinfo.unaids.org/"
    },
    "http://api-net.jfap.or.jp/status/2013/13nenpo/h25gaiyo.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/december/viiv-healthcare-announces-regulatory-submission-in-japan-for-single-pill-regimen-combining-dolutegravir-abacavir-and-lamivudine-for-the-treatment-of-hiv/",
      "status": "new",
      "txt": "http://api-net.jfap.or.jp/status/2013/13nenpo/h25gaiyo.pdf"
    },
    "http://apps.who.int/iris/bitstream/10665/128494/1/9789241507585_eng.pdf?ua=1": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/march/viiv-healthcare-gains-chmp-positive-opinion-for-juluca-dolutegra/",
      "status": "new",
      "txt": "http://apps.who.int/iris/bitstream/10665/128494/1/9789241507585_eng.pdf?ua=1"
    },
    "http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf?ua=1": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-first-phase-ii-hiv-prevention-study-re/",
      "status": "new",
      "txt": "http://apps.who.int/iris/bitstream/10665/186275/1/9789241509565_eng.pdf?ua=1"
    },
    "http://apps.who.int/iris/bitstream/10665/198064/1/9789241509893_eng.pdf?ua=1": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-first-phase-ii-hiv-prevention-study-re/",
      "status": "new",
      "txt": "http://apps.who.int/iris/bitstream/10665/198064/1/9789241509893_eng.pdf?ua=1"
    },
    "http://apps.who.int/iris/bitstream/10665/94334/1/9789241506168_eng.pdf?ua=1": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/croi-2018/addressing-hiv-in-adolescents/",
      "status": "new",
      "txt": "http://apps.who.int/iris/bitstream/10665/94334/1/9789241506168_eng.pdf?ua=1"
    },
    "http://atlas2018.org/cambodia-transgenders/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-msm-transgender-people/",
      "status": "new",
      "txt": "here"
    },
    "http://aumag.org/2017/03/30/accelerates-as-much-as-i-can/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can/",
      "status": "new",
      "txt": "All the World’s a Stage: ACCELERATE!’s “As Much As I Can” Amplifies the Voices of Black Gay Men through the Arts to Expand the Dialogue About HIV"
    },
    "http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=60132743": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/",
      "status": "new",
      "txt": "RETROVIR 10 mg/ml"
    },
    "http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=60524598": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/",
      "status": "new",
      "txt": "RETROVIR 100 mg/10 ml"
    },
    "http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=61182724": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/",
      "status": "new",
      "txt": "CELSENTRI 300 mg"
    },
    "http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=61312477": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/",
      "status": "new",
      "txt": "TELZIR 700 mg"
    },
    "http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=62070450": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/",
      "status": "new",
      "txt": "ZIAGEN 20 mg/ml"
    },
    "http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=62094362": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/",
      "status": "new",
      "txt": "CELSENTRI 150 mg"
    },
    "http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=62685155": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/",
      "status": "new",
      "txt": "TIVICAY 50 mg"
    },
    "http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=62715513": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/",
      "status": "new",
      "txt": "EPIVIR 150 mg"
    },
    "http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=63544054": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/",
      "status": "new",
      "txt": "TELZIR 50 mg/ml"
    },
    "http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=63894243": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/",
      "status": "new",
      "txt": "RETROVIR 250 mg"
    },
    "http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=64287253": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/",
      "status": "new",
      "txt": "TRIUMEQ 50 mg/600 mg/300 mg"
    },
    "http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=64777862": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/",
      "status": "new",
      "txt": "EPIVIR 300 mg"
    },
    "http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=64976070": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/",
      "status": "new",
      "txt": "TRIZIVIR 300 mg/150 mg/300 mg"
    },
    "http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=65521773": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/",
      "status": "new",
      "txt": "COMBIVIR 150 mg/300 mg"
    },
    "http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=68036070": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/",
      "status": "new",
      "txt": "EPIVIR 10 mg/ml"
    },
    "http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=68556562": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/",
      "status": "new",
      "txt": "ZIAGEN 300 mg"
    },
    "http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=69290545": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/",
      "status": "new",
      "txt": "RETROVIR 100 mg"
    },
    "http://base-donnees-publique.medicaments.gouv.fr/extrait.php?specid=69855489": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/",
      "status": "new",
      "txt": "KIVEXA 600 mg/300 mg"
    },
    "http://bit.ly/2FroqwS": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/our-people/one-million-positive-faces/",
      "status": "new",
      "txt": "putting your face to the campaign."
    },
    "http://careers.peopleclick.com/careerscp/client_gsk/external1931/en/search.do": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/careers/",
      "status": "new",
      "txt": "Job search"
    },
    "http://clinicaltrials.gov/show/NCT01227824": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/october/viiv-healthcare-announces-us-regulatory-submission-for-a-single-tablet-regimen-combining-dolutegravir-with-abacavir-and-lamivudine-for-people-living-with-hiv/",
      "status": "new",
      "txt": "http://clinicaltrials.gov/show/NCT01227824"
    },
    "http://clinicaltrials.gov/show/NCT01231516": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/october/viiv-healthcare-announces-us-regulatory-submission-for-a-single-tablet-regimen-combining-dolutegravir-with-abacavir-and-lamivudine-for-people-living-with-hiv/",
      "status": "new",
      "txt": "http://clinicaltrials.gov/show/NCT01231516"
    },
    "http://clinicaltrials.gov/show/NCT01449929": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/october/viiv-healthcare-announces-us-regulatory-submission-for-a-single-tablet-regimen-combining-dolutegravir-with-abacavir-and-lamivudine-for-people-living-with-hiv/",
      "status": "new",
      "txt": "http://clinicaltrials.gov/show/NCT01449929"
    },
    "http://clinicaltrials.gov/show/NCT01622790": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/october/viiv-healthcare-announces-us-regulatory-submission-for-a-single-tablet-regimen-combining-dolutegravir-with-abacavir-and-lamivudine-for-people-living-with-hiv/",
      "status": "new",
      "txt": "http://clinicaltrials.gov/show/NCT01622790"
    },
    "http://clinicaltrials.gov/show/NCT01910402": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/october/viiv-healthcare-announces-us-regulatory-submission-for-a-single-tablet-regimen-combining-dolutegravir-with-abacavir-and-lamivudine-for-people-living-with-hiv/",
      "status": "new",
      "txt": "http://clinicaltrials.gov/show/NCT01910402"
    },
    "http://cohintl.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/september/every-woman-every-child-and-viiv-healthcare-announce-the-winner-of-empowering-girls-in-emergency-settings-challenge-prize/",
      "status": "new",
      "txt": "Circle of Health International"
    },
    "http://colectivosol.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/february/positive-action-and-vida-digna-further-information/",
      "status": "new",
      "txt": "http://colectivosol.org/ "
    },
    "http://createsend.com/t/j-69D27C8C6BE569452540EF23F30FEDED": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/viiv-ist-1-im-patientview-report/",
      "status": "new",
      "txt": "Ergebnisbericht von PatientView"
    },
    "http://data.unicef.org/hiv-aids/emtct.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/mieux-nous-connaitre/",
      "status": "new",
      "txt": "http://data.unicef.org/hiv-aids/emtct.html"
    },
    "http://data.worldbank.org/about/country-classifications": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/july/viiv-healthcare-announces-further-initiatives-to-improve-access-to-hiv-medications-for-people-living-in-the-least-developed-countries/",
      "status": "new",
      "txt": "http://data.worldbank.org/about/country-classifications"
    },
    "http://data.worldbank.org/income-level/LMC": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/june/viiv-healthcare-announces-public-tender-agreement-with-botswana-ministry-of-health-for-dolutegravir/",
      "status": "new",
      "txt": "http://data.worldbank.org/income-level/LMC"
    },
    "http://desmondtutuhivfoundation.org.za/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/spark-igniting-change/",
      "status": "new",
      "txt": "Desmond Tutu HIV foundation"
    },
    "http://dukespace.lib.duke.edu/dspace/bitstream/handle/10161/13807/State%20of%20the%20Deep%20Southrevised%20online2.pdf?sequence=4": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative/",
      "status": "new",
      "txt": "State of HIV in the US Deep South"
    },
    "http://dx.doi.org/10.1016/S0140-6736(17)31917-7": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/",
      "status": "new",
      "txt": "http://dx.doi.org/10.1016/S0140-6736(17)31917-7"
    },
    "http://ecdc.europa.eu/en/publications/Publications/Continuum-of-HIV-care-2017.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/auf-dem-weg-zu-90-90-90-wie-sieht-es-in-europa-aus/",
      "status": "new",
      "txt": "http://ecdc.europa.eu/en/publications/Publications/Continuum-of-HIV-care-2017.pdf"
    },
    "http://ecdc.europa.eu/en/publications/Publications/hiv-aids-surveillance-in-Europe-2014.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/positive-partnerships-initiative-launches-in-estonia/",
      "status": "new",
      "txt": "http://ecdc.europa.eu/en/publications/Publications/hiv-aids-surveillance-in-Europe-2014.pdf"
    },
    "http://fight.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/qa-with-heather-brogan-piloting-a-new-mentoring-app-for-hiv-patients/",
      "status": "new",
      "txt": "Philadelphia FIGHT"
    },
    "http://files.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2014/UNAIDS_Gap_report_en.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/addressing-the-challenges-of-the-hiv-epidemic-in-africa/",
      "status": "new",
      "txt": "http://files.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2014/UNAIDS_Gap_report_en.pdf"
    },
    "http://gatewayhealthinstitute.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/improving-retention-of-breastfeeding-wlhiv-on-art-challenge-winner/",
      "status": "new",
      "txt": "Gateway Health Institute"
    },
    "http://genendit.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/young-britons-break-down-hiv-stigma-isolation-to-be-the-genendit/",
      "status": "new",
      "txt": "‘#GenEndIt’"
    },
    "http://gis.cdc.gov/GRASP/NCHHSTPAtlas/main.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/february/viiv-healthcare-expands-positive-action-southern-initiative-to-fight-hivaids-and-support-community-action/",
      "status": "new",
      "txt": "http://gis.cdc.gov/GRASP/NCHHSTPAtlas/main.html"
    },
    "http://glaxosmithkline.co.jp/viiv/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/report-a-side-effect/",
      "status": "new",
      "txt": "Japan"
    },
    "http://glaxosmithkline.co.jp/viiv/index.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/where-we-work/",
      "status": "new",
      "txt": "http://glaxosmithkline.co.jp/viiv/index.html"
    },
    "http://glaxosmithkline.co.jp/viiv/inquiry.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/where-we-work/",
      "status": "new",
      "txt": "http://glaxosmithkline.co.jp/viiv/inquiry.html"
    },
    "http://glaxosmithkline.co.jp/viiv/medical/index.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/lexiva-telzir/",
      "status": "new",
      "txt": "Information for Healthcare Professionals"
    },
    "http://glaxosmithkline.co.jp/viiv/medical/medical.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/tivicay/",
      "status": "new",
      "txt": "Information for Healthcare Professionals"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/en-gb/20190107-ARC-project-exec-summary-ABPI-Jan-7th-2019.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/",
      "status": "new",
      "txt": "UK Joint Working Agreement: Providing High Quality And Sustainable Care For Stable HIV Patients"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/en-gb/Kivexa-French-PM-2018-12-20.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/epzicom-kivexa/",
      "status": "new",
      "txt": "Monographie de Kivexa®"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/en-gb/Kivexa-PM-2018-12-20.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/epzicom-kivexa/",
      "status": "new",
      "txt": "Product Monograph for Kivexa®/"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/en-gb/Tivicay-adult-wwrs-06Dec2018-for-external-use-1.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/tivicay/",
      "status": "new",
      "txt": "Tivicay"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/en-gb/Tivicay-paed-wwrs-06Dec2018-for-external-use.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/tivicay/",
      "status": "new",
      "txt": "regulatory filings and registration of paediatric Tivicay"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/en-gb/Triumeq-French-PM-(2019-01-02).pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/triumeq/",
      "status": "new",
      "txt": "Monographie de Triumeq"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/en-gb/Triumeq-wwrs-06Dec2018-for-external-use-1.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/tivicay/",
      "status": "new",
      "txt": "Triumeq"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/18211_viiv_en.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/tivicay/",
      "status": "new",
      "txt": "Healthcare Professional Letter for Tivicay"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/18211_viiv_fr.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/tivicay/",
      "status": "new",
      "txt": "Lettre aux professionnels de la santé sur Tivicay"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/1q-4q-2010-hcp-fee-disclosure-report-033111.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-states/us-healthcare-professional-fee-disclosures/",
      "status": "new",
      "txt": "Q1-Q4 2010 HCP fee disclosure (PDF 62 KB) "
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/2011-ViiV-Reportable-HCP-Transactions.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-states/research-and-development-payments-in-the-us/",
      "status": "new",
      "txt": "US Research Payments 2011 (PDF 300 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/2012-viivq4_hcp-physicans-pmt-v2.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-states/us-healthcare-professional-fee-disclosures/",
      "status": "new",
      "txt": "Q1-Q4 2012 HCP fee disclosure (PDF 416 KB) "
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/2018-vh-compliance-program-us-operations_01-jul-2018.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/",
      "status": "new",
      "txt": "California Compliance Disclosure"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/3tc_french-pm-12-may-2017.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/epivir-3tc/",
      "status": "new",
      "txt": "Monographie de 3TC"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/3tc_pm-2017-05-12.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/epivir-3tc/",
      "status": "new",
      "txt": "Product Monograph for 3TC/"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/3TC_Ziagen_HCPL_30_Sept_2003_FrenchCanada.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/epivir-3tc/",
      "status": "new",
      "txt": "Lettre aux professionnels de la santé sur 3TC"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/3TC_Ziagen_HCPL_30_Sept_2003Canada.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/epivir-3tc/",
      "status": "new",
      "txt": "Healthcare Professional Letter for 3TC"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/AEB_VIIV.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/terms-and-conditions/",
      "status": "new",
      "txt": "Purchase Order Terms & Conditions"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Avis-public-sur-KivexaRKivexa_Trizivir_Ziagen_PA_18_June_2008_French.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/epzicom-kivexa/",
      "status": "new",
      "txt": "Avis public sur Kivexa®"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/celsentri_pm-2018-05-02.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/selzentry-celsentri/",
      "status": "new",
      "txt": "Product Monograph for Celsentri"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/CELSENTRI-film-coated-tablets-EN.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/selzentry-celsentri/",
      "status": "new",
      "txt": "Safety Data Sheet for Selzentry/Celsentri film-coated tablets"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/celsentri-french_pm-2018-05-02.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/selzentry-celsentri/",
      "status": "new",
      "txt": "Monographie de Celsentri"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/CELSENTRI-oral-solution-EN.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/selzentry-celsentri/",
      "status": "new",
      "txt": "Safety Data Sheet for Selzentry/Celsentri oral solution"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/CGA-ViiV-Cerps-Mai-2012-France.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/terms-and-conditions/",
      "status": "new",
      "txt": "Purchase Order Terms & Conditions"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/CHAIT-Press-release.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-collaborate-to-innovate/",
      "status": "new",
      "txt": "Collaboration for HIV/AIDS Immunological Therapy"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/combivir_pm-2017-05-12.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/combivir/",
      "status": "new",
      "txt": "Product Monograph for Combivir®"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/combivir-french_pm-2017-05-12.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/combivir/",
      "status": "new",
      "txt": "Monographie de Combivir®"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/epzicomwarncard.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/epzicom-kivexa/",
      "status": "new",
      "txt": "Epzicom warning card"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Final-2014-Positive-Action-Southern-Initiative-LOI-Application-.docx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/march/viiv-healthcare-announces-next-round-of-the-positive-action-southern-initiative-to-support-linkages-to-hivaids-care-and-treatment-adherence/",
      "status": "new",
      "txt": "application form"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Final-2014-Positive-Action-Southern-Initiative-LOI-Overview.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/march/viiv-healthcare-announces-next-round-of-the-positive-action-southern-initiative-to-support-linkages-to-hivaids-care-and-treatment-adherence/",
      "status": "new",
      "txt": "detailed information"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/General-conditions-of-purchase-ViiV-Belgium-FR-NL-01-07-2012.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/terms-and-conditions/",
      "status": "new",
      "txt": "Purchase Order Terms & Conditions"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/General-conditions-of-sale-ViiV-Belgium-FR-NL-01-07-2012.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/terms-and-conditions/",
      "status": "new",
      "txt": "Sales Terms & Conditions"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Healthcare-Professional-Letter-for-KivexaR-Kivexa_Trizivir_Ziagen_HCPL_18_June_2008.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/epzicom-kivexa/",
      "status": "new",
      "txt": "Healthcare Professional Letter for Kivexa®"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/hiv-tb_infographic-final.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-at-hiv-glasgow/",
      "status": "new",
      "txt": "iconographic  "
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/iapac_infographic_jan_2018_final.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/working-towards-90-90-90/fast-track-cities/",
      "status": "new",
      "txt": "  "
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/iapac_infographic_updated-16-nov-2016.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/fighting-hiv-together-collaboration-is-driving-progress-with-the-launch-of-new-fast-track-city-dashboards/",
      "status": "new",
      "txt": "  "
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/iapac-fast-track-cities.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/how-viiv-healthcare-is-helping-to-accelerate-city-hivaids-responses-through-our-collaboration/",
      "status": "new",
      "txt": "  "
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/juluca_pm-2018-08-27.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/juluca/",
      "status": "new",
      "txt": "Product Monograph for Juluca/"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/juluca_pm-french-2018-08-27.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/juluca/",
      "status": "new",
      "txt": "Monographie de Juluca"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Kivexa_Trizivir_Ziagen_HCPL_18_June_2008_FrenchCanada.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/trizivir/",
      "status": "new",
      "txt": "Lettre aux professionnels de la santé sur Trizivir®"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Kivexa_Trizivir_Ziagen_HCPL_18_June_2008Canada.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/trizivir/",
      "status": "new",
      "txt": "Healthcare Professional Letter for Trizivir®"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Kivexa_Trizivir_Ziagen_PA_18_June_2008_FrenchCanada.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/trizivir/",
      "status": "new",
      "txt": "Avis public sur Trizivir®"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Kivexa_Trizivir_Ziagen_PA_18_June_2008Canada.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/trizivir/",
      "status": "new",
      "txt": "Public Advisory on Trizivir®"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Lettre-aux-professionnels-de-la-sante-sur-KivexaR-Kivexa_Trizivir_Ziagen_HCPL_18_June_2008_French.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/epzicom-kivexa/",
      "status": "new",
      "txt": "Lettre aux professionnels de la santé sur Kivexa®"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/MTV-Shuga-Peer-Educators-Training-Guide.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/mtv-shuga/",
      "status": "new",
      "txt": "here"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Netherlands-Algemene-Inkoop-voorwaarden-01-10-2010.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/terms-and-conditions/",
      "status": "new",
      "txt": "Purchase Order Terms & Conditions"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/networks-of-care_final-web-version-reduced.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "status": "new",
      "txt": "ethnographic research here"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Australia-Patient-Group-Reporting-2011.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Australia (PDF 36 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Belgium-Patient-Group-Reporting-2011.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Belgium (PDF 35 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Canada-Patient-Group-Reporting-2011.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Canada (PDF 154 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/France-Patient-Group-Reporting-2011.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "France (PDF 38 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Germany-Patient-Group-Reporting-2011-Updated.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Germany (PDF 32 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Global-Group-Patient-Group-Reporting-2011.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Global (PDF 44 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Italy-Patient-Group-Reporting-2011.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Italy (PDF 61 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Mexico-Patient-Group-Reporting-2011.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Mexico (PDF 94 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Netherlands-Patient-Group-Reporting-2011.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Netherlands (PDF 10 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/PACF-Patient-Group-Reporting-2011.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Positive Action for Children Fund (PDF 117 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Portugal-Patient-Group-Reporting-2011.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Portugal (PDF 11 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Positive-Action-Patient-Group-Reporting-2011.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Positive Action (PDF 58 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Russia-Patient-Group-Reporting-2011.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Russia Patient (PDF 119 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Spain-Patient-Group-Reporting-2011.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Spain (PDF 28 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/Swiss-Patient-Reporting-2011.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Switzerland (PDF 95 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/UK-Patient-Group-Reporting-2011.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "United Kingdom (PDF 200 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2011/US-Patient-Group-Reporting-2011.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "United States (PDF 121 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-Belgium.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Belgium (PDF 66 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-Canada.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Canada (PDF 396 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-France.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "France (PDF 123 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-Germany.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Germany (PDF 236 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-Italy.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Italy (PDF 132 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-Japan.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Japan (PDF 134 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-Mexico.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Mexico (PDF 304 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-Netherlands.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Netherlands (PDF 133 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/grants-and-charitable-contributions-pacf-updated-17-06-13.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Positive Action for Children Fund (PDF 560 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-Paediatric-Seed-Fund.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Paediatric Innovation Seed Fund (PDF 274 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-Portugal.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Portugal (PDF 124 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-Positive-Action-Fund.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Positive Action (PDF 349 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-Spain.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Spain (PDF 154 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-Switzerland.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Switzerland (PDF 129 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-to-Australia-Based-Groups.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Australia (PDF 122 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-to-Global-HIV-Groups-2.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Global HIV organisations (PDF 308 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/Grants-and-Charitable-Contributions-US.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "United States (PDF 57 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2012/grants-and-charitable-donations-to-uk-based-patient-groups-in-2012.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "United Kingdom (PDF 86 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/australia.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Australia (PDF 285 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/belgium.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Belgium (PDF 59 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/canada.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Canada (PDF 434 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/france.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "France (PDF 63 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/germany.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Germany (PDF 17 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/italy.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Italy (PDF 63 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/japan.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Japan (PDF 25 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/netherlands.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Netherlands (PDF 10 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/pacf.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Positive Action for Children Fund (PDF 218 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/pan-eu.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Pan European (PDF 150 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/portugal.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Portugal (PDF 13 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/positive-action.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Positive Action (PDF 188 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/russia.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Russia (PDF 141 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/spain.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Spain (PDF 72 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/switzerland.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Switzerland (PDF 61 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/uk.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "UK (PDF 49 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2013/viiv-3q-2013.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "United States (PDF 34 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/annual-2014-viiv-grants-pdf-based-on-v60.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "United States (PDF 55 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/australia.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Australia (PDF 106 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/belgium.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Belgium (PDF 99 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/canada.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Canada (PDF 306 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/france.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "France (PDF 116 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/germany.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Germany (PDF 116 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/italy.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Italy (PDF 193 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/japan.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Japan (PDF 104 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/netherlands.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Netherlands (PDF 97 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/pacf-2014.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Positive Action for Children Fund (PDF 151 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/pan-eu-patient-group-reporting-2014.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Pan-European (PDF 151 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/portugal.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Portugal (PDF 180 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/positive-action.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Positive Action (PDF 216 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/russia.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Russia (PDF 100 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/spain.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Spain (PDF 114 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/switzerland.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Switzerland (PDF 103 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2014/uk-2014.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "UK (PDF 193 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/australia.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Australia (PDF 105 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/belgium.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Belgium (PDF 98 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/canada.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Canada (PDF 177 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/eu-2015.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Above Country EU (PDF 52 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/france.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "France (PDF 113 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/gappa-core-reporting.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "GAPPA Core Reporting (PDF 47 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/germany.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Germany (PDF 103 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/italy.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Italy (PDF 165 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/japan.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Japan (PDF 231 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/netherlands.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Netherlands (PDF 43 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/pacf.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "PACF (PDF 326 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/portugal.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Portugal (PDF 101 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/positive-action-for-adolescents.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Positive Action for Adolescents (PDF 96 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/positive-action-for-msmt.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Positive Action for MSMT (PDF 105 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/spain.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Spain (PDF 181 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/switzerland.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Switzerland (PDF 257 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2015/united-states.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "UNITED STATES.pdf (PDF 61 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/annual-2016-viiv-executive-summary-grant-listing.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Annual 2016 ViiV Executive Summary Grant Listing.pdf (PDF 143 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/belgium.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Belgium.pdf (PDF 8 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/france.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "France.pdf (PDF 26 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/gappa-core-reporting.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "GAPPA Core Reporting.pdf (PDF 132 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/germany.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Germany.pdf (PDF 23 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/italy.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Italy.pdf (PDF 70 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/netherlands.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Netherlands.pdf (PDF 52 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/pan-european.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Pan-European.pdf (PDF 90 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/positive-action-for-adolescents.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Positive Action for Adolescents.pdf (PDF 90 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/positive-action-for-children-fund.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Positive Action for Children Fund.pdf (PDF 53 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/positive-action-for-girls-and-women.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Positive Action for Girls and Women.pdf (PDF 58 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/positive-action-msm-transgender-programme.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Positive Action MSM & Transgender Programme.pdf (PDF 31 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/spain.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Spain.pdf (PDF 27 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/switzerland.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Switzerland.pdf (PDF 11 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2016/uk.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "UK.pdf (PDF 163 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/charitable-grants-to-us-entities.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Charitable Grants to US Entities.pdf (PDF 43 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/gappa-core-grants-budget-allocation-tracker.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "GAPPA Core Grants Budget Allocation Tracker.pdf (PDF 190 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/joint-working-agreements-global-strategic-initiatives-2017.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Joint Working Agreements - Global Strategic Initiatives 2017.pdf (PDF 88 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-australia.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Patient Group Reporting - Australia.pdf (PDF 245 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-belgium.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Patient Group Reporting - Belgium.pdf (PDF 70 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-canada.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Patient Group Reporting - Canada.pdf (PDF 116 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-germany.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Patient Group Reporting - Germany.pdf (PDF 80 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-italy.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Patient Group Reporting - Italy.pdf (PDF 158 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-japan.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Patient Group Reporting - Japan.pdf (PDF 272 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-msmt.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Patient Group Reporting - MSMT.pdf (PDF 202 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-netherlands.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Patient Group Reporting - Netherlands.pdf (PDF 177 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-paa.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Patient Group Reporting - PAA.pdf (PDF 228 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-pacf.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Patient Group Reporting - PACF.pdf (PDF 150 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-pae.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Patient Group Reporting - PAE.pdf (1) (PDF 177 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-pagw.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Patient Group Reporting - PAGW.pdf (PDF 99 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-spain.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Patient Group Reporting - Spain.pdf (PDF 196 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/NGO/2017/patient-group-reporting-switzerland.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/global/the-ngos-patient-advocacy-groups-we-fund/",
      "status": "new",
      "txt": "Patient Group Reporting - Switzerland.pdf (PDF 22 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/on_ViiV-AcquistoBeniServiziCondizioniGenerali_inglese.docx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/terms-and-conditions/",
      "status": "new",
      "txt": "Purchase Order Terms & Condition (English)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/on_ViiV-AcquistoBeniServiziCondizioniGenerali_italiano.docx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/terms-and-conditions/",
      "status": "new",
      "txt": "Purchase Order Terms & Condition (Italian)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/our-work-in-africa.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/addressing-the-challenges-of-the-hiv-epidemic-in-africa/",
      "status": "new",
      "txt": "  "
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/pa-msmt-strategy-paper-2018-2019-final.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-msm-transgender-people/",
      "status": "new",
      "txt": "Strategy Paper"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/pagw-call-for-proposals-guidance-notes-final-en.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-girls-women/",
      "status": "new",
      "txt": "guidance notes"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/positive-perspective-survey_-partner-infographic.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/positive-perspectives/",
      "status": "new",
      "txt": "*** IMAGE WITHOUT ALT TEXT ***"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/positive-perspective-survey_-plhiv-infographic.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/positive-perspectives/",
      "status": "new",
      "txt": "*** IMAGE WITHOUT ALT TEXT ***"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/positive-perspective-survey-infographic-final.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/understanding-the-concerns-of-people-living-with-hiv/",
      "status": "new",
      "txt": "infographic"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/positive-perspectives-survey-preliminary-insights-infographic.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/preliminary-positive-perspectives-survey-data-released-at-9th-international-aids-society-conference/",
      "status": "new",
      "txt": "this infographic"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/positive-perspectives-survey-report-finalcompressed.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/positive-perspectives/",
      "status": "new",
      "txt": "*** IMAGE WITHOUT ALT TEXT ***"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/positiveperspectives_partner-report.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/positive-perspectives/",
      "status": "new",
      "txt": "*** IMAGE WITHOUT ALT TEXT ***"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Public-Advisory-on-KivexaR-Kivexa_Trizivir_Ziagen_PA_18_June_2008.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/epzicom-kivexa/",
      "status": "new",
      "txt": "Public Advisory on Kivexa®"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/q1-q4-2013-physician-payment-report.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-states/us-healthcare-professional-fee-disclosures/",
      "status": "new",
      "txt": "Q1-Q4 2013 HCP fee disclosure (PDF 1.8 MB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Rescriptor-MktPM-20130305Canada.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/rescriptor/",
      "status": "new",
      "txt": "Product Monograph for Rescriptor"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Rescriptor-tablets-ENSafety-Data-Sheet.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/rescriptor/",
      "status": "new",
      "txt": "Safety Data Sheet for Rescriptor tablets"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Rescriptorfrench-MktPM-20130305Canada.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/rescriptor/",
      "status": "new",
      "txt": "Monographie de Rescriptor"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/retrovir_pm-2018-07-19.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/retrovir-azt/",
      "status": "new",
      "txt": "Product Monograph for Retrovir"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/retrovir-french_pm-2018-07-19.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/retrovir-azt/",
      "status": "new",
      "txt": "Monographie de Retrovir"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/singapore-terms-and-conditions.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/terms-and-conditions/",
      "status": "new",
      "txt": "Purchase Order Terms & Condition (English)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/t-and-c-english.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/terms-and-conditions/",
      "status": "new",
      "txt": "Purchase Order Terms & Conditions (English)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/t-and-c-spanish.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/terms-and-conditions/",
      "status": "new",
      "txt": "Purchase Order Terms & Conditions (Spanish)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/tc-po-viiv-june-english-2018-portugal.docx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/terms-and-conditions/",
      "status": "new",
      "txt": "Purchase Order Terms & Conditions (English)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Telzir_HCPL_17_July_2009_French-Canda.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/lexiva-telzir/",
      "status": "new",
      "txt": "Lettre aux professionnels de la santé sur Telzir®"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Telzir_HCPL_17_July_2009-Canda.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/lexiva-telzir/",
      "status": "new",
      "txt": "Healthcare Professional Letter for Telzir®"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Telzir_PA_17_July_2009_French-Canada.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/lexiva-telzir/",
      "status": "new",
      "txt": "Avis public sur Telzir"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Telzir_PA_17_July_2009-Canda.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/lexiva-telzir/",
      "status": "new",
      "txt": "Public Advisory on Telzir®"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/telzir_pm-2017-11-23.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/lexiva-telzir/",
      "status": "new",
      "txt": "Product Monograph for Telzir /"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/telzir-french_pm-2017-11-23.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/lexiva-telzir/",
      "status": "new",
      "txt": "Monographie de Telzir"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/tivicay_french_pm-2018-08-27.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/tivicay/",
      "status": "new",
      "txt": "Monographie de Tivicay"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/tivicay_pm-2018-08-27.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/tivicay/",
      "status": "new",
      "txt": "Product Monograph for Tivicay/"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/tivicay-adult-wwrs-11oct2018-for-external-use.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/our-approach-to-improving-access-to-medicines/",
      "status": "new",
      "txt": "Tivicay"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Tivicay-paed-wwrs-06Dec2018-for-external-use.docx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/paediatric-hiv-care/",
      "status": "new",
      "txt": "regulatory filings and registration of \n         \n           paediatric \n          Tivicay"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/tivicay-paed-wwrs-11oct2018-for-external-use.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/our-approach-to-improving-access-to-medicines/",
      "status": "new",
      "txt": "regulatory filings and registration of paediatric Tivicay"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/TRIUMEQ-PI-MG.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/august/viiv-healthcare-receives-fda-approval-for-triumeq/",
      "status": "new",
      "txt": "Triumeq US label"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/triumeq-wwrs-11oct2018-for-external-use.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/our-approach-to-improving-access-to-medicines/",
      "status": "new",
      "txt": "Triumeq"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/triumeq.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/triumeq/",
      "status": "new",
      "txt": "Product Monograph for Triumeq/"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/trizivir_pm-2018-01-15.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/trizivir/",
      "status": "new",
      "txt": "Product Monograph for Trizivir®"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/trizivir-french_pm-2018-07-31.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/trizivir/",
      "status": "new",
      "txt": "Monographie de Trizivir®"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/understanding-hiv-in-women-infographic_final.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/understanding-hiv-in-women-spotlight-on-the-gender-gap-in-hiv-research/",
      "status": "new",
      "txt": "*** IMAGE WITHOUT ALT TEXT ***"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/vhc_access-to-medicine-public-policy_feb-2018_for-publication_corrections_june2018.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/our-approach-to-improving-access-to-medicines/",
      "status": "new",
      "txt": "Click to read our full Access to Medicine policy"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-eu-statement-retention-in-care-final.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/",
      "status": "new",
      "txt": "Retention in care"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-eu-statement-testing.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/",
      "status": "new",
      "txt": "Exploring Issues around Testing in Europe"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-final-1q-4q-2011-hcp-fee-disclosure-report-to-pdf-031312.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-states/us-healthcare-professional-fee-disclosures/",
      "status": "new",
      "txt": "Q1-Q4 2011 HCP fee disclosure (PDF 109 KB) "
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-hc-pa-adolescents-infographic-v3-05-07-2016.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/croi-2018/addressing-hiv-in-adolescents/",
      "status": "new",
      "txt": "*** IMAGE WITHOUT ALT TEXT ***"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-hc-universal-healthcoverage-for-plhiv-policy-2.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/policy-papers/",
      "status": "new",
      "txt": "Universal Health Coverage (UHC) for PLHIV"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-healthcare_continuous-innovation-in-prevention-testing-treatment-and-care-of-hiv-policy-position-final.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/policy-papers/",
      "status": "new",
      "txt": "Continuous Innovation in Prevention, Testing, Treatment & Care of HIV"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-healthcare_funding-and-investment-in-hiv-policy-position_final.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/policy-papers/",
      "status": "new",
      "txt": "Funding and Investment in HIV"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-healthcare_global-hiv-policy-position-summary_final.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/policy-papers/",
      "status": "new",
      "txt": "Global HIV Policy"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-healthcare_hiv-testing-policy-position_final.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/policy-papers/",
      "status": "new",
      "txt": "Position on HIV Testing"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-healthcare_prevention-in-hiv-policy-position_final.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/policy-papers/",
      "status": "new",
      "txt": "Prevention in HIV"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-healthcare_retention-into-care-policy-position_final.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/policy-papers/",
      "status": "new",
      "txt": "Retention into Care"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-healthcare-access-to-medicines-policy-final.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/november/viiv-healthcare-at-icasa-improving-access-to-hiv-treatment-and-care-for-people-everywhere/",
      "status": "new",
      "txt": "https://www.viivhealthcare.com/media/112407/viiv-healthcare-access-to-medicines-policy-final.pdf"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-healthcare-company_california-compliance-declaration-for-01-jul-2018.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/",
      "status": "new",
      "txt": "California Compliance Declaration"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viiv-healthcare-us-research-payments-2010-final-report.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-states/research-and-development-payments-in-the-us/",
      "status": "new",
      "txt": "US Research Payments 2010 (PDF 211 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/ViiV-Research-Payments-YTD-2012-Disclosure.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-states/research-and-development-payments-in-the-us/",
      "status": "new",
      "txt": "US Research Payments 2012 (PDF 524 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/ViiV-Research-Payments-YTD-Dec-2013.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-states/research-and-development-payments-in-the-us/",
      "status": "new",
      "txt": "US Research Payments 2013 (PDF 459 KB)"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viivhc_penta-infographic-final-2.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/june/viiv-healthcare-joins-penta-foundation-in-search-for-strategies-to-achieve-remission-in-children-living-with-hiv/",
      "status": "new",
      "txt": "  "
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viivhc-stigma-and-discrimination-policy.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/policy-papers/",
      "status": "new",
      "txt": "Stigma and Discrimination"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viivhc-timeline-infographic_-180117.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-aids-2016/",
      "status": "new",
      "txt": "  "
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Viracept-oral-powde-EN-Safety-Data-Sheet.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/viracept/",
      "status": "new",
      "txt": "Safety Data Sheet for Viracept oral powder"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viracept-patient-information-sept-2016.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/viracept/",
      "status": "new",
      "txt": "Patient Product Information for Viracept"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/Viracept-Tablets-ENSafety-Data-Sheet.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/viracept/",
      "status": "new",
      "txt": "Safety Data Sheet for Viracept tablets"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/viracept-uspi-sept-2016.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/viracept/",
      "status": "new",
      "txt": "Prescribing information for Viracept"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/youth-hiv-fact-sheet-final.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "status": "new",
      "txt": "Click here"
    },
    "http://gskvideo.edgesuite.net/Viiv/viivhealthcare/pdf_files/master/main/ziagen_pm-french-2018-07-23.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/ziagen/",
      "status": "new",
      "txt": "Monographie de Ziagen"
    },
    "http://gskvideo.edgesuite.net/viivhealthcare/DTG/Videos/US/mp4/ViiV_Accelerate_Legal_Edits_V2.mp4": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/",
      "status": "new",
      "txt": "echoes the lives and voices"
    },
    "http://healthycanadians.gc.ca/publications/diseases-conditions-maladies-affections/hiv-aids-estimates-2014-vih-sida-estimations/index-eng.php": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-hivaids/about-hivaids-in-canada/",
      "status": "new",
      "txt": "Estimates of HIV incidence, prevalence and proportion undiagnosed in Canada, 2014 (2016). Accessed August 24, 2016."
    },
    "http://hivglasgow.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "HIV Drug Therapy"
    },
    "http://hni.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "status": "new",
      "txt": "Human Network International"
    },
    "http://home.netscape.com/download/index.html?cp=dju1": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/careers/how-to-apply/",
      "status": "new",
      "txt": "http://home.netscape.com/download/index.html?cp=dju1"
    },
    "http://hteam.nl/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/amsterdam-op-weg-naar-een-toekomst-zonder-nieuwe-hiv-infecties/",
      "status": "new",
      "txt": "www.hteam.nl"
    },
    "http://i-base.info/start/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/patienten-mit-hohen-cd4-zellzahlen-wer-profitiert-am-meisten-von/",
      "status": "new",
      "txt": "http://i-base.info/start/"
    },
    "http://impaactnetwork.org/studies/P1093.asp": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/june/viiv-healthcare-announces-fda-approval-to-lower-the-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv/",
      "status": "new",
      "txt": "http://impaactnetwork.org/studies/P1093.asp"
    },
    "http://inmagazine.ca/2018/08/spilling-the-tea-on-guys-who-party-and-play/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/",
      "status": "new",
      "txt": "MAX Ottawa and ViiV Healthcare launches Spill the Tea campaign"
    },
    "http://jasmyn.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/november/viiv-healthcare-awards-additional-round-of-grants-to-support-innovative-hiv-programs-aimed-at-reducing-disparities-in-the-southern-us/",
      "status": "new",
      "txt": "Jacksonville Area Sexual Minority Youth Network, Inc. (JASMYN)"
    },
    "http://jflag.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "status": "new",
      "txt": "J-FLAG"
    },
    "http://journals.lww.com/aidsonline/Abstract/publishahead/Effect_of_immediate_initiation_of_antiretroviral.97360.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/geringes-resistenzrisiko-auch-bei-sofortigem-art-beginn/",
      "status": "new",
      "txt": "Lodi S et al. AIDS: Post Acceptance: November 10, 2017 doi: 10.1097/QAD.0000000000001692"
    },
    "http://journals.lww.com/aidsonline/Abstract/publishahead/Temporal_trends_of_transmitted_HIV_drug_resistance.97362.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/uebertragene-hiv-resistenzen-seltener/",
      "status": "new",
      "txt": "Olsen A et al. AIDS: Post Acceptance: November 02, 2017 doi: 10.1097/QAD.0000000000001689"
    },
    "http://journals.lww.com/jaids/Abstract/publishahead/Bioequivalence_of_a_Dolutegravir,_Abacavir_and.97920.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/august/viiv-healthcare-receives-fda-approval-for-triumeq/",
      "status": "new",
      "txt": "http://journals.lww.com/jaids/Abstract/publishahead/Bioequivalence_of_a_Dolutegravir,_Abacavir_and.97920.aspx."
    },
    "http://livlife.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/",
      "status": "new",
      "txt": "Find out more"
    },
    "http://london.ejaf.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/april/global-partnership-launches-new-programme-with-goal-to-save-the-lives-of-thousands-of-children-affected-by-hiv-in-lesotho/",
      "status": "new",
      "txt": "london.ejaf.org"
    },
    "http://msdh.ms.gov/msdhsite/_static/resources/5714.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/march/viiv-healthcare-announces-next-round-of-the-positive-action-southern-initiative-to-support-linkages-to-hivaids-care-and-treatment-adherence/",
      "status": "new",
      "txt": "http://msdh.ms.gov/msdhsite/_static/resources/5070.pdf "
    },
    "http://mylan.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/july/viiv-healthcare-expands-commitment-to-addressing-gaps-in-paediatric-hiv-research-care-and-treatment/",
      "status": "new",
      "txt": "mylan.com"
    },
    "http://naesm.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-for-youth/",
      "status": "new",
      "txt": "National AIDS Education and Services for Minorities"
    },
    "http://pfizer.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/100-dedicated-to-hiv/",
      "status": "new",
      "txt": "Pfizer"
    },
    "http://positiveactionchallenges.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/viiv-healthcare-s-the-hive-and-positive-action-community-challenge-seek-outside-collaborations-in-order-to-innovate-for-people-living-with-hiv/",
      "status": "new",
      "txt": "the first Positive Action Community Challenge"
    },
    "http://positivelyuk.org/pregnancy/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/qa-with-angelina-namiba-on-viiv-healthcare-s-skills-workshop/",
      "status": "new",
      "txt": "Positively UK"
    },
    "http://programme.ias2017.org/Abstract/Abstract/3103": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/preliminary-positive-perspectives-survey-data-released-at-9th-international-aids-society-conference/",
      "status": "new",
      "txt": "http://programme.ias2017.org/Abstract/Abstract/3103"
    },
    "http://programme.ias2017.org/Programme/Session/104": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/see-you-in-paris-viiv-healthcare-the-international-aids-society-conference/",
      "status": "new",
      "txt": "Treat to Care: Evolving the management of HIV"
    },
    "http://programme.ias2017.org/Programme/Session/13": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/see-you-in-paris-viiv-healthcare-the-international-aids-society-conference/",
      "status": "new",
      "txt": "The New $90-$90-$90: Drugs Affordable for All"
    },
    "http://programme.ias2017.org/Programme/Session/200": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/see-you-in-paris-viiv-healthcare-the-international-aids-society-conference/",
      "status": "new",
      "txt": "Plenary session"
    },
    "http://programme.ias2017.org/Programme/Session/95": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/see-you-in-paris-viiv-healthcare-the-international-aids-society-conference/",
      "status": "new",
      "txt": "Accelerating Access to New HIV Medicines in Developing Countries"
    },
    "http://publichealth.jmir.org/2016/1/e22": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accelerate--initiative/",
      "status": "new",
      "txt": "Rates of Prevalent HIV Infection, Prevalent Diagnoses \n        \n          and \n         New Diagnoses Among Men Who Have Sex With Men (MSM) in the United States,"
    },
    "http://publichealth.jmir.org/article/downloadSuppFile/5684/34193": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accelerate--initiative/",
      "status": "new",
      "txt": "Multimedia Appendix of Rates of Prevalent HIV Infection, Prevalent Diagnoses \n        \n          and \n         New Diagnoses Among Men Who Have Sex with Men (MSM) in the United States,"
    },
    "http://quickfacts.census.gov/qfd/states/13000.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/october/viiv-healthcare-expands-program-to-reduce-hiv-disparities-in-southern-us/",
      "status": "new",
      "txt": "http://quickfacts.census.gov/qfd/states/13000.html"
    },
    "http://redlactrans.org.ar/site/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/february/positive-action-and-vida-digna-further-information/",
      "status": "new",
      "txt": "http://redlactrans.org.ar/site/"
    },
    "http://salamandertrust.net/project/4m-health-choice-child-life-perinatal-peer-mentoring-project-women-living-hiv/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/qa-with-angelina-namiba-on-viiv-healthcare-s-skills-workshop/",
      "status": "new",
      "txt": "Salamander Trust 4M Project"
    },
    "http://sentebale.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/spark-igniting-change/",
      "status": "new",
      "txt": "Sentebale"
    },
    "http://shmfoundation.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/improving-retention-of-breastfeeding-wlhiv-on-art-challenge-winner/",
      "status": "new",
      "txt": "SHM Foundation"
    },
    "http://siteresources.worldbank.org/INTHIVAIDS/Resources/375798-1103037153392/MSMReport.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/october/viiv-healthcare-awards-23-small-grants-to-help-alleviate-the-stigma-of-hiv-and-aids-in-the-msm-and-transgender-community-globally/",
      "status": "new",
      "txt": "http://siteresources.worldbank.org/INTHIVAIDS/Resources/375798-1103037153392/MSMReport.pdf"
    },
    "http://soundcloud.com/viiv-healthcare": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/",
      "status": "new",
      "txt": "ViiV Healthcare Effect"
    },
    "http://soundcloud.com/viiv-healthcare/anne-stangl-2": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/",
      "status": "new",
      "txt": "Anne Stangl"
    },
    "http://soundcloud.com/viiv-healthcare/annette-sohn-treat-asia-pt3": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/",
      "status": "new",
      "txt": "Annette Sohn TREAT Asia Pt3 060513"
    },
    "http://soundcloud.com/viiv-healthcare/josh-robbins-1": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/",
      "status": "new",
      "txt": "Josh Robbins"
    },
    "http://soundcloud.com/viiv-healthcare/josh-robbins-2": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/",
      "status": "new",
      "txt": "Josh Robbins"
    },
    "http://soundcloud.com/viiv-healthcare/sonalini-mirchandani-2": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/",
      "status": "new",
      "txt": "Sonalini Mirchandani"
    },
    "http://southernaids.files.wordpress.com/2011/10/hiv-aids-in-the-us-deep-south-trends-from-2008-2013.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative/",
      "status": "new",
      "txt": "HIV/AIDS in the U.S. Deep South: Trends from 2008-2013"
    },
    "http://tga-search.clients.funnelback.com/s/search.html?collection=tga-artg&profile=record&meta_i=291356": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/first-two-drug-single-pill-for-hiv-now-approved-for-use-in-austr/",
      "status": "new",
      "txt": "http://tga-search.clients.funnelback.com/s/search.html?collection=tga-artg&profile=record&meta_i=291356"
    },
    "http://the-power-of-love.webflow.io/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/de-leukste-dag-van-het-jaar-om-hiv-te-hebben/",
      "status": "new",
      "txt": "De Leukste Dag"
    },
    "http://tools.google.com/dlpage/gaoptout?hl=de": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/datenschutzerklaerung/",
      "status": "new",
      "txt": "http://tools.google.com/dlpage/gaoptout?hl=de"
    },
    "http://trabajandoenpositivo.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/trabajando-en-positivo/",
      "status": "new",
      "txt": "Trabajando en Positivo"
    },
    "http://viivhealthcare.smartsimple.ca/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals/independent-grants-and-support-programs/",
      "status": "new",
      "txt": "here"
    },
    "http://viivhealthcare.smartsimple.ca/s_Login.jsp": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/",
      "status": "new",
      "txt": "here"
    },
    "http://vimeo.com/69072969": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/hiv-treatment-and-care/european-network-of-young-hiv-experts/",
      "status": "new",
      "txt": "Watch the highlights from the European Network of Young HIV Experts in Paris in 2012"
    },
    "http://vimeo.com/99562770": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/fighting-hiv-together/positive-action-at-aids-2018/",
      "status": "new",
      "txt": "http://vimeo.com/99562770 "
    },
    "http://wellflorida.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/november/viiv-healthcare-awards-additional-round-of-grants-to-support-innovative-hiv-programs-aimed-at-reducing-disparities-in-the-southern-us/",
      "status": "new",
      "txt": "WellFlorida Council, Inc."
    },
    "http://www.aboundingprosperity.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-for-youth/",
      "status": "new",
      "txt": "Abounding Prosperity"
    },
    "http://www.aboutads.info/choices/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/privacy-policy/",
      "status": "new",
      "txt": "DAA website"
    },
    "http://www.aboutcookies.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/politique-de-cookies/",
      "status": "new",
      "txt": "www.aboutcookies.org"
    },
    "http://www.adharasevilla.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/overcoming-the-challenges-for-partners-of-people-living-with-hiv/",
      "status": "new",
      "txt": "Sevilla Checkpoint"
    },
    "http://www.adobe.com/de/privacy/opt-out.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/datenschutzerklaerung/",
      "status": "new",
      "txt": "http://www.adobe.com/de/privacy/opt-out.html"
    },
    "http://www.adph.org/aids/assets/Finalized_2012HIVSurveillance.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/march/viiv-healthcare-announces-next-round-of-the-positive-action-southern-initiative-to-support-linkages-to-hivaids-care-and-treatment-adherence/",
      "status": "new",
      "txt": "http://www.adph.org/aids/assets/Finalized_2012HIVSurveillance.pdf"
    },
    "http://www.advocatesforyouth.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-for-youth/",
      "status": "new",
      "txt": "Advocates for Youth"
    },
    "http://www.afao.org.au/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/afao-national-african-australian-hiv-network/",
      "status": "new",
      "txt": "www.afao.org.au"
    },
    "http://www.africaid-zvandiri.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "status": "new",
      "txt": "AFRICAID"
    },
    "http://www.aids-tage.de/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "Münchner AIDS- und Hepatitis-Tage"
    },
    "http://www.aids2018.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "AIDS 2018"
    },
    "http://www.aidsalliance.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/february/viiv-healthcare-s-positive-action-and-the-international-hivaids-alliance-tackle-hiv-stigma-in-six-central-american-countries/",
      "status": "new",
      "txt": "www.aidsalliance.org"
    },
    "http://www.aidsalliance.org/about/our-donors": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/february/positive-action-and-vida-digna-further-information/",
      "status": "new",
      "txt": "http://www.aidsalliance.org/about/our-donors"
    },
    "http://www.aidschicago.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-community-grants/",
      "status": "new",
      "txt": "  "
    },
    "http://www.aidsinfo.nih.gov/guidelines": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/february/viiv-healthcare-launches-eighth-phase-iii-study-in-two-drug-regi/",
      "status": "new",
      "txt": "www.aidsinfo.nih.gov/guidelines"
    },
    "http://www.amatuvida.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/our-commitment-to-latinx-communities-living-with-hiv/",
      "status": "new",
      "txt": "Ama Tu Vida"
    },
    "http://www.amfar.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/",
      "status": "new",
      "txt": "TREAT Asia/amfAR"
    },
    "http://www.amfar.org/treatasia.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/spark-igniting-change/",
      "status": "new",
      "txt": "TREAT Asia"
    },
    "http://www.apla.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-community-grants/",
      "status": "new",
      "txt": "  "
    },
    "http://www.assamede.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/",
      "status": "new",
      "txt": "ASSAMEDE"
    },
    "http://www.atlacatl.org.sv/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/february/positive-action-and-vida-digna-further-information/",
      "status": "new",
      "txt": "http://www.atlacatl.org.sv/"
    },
    "http://www.aurobindo.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/may/press-release/",
      "status": "new",
      "txt": "www.aurobindo.com"
    },
    "http://www.avert.org/professionals/hiv-around-world/sub-saharan-africa/lesotho": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/april/global-partnership-launches-new-programme-with-goal-to-save-the-lives-of-thousands-of-children-affected-by-hiv-in-lesotho/",
      "status": "new",
      "txt": "http://www.avert.org/professionals/hiv-around-world/sub-saharan-africa/lesotho"
    },
    "http://www.ayzh.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/september/every-woman-every-child-and-viiv-healthcare-announce-the-winner-of-empowering-girls-in-emergency-settings-challenge-prize/",
      "status": "new",
      "txt": "Ayzh"
    },
    "http://www.bienestar.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/our-commitment-to-latinx-communities-living-with-hiv/",
      "status": "new",
      "txt": "Bienestar Human Services"
    },
    "http://www.blackaids.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-community-grants/",
      "status": "new",
      "txt": "  "
    },
    "http://www.boomhealth.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-community-grants/",
      "status": "new",
      "txt": "  "
    },
    "http://www.btconferencing.com/globalaccess/?bid=54_attended": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/february/viiv-healthcare-announces-detailed-positive-phase-iii-results-for-investigational-two-drug-regimen-of-dolutegravir-and-rilpivirine-for-hiv-treatment/",
      "status": "new",
      "txt": "http://www.btconferencing.com/globalaccess/?bid=54_attended"
    },
    "http://www.catie.ca/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-hivaids/canadian-resources/",
      "status": "new",
      "txt": "www.catie.ca"
    },
    "http://www.cdc.gov/hiv/basics/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/august/viiv-healthcare-receives-fda-approval-for-triumeq/",
      "status": "new",
      "txt": "http://www.cdc.gov/hiv/basics/"
    },
    "http://www.cdc.gov/hiv/group/racialethnic/africanamericans/index.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/july/viiv-healthcare-announces-positive-action-us-southern-initiative-an-innovative-community-support-program-to-fight-hivaids/",
      "status": "new",
      "txt": "http://www.cdc.gov/hiv/group/racialethnic/africanamericans/index.html"
    },
    "http://www.cdc.gov/hiv/hispanics/resources/factsheets/hispanic.htm": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/july/viiv-healthcare-announces-positive-action-us-southern-initiative-an-innovative-community-support-program-to-fight-hivaids/",
      "status": "new",
      "txt": "http://www.cdc.gov/hiv/hispanics/resources/factsheets/hispanic.htm"
    },
    "http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/closing-the-gap-in-the-latinx-community/",
      "status": "new",
      "txt": "http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html"
    },
    "http://www.cdc.gov/hiv/library/reports/surveillance/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-fda-approval-of-selzentry-maraviroc/",
      "status": "new",
      "txt": "http://www.cdc.gov/hiv/library/reports/surveillance/"
    },
    "http://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2014-vol-26.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accelerate--initiative/",
      "status": "new",
      "txt": "HIV Surveillance Report"
    },
    "http://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-vol-25.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/november/viiv-healthcare-awards-additional-round-of-grants-to-support-innovative-hiv-programs-aimed-at-reducing-disparities-in-the-southern-us/",
      "status": "new",
      "txt": "http://www.cdc.gov/hiv/pdf/g-l/hiv_surveillance_report_vol_25.pdf"
    },
    "http://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-21-1.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accelerate--initiative/",
      "status": "new",
      "txt": "HIV Surveillance Supplemental Report"
    },
    "http://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-supplemental-report-vol-21-4.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-for-youth/",
      "status": "new",
      "txt": "HIV Surveillance Supplemental Report 2016"
    },
    "http://www.cdc.gov/hiv/pdf/research_mmp_StagesofCare.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/august/viiv-healthcare-receives-fda-approval-for-triumeq/",
      "status": "new",
      "txt": "http://www.cdc.gov/hiv/pdf/research_mmp_StagesofCare.pdf. Accessed July 28"
    },
    "http://www.cdc.gov/hiv/pdf/statistics_surveillance_raceEthnicity.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/march/viiv-healthcare-announces-next-round-of-the-positive-action-southern-initiative-to-support-linkages-to-hivaids-care-and-treatment-adherence/",
      "status": "new",
      "txt": "http://www.cdc.gov/hiv/pdf/statistics_surveillance_raceEthnicity.pdf"
    },
    "http://www.cdc.gov/hiv/resources/factsheets/geographic.htm": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/february/viiv-healthcare-expands-positive-action-southern-initiative-to-fight-hivaids-and-support-community-action/",
      "status": "new",
      "txt": "http://www.cdc.gov/hiv/resources/factsheets/geographic.htm"
    },
    "http://www.cdc.gov/hiv/resources/factsheets/us.htm": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/february/viiv-healthcare-expands-positive-action-southern-initiative-to-fight-hivaids-and-support-community-action/",
      "status": "new",
      "txt": "http://www.cdc.gov/hiv/resources/factsheets/us.htm"
    },
    "http://www.cdc.gov/hiv/risk/age/youth/index.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-for-youth/",
      "status": "new",
      "txt": "HIV Among Youth"
    },
    "http://www.cdc.gov/hiv/topics/surveillance/basic.htm": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/february/viiv-healthcare-expands-positive-action-southern-initiative-to-fight-hivaids-and-support-community-action/",
      "status": "new",
      "txt": "http://www.cdc.gov/hiv/topics/surveillance/basic.htm"
    },
    "http://www.cdc.gov/nchhstp/newsroom/docs/factsheets/cdc-msm-508.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/june/viiv-healthcare-announces-new-positive-action-project-in-us-for-msm-youth-calls-for-proposals/",
      "status": "new",
      "txt": "http://www.cdc.gov/hiv/pdf/HIV-MSM-english-508.pdf"
    },
    "http://www.cdc.gov/nchhstp/newsroom/docs/factsheets/hiv-data-trends-fact-sheet-508.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/standing-together/",
      "status": "new",
      "txt": "http://www.cdc.gov/nchhstp/newsroom/docs/factsheets/hiv-data-trends-fact-sheet-508.pdf"
    },
    "http://www.cdc.gov/nchhstp/newsroom/docs/HIV-Infections-2006-2009.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/september/viiv-healthcare-reaffirms-commitment-to-us-regions-hardest-hit-by-hivaids/",
      "status": "new",
      "txt": "http://www.cdc.gov/nchhstp/newsroom/docs/HIV-Infections-2006-2009.pdf"
    },
    "http://www.cdc.gov/washington/testimony/2010/t20100929.htm": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/october/viiv-healthcare-acts-to-improve-access-to-hiv-medicines-in-united-states-for-those-most-in-need/",
      "status": "new",
      "txt": "http://www.cdc.gov/washington/testimony/2010/t20100929.htm"
    },
    "http://www.census.gov/prod/cen2010/briefs/c2010br-04.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/february/viiv-healthcare-expands-positive-action-southern-initiative-to-fight-hivaids-and-support-community-action/",
      "status": "new",
      "txt": "http://www.census.gov/prod/cen2010/briefs/c2010br-04.pdf."
    },
    "http://www.centeronhalsted.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-for-youth/",
      "status": "new",
      "txt": "Center on Halsted"
    },
    "http://www.ceshhar.org.zw/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-centre-for-sexual-health-and-hivaids-research-ceshhar-zimbabwe/",
      "status": "new",
      "txt": "here"
    },
    "http://www.chicagohouse.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-community-grants/",
      "status": "new",
      "txt": "  "
    },
    "http://www.chiva.org.uk/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/young-britons-break-down-hiv-stigma-isolation-to-be-the-genendit/",
      "status": "new",
      "txt": "Children’s HIV Association"
    },
    "http://www.chiva.org.uk/our-work/schools": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/young-britons-break-down-hiv-stigma-isolation-to-be-the-genendit/",
      "status": "new",
      "txt": "Educate Yourself: Working Towards HIV Friendly Schools"
    },
    "http://www.chiva.org.uk/our-work/support-camp/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/young-britons-break-down-hiv-stigma-isolation-to-be-the-genendit/",
      "status": "new",
      "txt": "Annual CHIVA Support Camp"
    },
    "http://www.clinicalstudydatarequest.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/january/viiv-healthcare-to-make-available-anonymised-patient-level-data-from-its-clinical-trials/",
      "status": "new",
      "txt": "www.clinicalstudydatarequest.com"
    },
    "http://www.clinicaltrials.gov/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/july/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen/",
      "status": "new",
      "txt": "www.clinicaltrials.gov"
    },
    "http://www.clinicaltrials.gov/show/NCT01263015": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/october/viiv-healthcare-announces-us-regulatory-submission-for-a-single-tablet-regimen-combining-dolutegravir-with-abacavir-and-lamivudine-for-people-living-with-hiv/",
      "status": "new",
      "txt": "http://www.clinicaltrials.gov/show/NCT01263015"
    },
    "http://www.clintonhealthaccess.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/december/mylans-tentative-fda-approval-for-paeds-formulations-of-abacavirlamivudine-through-innovative-collaboration-with-viiv-healthcare-and-chai/",
      "status": "new",
      "txt": "www.clintonhealthaccess.org"
    },
    "http://www.croiconference.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "CROI"
    },
    "http://www.csrwire.com/press_releases/40314-ViiV-Healthcare-Awards-1-Million-in-Grants-for-Positive-Action-for-Women-in-the-U-S-": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-for-women/",
      "status": "new",
      "txt": "press release"
    },
    "http://www.ctu.mrc.ac.uk/cascade/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/uebertragene-hiv-resistenzen-seltener/",
      "status": "new",
      "txt": "CASCADE-Serokonverter-Kohorte"
    },
    "http://www.cvent.com/events/viiv-medical-education-hiv-aging/custom-22-ce535d9309cd45b39c94a43b34ccf76e.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/educating-healthcare-professionals/",
      "status": "new",
      "txt": "ViiV Healthcare Medical Education"
    },
    "http://www.dhh.louisiana.gov/assets/oph/HIVSTD/hiv-aids/2014/Second_Quarter2014.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/october/viiv-healthcare-expands-program-to-reduce-hiv-disparities-in-southern-us/",
      "status": "new",
      "txt": "http://www.dhh.louisiana.gov/assets/oph/HIVSTD/hiv-aids/2014/Second_Quarter2014.pdf"
    },
    "http://www.doeak.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/deutsch-oesterreichischer-aids-kongress/",
      "status": "new",
      "txt": "http://www.doeak.com/"
    },
    "http://www.doeak2019.de/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "Deutsch-Österreichischer AIDS-Kongress"
    },
    "http://www.dzif-annual-meeting2018.de/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "Gemeinsame Jahrestagung DGI DZIF"
    },
    "http://www.eacs-conference2017.com/index.php?article_id=1": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/tackling-hiv-challenges-in-europe/",
      "status": "new",
      "txt": "16th European AIDS Conference"
    },
    "http://www.eacs-conference2017.com/index.php?article_id=166": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/tackling-hiv-challenges-in-europe/",
      "status": "new",
      "txt": "Liverpool Drug Interactions Session: Key Clinical Pharmacology Issues of Current and Future ART"
    },
    "http://www.eacs-conference2019.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "EACS"
    },
    "http://www.edurant.com/hcp/prescribing-information": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/",
      "status": "new",
      "txt": "Prescribing Information"
    },
    "http://www.edurant.com/shared/prescribing-information-edurant.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/july/phase-ii-study-results-showed-comparable-viral-suppression-rates-at-96-weeks-for-a-two-drug-regimen/",
      "status": "new",
      "txt": "Product Information"
    },
    "http://www.edurant.com/sites/default/files/EDURANT-PI.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/june/viiv-healthcare-announces-new-collaboration-with-janssen/",
      "status": "new",
      "txt": "http://www.edurant.com/sites/default/files/EDURANT-PI.pdf"
    },
    "http://www.ema.europa.eu/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/may/viiv-healthcare-reports-positive-results-for-landmark-phase-iii-/",
      "status": "new",
      "txt": "www.ema.europa.eu"
    },
    "http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002264/WC500118874.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/viiv-healthcare-presents-three-year-data-for-investigational-long-acting-injectable-two-drug-hiv-regimen/",
      "status": "new",
      "txt": "here"
    },
    "http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/002753/WC500218158.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/december/viiv-healthcare-announces-chmp-positive-opinion-to-lower-the-age-and-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv-in-europe/",
      "status": "new",
      "txt": "http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/002753/WC500218158.pdf"
    },
    "http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002264/human_med_001513.jsp&mid=WC0b01ac058001d124": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/march/viiv-healthcare-gains-chmp-positive-opinion-for-juluca-dolutegra/",
      "status": "new",
      "txt": "rilpivirine"
    },
    "http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002753/human_med_001720.jsp&mid=WC0b01ac058001d124": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/march/viiv-healthcare-gains-chmp-positive-opinion-for-juluca-dolutegra/",
      "status": "new",
      "txt": "dolutegravir"
    },
    "http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/03/news_detail_002925.jsp&mid=WC0b01ac058004d5c1": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/may/viiv-healthcare-reports-positive-results-for-landmark-phase-iii-/",
      "status": "new",
      "txt": "http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/03/news_detail_002925.jsp&mid=WC0b01ac058004d5c1"
    },
    "http://www.euro.who.int/__data/assets/pdf_file/0019/324370/HIV-AIDS-surveillance-Europe-2015.pdf?ua=1": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/",
      "status": "new",
      "txt": "http://www.euro.who.int/__data/assets/pdf_file/0019/324370/HIV-AIDS-surveillance-Europe-2015.pdf?ua=1"
    },
    "http://www.euro.who.int/en/health-topics/communicable-diseases/hivaids/data-and-statistics/infographic-newly-diagnosed-hiv-infections-in-the-who-european-region": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-/",
      "status": "new",
      "txt": "http://www.euro.who.int/en/health-topics/communicable-diseases/hivaids/data-and-statistics/infographic-newly-diagnosed-hiv-infections-in-the-who-european-region"
    },
    "http://www.euro.who.int/en/health-topics/communicable-diseases/hivaids/data-and-statistics/infographic-newly-diagnosed-hiv-infections-in-the-who-european-region,-2016": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/march/viiv-healthcare-gains-chmp-positive-opinion-for-juluca-dolutegra/",
      "status": "new",
      "txt": "http://www.euro.who.int/en/health-topics/communicable-diseases/hivaids/data-and-statistics/infographic-newly-diagnosed-hiv-infections-in-the-who-european-region,-2016"
    },
    "http://www.euro.who.int/en/health-topics/communicable-diseases/hivaids/publications/2016/hivaids-surveillance-in-europe-2015-2016": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/",
      "status": "new",
      "txt": "http://www.euro.who.int/en/health-topics/communicable-diseases/hivaids/publications/2016/hivaids-surveillance-in-europe-2015-2016"
    },
    "http://www.fast-trackcities.org/survey/index.php/649523": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/november/fast-track-cities-survey-data-provide-insights-into-quality-of-life-of-people-living-with-hiv/",
      "status": "new",
      "txt": "Fast-Track Cities Quality of Life Survey"
    },
    "http://www.fda.gov/medwatch": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/february/viiv-healthcare-launches-eighth-phase-iii-study-in-two-drug-regi/",
      "status": "new",
      "txt": "www.fda.gov/medwatch"
    },
    "http://www.friendsforlifecorp.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/november/viiv-healthcare-awards-additional-round-of-grants-to-support-innovative-hiv-programs-aimed-at-reducing-disparities-in-the-southern-us/",
      "status": "new",
      "txt": "Friends for Life"
    },
    "http://www.google.com/settings/ads": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/datenschutzerklaerung/",
      "status": "new",
      "txt": "http://www.google.com/settings/ads"
    },
    "http://www.gsk.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/july/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen/",
      "status": "new",
      "txt": "www.gsk.com"
    },
    "http://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/report-a-side-effect/",
      "status": "new",
      "txt": "Report a side effect"
    },
    "http://www.gsk.com/en-gb/investors/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/contact-us/",
      "status": "new",
      "txt": "GlaxoSmithKline's Investor Relations"
    },
    "http://www.gsk.com/en-gb/investors/corporate-reporting/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/100-dedicated-to-hiv/",
      "status": "new",
      "txt": "£2.3 billion in 2015"
    },
    "http://www.gsk.com/en-gb/media/press-releases/2014/viiv-healthcare-receives-eu-marketing-authorisation-for-triumeq-dolutegravirabacavirlamivudine-a-new-once-daily-single-pill-regimen-for-the-treatment-of-hiv/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/december/viiv-healthcare-announces-regulatory-submission-in-japan-for-single-pill-regimen-combining-dolutegravir-abacavir-and-lamivudine-for-the-treatment-of-hiv/",
      "status": "new",
      "txt": "the European Commission (EC) granted marketing authorisation in September 2014"
    },
    "http://www.gsk.it/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2017/novembre/viiv-healthcare-annuncia-la-partenza-dello-studio-di-fase-iii-co/",
      "status": "new",
      "txt": "www.gsk.it"
    },
    "http://www.happiapp.nl/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/happi-app/",
      "status": "new",
      "txt": "www.happiapp.nl"
    },
    "http://www.hayaresearchunit.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/addressing-the-challenges-of-the-hiv-epidemic-in-africa/",
      "status": "new",
      "txt": "CLICK HERE FOR MORE INFO ON THE HAYA PROGRAMME"
    },
    "http://www.hf-prevention.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/",
      "status": "new",
      "txt": "http://www.hf-prevention.com/"
    },
    "http://www.hiv-kontrovers.de/hivkontrovers/front_content.php": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "HIV Kontrovers"
    },
    "http://www.hiv-sti-fortbildung.de/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/let-s-talk-about-sex/",
      "status": "new",
      "txt": "hier"
    },
    "http://www.hiv411.ca/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-hivaids/canadian-resources/",
      "status": "new",
      "txt": "www.hiv411.ca"
    },
    "http://www.hivdigital.ee/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/positive-partnerships-initiative-launches-in-estonia/",
      "status": "new",
      "txt": "Click here"
    },
    "http://www.hivglasgow.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-hiv-glasgow/",
      "status": "new",
      "txt": "conference website"
    },
    "http://www.hivglasgow.org/scientific-programme-2": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-hiv-glasgow/",
      "status": "new",
      "txt": "full programme"
    },
    "http://www.hivhealthyliving.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "3rd European Healthy Living with HIV"
    },
    "http://www.hivnet.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/de-mensen-van-de-hiv-vereniging/",
      "status": "new",
      "txt": "www.hivnet.org"
    },
    "http://www.hivplusmag.com/stigma/2017/2/06/stories-black-gay-men-south-are-seldom-told-until-now": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can/",
      "status": "new",
      "txt": "Stories of Black Gay Men in the South are Seldom Told, Until Now"
    },
    "http://www.hivtestingweek.eu/about-testing-week": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/november/hiv-testing-week/",
      "status": "new",
      "txt": "http://www.hivtestingweek.eu/about-testing-week"
    },
    "http://www.hivuitdekast.nl/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/hiv-uit-de-kast-campagne/",
      "status": "new",
      "txt": "www.hivuitdekast.nl"
    },
    "http://www.hptn.org/research/studies/176": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/december/viiv-healthcare-announces-start-of-phase-iii-study-evaluating-long-acting-cabotegravir-for-hiv-prevention/",
      "status": "new",
      "txt": "www.hptn.org/research/studies/176"
    },
    "http://www.iapac.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/may/viiv-healthcare-and-the-international-association-of-providers-of-aids-care-to-collaborate-on-fast-track-cities/",
      "status": "new",
      "txt": "www.iapac.org"
    },
    "http://www.iapac.org/cities/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/how-viiv-healthcare-is-helping-to-accelerate-city-hivaids-responses-through-our-collaboration/",
      "status": "new",
      "txt": "Fast-Track Cities"
    },
    "http://www.iapac.org/fast-track-cities/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/accelerating-city-hivaids-responses-through-collaboration/",
      "status": "new",
      "txt": "Fast-Track Cities"
    },
    "http://www.ias2017.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-host-the-inaugural-implementation-science-network-meeting-in-paris/",
      "status": "new",
      "txt": "International AIDS Society (IAS) Conference"
    },
    "http://www.ias2017.org/Conference-Objectives": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-to-host-inaugural-implementation-science-network-meeting-in-paris/",
      "status": "new",
      "txt": "http://www.ias2017.org/Conference-Objectives"
    },
    "http://www.ias2017.org/Media-Centre/Press-Releases/ArticleID/95/CIPHER-grants-and-fellowships-encourage-innovative-responses-to-paediatric-and-adolescent-HIV": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/we-re-allies-the-power-of-partnership/",
      "status": "new",
      "txt": "CIPHER grants and fellowships encourage innovative responses to paediatric and adolescent HIV"
    },
    "http://www.ias2017.org/Media-Centre/Press-Releases/ArticleID/97/IAS-2017-highlights-innovative-approaches-to-overcome-stigma-and-discrimination-against-key-populations": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/we-re-allies-the-power-of-partnership/",
      "status": "new",
      "txt": "IAS 2017 highlights innovative approaches to overcome stigma and discrimination against key populations"
    },
    "http://www.ias2017.org/Programme/Abstracts/Track-Categories": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-to-host-inaugural-implementation-science-network-meeting-in-paris/",
      "status": "new",
      "txt": "own scientific track"
    },
    "http://www.iasociety.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/",
      "status": "new",
      "txt": "International AIDS Society"
    },
    "http://www.iasociety.org/CIPHER": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/paediatric-innovation-seed-fund/",
      "status": "new",
      "txt": "unrestricted grant to the International AIDS Society (IAS) CIPHER research programme"
    },
    "http://www.iasociety.org/Default.aspx?pageId=707": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/our-approach-to-rd/",
      "status": "new",
      "txt": "Towards an HIV Cure Industry Collaborative Group"
    },
    "http://www.idweek.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "Jahreskongress der Infectious Diseases Society of America (IDSA) (ID-Week)"
    },
    "http://www.ikambere.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/",
      "status": "new",
      "txt": "IKAMBERE"
    },
    "http://www.imstilljosh.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/",
      "status": "new",
      "txt": "www.ImStillJosh.com"
    },
    "http://www.infektiologie-update.de/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "11. Deutsches Infektiologie-Update 2018"
    },
    "http://www.inquisithealth.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/qa-with-heather-brogan-piloting-a-new-mentoring-app-for-hiv-patients/",
      "status": "new",
      "txt": "InquisitHealth"
    },
    "http://www.irishouse.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/our-commitment-to-latinx-communities-living-with-hiv/",
      "status": "new",
      "txt": "Iris House"
    },
    "http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/EDURANT-pi.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-/",
      "status": "new",
      "txt": "http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/EDURANT-pi.pdf"
    },
    "http://www.kff.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kaiser-family-foundation/",
      "status": "new",
      "txt": "Kaiser Family Foundation"
    },
    "http://www.kff.org/hivaids/upload/3029-10.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/september/viiv-healthcare-awards-southern-initiative-grants-to-reduce-hiv-disparities-among-african-americans-and-latinos/",
      "status": "new",
      "txt": "http://www.kff.org/hivaids/upload/3029-10.pdf"
    },
    "http://www.kff.org/hivaids/upload/3029-12.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/september/viiv-healthcare-reaffirms-commitment-to-us-regions-hardest-hit-by-hivaids/",
      "status": "new",
      "txt": "http://www.kff.org/hivaids/upload/3029-12.pdf"
    },
    "http://www.kit2018.de/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "KIT 2018"
    },
    "http://www.livlife.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/positive-perspectives/",
      "status": "new",
      "txt": "www.livlife.com"
    },
    "http://www.medicines.org.uk/EMC/medicine/10419/SPC/Retrovir+100+mg+10ml%2c+oral+solution/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/retrovir-azt/",
      "status": "new",
      "txt": "Retrovir oral solution summary of product characteristics"
    },
    "http://www.medicines.org.uk/EMC/medicine/12444/SPC/Retrovir+250mg+Capsules/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/retrovir-azt/",
      "status": "new",
      "txt": "Retrovir 250mg capsules summary of product characteristics"
    },
    "http://www.medicines.org.uk/emc/medicine/13678/PIL/Retrovir+100+mg+10ml%2c+oral+solution/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/retrovir-azt/",
      "status": "new",
      "txt": "Retrovir oral solution patient information leaflet"
    },
    "http://www.medicines.org.uk/EMC/medicine/14818/SPC/Telzir+Oral+Suspension/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/lexiva-telzir/",
      "status": "new",
      "txt": "Telzir oral suspension summary of product characteristics"
    },
    "http://www.medicines.org.uk/EMC/medicine/14819/SPC/Telzir+700+mg+film-coated+tablets/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/lexiva-telzir/",
      "status": "new",
      "txt": "Telzir 700mg tablets summary of product characteristics"
    },
    "http://www.medicines.org.uk/emc/medicine/15419/PIL/Telzir%20Oral%20Suspension%2050mg/ml/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/lexiva-telzir/",
      "status": "new",
      "txt": "Telzir oral suspension patient information leaflet"
    },
    "http://www.medicines.org.uk/emc/medicine/15628/PIL/Kivexa%20600mg/300mg%20Tablets/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/epzicom-kivexa/",
      "status": "new",
      "txt": "Patient Information Leaflet (Kivexa)"
    },
    "http://www.medicines.org.uk/EMC/medicine/15707/SPC/Kivexa+film-coated+tablets/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/epzicom-kivexa/",
      "status": "new",
      "txt": "ummary of Product Characteristics (Kivexa)"
    },
    "http://www.medicines.org.uk/EMC/medicine/20386/SPC/Celsentri+150mg+film-coated+tablets/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-presents-phase-iii-data-comparing-once-daily-maraviroc-in-combination/",
      "status": "new",
      "txt": "http://www.medicines.org.uk/EMC/medicine/20386/SPC/Celsentri+150mg+film-coated+tablets/"
    },
    "http://www.medicines.org.uk/EMC/medicine/2475/SPC/Ziagen+20+mg+ml+Oral+Solution/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/ziagen/",
      "status": "new",
      "txt": "Ziagen oral solution summary of Product Characteristics"
    },
    "http://www.medicines.org.uk/EMC/medicine/2476/SPC/Ziagen+300+mg+Film+Coated+Tablets/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/ziagen/",
      "status": "new",
      "txt": "Ziagen tablets summary of Product Characteristics"
    },
    "http://www.medicines.org.uk/emc/medicine/28545": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/tivicay/",
      "status": "new",
      "txt": "European Summary of Prescribing Information"
    },
    "http://www.medicines.org.uk/emc/medicine/28546": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/tivicay/",
      "status": "new",
      "txt": "European Patient Information Leaflet"
    },
    "http://www.medicines.org.uk/emc/medicine/29174": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/triumeq/",
      "status": "new",
      "txt": "European Patient Information Leaflet"
    },
    "http://www.medicines.org.uk/emc/medicine/29178": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/triumeq/",
      "status": "new",
      "txt": "European Summary of Prescribing Information"
    },
    "http://www.medicines.org.uk/emc/medicine/3855/PIL/Retrovir10%20mg/ml%20IV%20for%20Infusion/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/retrovir-azt/",
      "status": "new",
      "txt": "Retrovir IV for infusion patient information leaflet"
    },
    "http://www.medicines.org.uk/emc/medicine/3857/PIL/Combivir+Film+Coated+Tablets/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/combivir/",
      "status": "new",
      "txt": "Patient information leaflet for Combivir"
    },
    "http://www.medicines.org.uk/emc/medicine/4426/PIL/Ziagen+300+mg+Film+Coated+Tablets/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/ziagen/",
      "status": "new",
      "txt": "Ziagen tablets Patient Information Leaflet"
    },
    "http://www.medicines.org.uk/EMC/medicine/4453/SPC/Trizivir+film-coated+tablets/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/trizivir/",
      "status": "new",
      "txt": "Summary of Product Characteristics"
    },
    "http://www.medicines.org.uk/EMC/medicine/725/SPC/Combivir+Film+Coated+Tablets/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/combivir/",
      "status": "new",
      "txt": "Summary of Product Characteristics for Combivir"
    },
    "http://www.medicines.org.uk/EMC/medicine/743/SPC/Epivir+Oral+Solution/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/epivir-3tc/",
      "status": "new",
      "txt": "Epivir oral solution summary of product characteristics"
    },
    "http://www.medicines.org.uk/EMC/medicine/744/SPC/Epivir+150+mg+film-coated+tablets/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/epivir-3tc/",
      "status": "new",
      "txt": "Epivir 150 mg tablets summary of product characteristics"
    },
    "http://www.medicines.org.uk/emc/medicine/9001/PIL/Ziagen+20+mg+ml+Oral+Solution/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/ziagen/",
      "status": "new",
      "txt": "Ziagen oral solution patient information leaflet"
    },
    "http://www.medicines.org.uk/emc/medicine/9200/PIL/Trizivir+film-coated+tablets/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/trizivir/",
      "status": "new",
      "txt": "Patient Information Leaflet"
    },
    "http://www.microsoft.com/windows/ie/default.asp": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/careers/how-to-apply/",
      "status": "new",
      "txt": "http://www.microsoft.com/windows/ie/default.asp"
    },
    "http://www.mmm-online.com/mmm-awards/industry-marketer-of-the-year-2015/article/440218/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/october/viiv-healthcare-employee-named-top-marketer-in-healthcare-industry-by-medical-marketing-media/",
      "status": "new",
      "txt": "Medical Marketing & Media"
    },
    "http://www.msds-gsk.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/lexiva-telzir/",
      "status": "new",
      "txt": "Safety Data Sheet"
    },
    "http://www.mtvstayingalive.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/",
      "status": "new",
      "txt": "MTV/Staying Alive Foundation"
    },
    "http://www.nashvillecares.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/november/viiv-healthcare-awards-additional-round-of-grants-to-support-innovative-hiv-programs-aimed-at-reducing-disparities-in-the-southern-us/",
      "status": "new",
      "txt": "Nashville CARES"
    },
    "http://www.nastad.org/sites/default/files/Guide-LGBTQ-for-Adult-Healthcare-Providers-05-2012.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-expands-u-s--commitment-to-youth-living-with-hiv/",
      "status": "new",
      "txt": "http://www.nastad.org/sites/default/files/Guide-LGBTQ-for-Adult-Healthcare-Providers-05-2012.pdf"
    },
    "http://www.nejm.org/doi/pdf/10.1056/NEJMoa1105243": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/frueher-therapiebeginn-kann-resistenzentwicklung-verhindern/",
      "status": "new",
      "txt": "Cohen MS et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11;365(6):493-505"
    },
    "http://www.networkadvertising.org/choices/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/privacy-policy/",
      "status": "new",
      "txt": "NAI website"
    },
    "http://www.newnownext.com/lgbt-plays-off-broadway-nyc-theater/05/2018/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/",
      "status": "new",
      "txt": "soul-stirring."
    },
    "http://www.nhivna.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/qa-with-angelina-namiba-on-viiv-healthcare-s-skills-workshop/",
      "status": "new",
      "txt": "National HIV Nurses Association"
    },
    "http://www.nhs.uk/conditions/HIV/Pages/Introduction.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/august/viiv-healthcare-receives-fda-approval-for-triumeq/",
      "status": "new",
      "txt": "http://www.nhs.uk/conditions/HIV/Pages/Introduction.aspx."
    },
    "http://www.nmac.org/meet-the-2018-youth-initiative-scholars": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/",
      "status": "new",
      "txt": " \n           \n            NMAC Announces 2018 Youth Initiative Scholars  \n           Learn more and meet the 2018 scholars here. \n            "
    },
    "http://www.npsitalia.net/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/hiv-behind-bars-supporting-hiv-research-education-and-testing-in-italian-prisons/",
      "status": "new",
      "txt": "www.npsitalia.net"
    },
    "http://www.nshpc.ucl.ac.uk/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/december/global-agenda-for-elimination-of-mother-to-child-transmission-of-hiv-positive-action-for-children-fund-calls-for-proposals-to-fill-the-gaps/",
      "status": "new",
      "txt": "http://www.nshpc.ucl.ac.uk/"
    },
    "http://www.pedaids.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/improving-retention-of-breastfeeding-wlhiv-on-art-challenge-winner/",
      "status": "new",
      "txt": "Elizabeth Glaser Pediatric AIDS Foundation"
    },
    "http://www.pepfar.gov/press/releases/260085.htm": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/a-look-back-at-aids-2016/",
      "status": "new",
      "txt": "DREAMS, also announced the winners of its Innovation Challenge"
    },
    "http://www.pfizer.com/home/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/february/david-redfern-appointed-as-chairman-of-the-board-for-viiv-healthcare/",
      "status": "new",
      "txt": "www.pfizer.com"
    },
    "http://www.phac-aspc.gc.ca/aids-sida/pr/index-eng.php": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/about-hivaids/about-hivaids-in-canada/",
      "status": "new",
      "txt": "Public Health Agency of Canada. Populations at Risk. Accessed April 10, 2015."
    },
    "http://www.pinknews.co.uk/2017/08/17/uganda-pride-cancelled-amid-threats-police-arrest-and-physical-harm/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/pride-around-the-world/",
      "status": "new",
      "txt": "http://www.pinknews.co.uk/2017/08/17/uganda-pride-cancelled-amid-threats-police-arrest-and-physical-harm/"
    },
    "http://www.positiveactionchallenges.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "status": "new",
      "txt": "Positive Action Challenges"
    },
    "http://www.positiveperspectives.info/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/preliminary-positive-perspectives-survey-data-released-at-9th-international-aids-society-conference/",
      "status": "new",
      "txt": "LiV Life website"
    },
    "http://www.positivewomen.org.au/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/positive-women-victoria-community-camp/",
      "status": "new",
      "txt": "http://www.positivewomen.org.au/"
    },
    "http://www.positivewomen.org.au/women-and-hiv/an-overview/in-australia": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/positive-women-victoria-community-camp/",
      "status": "new",
      "txt": "http://www.positivewomen.org.au/women-and-hiv/an-overview/in-australia"
    },
    "http://www.projectinform.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-community-grants/",
      "status": "new",
      "txt": "  "
    },
    "http://www.raininc.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/november/viiv-healthcare-awards-additional-round-of-grants-to-support-innovative-hiv-programs-aimed-at-reducing-disparities-in-the-southern-us/",
      "status": "new",
      "txt": "RAIN, Inc."
    },
    "http://www.redtrasex.org.ar/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/february/positive-action-and-vida-digna-further-information/",
      "status": "new",
      "txt": "http://www.redtrasex.org.ar/ "
    },
    "http://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2017/Ausgaben/39_17.pdf?__blob=publicationFile": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/deutsche-aids-hilfe-startet-die-informationskampagne-zum-welt-ai/",
      "status": "new",
      "txt": "Robert-Koch-Institut, Epidemiologisches Bulletin 39/2017"
    },
    "http://www.rwhp.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/november/viiv-healthcare-awards-additional-round-of-grants-to-support-innovative-hiv-programs-aimed-at-reducing-disparities-in-the-southern-us/",
      "status": "new",
      "txt": "Rural Women’s Health Project"
    },
    "http://www.sanitapenitenziaria.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/hiv-behind-bars-supporting-hiv-research-education-and-testing-in-italian-prisons/",
      "status": "new",
      "txt": "www.sanitapenitenziaria.org"
    },
    "http://www.sciencedirect.com/science/journal/23523018/2/5": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-s-commitment-to-implementation-science/",
      "status": "new",
      "txt": "Volume 2, Issue 5"
    },
    "http://www.sciencedirect.com/science/journal/23523018/2/5?sdc=1": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-host-the-inaugural-implementation-science-network-meeting-in-paris/",
      "status": "new",
      "txt": "Volume 2, Issue 5"
    },
    "http://www.selzentry.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/march/regulatory-update-celsentriselzentry-maraviroc/",
      "status": "new",
      "txt": "www.selzentry.com"
    },
    "http://www.shionogi-inc.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/july/positive-phase-iib-data-on-investigational-once-daily-integrase-inhibitor-572-presented-at-international-aids-conference/",
      "status": "new",
      "txt": "www.shionogi-inc.com"
    },
    "http://www.shionogi.co.jp/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/july/positive-phase-iib-data-on-investigational-once-daily-integrase-inhibitor-572-presented-at-international-aids-conference/",
      "status": "new",
      "txt": "www.shionogi.co.jp"
    },
    "http://www.shionogi.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/100-dedicated-to-hiv/",
      "status": "new",
      "txt": "Shionogi"
    },
    "http://www.sidaccueil.fr/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/",
      "status": "new",
      "txt": "SID’ACCUEIL"
    },
    "http://www.sisterlove.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-community-grants/",
      "status": "new",
      "txt": "  "
    },
    "http://www.soteni.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/the-community-led-hivaids-prevention-project-kenya/",
      "status": "new",
      "txt": "SOTENI Kenya"
    },
    "http://www.stigmaactionnetwork.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/",
      "status": "new",
      "txt": "The Stigma Action Network"
    },
    "http://www.taepusa.org/Portals/0/Documents/Louisiana%20SHARP%20Report.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/march/viiv-healthcare-announces-next-round-of-the-positive-action-southern-initiative-to-support-linkages-to-hivaids-care-and-treatment-adherence/",
      "status": "new",
      "txt": "http://www.taepusa.org/Portals/0/Documents/Louisiana%20SHARP%20Report.pdf"
    },
    "http://www.teampata.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/fighting-hiv-together/the-fight-to-end-mother-to-child-transmission-of-hiv/",
      "status": "new",
      "txt": "Paediatric & Adolescent Treatment Africa (PATA)"
    },
    "http://www.telegraph.co.uk/education/stem-awards/healthcare/working-on-a-cure-for-hiv/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/croi-2018/leading-the-way-in-hiv-on-international-women-s-day/",
      "status": "new",
      "txt": "here"
    },
    "http://www.thebody.com/content/79787/black-gay-and-bisexual-men-create-an-immersive-int.html?getPage=1": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can/",
      "status": "new",
      "txt": "Black Gay and Bisexual Men Create an Immersive, Intimate Performance in Two Southern Cities"
    },
    "http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(15)00152-8/abstract": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/",
      "status": "new",
      "txt": "http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(15)00152-8/abstract"
    },
    "http://www.tivicay.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/tivicay/",
      "status": "new",
      "txt": "please visit our promotional website."
    },
    "http://www.treatmentactiongroup.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-community-grants/",
      "status": "new",
      "txt": "  "
    },
    "http://www.treatmentactiongroup.org/press/ete-southern": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative/",
      "status": "new",
      "txt": "Treatment Action Group"
    },
    "http://www.twitter.com/viivhc": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-aids-2016/",
      "status": "new",
      "txt": "@ViiVHC"
    },
    "http://www.unaids.org/believeitdoit/get-the-facts.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/november/viiv-healthcare-commits-nearly-4m-in-positive-action-for-children-fund-grants-for-programmes-focused-on-alleviating-burden-of-hiv-on-women-and-children/",
      "status": "new",
      "txt": "\"UNAIDS Fact Sheet.\" UNAIDS Believe It, Do It: Get the Facts. UNAIDS, 2009. Web. 3 Oct 2012."
    },
    "http://www.unaids.org/believeitdoit/the-global-plan.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/november/viiv-healthcare-announces-new-grants-in-support-of-ending-mother-to-child-transmission-of-hiv/",
      "status": "new",
      "txt": "UNAIDS' Global Plan"
    },
    "http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/december/viiv-healthcare-commits-34m-in-positive-action-for-children-fund-grants-for-programmes-focused-on-prevention-of-mother-to-child-transmission-of-hiv/",
      "status": "new",
      "txt": "http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS_Global_Report_2013_en.pdf"
    },
    "http://www.unaids.org/en/regionscountries/countries/armenia": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-extends-medicines-patent-pool-licence-agreement/",
      "status": "new",
      "txt": "http://www.unaids.org/en/regionscountries/countries/armenia"
    },
    "http://www.unaids.org/en/regionscountries/countries/botswana": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/helping-botswana-treat-all-people-living-with-hiv/",
      "status": "new",
      "txt": "http://www.unaids.org/en/regionscountries/countries/botswana"
    },
    "http://www.unaids.org/en/regionscountries/countries/lesotho": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/april/global-partnership-launches-new-programme-with-goal-to-save-the-lives-of-thousands-of-children-affected-by-hiv-in-lesotho/",
      "status": "new",
      "txt": "http://www.unaids.org/en/regionscountries/countries/lesotho"
    },
    "http://www.unaids.org/en/regionscountries/countries/morocco": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-extends-medicines-patent-pool-licence-agreement/",
      "status": "new",
      "txt": "http://www.unaids.org/en/regionscountries/countries/morocco"
    },
    "http://www.unaids.org/en/regionscountries/countries/republicofmoldova": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-extends-medicines-patent-pool-licence-agreement/",
      "status": "new",
      "txt": "http://www.unaids.org/en/regionscountries/countries/republicofmoldova"
    },
    "http://www.unaids.org/en/resources/909090": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/our-people/one-million-positive-faces/",
      "status": "new",
      "txt": "90-90-90 goals"
    },
    "http://www.unaids.org/en/resources/campaigns/2014/2014gapreport/factsheet/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/mieux-nous-connaitre/",
      "status": "new",
      "txt": "http://www.unaids.org/en/resources/campaigns/2014/2014gapreport/factsheet/"
    },
    "http://www.unaids.org/en/resources/campaigns/2014/2014gapreport/gapreport/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/fighting-hiv-together/hiv-a-virus-that-thrives-on-inequality/",
      "status": "new",
      "txt": "http://www.unaids.org/en/resources/campaigns/2014/2014gapreport/gapreport/"
    },
    "http://www.unaids.org/en/resources/campaigns/HowAIDSchangedeverything/factsheet": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/100-dedicated-to-hiv/",
      "status": "new",
      "txt": "36.9 million people living with the virus"
    },
    "http://www.unaids.org/en/resources/documents/2014/90-90-90": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/viiv-healthcare-s-positive-partnerships-accelerates-progress-towards-90-90-90-goals-in-estonia/",
      "status": "new",
      "txt": "UNAIDS 90-90-90"
    },
    "http://www.unaids.org/en/resources/documents/2014/JC2686_WAD2014report": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/deutsche-aids-hilfe-startet-die-informationskampagne-zum-welt-ai/",
      "status": "new",
      "txt": "UNAIDS 2014: Ending the Epidemic by 2030"
    },
    "http://www.unaids.org/en/resources/documents/2017/2017-agenda-zero-discrimination-health-care": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/our-people/one-million-positive-faces/",
      "status": "new",
      "txt": "Zero Discrimination Agenda"
    },
    "http://www.unaids.org/en/resources/documents/2017/90-90-90": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/championing-effective-hiv-care-for-plhiv/",
      "status": "new",
      "txt": "http://www.unaids.org/en/resources/documents/2017/90-90-90"
    },
    "http://www.unaids.org/en/resources/fact-sheet": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-shares-data-from-its-innovative-portfolio-with-h/",
      "status": "new",
      "txt": "http://www.unaids.org/en/resources/fact-sheet"
    },
    "http://www.unaids.org/en/resources/fact-sheet.%20Last%20accessed%20November%202018": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/advancing-hiv-science-and-rd/we-research-and-develop-new-hiv-medicines/",
      "status": "new",
      "txt": "http://www.unaids.org/en/resources/fact-sheet. Last accessed November 2018"
    },
    "http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2015/february/20150217_PR_all-in": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-adolescents/",
      "status": "new",
      "txt": "http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2015/february/20150217_PR_all-in"
    },
    "http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2017/november/20171121_righttohealth_report": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/art-erreicht-mehr-als-20-mio-menschen/",
      "status": "new",
      "txt": "Pressemeldung"
    },
    "http://www.unaids.org/fr/resources/documents/2014/90-90-90": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/",
      "status": "new",
      "txt": "http://www.unaids.org/fr/resources/documents/2014/90-90-90"
    },
    "http://www.unaids.org/sites/default/files/country/documents/EST_narrative_report_2016.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/positive-partnerships-initiative-launches-in-estonia/",
      "status": "new",
      "txt": "http://www.unaids.org/sites/default/files/country/documents/EST_narrative_report_2016.pdf"
    },
    "http://www.unaids.org/sites/default/files/country/documents/LSO_narrative_report_2015.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/april/global-partnership-launches-new-programme-with-goal-to-save-the-lives-of-thousands-of-children-affected-by-hiv-in-lesotho/",
      "status": "new",
      "txt": "http://www.unaids.org/sites/default/files/country/documents/LSO_narrative_report_2015.pdf"
    },
    "http://www.unaids.org/sites/default/files/country/documents/UKR_narrative_report_2015.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-extends-medicines-patent-pool-licence-agreement/",
      "status": "new",
      "txt": "http://www.unaids.org/sites/default/files/country/documents/UKR_narrative_report_2015.pdf"
    },
    "http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/factsheet/2012/20120417_FS_adolescentsyoungpeoplehiv_en.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/croi-2018/leading-the-way-in-hiv-on-international-women-s-day/",
      "status": "new",
      "txt": "http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/factsheet/2012/20120417_FS_adolescentsyoungpeoplehiv_en.pdf"
    },
    "http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/unaidspublication/2014/UNAIDS_Gap_report_en.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-girls-women/",
      "status": "new",
      "txt": "http://www.unaids.org/sites/default/files/en/media/unaids/contentassets/documents/unaidspublication/2014/UNAIDS_Gap_report_en.pdf"
    },
    "http://www.unaids.org/sites/default/files/media_asset/09_ChildrenandpregnantwomenlivingwithHIV.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/mieux-nous-connaitre/",
      "status": "new",
      "txt": "http://www.unaids.org/sites/default/files/media_asset/09_ChildrenandpregnantwomenlivingwithHIV.pdf"
    },
    "http://www.unaids.org/sites/default/files/media_asset/2014unaidsguidancenote_stigma_en.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/",
      "status": "new",
      "txt": "http://www.unaids.org/sites/default/files/media_asset/2014unaidsguidancenote_stigma_en.pdf"
    },
    "http://www.unaids.org/sites/default/files/media_asset/20151027_UNAIDS_PCB37_15_18_EN_rev1.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/july/aria-study-shows-superior-efficacy-of-triumeq-for-treatment-na%c3%afve-women-living-with-hiv/",
      "status": "new",
      "txt": "http://www.unaids.org/sites/default/files/media_asset/20151027_UNAIDS_PCB37_15_18_EN_rev1.pdf"
    },
    "http://www.unaids.org/sites/default/files/media_asset/20170720_Data_book_2017_en.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/hiv-a-virus-that-thrives-on-inequality/",
      "status": "new",
      "txt": "http://www.unaids.org/sites/default/files/media_asset/20170720_Data_book_2017_en.pdf"
    },
    "http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/june/viiv-healthcare-announces-fda-approval-to-lower-the-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv/",
      "status": "new",
      "txt": "http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf"
    },
    "http://www.unaids.org/sites/default/files/media_asset/90-90-90_fr.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/viiv-healthcare-en-france/",
      "status": "new",
      "txt": "http://www.unaids.org/sites/default/files/media_asset/90-90-90_fr.pdf"
    },
    "http://www.unaids.org/sites/default/files/media_asset/JC2385_ProgressReportGlobalPlan_en_0.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/november/viiv-healthcare-announces-new-grants-in-support-of-ending-mother-to-child-transmission-of-hiv/",
      "status": "new",
      "txt": "http://www.unaids.org/sites/default/files/media_asset/JC2385_ProgressReportGlobalPlan_en_0.pdf"
    },
    "http://www.unaids.org/sites/default/files/media_asset/JC2687_TheCitiesReport_en.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/how-viiv-healthcare-is-helping-to-accelerate-city-hivaids-responses-through-our-collaboration/",
      "status": "new",
      "txt": "http://www.unaids.org/sites/default/files/media_asset/JC2687_TheCitiesReport_en.pdf"
    },
    "http://www.unaids.org/sites/default/files/media_asset/MDG6Report_en.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/september/viiv-healthcare-welcomes-the-fda-s-tentative-approval-of-the-first-generic-dolutegravir-from-aurobindo-pharma/",
      "status": "new",
      "txt": "http://www.unaids.org/sites/default/files/media_asset/MDG6Report_en.pdf"
    },
    "http://www.unaids.org/sites/default/files/media_asset/RighttoHealthReport_Full_web%2020%20Nov.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/art-erreicht-mehr-als-20-mio-menschen/",
      "status": "new",
      "txt": "Report"
    },
    "http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/ageing-with-hiv/",
      "status": "new",
      "txt": "http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf."
    },
    "http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Global_Report_2013_en_1.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/june/viiv-healthcare-announces-fda-approval-to-lower-the-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv/",
      "status": "new",
      "txt": "http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Global_Report_2013_en_1.pdf"
    },
    "http://www.unaids.org/sites/default/files/media_asset/UNAIDS_with-your-help_en.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/fighting-hiv-together/",
      "status": "new",
      "txt": "http://www.unaids.org/sites/default/files/media_asset/UNAIDS_with-your-help_en.pdf"
    },
    "http://www.unaids.org/sites/default/files/media_asset/unaids-data-2018_en.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/understanding-hiv-stigma-and-discrimination/",
      "status": "new",
      "txt": "http://www.unaids.org/sites/default/files/media_asset/unaids-data-2018_en.pdf"
    },
    "http://www.unfpa.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "status": "new",
      "txt": "the United Nations Population Fund"
    },
    "http://www.unive.it/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/hiv-behind-bars-supporting-hiv-research-education-and-testing-in-italian-prisons/",
      "status": "new",
      "txt": "www.unive.it"
    },
    "http://www.unive.it/pag/13526/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/hiv-behind-bars-supporting-hiv-research-education-and-testing-in-italian-prisons/",
      "status": "new",
      "txt": "Ca' Foscari University"
    },
    "http://www.vidadignamexico.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/february/positive-action-and-vida-digna-further-information/",
      "status": "new",
      "txt": "http://www.vidadignamexico.org/"
    },
    "http://www.viiv-clinicalstudyregister.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals/viiv-healthcare-clinical-study-register/",
      "status": "new",
      "txt": "Go to the ViiV Healthcare Clinical Study Register"
    },
    "http://www.viiv-clinicaltrialregister.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/january/viiv-healthcare-to-make-available-anonymised-patient-level-data-from-its-clinical-trials/",
      "status": "new",
      "txt": "www.viiv-clinicaltrialregister.com"
    },
    "http://www.viivexchange.com/routing": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/report-a-side-effect/",
      "status": "new",
      "txt": "Healthcare professionals"
    },
    "http://www.viivhealthcare.com.au/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/october/viiv-healthcare-awards-new-grants-to-accelerate-community-led-so/",
      "status": "new",
      "txt": "www.viivhealthcare.com.au"
    },
    "http://www.viivhealthcare.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/july/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen/",
      "status": "new",
      "txt": "www.viivhealthcare.com"
    },
    "http://www.viivhealthcare.com/?_ga=2.184407462.1692100571.1540457268-611046378.1540288069": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2016/viiv-healthcare-to-progress-collaboration-with-janssen-to-develo/",
      "status": "new",
      "txt": "www.viivhealthcare.com"
    },
    "http://www.virology-education.com/event/upcoming/10th-workshop-hiv-pediatrics/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "International Workshop on HIV Pediatrics"
    },
    "http://www.virology-education.com/event/upcoming/14th-co-infection-workshop-2018/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "Co-Infection Workshop 2018"
    },
    "http://www.virology-education.com/event/upcoming/16th-european-hiv-hepatitis-workshop-2018/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "European Meeting on HIV & Hepatitis"
    },
    "http://www.virology-education.com/event/upcoming/9th-international-workshop-hiv-aging-2018/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "9th International Workshop on HIV and Aging"
    },
    "http://www.virology-education.com/event/upcoming/international-workshop-hiv-women": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "HIV & Women 2018"
    },
    "http://www.virology-meeting.de/registration-abstracts/registration/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "27th Annual Meeting of the Society for Virology (GfV)"
    },
    "http://www.vodacom.com/about-us/foundation/foundation-home": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/april/global-partnership-launches-new-programme-with-goal-to-save-the-lives-of-thousands-of-children-affected-by-hiv-in-lesotho/",
      "status": "new",
      "txt": "http://www.vodacom.com/about-us/foundation/foundation-home"
    },
    "http://www.vodafone.com/content/index/about/foundation.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/april/global-partnership-launches-new-programme-with-goal-to-save-the-lives-of-thousands-of-children-affected-by-hiv-in-lesotho/",
      "status": "new",
      "txt": "http://www.vodafone.com/content/index/about/foundation.html"
    },
    "http://www.vodafone.com/content/index/about/foundation/mobilising-maternal-health.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/april/global-partnership-launches-new-programme-with-goal-to-save-the-lives-of-thousands-of-children-affected-by-hiv-in-lesotho/",
      "status": "new",
      "txt": "http://www.vodafone.com/content/index/about/foundation/mobilising-maternal-health.html"
    },
    "http://www.w3.org/TR/WCAG20/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accessibility/",
      "status": "new",
      "txt": "World Wide Web Consortium Web Accessibility Initiative (WCAG WAI) 2.0 guidelines"
    },
    "http://www.waaids.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/wa-aids-council-ageing-and-hiv/",
      "status": "new",
      "txt": "http://www.waaids.com/"
    },
    "http://www.welvista.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2010/october/viiv-healthcare-acts-to-improve-access-to-hiv-medicines-in-united-states-for-those-most-in-need/",
      "status": "new",
      "txt": "www.welvista.org"
    },
    "http://www.who.int/features/factfiles/hiv/en/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/",
      "status": "new",
      "txt": "http://www.who.int/features/factfiles/hiv/en/"
    },
    "http://www.who.int/gho/hiv/en/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/helping-botswana-treat-all-people-living-with-hiv/",
      "status": "new",
      "txt": "http://www.who.int/gho/hiv/en/"
    },
    "http://www.who.int/hiv/pub/arv/arv-2016/en/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/february/viiv-healthcare-launches-eighth-phase-iii-study-in-two-drug-regi/",
      "status": "new",
      "txt": "http://www.who.int/hiv/pub/arv/arv-2016/en/"
    },
    "http://www.who.int/hiv/pub/arv/policy-brief-arv-2015/en/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/june/viiv-healthcare-announces-public-tender-agreement-with-botswana-ministry-of-health-for-dolutegravir/",
      "status": "new",
      "txt": "http://www.who.int/hiv/pub/arv/policy-brief-arv-2015/en/"
    },
    "http://www.who.int/hiv/pub/guidelines/arv2013/arvs2013upplement_march2014/en/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/april/viiv-healthcare-announces-new-initiatives-to-improve-access-to-dolutegravir-licence-to-the-medicines-patent-pool/",
      "status": "new",
      "txt": "http://www.who.int/hiv/pub/guidelines/arv2013/arvs2013upplement_march2014/en/."
    },
    "http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/april/global-partnership-launches-new-programme-with-goal-to-save-the-lives-of-thousands-of-children-affected-by-hiv-in-lesotho/",
      "status": "new",
      "txt": "http://www.who.int/hiv/pub/guidelines/earlyrelease-arv/en/"
    },
    "http://www.who.int/hiv/pub/toolkits/YoungPeople_Techical_Guidance_GlobalFundR10_May2010.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2015/march/viiv-healthcare-launches-new-global-positive-action-programme-focused-on-msm-and-transgender-populations/",
      "status": "new",
      "txt": "http://www.who.int/hiv/pub/toolkits/YoungPeople_Techical_Guidance_GlobalFundR10_May2010.pdf"
    },
    "http://www.who.int/hiv/topics/mtct/en/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/november/viiv-healthcare-announces-new-grants-in-support-of-ending-mother-to-child-transmission-of-hiv/",
      "status": "new",
      "txt": "World Health Organisation’s prevention of mother to child transmission (PMTCT) Strategy"
    },
    "http://www.who.int/hiv/topics/paediatric/en/index.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2013/december/viiv-healthcare-commits-34m-in-positive-action-for-children-fund-grants-for-programmes-focused-on-prevention-of-mother-to-child-transmission-of-hiv/",
      "status": "new",
      "txt": "http://www.who.int/hiv/topics/paediatric/en/index.html"
    },
    "http://www.who.int/maternal_child_adolescent/epidemiology/adolescence/en/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/croi-2018/addressing-hiv-in-adolescents/",
      "status": "new",
      "txt": "http://www.who.int/maternal_child_adolescent/epidemiology/adolescence/en/"
    },
    "http://www.who.int/mediacentre/factsheets/fs317/en/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/july/viiv-healthcare-and-neat-id-announce-results-from-the-neat-022-study-at-the-international-aids-society-meeting-in-paris/",
      "status": "new",
      "txt": "http://www.who.int/mediacentre/factsheets/fs317/en/"
    },
    "http://www.who.int/mediacentre/factsheets/fs334/en": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/croi-2018/leading-the-way-in-hiv-on-international-women-s-day/",
      "status": "new",
      "txt": "http://www.who.int/mediacentre/factsheets/fs334/en"
    },
    "http://www.who.int/mediacentre/factsheets/fs345/en/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-adolescents/",
      "status": "new",
      "txt": "http://www.who.int/mediacentre/factsheets/fs345/en/"
    },
    "http://www.who.int/mediacentre/factsheets/fs360/en/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/may/viiv-healthcare-reports-positive-results-for-landmark-phase-iii-/",
      "status": "new",
      "txt": "http://www.who.int/mediacentre/factsheets/fs360/en/"
    },
    "http://www.who.int/mediacentre/news/releases/2007/pr37/en/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/announcing-the-2016-every-footsteps-counts-winners/",
      "status": "new",
      "txt": "http://www.who.int/mediacentre/news/releases/2007/pr37/en/"
    },
    "http://www.who.int/mediacentre/news/releases/2014/focus-adolescent-health/en/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/spark-igniting-change/",
      "status": "new",
      "txt": "http://www.who.int/mediacentre/news/releases/2014/focus-adolescent-health/en/"
    },
    "http://www.wir-ruhr.de/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/das-innovative-zentrum-fuer-sexuelle-gesundheit-und-medizin-wir-/",
      "status": "new",
      "txt": "hier"
    },
    "http://www.zambart.org.zm/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/improving-retention-of-breastfeeding-wlhiv-on-art-challenge-winner/",
      "status": "new",
      "txt": "Zambart"
    },
    "https://academic.oup.com/jid/article/216/12/1525/4743770": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/begleiterkrankungen-bei-hiv-patienten-daten-aus-den-usa/",
      "status": "new",
      "txt": "Gallant J et al. Comorbidities Among US Patients With Prevalent HIV Infection—A Trend Analysis. The Journal of Infectious Diseases, Volume 216, Issue 12, 19 December 2017, Pages 1525–1533"
    },
    "https://amplifychange.org/grantees/grants/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amplifychange/",
      "status": "new",
      "txt": "https://amplifychange.org/grantees/grants/"
    },
    "https://assonouvelleaube.wordpress.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/",
      "status": "new",
      "txt": "NOUVELLE AUBE"
    },
    "https://au.viivexchange.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/inside-hiv-the-podcast-for-positive-people/",
      "status": "new",
      "txt": "ViiV Exchange for HCPs"
    },
    "https://au.viivexchange.com/hcp/celsentri/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/celsentri-/",
      "status": "new",
      "txt": "Celsentri clinical data and webcasts (Website)"
    },
    "https://au.viivexchange.com/hcp/patient-support/tivicay-patient-booklet/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/tivicay-/",
      "status": "new",
      "txt": "Tivicay Consumer Medicine Information (HTML)"
    },
    "https://au.viivexchange.com/hcp/patient-support/triumeq-patient-booklet/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/triumeq-/",
      "status": "new",
      "txt": "Triumeq Consumer Medicine Information (HTML)"
    },
    "https://au.viivexchange.com/hcp/tivicay/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/tivicay-/",
      "status": "new",
      "txt": "Tivicay clinical data and webcasts (Website)"
    },
    "https://au.viivexchange.com/hcp/triumeq/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/our-medicines/triumeq-/",
      "status": "new",
      "txt": "Triumeq clinical data and webcasts (Website)"
    },
    "https://clinicalstudydatarequest.com/Study-Sponsors-ViiV-Details.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/committed-to-data-transparency/",
      "status": "new",
      "txt": "https://clinicalstudydatarequest.com/Study-Sponsors-ViiV-Details.aspx"
    },
    "https://clinicaltrials.gov/ct2/show/NCT02120352": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-presents-three-year-data-for-investigational-lon/",
      "status": "new",
      "txt": "https://clinicaltrials.gov/ct2/show/NCT02120352"
    },
    "https://clinicaltrials.gov/ct2/show/NCT02422797?term=dolutegravir+AND+sword&cond=HIV&rank=1": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/may/viiv-healthcare-reports-positive-results-for-landmark-phase-iii-/",
      "status": "new",
      "txt": "https://clinicaltrials.gov/ct2/show/NCT02422797?term=dolutegravir+AND+sword&cond=HIV&rank=1"
    },
    "https://clinicaltrials.gov/ct2/show/NCT02429791?term=dolutegravir+AND+sword&cond=HIV&rank=3": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/may/viiv-healthcare-reports-positive-results-for-landmark-phase-iii-/",
      "status": "new",
      "txt": "https://clinicaltrials.gov/ct2/show/NCT02429791?term=dolutegravir+AND+sword&cond=HIV&rank=3"
    },
    "https://clinicaltrials.gov/ct2/show/NCT02831673%20%20": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/viiv-healthcare-receives-chmp-positive-opinion-for-tivicay-eu-label-update-with-gemini-study-data-for-the-2-drug-regimen-of-tivicay-plus-lamivudine/",
      "status": "new",
      "txt": "https://clinicaltrials.gov/ct2/show/NCT02831673"
    },
    "https://clinicaltrials.gov/ct2/show/NCT02831764%20": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/viiv-healthcare-receives-chmp-positive-opinion-for-tivicay-eu-label-update-with-gemini-study-data-for-the-2-drug-regimen-of-tivicay-plus-lamivudine/",
      "status": "new",
      "txt": "https://clinicaltrials.gov/ct2/show/NCT02831764"
    },
    "https://clinicaltrials.gov/ct2/show/NCT02938520": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/",
      "status": "new",
      "txt": "https://clinicaltrials.gov/ct2/show/NCT02938520"
    },
    "https://clinicaltrials.gov/ct2/show/NCT02938520?term=FLAIR&cond=HIV&rank=2": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/viiv-healthcare-presents-three-year-data-for-investigational-long-acting-injectable-two-drug-hiv-regimen/",
      "status": "new",
      "txt": "https://clinicaltrials.gov/ct2/show/NCT02938520?term=FLAIR&cond=HIV&rank=2"
    },
    "https://clinicaltrials.gov/ct2/show/NCT02938520?term=FLAIR+Cabotegravir&rank=1": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/viiv-healthcare-reports-positive-48-week-results-for-first-pivot/",
      "status": "new",
      "txt": "https://clinicaltrials.gov/ct2/show/NCT02938520?term=FLAIR+Cabotegravir&rank=1"
    },
    "https://clinicaltrials.gov/ct2/show/NCT02951052": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/viiv-healthcare-reports-positive-48-week-results-for-first-pivot/",
      "status": "new",
      "txt": "https://clinicaltrials.gov/ct2/show/NCT02951052"
    },
    "https://clinicaltrials.gov/ct2/show/NCT02951052?term=ATLAS&cond=HIV&rank=3": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/viiv-healthcare-presents-three-year-data-for-investigational-long-acting-injectable-two-drug-hiv-regimen/",
      "status": "new",
      "txt": "https://clinicaltrials.gov/ct2/show/NCT02951052?term=ATLAS&cond=HIV&rank=3"
    },
    "https://clinicaltrials.gov/ct2/show/NCT02951052?term=ATLAS+cabotegravir&rank=1": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/iiv-healthcare-starts-third-phase-iii-hiv-treatment-study-invest/",
      "status": "new",
      "txt": "https://clinicaltrials.gov/ct2/show/NCT02951052?term=ATLAS+cabotegravir&rank=1"
    },
    "https://clinicaltrials.gov/ct2/show/NCT03164564": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/november/viiv-healthcare-announces-start-of-phase-iii-study-of-long-actin/",
      "status": "new",
      "txt": "https://clinicaltrials.gov/ct2/show/NCT03164564"
    },
    "https://clinicaltrials.gov/ct2/show/NCT03299049": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/",
      "status": "new",
      "txt": "https://clinicaltrials.gov/ct2/show/NCT03299049"
    },
    "https://clinicaltrials.gov/ct2/show/NCT03299049?term=ATLAS-2M&rank=1": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/viiv-healthcare-presents-three-year-data-for-investigational-long-acting-injectable-two-drug-hiv-regimen/",
      "status": "new",
      "txt": "https://clinicaltrials.gov/ct2/show/NCT03299049?term=ATLAS-2M&rank=1"
    },
    "https://cu.viivhealthcare.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/report-a-side-effect/",
      "status": "new",
      "txt": "Compassionate Use"
    },
    "https://de-de.facebook.com/help/568137493302217": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/datenschutzerklaerung/",
      "status": "new",
      "txt": "https://de-de.facebook.com/help/568137493302217"
    },
    "https://dph.georgia.gov/sites/dph.georgia.gov/files/related_files/site_page/2011%20Georgia%20HIV%20AIDS%20Fact%20Sheet.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/march/viiv-healthcare-announces-next-round-of-the-positive-action-southern-initiative-to-support-linkages-to-hivaids-care-and-treatment-adherence/",
      "status": "new",
      "txt": "https://dph.georgia.gov/sites/dph.georgia.gov/files/related_files/site_page/2011%20Georgia%20HIV%20AIDS%20Fact%20Sheet.pdf"
    },
    "https://ec.europa.eu/info/law/law-topic/data-protection/data-transfers-outside-eu/model-contracts-transfer-personal-data-third-countries_en": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/privacy-verklaring/",
      "status": "new",
      "txt": "hier"
    },
    "https://ec.europa.eu/info/strategy/justice-and-fundamental-rights/data-protection/data-transfers-outside-eu/model-contracts-transfer-personal-data-third-countries_en": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/politique-de-protection-des-donnees-personnelles/",
      "status": "new",
      "txt": "ici"
    },
    "https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/Status-of-HIV-response-in-EU-EEA-2016-30-jan-2017.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/tackling-hiv-challenges-in-europe/",
      "status": "new",
      "txt": "https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/Status-of-HIV-response-in-EU-EEA-2016-30-jan-2017.pdf"
    },
    "https://en-gb.facebook.com/help/568137493302217": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ch/privacy-notice/",
      "status": "new",
      "txt": "https://en-gb.facebook.com/help/568137493302217"
    },
    "https://eu5.salesforce.com/0012400000DiLUs": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-collaborathon-grants-announced/",
      "status": "new",
      "txt": "Give Hope Ethiopia"
    },
    "https://eu5.salesforce.com/0012400000hXknD": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-collaborathon-grants-announced/",
      "status": "new",
      "txt": "Centre de Recherches et d'Informations Pour la Santé au TOGO (ONG CRIPS-TOGO)"
    },
    "https://everyfootstepcounts.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/report-a-side-effect/",
      "status": "new",
      "txt": "Every Footstep Counts"
    },
    "https://everyfootstepcounts.com/meet-the-judges/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/qa-with-every-footstep-counts-judge-amaya-gillespie-from-unicef/",
      "status": "new",
      "txt": "via the EFC competition website"
    },
    "https://everyfootstepcounts.com/the-competition/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/qa-with-every-footstep-counts-judge-amaya-gillespie-from-unicef/",
      "status": "new",
      "txt": "Cast your vote today"
    },
    "https://everyfootstepcounts.com/the-competition/meet-the-judges/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/qa-with-every-footstep-counts-judge-amaya-gillespie-from-unicef/",
      "status": "new",
      "txt": "the EFC 2016 video entries"
    },
    "https://facebook.com/ViiVHealthcare/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-at-hiv-glasgow/",
      "status": "new",
      "txt": "Facebook"
    },
    "https://fr.viivexchange.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-medicaments-en-france/",
      "status": "new",
      "txt": "https://fr.viivexchange.com/"
    },
    "https://free.unaids.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/our-people/from-classroom-to-congress-hall-my-year-at-viiv/",
      "status": "new",
      "txt": "Start Free super fast-track targets"
    },
    "https://gsk.wd5.myworkdayjobs.com/ViiV_Careers": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/careers/job-search/",
      "status": "new",
      "txt": "please click here"
    },
    "https://hivimplementationscience.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/report-a-side-effect/",
      "status": "new",
      "txt": "Implementation Science"
    },
    "https://hivimplementationscience.com/get-involved.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/metrics-matter-measuring-impact-in-hiv-implementation/",
      "status": "new",
      "txt": "join our implementation science network online"
    },
    "https://hivimplementationscience.com/get-involved/supporting-implementation1.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/metrics-matter-measuring-impact-in-hiv-implementation/",
      "status": "new",
      "txt": "sign up to attend"
    },
    "https://impaactnetwork.org/studies/p1093.asp": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/paediatric-hiv-care/",
      "status": "new",
      "txt": "P1093 study"
    },
    "https://journals.lww.com/jaids/Abstract/2018/01010/Belief_in_Treatment_as_Prevention_and_Its.2.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/therapie-als-praevention-tasp-wie-gross-ist-das-wissen-bei-msm/",
      "status": "new",
      "txt": "Card KG et al. Belief in Treatment as Prevention and Its Relationship to HIV Status and Behavioral Risk. J Acquir Immune Defic Syndr: January 1, 2018 - Volume 77 - Issue 1 - p 8–16"
    },
    "https://journals.lww.com/jaids/Abstract/publishahead/Hiv_Drug_Resistance_in_Adults_Receiving_Early.96773.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/frueher-therapiebeginn-kann-resistenzentwicklung-verhindern/",
      "status": "new",
      "txt": "Palumbo P et al. HIV Drug Resistance in Adults Receiving Early Versus Delayed Antiretroviral Therapy: HPTN 052. J Acquir Immune Defic Syndr: Post Acceptance: December 28, 2017. doi: 10.1097/QAI.0000000000001623"
    },
    "https://kein-aids-fuer-alle.de/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/auf-dem-weg-zu-90-90-90-wie-sieht-es-in-europa-aus/",
      "status": "new",
      "txt": "Kein AIDS für alle!"
    },
    "https://kirby.unsw.edu.au/report/annual-surveillance-report-hiv-viral-hepatitis-stis-2016": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/october/viiv-healthcare-awards-new-grants-to-accelerate-community-led-so/",
      "status": "new",
      "txt": "https://kirby.unsw.edu.au/report/annual-surveillance-report-hiv-viral-hepatitis-stis-2016"
    },
    "https://livlife.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/report-a-side-effect/",
      "status": "new",
      "txt": "LiV Life Patient Site"
    },
    "https://livlife.com/en-gb/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/championing-effective-hiv-care-for-plhiv/",
      "status": "new",
      "txt": "LiVLife platform"
    },
    "https://livlife.com/living-with-hiv/treatment.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/how-the-unity-tool-can-help-conversations-between-plhiv-and-their-hcp/",
      "status": "new",
      "txt": "LiVLife.com"
    },
    "https://maraviroc.viivhealthcare.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/selzentry-celsentri/",
      "status": "new",
      "txt": "please visit our promotional website."
    },
    "https://medicinespatentpool.org/licence-post/dolutegravir-paediatrics-dtg": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/paediatric-hiv-care/",
      "status": "new",
      "txt": "Pool."
    },
    "https://onlinelibrary.wiley.com/doi/pdf/10.1111/cei.12814": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/october/viiv-healthcare-awards-new-grants-to-accelerate-community-led-so/",
      "status": "new",
      "txt": "http://onlinelibrary.wiley.com/doi/10.1111/cei.12814/pdf"
    },
    "https://pacf.secure.force.com/PAEGrantApplication": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-weltweit/artikel/positive-action/",
      "status": "new",
      "txt": "zum Bewerbungsformular"
    },
    "https://pacf.secure.force.com/PAEGrantApplication/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-europe/",
      "status": "new",
      "txt": "Find out more about the grants and apply online."
    },
    "https://pata.proversity.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/fighting-hiv-together/the-fight-to-end-mother-to-child-transmission-of-hiv/",
      "status": "new",
      "txt": "online course"
    },
    "https://patientview-plus.wetransfer.com/downloads/e77cde296ebb41cdbd26905d64e45dfe20170316212814/ec838e": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/press-releases/2017/viiv-healthcare-ranks-1-in-patientview-corporate-reputation-survey/",
      "status": "new",
      "txt": "Click here to read the full PatientView press release"
    },
    "https://penta-id.org/hiv/odyssey-penta-20/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/paediatric-hiv-care/",
      "status": "new",
      "txt": "ODYSSEY clinical trial"
    },
    "https://positiveaction.force.com/pacf/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/",
      "status": "new",
      "txt": "PACF Online Community"
    },
    "https://positiveaction.force.com/pacf/login": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/",
      "status": "new",
      "txt": "www.positiveaction.force.com/pacf/login"
    },
    "https://prezi.com/view/6IDewyFX8eIE9wAqZRNQ/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/",
      "status": "new",
      "txt": "\"As Much as I Can\" Prezi: Overview of the Immersive Theater Experience"
    },
    "https://pwnusa.wordpress.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-community-grants/",
      "status": "new",
      "txt": "  "
    },
    "https://soundcloud.com/user-345239311/implementation-science-podcast-episode-3-external/s-phzFb": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-host-the-inaugural-implementation-science-network-meeting-in-paris/",
      "status": "new",
      "txt": "  "
    },
    "https://soundcloud.com/viiv-healthcare/anette-sohn-treat-asia-pt2": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/",
      "status": "new",
      "txt": "Anette Sohn TREAT Asia Pt2 060513"
    },
    "https://soundcloud.com/viiv-healthcare/anne-stangl-1": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/",
      "status": "new",
      "txt": "Anne Stangl"
    },
    "https://soundcloud.com/viiv-healthcare/annette-sohn-treat-asia-pt1": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/",
      "status": "new",
      "txt": "Annette Sohn TREAT Asia Pt1 060513"
    },
    "https://soundcloud.com/viiv-healthcare/annette-sohn-treat-asia-pt4": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/",
      "status": "new",
      "txt": "Annette Sohn TREAT Asia Pt4 060513"
    },
    "https://soundcloud.com/viiv-healthcare/annette-sohn-treat-asia-pt5": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/amfar-treat-asia/",
      "status": "new",
      "txt": "Annette Sohn TREAT Asia Pt5 060513"
    },
    "https://soundcloud.com/viiv-healthcare/sonalini-mirchandani-1": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/",
      "status": "new",
      "txt": "Sonalini Mirchandani"
    },
    "https://teampata.org/c3/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/fighting-hiv-together/the-fight-to-end-mother-to-child-transmission-of-hiv/",
      "status": "new",
      "txt": "https://teampata.org/c3/"
    },
    "https://translate.google.co.uk/translate?hl=en&sl=auto&tl=en&u=http%3A%2F%2Fportalsaude.saude.gov.br%2Findex.php%2Fcidadao%2Fprincipal%2Fagencia-saude%2F25857-saude-oferecera-melhor-tratamento-do-mundo-para-hiv-aids": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/december/new-agreement-with-ministry-of-health-will-enable-access-to-dolutegravir-for-the-treatment-of-hiv-under-the-national-health-programme-in-brazil/",
      "status": "new",
      "txt": "https://translate.google.co.uk/translate?hl=en&sl=auto&tl=en&u=http%3A%2F%2Fportalsaude.saude.gov.br%2Findex.php%2Fcidadao%2Fprincipal%2Fagencia-saude%2F25857-saude-oferecera-melhor-tratamento-do-mundo-para-hiv-aids"
    },
    "https://twitter.com/4Mproject": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/qa-with-angelina-namiba-on-viiv-healthcare-s-skills-workshop/",
      "status": "new",
      "txt": "follow their work on Twitter"
    },
    "https://twitter.com/hashtag/EveryFootstepCounts?src=hash": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/qa-with-every-footstep-counts-judge-amaya-gillespie-from-unicef/",
      "status": "new",
      "txt": "#EveryFootstepCounts"
    },
    "https://twitter.com/hashtag/KnowYourStatus?src=hash": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/championing-effective-hiv-care-for-plhiv/",
      "status": "new",
      "txt": "Knowing your status"
    },
    "https://twitter.com/search?src=typd&q=%23millionpositivefaces": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/our-people/one-million-positive-faces/",
      "status": "new",
      "txt": "#MillionPositiveFaces"
    },
    "https://twitter.com/stigmaactionnet": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/",
      "status": "new",
      "txt": "Twitter"
    },
    "https://twitter.com/viivhc": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/contact-us/social-media-at-viiv-healthcare/",
      "status": "new",
      "txt": "Visit our Twitter page"
    },
    "https://twitter.com/ViiVHC": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/report-a-side-effect/",
      "status": "new",
      "txt": "*** IMAGE WITHOUT ALT TEXT ***"
    },
    "https://twitter.com/viivhc?lang=en-gb": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-hiv-glasgow/",
      "status": "new",
      "txt": "@ViiVHC"
    },
    "https://twitter.com/ViiVHC?lang=en-gb": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-to-host-inaugural-implementation-science-network-meeting-in-paris/",
      "status": "new",
      "txt": "@ViiVHC"
    },
    "https://twitter.com/ViiVHC?ref_src=twsrc%5Egoogle%7Ctwcamp%5Eserp%7Ctwgr%5Eauthor": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/tackling-hiv-challenges-in-europe/",
      "status": "new",
      "txt": "Twitter"
    },
    "https://uk.gsk.com/en-gb/careers/undergraduates/industrial-placements/viiv-healthcare/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/our-people/from-classroom-to-congress-hall-my-year-at-viiv/",
      "status": "new",
      "txt": "apply online"
    },
    "https://urldefense.proofpoint.com/v2/url?u=http-3A__instinctmagazine.com_post_nyc-2Dtheatre-2Dgoers-2Dare-2Dexcited-2Dnew-2Dinteractive-2Dplay-2Dabout-2Dhiv-2Dblack-2Dgay-2Dcommunity_&d=DwMFAg&c=9wxE0DgWbPxd1HCzjwN8Eaww1--ViDajIU4RXCxgSXE&r=CobvSBKGqGmgB3t93oNM-xt5o9vBEpOeGFrzImOXKqs&m=uXxcme3ssxy1J0fz5TVzYLRI0qmMCzbBonKuXY--H4Y&s=aOf5eCRmuWZvVg_bE6uMdmq5DplW79trQdZy-3awchk&e=": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/",
      "status": "new",
      "txt": "NYC Theatre Goers Are Excited For A New Interactive Play About HIV In the Black Gay Community"
    },
    "https://urldefense.proofpoint.com/v2/url?u=http-3A__swaysuniverse.com_hiv-2Daids-2Dawareness-2Dwith-2Demil-2Dwilbekin-2Dand-2Dmarc-2Dmeachem_&d=DwMFAg&c=9wxE0DgWbPxd1HCzjwN8Eaww1--ViDajIU4RXCxgSXE&r=5VK8tbQzGP3ijz5oJvoxPdWvWQv_VKPksLwFzpGaRrc&m=0N_H0DN__F8bnGqyd0oBYii6v6TxG_e4lYK65iKZLzM&s=7kFoe-NaSrJnO8C_xvDGZD4idX-gpk_H0_ad7_9tY-k&e=": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/",
      "status": "new",
      "txt": "New Theatrical play, As Much As I Can discussing HIV/AIDS Awareness with Emil Wilbekin and Marc Meachem"
    },
    "https://urldefense.proofpoint.com/v2/url?u=http-3A__www.edurant.com_hcp_prescribing-2Dinformation&d=DwMGaQ&c=9wxE0DgWbPxd1HCzjwN8Eaww1--ViDajIU4RXCxgSXE&r=6h7hpGyedwkht0DbYj72ha0FbipMPvCfJ2tYVxtfyu3hbmWWImBMDtaktZb3rIGv&m=Be0LwqZk7DeQS6_NEyv1pnwV8U17q2l4V2edmx_Hl74&s=sqVu2UeMq3pM_kQ6so4LxrtWvjaysQiPInjJGSuApN4&e=": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/iiv-healthcare-starts-third-phase-iii-hiv-treatment-study-invest/",
      "status": "new",
      "txt": "Prescribing Information"
    },
    "https://urldefense.proofpoint.com/v2/url?u=http-3A__www.ema.europa.eu_docs_en-5FGB_document-5Flibrary_EPAR-5F-2D-5FProduct-5FInformation_human_002264_WC500118874.pdf&d=DwMGaQ&c=9wxE0DgWbPxd1HCzjwN8Eaww1--ViDajIU4RXCxgSXE&r=J7wB1SLKWKA1gpwYoceY-y3xkhr4mhsieeIqcp-JNNE&m=CdcV4p0HxpVK7G7c7n0NMFDiNuHcQWwWSxPxU7Cs5NY&s=ra-RAn76KyzkyqsvXvDnUqQ7cNiiQ4g-hm0yMY_AhM8&e=": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/",
      "status": "new",
      "txt": "http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002264/WC500118874.pdf"
    },
    "https://urldefense.proofpoint.com/v2/url?u=http-3A__www.janssenlabels.com_package-2Dinsert_product-2Dmonograph_prescribing-2Dinformation_EDURANT-2Dpi.pdf&d=DwMGaQ&c=9wxE0DgWbPxd1HCzjwN8Eaww1--ViDajIU4RXCxgSXE&r=J7wB1SLKWKA1gpwYoceY-y3xkhr4mhsieeIqcp-JNNE&m=CdcV4p0HxpVK7G7c7n0NMFDiNuHcQWwWSxPxU7Cs5NY&s=FembPrhrNjB2_SBd-TjvfGRbCi1XGave-2E-ZpDPeqU&e=": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/",
      "status": "new",
      "txt": "http://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/EDURANT-pi.pdf"
    },
    "https://urldefense.proofpoint.com/v2/url?u=http-3A__www.newnownext.com_lgbt-2Dplays-2Doff-2Dbroadway-2Dnyc-2Dtheater_05_2018_&d=DwMFAg&c=9wxE0DgWbPxd1HCzjwN8Eaww1--ViDajIU4RXCxgSXE&r=jKuTeve0INNCpu92lJCYckHau6lp5OB0eqbH2Pg3ssY&m=JntzrdhnpHf5jEosznhe-9BByBOZ3_dwNqRKKWYGC_E&s=21kxbKPY1KNtayoa5e5WfR6jRxOE4Jef0Pp9Sus7zIA&e=": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/",
      "status": "new",
      "txt": "5 New Must-See Queer Plays In NYC"
    },
    "https://urldefense.proofpoint.com/v2/url?u=https-3A__blavity.com_this-2Dinteractive-2Dnew-2Dplay-2Dexplores-2Dhivs-2Deffect-2Don-2Dgay-2Dblack-2Dmen&d=DwMFAg&c=9wxE0DgWbPxd1HCzjwN8Eaww1--ViDajIU4RXCxgSXE&r=5VK8tbQzGP3ijz5oJvoxPdWvWQv_VKPksLwFzpGaRrc&m=0N_H0DN__F8bnGqyd0oBYii6v6TxG_e4lYK65iKZLzM&s=RO2K2vSNJ1XOL9lwIjMslnXt72h6PJB0cQaIvSMJIRI&e=": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/",
      "status": "new",
      "txt": "This Interactive New Play Explores HIV's Effect On Gay Black Men"
    },
    "https://urldefense.proofpoint.com/v2/url?u=https-3A__www.billboard.com_articles_news_pride_8454709_as-2Dmuch-2Das-2Di-2Dcan-2Dtheater-2Dnew-2Dyork-2Dhiv-2Dblack-2Dgay-2Dmen&d=DwMFAg&c=9wxE0DgWbPxd1HCzjwN8Eaww1--ViDajIU4RXCxgSXE&r=5VK8tbQzGP3ijz5oJvoxPdWvWQv_VKPksLwFzpGaRrc&m=0N_H0DN__F8bnGqyd0oBYii6v6TxG_e4lYK65iKZLzM&s=wVEKFa3lPExtz1RTZ4JzI8LIQuyrm3Gdlm4VyzvXNwE&e=": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/",
      "status": "new",
      "txt": "'As Much As I Can' Immersive Theater Show Shines Light on HIV Gay Black Men"
    },
    "https://urldefense.proofpoint.com/v2/url?u=https-3A__www.hivplusmag.com_stigma_2018_5_11_immersive-2Dproject-2Dabout-2Dhiv-2Dcomes-2Dnyc&d=DwMFAg&c=9wxE0DgWbPxd1HCzjwN8Eaww1--ViDajIU4RXCxgSXE&r=5VK8tbQzGP3ijz5oJvoxPdWvWQv_VKPksLwFzpGaRrc&m=0N_H0DN__F8bnGqyd0oBYii6v6TxG_e4lYK65iKZLzM&s=bTvBNF4UKPLGUgRNvrKk_BTS5tZ-W7lXT_BpVX0fLtY&e=": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/",
      "status": "new",
      "txt": "Immersive Project About HIV Comes To NYC"
    },
    "https://urldefense.proofpoint.com/v2/url?u=https-3A__www.poz.com_article_immersive-2Dtheater-2Dhiv-2Dgay-2Dblack-2Dmen-2Dreturns-2Dstage&d=DwMFAg&c=9wxE0DgWbPxd1HCzjwN8Eaww1--ViDajIU4RXCxgSXE&r=5VK8tbQzGP3ijz5oJvoxPdWvWQv_VKPksLwFzpGaRrc&m=0N_H0DN__F8bnGqyd0oBYii6v6TxG_e4lYK65iKZLzM&s=az_4i6XcL5uzLOv-s5y5ozSHTsOKWYejpGh-Xtts9gw&e=": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/",
      "status": "new",
      "txt": "Immersive Theater About HIV and Gay Black Men Returns to the Stage"
    },
    "https://urldefense.proofpoint.com/v2/url?u=https-3A__www.theroot.com_powerful-2Dimmersive-2Dplay-2Das-2Dmuch-2Das-2Di-2Dcan-2Dbrings-2Dvoices-2D1826023725&d=DwMFAg&c=9wxE0DgWbPxd1HCzjwN8Eaww1--ViDajIU4RXCxgSXE&r=jKuTeve0INNCpu92lJCYckHau6lp5OB0eqbH2Pg3ssY&m=JntzrdhnpHf5jEosznhe-9BByBOZ3_dwNqRKKWYGC_E&s=WT2QqsSRPqnWwuFLIbgALQRVVCXWjMYA_oWEQKZANSw&e=": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/",
      "status": "new",
      "txt": "Powerful, Immersive Play As Much as I Can Brings Voices of Southern Gay Black Men and HIV/AIDS Awareness to Harlem"
    },
    "https://us.viivhealthcare.com/as-much-as-i-can.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/",
      "status": "new",
      "txt": "ACCELERATE! \"As Much as I Can\" feature article"
    },
    "https://us.viivhealthcare.com/media/124293/viivhc-hiv-in-the-us-final-6172016.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/standing-together/",
      "status": "new",
      "txt": "Click to enlarge the infographic above."
    },
    "https://us.viivhealthcare.com/media/124384/general-conditions-of-sale-viiv-belgium-fr-nl-01-07-2012.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/terms-and-conditions/",
      "status": "new",
      "txt": "Sales Terms & Conditions"
    },
    "https://us.viivhealthcare.com/media/124385/general-conditions-of-purchase-viiv-belgium-fr-nl-01-07-2012.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/terms-and-conditions/",
      "status": "new",
      "txt": "Purchase Order Terms & Conditions"
    },
    "https://us.viivhealthcare.com/media/124386/cga-viiv-cerps-mai-2012-france.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/terms-and-conditions/",
      "status": "new",
      "txt": "Purchase Order Terms & Conditions"
    },
    "https://us.viivhealthcare.com/media/124387/aeb_viiv.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/terms-and-conditions/",
      "status": "new",
      "txt": "Purchase Order Terms & Conditions"
    },
    "https://us.viivhealthcare.com/media/124388/viiv-acquistobeniservizicondizionigenerali_italiano.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/terms-and-conditions/",
      "status": "new",
      "txt": "Purchase Order Terms & Condition (Italian)"
    },
    "https://us.viivhealthcare.com/media/124389/viiv-general-terms-and-conditions-4.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/terms-and-conditions/",
      "status": "new",
      "txt": "Purchase Order Terms & Condition (English)"
    },
    "https://us.viivhealthcare.com/media/124390/netherlands-algemene-inkoop-voorwaarden-01-10-2010.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/terms-and-conditions/",
      "status": "new",
      "txt": "Purchase Order Terms & Conditions"
    },
    "https://us.viivhealthcare.com/media/124391/singapore-terms-and-conditions.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/terms-and-conditions/",
      "status": "new",
      "txt": "Purchase Order Terms & Condition (English)"
    },
    "https://us.viivhealthcare.com/media/124392/condiciones-pedido-espa%C3%B1ol-viiv.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/terms-and-conditions/",
      "status": "new",
      "txt": "Purchase Order Terms & Conditions (Spanish)"
    },
    "https://us.viivhealthcare.com/media/124393/condiciones-pedido-ingl%C3%A9s-viiv.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/terms-and-conditions/",
      "status": "new",
      "txt": "Purchase Order Terms & Conditions (English)"
    },
    "https://us.viivhealthcare.com/media/124418/meet-me-where-i-want-to-be-report-final.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/",
      "status": "new",
      "txt": "key insights"
    },
    "https://us.viivhealthcare.com/media/124419/accelerate-backgrounder.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/",
      "status": "new",
      "txt": "ACCELERATE! Backgrounder"
    },
    "https://us.viivhealthcare.com/media/124420/accelerate-research-fact-sheet.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/",
      "status": "new",
      "txt": "“Meet Me Where I Want to Be” Ethnographic Research Study Fact Sheet"
    },
    "https://us.viivhealthcare.com/media/124421/accelerate-empowerment-fact-sheet.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/",
      "status": "new",
      "txt": "Activating Insights: Community Investments to Boost Empowerment and Strengthen Networks."
    },
    "https://us.viivhealthcare.com/media/124422/accelerate-sex-ed-fact-sheet.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/",
      "status": "new",
      "txt": "Activating Insights: Community Investments to Make Sex Education Relevant"
    },
    "https://us.viivhealthcare.com/media/124423/accelerate-testing-fact-sheet.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/",
      "status": "new",
      "txt": "Activating Insights: Community Investments to Make Testing a Bridge to Prevention, Care, and Treatment"
    },
    "https://us.viivhealthcare.com/media/124428/pafw-backgrounder-final.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-for-women/",
      "status": "new",
      "txt": "Positive Action for Women"
    },
    "https://us.viivhealthcare.com/media/124433/youth-hiv-fact-sheet-final.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-for-youth/",
      "status": "new",
      "txt": "Click here"
    },
    "https://us.viivhealthcare.com/media/124442/viivus-pasi-infographic-final.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative-resources/",
      "status": "new",
      "txt": "view our infographic."
    },
    "https://us.viivhealthcare.com/media/124445/viiv_healthcare-narrative_spanish.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/es/",
      "status": "new",
      "txt": "haga clic aquí"
    },
    "https://us.viivhealthcare.com/media/124457/meet-me-where-i-want-to-be-ethnographic-research-study-infographic_may-17-2017-300.jpg": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/",
      "status": "new",
      "txt": "“Meet Me Where I Want to Be” Ethnographic Research Study Infographic"
    },
    "https://us.viivhealthcare.com/media/124466/amaic-fact-sheet-june-2017.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/",
      "status": "new",
      "txt": "ACCELERATE! \"As Much as I Can\" fact sheet"
    },
    "https://us.viivhealthcare.com/media/124470/networks-of-care_final-web-version-reduced.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-for-women/",
      "status": "new",
      "txt": "ethnographic research here"
    },
    "https://us.viivhealthcare.com/media/124473/grantee-spotlight-flyer.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-for-women/",
      "status": "new",
      "txt": "grantee snapshot"
    },
    "https://us.viivhealthcare.com/media/124477/viiv_pasi_grantee_brotherhood_final_8302017.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative-resources/",
      "status": "new",
      "txt": "Brotherhood, Inc."
    },
    "https://us.viivhealthcare.com/media/124478/viiv_pasi_grantee_rwhp_final_8302017.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative-resources/",
      "status": "new",
      "txt": "Rural Women’s Health Project"
    },
    "https://us.viivhealthcare.com/media/124479/viiv_pasi_grantee_someone-cares_final_8302017.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative-resources/",
      "status": "new",
      "txt": "Someone Cares, Inc."
    },
    "https://us.viivhealthcare.com/media/124480/viiv_pasi_grantee_grace-house_final_8302017.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative-resources/",
      "status": "new",
      "txt": "Grace House"
    },
    "https://us.viivhealthcare.com/media/124481/viiv_pasi_grantee_rain_final_8302017.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative-resources/",
      "status": "new",
      "txt": "RAIN"
    },
    "https://us.viivhealthcare.com/media/124482/viiv_pasi_grantee_sisterlove_final_8302017.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative-resources/",
      "status": "new",
      "txt": "SisterLove, Inc."
    },
    "https://us.viivhealthcare.com/media/124483/viiv_pasi_grantee_jasmyn_final_8302017.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative-resources/",
      "status": "new",
      "txt": "JASMYN"
    },
    "https://us.viivhealthcare.com/media/124484/viiv_pasi_grantee_friends-for-life_final_8302017.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative-resources/",
      "status": "new",
      "txt": "Friends For Life"
    },
    "https://us.viivhealthcare.com/media/124495/vhc-pasi-grantee-nashville-cares-story-final-101017.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative-resources/",
      "status": "new",
      "txt": "Nashville CARES"
    },
    "https://us.viivhealthcare.com/media/124505/viiv-healthcare-pacg-2018-rfp.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-community-grants/",
      "status": "new",
      "txt": "here"
    },
    "https://us.viivhealthcare.com/media/124564/vhc_pasi-infographic_final_digital_4618.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative/",
      "status": "new",
      "txt": "click here"
    },
    "https://us.viivhealthcare.com/media/124736/accelerate-baltimore-fact-sheet-2018.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/",
      "status": "new",
      "txt": "Setting the Scene: Characteristics of the HIV Epidemic Among Black Gay and Bisexual Men in Baltimore"
    },
    "https://us.viivhealthcare.com/media/124737/accelerate-jackson-fact-sheet-2018.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/accelerate--initiative-resources/",
      "status": "new",
      "txt": "Setting the Scene: Characteristics of the HIV Epidemic Among Black Gay and Bisexual Men in Jackson"
    },
    "https://us.viivhealthcare.com/positive-action-for-women.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "status": "new",
      "txt": "Positive Action for Women"
    },
    "https://us.viivhealthcare.com/positive-action-for-youth.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "status": "new",
      "txt": "Positive Action for Youth"
    },
    "https://viiv-cu-portal.idea-point.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/bundesweites-treffen-fuer-hiv-positive-jugendliche/$NewsURL_01/",
      "status": "new",
      "txt": "Compassionate Use"
    },
    "https://vimeo.com/92973193": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/fighting-hiv-together/positive-action-at-aids-2018/",
      "status": "new",
      "txt": "https://vimeo.com/92973193 "
    },
    "https://we.tl/LFu1QKB6OY": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/march/viiv-healthcare-ranks-1-in-patientview-corporate-reputation-surv/",
      "status": "new",
      "txt": "Click here to read the full PatientView press release "
    },
    "https://www.aacqa.gov.au/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/community-partnerships/wa-aids-council-ageing-and-hiv/",
      "status": "new",
      "txt": "Australian Aged Care Quality Agency"
    },
    "https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204790lbl.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/helping-botswana-treat-all-people-living-with-hiv/",
      "status": "new",
      "txt": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204790lbl.pdf"
    },
    "https://www.acon.org.au/wp-content/uploads/2017/09/HOS-Ageing-2017_V6_web.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/october/viiv-healthcare-awards-new-grants-to-accelerate-community-led-so/",
      "status": "new",
      "txt": "http://www.acon.org.au/wp-content/uploads/2017/09/HOS-Ageing-2017_V6_web.pdf"
    },
    "https://www.afao.org.au/wp-content/uploads/2017/12/HIV-in-Australia-2018.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/first-two-drug-single-pill-for-hiv-now-approved-for-use-in-austr/",
      "status": "new",
      "txt": "https://www.afao.org.au/wp-content/uploads/2017/12/HIV-in-Australia-2018.pdf"
    },
    "https://www.aids2018.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/driving-change-through-implementation-science/",
      "status": "new",
      "txt": "AIDS 2018"
    },
    "https://www.aidshilfe.de/event/bundesweites-positiventreffen-1-termin": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "Bundesweites Positiventreffen – 4. Termin"
    },
    "https://www.aidshilfe.de/event/bundesweites-positiventreffen-2-termin": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "Bundesweites Positiventreffen – 2. Termin"
    },
    "https://www.aidshilfe.de/event/bundesweites-positiventreffen-3-termin": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "Bundesweites Positiventreffen – 3. Termin"
    },
    "https://www.aidshilfe.de/event/bundesweites-positiventreffen-4-termin": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "Bundesweites Positiventreffen – 4. Termin"
    },
    "https://www.aidshilfe.de/event/bundesweites-positiventreffen-5-termin": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "Bundesweites Positiventreffen – 5. Termin (Thema: Gesund, gesünder, gesündigt!)"
    },
    "https://www.aidshilfe.de/event/bundesweites-treffen-hiv-positive-heterosexuelle-frauen-maenner-1-treffen": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "Bundesweites Treffen für HIV-positive heterosexuelle Frauen und Männer – 1. Treffen"
    },
    "https://www.aidshilfe.de/event/bundesweites-treffen-hiv-positive-heterosexuelle-frauen-maenner-2-treffen": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "Bundesweites Treffen für HIV-positive heterosexuelle Frauen und Männer – 2. Treffen"
    },
    "https://www.aidshilfe.de/event/bundesweites-treffen-hiv-positive-jugendliche": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/bundesweites-treffen-fuer-hiv-positive-jugendliche/",
      "status": "new",
      "txt": "https://www.aidshilfe.de/event/bundesweites-treffen-hiv-positive-jugendliche"
    },
    "https://www.aidshilfe.de/event/bundesweites-treffen-hiv-positive-migrantinnen-kinder-0": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "Bundesweites Treffen für HIV-positive Migrant/innen und ihre Kinder"
    },
    "https://www.aidshilfe.de/event/bundesweites-treffen-hiv-positiver-aidskranker-frauen-1-treffen-1": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "Bundesweites Treffen HIV-positiver und aidskranker Frauen – 1. Treffen"
    },
    "https://www.aidshilfe.de/event/bundesweites-treffen-hiv-positiver-aidskranker-frauen-2-treffen-1": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "Bundesweites Treffen HIV-positiver und aidskranker Frauen – 2. Treffen"
    },
    "https://www.aidshilfe.de/event/bundesweites-treffen-hiv-positiver-aidskranker-frauen-3-treffen-1": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "Bundesweites Treffen HIV-positiver und aidskranker Frauen – 3. Treffen"
    },
    "https://www.aidshilfe.de/event/netzwerk-frauen-aids-1-treffen-1": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "Netzwerk Frauen und Aids – 1. Treffen"
    },
    "https://www.aidshilfe.de/event/netzwerk-frauen-aids-2-treffen-1": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "Netzwerk Frauen und Aids – 2. Treffen"
    },
    "https://www.aidshilfe.de/event/positive-begegnungen-konferenz-leben-hiv-0": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "Positive Begegnungen – Konferenz zum Leben mit HIV"
    },
    "https://www.aidshilfe.de/event/themenwerkstatt-bilder-hiv-0": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "Themenwerkstatt „Bilder von HIV“"
    },
    "https://www.aidshilfe.de/event/themenwerkstatt-reha-kommen-0": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "Themenwerkstatt „Reha, wir kommen!“"
    },
    "https://www.aidshilfe.de/event/your-buddy-zweiteilig-teil-1-2": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "I'm your Buddy – 1. Teil (zweiteiliges Seminar)"
    },
    "https://www.aidshilfe.de/event/your-buddy-zweiteilig-teil-2-3": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "I'm your Buddy – 1. Teil (zweiteiliges Seminar)"
    },
    "https://www.aidshilfe.de/events?f-qc=&f-date=All&f-reg=All&f-type=All&f-target=38&page=2": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "Bundesweites Treffen für HIV-positive heterosexuelle Frauen und Männer – 3. Treffen"
    },
    "https://www.aidshilfe.de/meldung/ende-aids-2020-erreichen-kampagnenstart-deutschen-aids-hilfe": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/deutsche-aids-hilfe-startet-die-informationskampagne-zum-welt-ai/",
      "status": "new",
      "txt": "Deutsche AIDS-Hilfe"
    },
    "https://www.asm.org/index.php/asm-microbe-2018": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "ASM Microbe (ICAAC)"
    },
    "https://www.avert.org/professionals/hiv-around-world/latin-america/brazil": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/striking-the-balance-through-flexible-pricing/",
      "status": "new",
      "txt": "https://www.avert.org/professionals/hiv-around-world/latin-america/brazil#footnote67_twszu4g"
    },
    "https://www.avert.org/professionals/hiv-social-issues/key-affected-populations": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "status": "new",
      "txt": "https://www.avert.org/professionals/hiv-social-issues/key-affected-populations"
    },
    "https://www.avert.org/professionals/hiv-social-issues/key-affected-populations/transgender": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/fighting-hiv-together/hiv-a-virus-that-thrives-on-inequality/",
      "status": "new",
      "txt": "https://www.avert.org/professionals/hiv-social-issues/key-affected-populations/transgender"
    },
    "https://www.carolinarain.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-for-youth/",
      "status": "new",
      "txt": "RAIN, Inc."
    },
    "https://www.cdc.gov/hiv/group/age/youth/index.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-expands-u-s--commitment-to-youth-living-with-hiv/",
      "status": "new",
      "txt": "https://www.cdc.gov/hiv/group/age/youth/index.html"
    },
    "https://www.cdc.gov/hiv/group/gender/women/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative/",
      "status": "new",
      "txt": "HIV Among Women"
    },
    "https://www.cdc.gov/hiv/group/racialethnic/hispaniclatinos/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/closing-the-gap-in-the-latinx-community/",
      "status": "new",
      "txt": "https://www.cdc.gov/hiv/group/racialethnic/hispaniclatinos/"
    },
    "https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2015-vol-27.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-for-women/",
      "status": "new",
      "txt": "HIV Surveillance Report 2015"
    },
    "https://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-surveillance-report-2016-vol-28.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative/",
      "status": "new",
      "txt": "HIV Surveillance Report 2016"
    },
    "https://www.cdc.gov/hiv/pdf/policies/cdc-hiv-in-the-south-issue-brief.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-southern-initiative/",
      "status": "new",
      "txt": "HIV in the Southern United States"
    },
    "https://www.cdc.gov/hiv/surveillance/resources/reports/2009report/pdf/table21.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2012/july/viiv-healthcare-expands-support-for-hiv-prevention-and-education-in-hard-hit-us-region/",
      "status": "new",
      "txt": "Centers for Disease Control and Prevention. HIV Surveillance Report 2009, Table 21. 2011"
    },
    "https://www.chcf.org/publication/building-peer-support-programs-to-manage-chronic-disease-seven-models-for-success/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-for-youth/",
      "status": "new",
      "txt": "Building Peer Support Programs to Manage Chronic Disease: Seven Models for Success"
    },
    "https://www.chcf.org/wp-content/uploads/2017/12/PDF-BuildingPeerSupportPrograms.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-expands-u-s--commitment-to-youth-living-with-hiv/",
      "status": "new",
      "txt": "https://www.chcf.org/wp-content/uploads/2017/12/PDF-BuildingPeerSupportPrograms.pdf"
    },
    "https://www.chip.dk/Portals/0/files/Conferences/EACS%202017/Kamilla%20Laut%20Late%20Persentation_EACS_poster%2020.10.17.pdf?ver=2017-10-24-094235-067&timestamp=1508947980562": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/auf-dem-weg-zu-90-90-90-wie-sieht-es-in-europa-aus/",
      "status": "new",
      "txt": "Laut K et al. EACS Mailand 2017; # PE 26/6"
    },
    "https://www.chiva.org.uk/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/spark-igniting-change/",
      "status": "new",
      "txt": "CHIVA"
    },
    "https://www.clinicaltrialsregister.eu/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/committed-to-data-transparency/",
      "status": "new",
      "txt": "https://www.clinicaltrialsregister.eu"
    },
    "https://www.dagnae.de/fortbildung-2/workshops-2/workshop-jahresversammlung/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "dagnä-Workshop"
    },
    "https://www.destatis.de/DE/ZahlenFakten/GesellschaftStaat/Bevoelkerung/Sterbefaelle/Tabellen/TabellenLebenserwartung.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/antiretrovirale-kombinationstherapie-eine-erfolgsgeschichte/",
      "status": "new",
      "txt": "Statistisches Bundesamt, Lebenserwartung in Deutschland"
    },
    "https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2018-PI-01956-1&d=2018062916114622483": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-shares-data-from-landmark-2-drug-regimen-trials-/",
      "status": "new",
      "txt": "https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2018-PI-01956-1&d=2018062916114622483"
    },
    "https://www.enyhe.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/hiv-treatment-and-care/european-network-of-young-hiv-experts/",
      "status": "new",
      "txt": "Join the ENYHE network"
    },
    "https://www.everywomaneverychild.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/improving-retention-of-breastfeeding-wlhiv-on-art-challenge-winner/",
      "status": "new",
      "txt": "Every Woman, Every Child"
    },
    "https://www.facebook.com/events/461388830968639/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/events-at-aids-2018/",
      "status": "new",
      "txt": "tell us you’re ‘attending’"
    },
    "https://www.facebook.com/groups/positiveaction.msmt/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-msm-transgender-people/",
      "status": "new",
      "txt": "join our group"
    },
    "https://www.facebook.com/PositiveAction.HIV/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/contact-us/social-media-at-viiv-healthcare/",
      "status": "new",
      "txt": "Facebook page"
    },
    "https://www.facebook.com/StigmaActionNetwork": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/stigma-action-network/",
      "status": "new",
      "txt": "Facebook page"
    },
    "https://www.facebook.com/ViiVHealthcare/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/report-a-side-effect/",
      "status": "new",
      "txt": "*** IMAGE WITHOUT ALT TEXT ***"
    },
    "https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/401662/2014_PHE_HIV_annual_report_draft_Final_07-01-2015.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/young-britons-break-down-hiv-stigma-isolation-to-be-the-genendit/",
      "status": "new",
      "txt": "Public Health England, 2014"
    },
    "https://www.greaterthan.org/campaigns/empowered/empowered-trans-women-and-hiv-about/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kaiser-family-foundation/",
      "status": "new",
      "txt": "Empowered: Trans Women & HIV"
    },
    "https://www.gsk-kontakt.de/contact_viiv/index.html?contentarea=prof&referer=viivhealthcare.com": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/unser-engagement-in-deutschland/artikel/spickzettel-unterstuetzung-bei-der-fruehen-diagnose-informatione/",
      "status": "new",
      "txt": "Nebenwirkung melden"
    },
    "https://www.gsk.com/en-gb/about-us/policies-codes-and-standards/binding-corporate-rules/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/informativa-sulla-privacy/",
      "status": "new",
      "txt": "il documento disponibile a questo link."
    },
    "https://www.gsk.com/en-gb/behind-the-science/access-to-healthcare/30-years-and-counting-the-fight-against-hiv/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/croi-2018/advancing-hiv-science-through-collaboration/",
      "status": "new",
      "txt": "the first HIV treatment"
    },
    "https://www.gsk.com/en-gb/contact-us/privacy-contact-information/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/privacy-verklaring/",
      "status": "new",
      "txt": "hier"
    },
    "https://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/contact-us/social-media-at-viiv-healthcare/",
      "status": "new",
      "txt": "https://www.gsk.com/en-gb/contact-us/report-a-possible-side-effect/"
    },
    "https://www.gsk.com/en-gb/contact-us/worldwide/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/informativa-sulla-privacy/",
      "status": "new",
      "txt": "Elenco dei contatti"
    },
    "https://www.gsk.com/en-gb/media/press-releases/2014/gsk-leads-access-to-medicine-index-2014/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/november/gsk-ranked-top-of-the-2014-access-to-medicines-atm-index-for-the-fourth-consecutive-time/",
      "status": "new",
      "txt": "http://www.gsk.com/en-gb/media/press-releases/2014/gsk-leads-access-to-medicine-index-2014/"
    },
    "https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-phase-3-results-from-the-brighte-study-of-fostemsavir-in-heavily-treatment-experienced-patients-with-hiv/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2017/ottobre/viiv-healthcare-annuncia-i-risultati-positivi-dello-studio-di-fa/",
      "status": "new",
      "txt": "qui"
    },
    "https://www.gsk.com/en-gb/responsibility/operating-responsibly/engaging-with-healthcare-professionals/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/about-us/corporate-ethics-and-compliance/united-kingdom/viiv-healthcare-disclosure-of-payments-to-uk-based-healthcare-professionals-and-healthcare-organisations-and-patient-organisations/",
      "status": "new",
      "txt": "GSK disclosure page"
    },
    "https://www.gsk.it/cookie-policy/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/informativa-sulla-privacy/",
      "status": "new",
      "txt": "Politica sui cookie"
    },
    "https://www.gsksource.com/gskprm/htdocs/documents/ZIAGENWARNCARD.PDF": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/ziagen/",
      "status": "new",
      "txt": "Ziagen warning card"
    },
    "https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Combivir/pdf/COMBIVIR.PDF": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/combivir/",
      "status": "new",
      "txt": "Prescribing information for Combivir"
    },
    "https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Epivir/pdf/EPIVIR-PI-PIL.PDF": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/july/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen/",
      "status": "new",
      "txt": "https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Epivir/pdf/EPIVIR-PI-PIL.PDF"
    },
    "https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Epzicom/pdf/EPZICOM-PI-MG.PDF": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/epzicom-kivexa/",
      "status": "new",
      "txt": "Prescribing information and medication guide"
    },
    "https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Juluca/pdf/JULUCA-PI-PIL.PDF": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/juluca/",
      "status": "new",
      "txt": "Prescribing Information and Patient Information Leaflet for Juluca®"
    },
    "https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Lexiva/pdf/LEXIVA-PI-PIL.PDF": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/lexiva-telzir/",
      "status": "new",
      "txt": "Prescribing information for Lexiva"
    },
    "https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Rescriptor/pdf/RESCRIPTOR-PI-PIL.PDF": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/rescriptor/",
      "status": "new",
      "txt": "Prescribing information for Rescriptor"
    },
    "https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Retrovir/pdf/RETROVIR-PI.PDF": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/retrovir-azt/",
      "status": "new",
      "txt": "Prescribing Information for Retrovir oral & injection"
    },
    "https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Selzentry/pdf/SELZENTRY-PI-MG-IFU.PDF": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-announces-fda-approval-of-selzentry-maraviroc/",
      "status": "new",
      "txt": "here"
    },
    "https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Selzentry/pdf/SELZENTRY-PI-MG.PDF": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/october/viiv-healthcare-announces-fda-approval-of-selzentry-maraviroc-for-use-in-children-and-adolescents-living-with-hiv/",
      "status": "new",
      "txt": "https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Selzentry/pdf/SELZENTRY-PI-MG.PDF"
    },
    "https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Tivicay/pdf/TIVICAY-PI-PIL.PDF": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/july/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen/",
      "status": "new",
      "txt": "https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Tivicay/pdf/TIVICAY-PI-PIL.PDF"
    },
    "https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Triumeq/pdf/TRIUMEQ-PI-MG.PDF": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-reports-positive-48-week-results-for-second-phase-iii-study-for-novel-long-acting-injectable-hiv-treatment-regimen/",
      "status": "new",
      "txt": "https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Triumeq/pdf/TRIUMEQ-PI-MG.PDF"
    },
    "https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Triumeq/pdf/TRIUMEQ-PI-MG.PDF.": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/july/aria-study-shows-superior-efficacy-of-triumeq-for-treatment-na%c3%afve-women-living-with-hiv/",
      "status": "new",
      "txt": "https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Triumeq/pdf/TRIUMEQ-PI-MG.PDF."
    },
    "https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Trizivir/pdf/TRIZIVIR-PI-MG.PDF": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/trizivir/",
      "status": "new",
      "txt": "Prescribing information and medication guide for Trizivir"
    },
    "https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Trizivir/pdf/TRIZIVIRWARNCARD.PDF": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/trizivir/",
      "status": "new",
      "txt": "Trizivir warning card for US residents"
    },
    "https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Ziagen/pdf/ZIAGEN-PI-MG.PDF": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-medicines/ziagen/",
      "status": "new",
      "txt": "Prescribing information and medication guide for Ziagen"
    },
    "https://www.hiv.gov/federal-response/national-hiv-aids-strategy/nhas-update": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/standing-together/",
      "status": "new",
      "txt": "https://www.hiv.gov/federal-response/national-hiv-aids-strategy/nhas-update"
    },
    "https://www.hivplusmag.com/stigma/2018/5/11/immersive-project-about-hiv-comes-nyc": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/",
      "status": "new",
      "txt": "HIV Plus Magazine"
    },
    "https://www.iapac.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/november/fast-track-cities-survey-data-provide-insights-into-quality-of-life-of-people-living-with-hiv/",
      "status": "new",
      "txt": "www.iapac.org"
    },
    "https://www.iapac.org/2018/11/29/fast-track-cities-interim-quality-of-life-survey-data-release/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/november/fast-track-cities-survey-data-provide-insights-into-quality-of-life-of-people-living-with-hiv/",
      "status": "new",
      "txt": "The initial findings released today"
    },
    "https://www.ias2017.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/viiv-healthcare-to-host-inaugural-implementation-science-network-meeting-in-paris/",
      "status": "new",
      "txt": "IAS Conference in Paris"
    },
    "https://www.iasociety.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "status": "new",
      "txt": "International AIDS Society"
    },
    "https://www.iasociety.org/adolescent-hiv-treatment-coalition": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/spark-igniting-change/",
      "status": "new",
      "txt": "Adolescent HIV Coalition"
    },
    "https://www.iasociety.org/CIPHER": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/december/viiv-healthcare-update-on-commitments-regarding-the-clinical-development-and-registration-of-age-appropriate-formulations-of-dolutegravir-for-the-treatment-of-hiv-in-infant-and-children/",
      "status": "new",
      "txt": "CIPHER"
    },
    "https://www.iasociety.org/Web/WebContent/File/CIPHER_policy_brief_ado_EN.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-adolescents/",
      "status": "new",
      "txt": "CIPHER/WHO Global Research Agenda for Adolescents Living With HIV"
    },
    "https://www.imaginamas.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/consejos-menos-es-mas/imagina-mas/",
      "status": "new",
      "txt": "Imagina MÁS"
    },
    "https://www.imaginamas.org/inicio/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/es-es/spanish-articles/conoce-a-los-protagonistas/",
      "status": "new",
      "txt": "ImaginaMas "
    },
    "https://www.latinoaids.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-community-grants/",
      "status": "new",
      "txt": "  "
    },
    "https://www.latinoaids.org/about/about.php": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/closing-the-gap-in-the-latinx-community/",
      "status": "new",
      "txt": "https://www.latinoaids.org/about/about.php"
    },
    "https://www.latinoaids.org/programs/deepsouth/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/closing-the-gap-in-the-latinx-community/",
      "status": "new",
      "txt": "Latinos in the Deep South"
    },
    "https://www.latinoaids.org/programs/latino_religious/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/closing-the-gap-in-the-latinx-community/",
      "status": "new",
      "txt": "Latino Religious Leadership Project"
    },
    "https://www.linkedin.com/company/612511/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/events-at-aids-2018/",
      "status": "new",
      "txt": "LinkedIn"
    },
    "https://www.linkedin.com/company/viiv-healthcare": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/report-a-side-effect/",
      "status": "new",
      "txt": "*** IMAGE WITHOUT ALT TEXT ***"
    },
    "https://www.linkedin.com/company/viiv-healthcare/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/contact-us/social-media-at-viiv-healthcare/",
      "status": "new",
      "txt": "Visit our LinkedIn page"
    },
    "https://www.linkedin.com/jobs/viiv-healthcare-jobs": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/our-people/sabena-solomon-pursues-diverse-career-opportunities-at-viiv-healthcare/",
      "status": "new",
      "txt": "check out our postings on LinkedIn"
    },
    "https://www.linkedin.com/vsearch/j?keywords=ViiV%20Healthcare&f_C=612511&sb=Jobs%20at%20ViiV%20Healthcare&trk=tyah&trkInfo=clickedVertical%3Asuggestion%2CclickedEntityId%3A612511%2Cidx%3A1-3-3%2CtarId%3A1464088405307%2Ctas%3Aviiv%20healthcare%20": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/qa-with-heather-brogan-piloting-a-new-mentoring-app-for-hiv-patients/",
      "status": "new",
      "txt": "job opportunities on LinkedIn"
    },
    "https://www.livlife.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/report-a-side-effect/",
      "status": "new",
      "txt": "LiV Life Patient Site"
    },
    "https://www.medicines.org.uk/emc/medicine/28545": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/july/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen/",
      "status": "new",
      "txt": "https://www.medicines.org.uk/emc/medicine/28545"
    },
    "https://www.medicines.org.uk/emc/product/2211/pil": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/retrovir-azt/",
      "status": "new",
      "txt": "Retrovir 250mg capsules patient information leaflet"
    },
    "https://www.medicines.org.uk/emc/product/5555/pil": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/lexiva-telzir/",
      "status": "new",
      "txt": "Telzir 700mg tablets patient information leaflet"
    },
    "https://www.medicines.org.uk/emc/product/6159/pil": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/selzentry-celsentri/",
      "status": "new",
      "txt": "Celsentri 300mg & 150mg tablets Patient Information Leaflet (PIL)"
    },
    "https://www.medicines.org.uk/emc/product/6159/smpc": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/selzentry-celsentri/",
      "status": "new",
      "txt": "Celsentri tablet summary of product characteristics"
    },
    "https://www.medicines.org.uk/emc/product/8048/pil": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/epivir-3tc/",
      "status": "new",
      "txt": "Epivir 150mg tablets patient information leaflet"
    },
    "https://www.medicines.org.uk/emc/product/9246": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/juluca/",
      "status": "new",
      "txt": "European Summary of Product Information"
    },
    "https://www.medicines.org.uk/emc/product/942/pil": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/epivir-3tc/",
      "status": "new",
      "txt": "Epivir oral solution patient information leaflet"
    },
    "https://www.medicines.org.uk/emc/product/943": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/july/viiv-healthcare-presents-phase-iii-data-showing-two-drug-regimen/",
      "status": "new",
      "txt": "https://www.medicines.org.uk/emc/product/943"
    },
    "https://www.medicines.org.uk/emc/product/943/pil": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-medicines/epivir-3tc/",
      "status": "new",
      "txt": "Epivir 300mg tablets patient information leaflet"
    },
    "https://www.millionpositivefaces.nl/en/we-are-already-taking-part": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/our-people/one-million-positive-faces/",
      "status": "new",
      "txt": "Take part"
    },
    "https://www.nastad.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/positive-action-community-grants/",
      "status": "new",
      "txt": "  "
    },
    "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096184/?tool": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/how-the-unity-tool-can-help-conversations-between-plhiv-and-their-hcp/",
      "status": "new",
      "txt": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096184/?tool"
    },
    "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4569751/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/patienten-mit-hohen-cd4-zellzahlen-wer-profitiert-am-meisten-von/",
      "status": "new",
      "txt": "Molina JM et al. Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial Lancet HIV 2018 [epub ahead of print]"
    },
    "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555438/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/antiretrovirale-kombinationstherapie-eine-erfolgsgeschichte/",
      "status": "new",
      "txt": "The Antiretroviral Cohort Collaboration Lancet HIV 2017 Aug. 4(8): e349-e356"
    },
    "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555438/figure/fig3/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/antiretrovirale-kombinationstherapie-eine-erfolgsgeschichte/",
      "status": "new",
      "txt": "Lebenserwartung"
    },
    "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978668/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/mapping-an-hiv-free-future/paediatric-hiv-care/",
      "status": "new",
      "txt": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5978668/"
    },
    "https://www.ncbi.nlm.nih.gov/pubmed/15989434": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/schulung-und-selbstmanagement-koennen-die-adhaerenz-verbessern/",
      "status": "new",
      "txt": "AIMS-System"
    },
    "https://www.nih.gov/news-events/news-releases/treating-hiv-infected-infants-early-helps-them-live-longer": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/croi-2018/leading-the-way-in-hiv-on-international-women-s-day/",
      "status": "new",
      "txt": "https://www.nih.gov/news-events/news-releases/treating-hiv-infected-infants-early-helps-them-live-longer"
    },
    "https://www.paediatrichivactionplan.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2018/december/viiv-healthcare-update-on-commitments-regarding-the-clinical-development-and-registration-of-age-appropriate-formulations-of-dolutegravir-for-the-treatment-of-hiv-in-infant-and-children/",
      "status": "new",
      "txt": "collective global goal of achieving an AIDS-free generation"
    },
    "https://www.positiveactionchallenges.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/viiv-healthcare-s-the-hive-and-positive-action-community-challenge-seek-outside-collaborations-in-order-to-innovate-for-people-living-with-hiv/",
      "status": "new",
      "txt": "Positive Action Community Challenge"
    },
    "https://www.positiveactionchallenges.com/challenges.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/improving-retention-of-breastfeeding-wlhiv-on-art-challenge-winner/",
      "status": "new",
      "txt": "Positive Action Challenge Prizes"
    },
    "https://www.positiveactionchallenges.com/challenges/combating-stigma-discrimination-in-healthcare-settings.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/we-re-allies-the-power-of-partnership/",
      "status": "new",
      "txt": "Tackling Stigma and Discrimination in Healthcare Settings"
    },
    "https://www.positiveactionchallenges.com/challenges/Zvandiri.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "status": "new",
      "txt": "Zvandiri Challenge"
    },
    "https://www.positiveactionchallenges.com/Winners/Combating-Stigma-and-Discrimination-in-Healthcare-Settings.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "status": "new",
      "txt": "Zero Stigma, Discrimination & Violence to Zero HIV"
    },
    "https://www.positiveactionchallenges.com/Winners/Every-Hour-Matters.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "status": "new",
      "txt": "winners"
    },
    "https://www.pozandproud.nl/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/rethink-verhalen/interview-jorgen--vrijwilliger-voor-poz-proud/",
      "status": "new",
      "txt": "Poz&Proud"
    },
    "https://www.preventionaccess.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/u-u-undetectable-equals-untransmittable/",
      "status": "new",
      "txt": "https://www.preventionaccess.org/"
    },
    "https://www.research-on-stage.de/video-detail.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/vfa-research-on-stage-ueber-die-bedeutung-medizinischer-forschun/",
      "status": "new",
      "txt": "https://www.research-on-stage.de/video-detail.html"
    },
    "https://www.rosminzdrav.ru/news/2017/05/16/5440-informatsiya-minzdrava-rossii-otnositelno-sluchaev-vich-v-rossii-po-itogam-2016-goda": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2017/october/tivicay-and-celsentri-now-included-in-the-essential-drug-list-in-russia/",
      "status": "new",
      "txt": "https://www.rosminzdrav.ru/news/2017/05/16/5440-informatsiya-minzdrava-rossii-otnositelno-sluchaev-vich-v-rossii-po-itogam-2016-goda"
    },
    "https://www.sidaventure.re/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/",
      "status": "new",
      "txt": "SID’AVENTURE"
    },
    "https://www.thestar.com/news/canada/2016/12/01/trudeau-marks-world-aids-day-says-fight-against-hiv-can-be-won.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/croi-2018/leading-the-way-in-hiv-on-international-women-s-day/",
      "status": "new",
      "txt": "https://www.thestar.com/news/canada/2016/12/01/trudeau-marks-world-aids-day-says-fight-against-hiv-can-be-won.html"
    },
    "https://www.togetherforgirls.org/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "status": "new",
      "txt": "Together for Girls"
    },
    "https://www.unicef.org/publicpartnerships/files/HIVAIDS_and_Children_2013_Thematic_Report.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/spark-igniting-change/",
      "status": "new",
      "txt": "https://www.unicef.org/publicpartnerships/files/HIVAIDS_and_Children_2013_Thematic_Report.pdf"
    },
    "https://www.unity-tool.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/advancing-hiv-treatment-and-care/how-the-unity-tool-can-help-conversations-between-plhiv-and-their-hcp/",
      "status": "new",
      "txt": "Unity Tool"
    },
    "https://www.viiv-clinicalstudyregister.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/committed-to-data-transparency/",
      "status": "new",
      "txt": "clinical study register"
    },
    "https://www.viivexchange.ca/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/",
      "status": "new",
      "txt": "  "
    },
    "https://www.viivexchange.com/routing": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/bundesweites-treffen-fuer-hiv-positive-jugendliche/$NewsURL_01/",
      "status": "new",
      "txt": "ViiV Exchange website"
    },
    "https://www.viivhealthcare.ca/media/126956/celsentri.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/celsentri/",
      "status": "new",
      "txt": "Product Monograph for CELSENTRI®"
    },
    "https://www.viivhealthcare.ca/media/126965/trizivir-french.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/trizivir/",
      "status": "new",
      "txt": "/Monographie de TRIZIVIR®"
    },
    "https://www.viivhealthcare.ca/media/126968/rescriptor.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/rescriptor/",
      "status": "new",
      "txt": "Product Monograph for RESCRIPTOR®"
    },
    "https://www.viivhealthcare.ca/media/126977/combivir.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/combivir/",
      "status": "new",
      "txt": "Product Monograph for COMBIVIR®"
    },
    "https://www.viivhealthcare.ca/media/126980/triumeq-french.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/triumeq/",
      "status": "new",
      "txt": "/Monographie de Triumeq®"
    },
    "https://www.viivhealthcare.ca/media/126992/retrovir.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/retrovirazt/",
      "status": "new",
      "txt": "Product Monograph for RETROVIR/AZT®"
    },
    "https://www.viivhealthcare.ca/media/127012/3tc.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/3tc/",
      "status": "new",
      "txt": "Product Monograph for 3TC®"
    },
    "https://www.viivhealthcare.ca/media/147605/tivicay_media_release_english.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/",
      "status": "new",
      "txt": "(2013) ViiV Healthcare receives approval for Tivicay® (dolutegravir) in Canada for the treatment of HIV"
    },
    "https://www.viivhealthcare.ca/media/151922/telzir.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/telzir/",
      "status": "new",
      "txt": "Product Monograph for TELZIR®"
    },
    "https://www.viivhealthcare.ca/media/151925/tivicay.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/tivicay/",
      "status": "new",
      "txt": "Product Monograph for Tivicay®"
    },
    "https://www.viivhealthcare.ca/media/151928/triumeq.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/triumeq/",
      "status": "new",
      "txt": "Product Monograph for Triumeq®"
    },
    "https://www.viivhealthcare.ca/media/151931/trizivir.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/trizivir/",
      "status": "new",
      "txt": "Product Monograph for TRIZIVIR®"
    },
    "https://www.viivhealthcare.ca/media/151934/ziagen.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/ziagen/",
      "status": "new",
      "txt": "Product Monograph for ZIAGEN®"
    },
    "https://www.viivhealthcare.ca/media/162886/viiv_healthcare_canada_grants__charitable_contributions_2011en_fr.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/",
      "status": "new",
      "txt": "2011"
    },
    "https://www.viivhealthcare.ca/media/162889/viiv_healthcare_canada_grants__charitable_contributions_2012en_fr.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/",
      "status": "new",
      "txt": "2012"
    },
    "https://www.viivhealthcare.ca/media/162892/viiv_healthcare_canada_grants__charitable_contributions_2013en_fr.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/",
      "status": "new",
      "txt": "2013"
    },
    "https://www.viivhealthcare.ca/media/162895/viiv_healthcare_canada_grants__charitable_contributions_2014_en_fr.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/",
      "status": "new",
      "txt": "2014"
    },
    "https://www.viivhealthcare.ca/media/162922/pacip_-_2008en_fr.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/",
      "status": "new",
      "txt": "2008"
    },
    "https://www.viivhealthcare.ca/media/162925/pacip_-_2009en_fr.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/",
      "status": "new",
      "txt": "2009"
    },
    "https://www.viivhealthcare.ca/media/162928/pacip_-_2010en_fr.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/",
      "status": "new",
      "txt": "2010"
    },
    "https://www.viivhealthcare.ca/media/162931/pacip_-_2011en_fr.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/",
      "status": "new",
      "txt": "2011"
    },
    "https://www.viivhealthcare.ca/media/162934/pacip_-_2012en_fr.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/",
      "status": "new",
      "txt": "2012"
    },
    "https://www.viivhealthcare.ca/media/162937/pacip_-_2013en_fr.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/",
      "status": "new",
      "txt": "2013"
    },
    "https://www.viivhealthcare.ca/media/163886/positive-action-canada-aboriginal-initiative-2014-results-final-english-and-french.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/",
      "status": "new",
      "txt": "2014"
    },
    "https://www.viivhealthcare.ca/media/169748/kivexa.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/kivexa/",
      "status": "new",
      "txt": "Product Monograph for KIVEXA®"
    },
    "https://www.viivhealthcare.ca/media/170207/northern_initiative_grant_list_-_2013en_fr.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/",
      "status": "new",
      "txt": "2013"
    },
    "https://www.viivhealthcare.ca/media/173775/3tc-french.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/3tc/",
      "status": "new",
      "txt": "/Monographie de 3TC®"
    },
    "https://www.viivhealthcare.ca/media/173778/celsentri-french.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/celsentri/",
      "status": "new",
      "txt": "/Monographie de CELSENTRI®"
    },
    "https://www.viivhealthcare.ca/media/173781/combivir-french.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/combivir/",
      "status": "new",
      "txt": "/Monographie de COMBIVIR®"
    },
    "https://www.viivhealthcare.ca/media/173784/rescriptor-french.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/rescriptor/",
      "status": "new",
      "txt": "/Monographie de RESCRIPTOR®"
    },
    "https://www.viivhealthcare.ca/media/173787/retrovir-french.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/retrovirazt/",
      "status": "new",
      "txt": "/Monographie de RETROVIR/AZT®"
    },
    "https://www.viivhealthcare.ca/media/173790/telzir-french.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/telzir/",
      "status": "new",
      "txt": "/Monographie de TELZIR®"
    },
    "https://www.viivhealthcare.ca/media/173793/tivicay_french.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/tivicay/",
      "status": "new",
      "txt": "/Monographie de Tivicay®"
    },
    "https://www.viivhealthcare.ca/media/173802/ziagen-french.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/ziagen/",
      "status": "new",
      "txt": "/Monographie de ZIAGEN®"
    },
    "https://www.viivhealthcare.ca/media/173805/kivexa-french.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/kivexa/",
      "status": "new",
      "txt": "/Monographie de KIVEXA®"
    },
    "https://www.viivhealthcare.ca/media/179534/international_womens_day.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/",
      "status": "new",
      "txt": "International Women's Day"
    },
    "https://www.viivhealthcare.ca/media/181990/2015-positive-action-canada-aboriginal-initiative-results.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/",
      "status": "new",
      "txt": "2015"
    },
    "https://www.viivhealthcare.ca/media/181993/2015-positive-action-canada-innovation-program-results.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/",
      "status": "new",
      "txt": "2015"
    },
    "https://www.viivhealthcare.ca/media/181996/2015-viiv-healthcare-canada-community-grants.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/",
      "status": "new",
      "txt": "2015"
    },
    "https://www.viivhealthcare.ca/media/187446/20160513-viiv-healthcare-mpp-dtg-extension.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/",
      "status": "new",
      "txt": "Dolutegravir Medicine Patent Pool License extension"
    },
    "https://www.viivhealthcare.ca/media/197780/asian-community-aids-services.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/",
      "status": "new",
      "txt": "5 Year Sponsorship by ViiV Healthcare to the Asian Community AIDS Services"
    },
    "https://www.viivhealthcare.ca/media/198512/proud-sponsors-of-cahr-2016.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/",
      "status": "new",
      "txt": "Proud Sponsor of CAHR 2016"
    },
    "https://www.viivhealthcare.ca/media/198522/veng-infography_final-version.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/",
      "status": "new",
      "txt": "IAPAC / ViiV Healthcare Collaboration in 16 Fast-Track Cities"
    },
    "https://www.viivhealthcare.ca/media/199395/ewec-pacc-shr-prize_comms-veng.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/",
      "status": "new",
      "txt": "Launch of the Empowering Girls in Emergency Settings Challenge"
    },
    "https://www.viivhealthcare.ca/media/199397/penta-infographic-veng.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/",
      "status": "new",
      "txt": "VIIV Healthcare / PENTA Collaboration on the EPIICAL Consortium"
    },
    "https://www.viivhealthcare.ca/media/203097/world-aids-day-2016-media-release-english-final.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/",
      "status": "new",
      "txt": "World AIDS Day: Is Complacency the new HIV crisis?"
    },
    "https://www.viivhealthcare.ca/media/203434/2016-pac-indigenous-initiative-results-final.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/",
      "status": "new",
      "txt": "2016"
    },
    "https://www.viivhealthcare.ca/media/203437/2016-positive-action-canada-innovation-program-results-final.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/",
      "status": "new",
      "txt": "2016"
    },
    "https://www.viivhealthcare.ca/media/203637/2016-viiv-healthcare-canada-community-grants.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/",
      "status": "new",
      "txt": "2016"
    },
    "https://www.viivhealthcare.ca/media/204609/honouring-the-memory-of-dr-mark-wainberg_en.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/",
      "status": "new",
      "txt": "Honouring the memory of Dr Mark Wainberg"
    },
    "https://www.viivhealthcare.ca/media/205127/2017-positive-action-canada-indigenous-initiative-program-overview.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/",
      "status": "new",
      "txt": "here"
    },
    "https://www.viivhealthcare.ca/media/205130/2017-positive-action-canada-innovation-program-overview.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/",
      "status": "new",
      "txt": "here"
    },
    "https://www.viivhealthcare.ca/media/209550/mwf-press-release.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/media/",
      "status": "new",
      "txt": "CAHR launches a program to support Canadian researchers"
    },
    "https://www.viivhealthcare.ca/media/209560/2018-pihvot-leave-behind-en.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/healthcare-professionals/independent-grants-and-support-programs/",
      "status": "new",
      "txt": "here"
    },
    "https://www.viivhealthcare.ca/media/209567/juluca.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/juluca/",
      "status": "new",
      "txt": "Product Monograph for Juluca®"
    },
    "https://www.viivhealthcare.ca/media/209568/juluca-french.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/juluca/",
      "status": "new",
      "txt": "/Monographie de Juluca"
    },
    "https://www.viivhealthcare.ca/media/209570/18211_viiv_en.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/our-medicines/triumeq/",
      "status": "new",
      "txt": "June 5, 2018 - Important Safety Information on TIVICAY, TRIUMEQ and JULUCA"
    },
    "https://www.viivhealthcare.ca/media/209587/community-grants-en.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-ca/community-partnerships/community-involvement/",
      "status": "new",
      "txt": "Read the Community Grants Brochure"
    },
    "https://www.viivhealthcare.com.au/media/124108/third-party-sponsorship-report-011015-to-300416-final.xlsx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/transparency-reporting/",
      "status": "new",
      "txt": "Third Party Sponsorship Report"
    },
    "https://www.viivhealthcare.com.au/media/124109/hcp-tov-report-011015-to-300416.xlsx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/transparency-reporting/",
      "status": "new",
      "txt": "HCP Transfer of Value Report for the period 1/10/15 to 30/04/16"
    },
    "https://www.viivhealthcare.com.au/media/124136/xxhcp-tov-010516-to-311016.xlsx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/transparency-reporting/",
      "status": "new",
      "txt": "HCP Transfer of Value Report for the period 1/05/16 to 31/10/16"
    },
    "https://www.viivhealthcare.com.au/media/124152/hcp-tov-report-011116-to-300417.xlsx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/transparency-reporting/",
      "status": "new",
      "txt": "HCP Transfer of Value Report for the period 1/11/16 to 30/04/17"
    },
    "https://www.viivhealthcare.com.au/media/124190/critical-steps-towards-addressing-hiv-in-australia_viiv-australia-report.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/2017/september/critical-steps-towards-addressing-hiv-in-australia-a-report-from/",
      "status": "new",
      "txt": "To view the full interactive report click here."
    },
    "https://www.viivhealthcare.com.au/media/124198/hcp-tov-report-010517-to-311017.xlsx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/transparency-reporting/",
      "status": "new",
      "txt": "HCP Transfer of Value Report for the period 1/05/17 to 31/10/17"
    },
    "https://www.viivhealthcare.com.au/media/124219/juluca_pi_001_approved-002.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/viiv-news/press-releases/first-two-drug-single-pill-for-hiv-now-approved-for-use-in-austr/",
      "status": "new",
      "txt": "https://www.viivhealthcare.com.au/media/124219/juluca_pi_001_approved-002.pdf"
    },
    "https://www.viivhealthcare.com.au/media/124225/hcp-tov-report-011117-to-300418.xlsx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/transparency-reporting/",
      "status": "new",
      "txt": "HCP Transfer of Value Report for the period 1/11/17 to 30/04/18"
    },
    "https://www.viivhealthcare.com.au/media/124232/hcp-transactions-may_oct-17.xlsx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-au/transparency-reporting/",
      "status": "new",
      "txt": "HCP Transfer of Value Report for the period of 1/05/17 to 31/10/17"
    },
    "https://www.viivhealthcare.com/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/new-results-from-the-positive-perspectives-global-survey-provide/",
      "status": "new",
      "txt": "www.viivhealthcare.com"
    },
    "https://www.viivhealthcare.com/?sc_lang=en": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2011/march/regulatory-update-celsentriselzentry-maraviroc/",
      "status": "new",
      "txt": "www.viivhealthcare.com"
    },
    "https://www.viivhealthcare.com/advancing-hiv-science-and-rd/we-collaborate-to-innovate.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-approach-to-rd/",
      "status": "new",
      "txt": "Find out more about how we collaborate to innovate"
    },
    "https://www.viivhealthcare.com/ch/positive-action.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/closing-the-gap-in-the-latinx-community/",
      "status": "new",
      "txt": "Positive Action"
    },
    "https://www.viivhealthcare.com/mapping-an-hiv-free-future.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/hiv-behind-bars-improving-hiv-testing-in-italian-prisons/",
      "status": "new",
      "txt": "our commitment to mapping an HIV free future"
    },
    "https://www.viivhealthcare.com/mapping-an-hiv-free-future/working-towards-90-90-90/positive-partnerships.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/hiv-behind-bars-improving-hiv-testing-in-italian-prisons/",
      "status": "new",
      "txt": "our Positive Partnerships programme"
    },
    "https://www.viivhealthcare.com/mapping-an-hiv-free-future/working-towards-90-90-90/positive-partnerships/italy.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/hiv-behind-bars-improving-hiv-testing-in-italian-prisons/",
      "status": "new",
      "txt": "Positive Partnership project"
    },
    "https://www.viivhealthcare.com/media/124425/infographies_iapac_viiv_franc-ais_0616.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/lactualite-en-direct/",
      "status": "new",
      "txt": "  août 18  \n       \n        \n       \n       \n       Infographie IAPAC - ViiV Healthcare 18/08/2016 \n       16 villes engagées dans l'accélaration de la riposte contre le VIH (initiative ‘FAST-TRACK CITIES’).... \n       "
    },
    "https://www.viivhealthcare.com/media/124824/viiv_brochure_bassa.pdf.html": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/italia/",
      "status": "new",
      "txt": ""
    },
    "https://www.viivhealthcare.com/media/124917/cp_12012017.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/lactualite-en-direct/",
      "status": "new",
      "txt": "  janv. 12  \n       \n        \n       \n       \n       Communiqué de Presse 12/01/2017 \n       Programme Positive Action Community Grants de ViiV Healthcare France : 100 000 € pour les premiers l... \n       "
    },
    "https://www.viivhealthcare.com/media/124926/cp_01122016.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/lactualite-en-direct/",
      "status": "new",
      "txt": "  déc. 01  \n       \n        \n       \n       \n       Communiqué de presse 01/12/2016 \n       Paris lance le premier tableau de bord des villes participant à l'initiative Fast-Track Cities pour ... \n       "
    },
    "https://www.viivhealthcare.com/media/124927/cp_11012017.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/lactualite-en-direct/",
      "status": "new",
      "txt": "  janv. 11  \n       \n        \n       \n       \n       Communiqué de presse 11/01/2017 \n       ViiV Healthcare verse des subventions pour les programmes de lutte contre le VIH gérés par et pour l... \n       "
    },
    "https://www.viivhealthcare.com/media/124928/cp_29062016.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/lactualite-en-direct/",
      "status": "new",
      "txt": "  juin 29  \n       \n        \n       \n       \n       Communiqué de presse 29/06/2016 \n       ViiV Healthcare s’associe à la fondation PENTA pour mettre au point des stratégies... \n       "
    },
    "https://www.viivhealthcare.com/media/124929/cp_03062016.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/lactualite-en-direct/",
      "status": "new",
      "txt": "  juin 03  \n       \n        \n       \n       \n       Communiqué de presse 03/06/2016 \n       Le ministère de la santé du Botswana attribue à ViiV Healthcare un appel d'offres public portant sur... \n       "
    },
    "https://www.viivhealthcare.com/media/124930/cp_31052016.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/lactualite-en-direct/",
      "status": "new",
      "txt": "  mai 31  \n       \n        \n       \n       \n       Communiqué de presse 31/05/2016 \n       ViiV Healthcare et l'Association internationale des prestataires de santé spécialisés dans le SIDA (...    \n       "
    },
    "https://www.viivhealthcare.com/media/124947/charte_vm_signee_15_10_2014.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/politique-qualite-en-matiere-dinformation-promotionnelle/",
      "status": "new",
      "txt": "Charte de l’information par démarchage ou prospection visant à la promotion des médicaments"
    },
    "https://www.viivhealthcare.com/media/125470/541776_viiv_ins_infodigit_hsh_265x570-2508.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/lactualite-en-direct/",
      "status": "new",
      "txt": "  déc. 04  \n       \n        \n       \n       \n       Infographie - HSH et Personnes Transgenres \n       Le programme Positive Action MSM and Transgender soutient les organisations qui agissent afin de réd... \n       "
    },
    "https://www.viivhealthcare.com/media/125473/cp_informations-sur-la-perception-des-pvvih-_-nouveaux-r%C3%A9sultats-de-l-enqu%C3%AAte-mondiale-positive-perspectives.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/lactualite-en-direct/",
      "status": "new",
      "txt": "  oct. 25  \n       \n        \n       \n       \n       Communiqué de presse 25/10/2017 \n       ViiV Healthcare présente les résultats de l’enquête mondiale Positive Perspectives qui apportent des... \n       "
    },
    "https://www.viivhealthcare.com/media/125552/1711063-viiv-positive-perspective-survey-report-8-1.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/nl-nl/welkom/",
      "status": "new",
      "txt": "Download hier het rapport"
    },
    "https://www.viivhealthcare.com/media/125629/529948_viiv_ins_infodigit_ado_265x795-2508.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/lactualite-en-direct/",
      "status": "new",
      "txt": "  déc. 01  \n       \n        \n       \n       \n       Infographie - Impact du VIH sur les adolescents \n       Positive Action for adolescent à pour but d'aider à l’évaluation de l’impact de nouvelles interventi... \n       "
    },
    "https://www.viivhealthcare.com/media/125766/hiv-tb_infographic-final.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/viiv-healthcare-at-hiv-glasgow/",
      "status": "new",
      "txt": "Global Challenges of Fighting HIV/TB Co-Infection  "
    },
    "https://www.viivhealthcare.com/media/126290/acces-aux-traitements-infographique.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/bienvenue/",
      "status": "new",
      "txt": "  oct. 03  \n       \n        \n       \n       \n       L’enjeu : Travailler ensemble pour un accès universel à l’échelle mondiale, 10 millions de personnes bénéficient d’un traitement ARV. Mais selon ses guidelines, l’OMS estime que 26 millions de personnes sont éligibles à ce traitement. \n       "
    },
    "https://www.viivhealthcare.com/media/126291/journalistes-positive-action-community-grants-france-2018.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/bienvenue/",
      "status": "new",
      "txt": "  avr. 10  \n       \n        \n       \n       \n       Programme Positive Action Community Grants de ViiV Healthcare France : lauréats de l’appel à projet destiné aux associations de lutte contre le sida pour améliorer l’accès au dépistage du VIH en 2018. \n       "
    },
    "https://www.viivhealthcare.com/media/126294/541784_viiv_ins_infodigit_femme-hiv_265x920_exe.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/bienvenue/",
      "status": "new",
      "txt": "  sept. 28  \n       \n        \n       \n       \n       Dans le monde, la moitié des personnes vivant avec le VIH sont des femmes. Les taux d’infection chez les jeunes femmes (âgées de 15 à 24 ans) sont 2 fois plus élevés que chez les jeunes hommes. \n       "
    },
    "https://www.viivhealthcare.com/media/126295/561487_viiv_ins_infodigit_girls-women_265x1005_exe.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/bienvenue/",
      "status": "new",
      "txt": "  oct. 01  \n       \n        \n       \n       \n       Le VIH/SIDA chez les femmes âgées de 15 à 44 ans est la première cause de décès dans le monde. La prévalence du VIH est jusqu’à 8 fois plus élevée dans certains pays chez les adolescentes et les jeunes femmes que chez les hommes. \n       "
    },
    "https://www.viivhealthcare.com/media/58599/us_tivicay.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/us-news/us-articles/2016/viiv-healthcare-extends-medicines-patent-pool-licence-agreement/",
      "status": "new",
      "txt": "https://www.viivhealthcare.com/media/58599/us_tivicay.pdf"
    },
    "https://www.viivhealthcare.com/media/66223/CHAIT-Press-release.pdf": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/innovators-and-disruptors-in-hiv/our-approach-to-rd/",
      "status": "new",
      "txt": "Collaboration for HIV/AIDS Immunological Therapy"
    },
    "https://www.viivhealthcare.com/media/press-releases/2012/july/viiv-healthcare-expands-commitment-to-addressing-gaps-in-paediatric-hiv-research-care-and-treatment.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-approach-to-rd/",
      "status": "new",
      "txt": "ollaboration with CHAI & Mylan"
    },
    "https://www.viivhealthcare.com/media/press-releases/2013/february/viiv-healthcare-announces-a-voluntary-licence-agreement-with-the-medicines-patent-pool-to-increase-access-to-hiv-medicines-for-children.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/november/gsk-ranked-top-of-the-2014-access-to-medicines-atm-index-for-the-fourth-consecutive-time/",
      "status": "new",
      "txt": "/media/press-releases/2013/february/viiv-healthcare-announces-a-voluntary-licence-agreement-with-the-medicines-patent-pool-to-increase-access-to-hiv-medicines-for-children.aspx"
    },
    "https://www.viivhealthcare.com/media/press-releases/2014/april/viiv-healthcare-announces-new-initiatives-to-improve-access-to-dolutegravir-licence-to-the-medicines-patent-pool.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2014/november/gsk-ranked-top-of-the-2014-access-to-medicines-atm-index-for-the-fourth-consecutive-time/",
      "status": "new",
      "txt": "/media/press-releases/2014/april/viiv-healthcare-announces-new-initiatives-to-improve-access-to-dolutegravir-licence-to-the-medicines-patent-pool.aspx"
    },
    "https://www.viivhealthcare.com/media/press-releases/2016/may/viiv-healthcare-and-the-international-association-of-providers-of-aids-care-to-collaborate-on-fast-track-cities.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/how-viiv-healthcare-is-helping-to-accelerate-city-hivaids-responses-through-our-collaboration/",
      "status": "new",
      "txt": "https://www.viivhealthcare.com/media/press-releases/2016/may/viiv-healthcare-and-the-international-association-of-providers-of-aids-care-to-collaborate-on-fast-track-cities.aspx"
    },
    "https://www.viivhealthcare.com/our-stories/advancing-hiv-treatment-and-care/hiv-is-a-global-issue-that-needs-an-ongoing-collaborative-response.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/hiv-treatment-and-care/the-positive-perspectives-survey/",
      "status": "new",
      "txt": "HIV is a global issue that needs an ongoing collaborative response"
    },
    "https://www.viivhealthcare.com/our-stories/advancing-hiv-treatment-and-care/overcoming-the-challenges-for-partners-of-people-living-with-hiv.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/hiv-treatment-and-care/the-positive-perspectives-survey/",
      "status": "new",
      "txt": "Overcoming the challenges for partners of people living with HIV"
    },
    "https://www.viivhealthcare.com/our-stories/advancing-hiv-treatment-and-care/understanding-the-concerns-of-people-living-with-hiv.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/hiv-treatment-and-care/the-positive-perspectives-survey/",
      "status": "new",
      "txt": "Understanding the concerns of people living with HIV"
    },
    "https://www.viivhealthcare.com/our-stories/innovation-hiv-science/preliminary-positive-perspectives-survey-data-released-at-9th-international-aids-society-conference.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/hiv-treatment-and-care/the-positive-perspectives-survey/",
      "status": "new",
      "txt": "*** IMAGE WITHOUT ALT TEXT ***"
    },
    "https://www.viivhealthcare.com/our-stories/innovation-hiv-science/pride-around-the-world.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "status": "new",
      "txt": "Pride around the world"
    },
    "https://www.viivhealthcare.com/supporting-the-community.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "status": "new",
      "txt": "Community"
    },
    "https://www.viivhealthcare.com/supporting-the-community/case-studies/mtv-shuga.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "status": "new",
      "txt": "MTV Shuga"
    },
    "https://www.viivhealthcare.com/supporting-the-community/case-studies/the-centre-for-sexual-health-and-hivaids-research-ceshhar-zimbabwe.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "status": "new",
      "txt": "AFRICAID Zvandiri"
    },
    "https://www.viivhealthcare.com/supporting-the-community/positive-action-at-aids-2018.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/championing-360-degree-hiv-care/events-at-aids-2018/",
      "status": "new",
      "txt": "Positive Action at AIDS 2018"
    },
    "https://www.viivhealthcare.com/supporting-the-community/positive-action-programmes/paediatric-innovation-seed-fund.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/aids-2018-amsterdam/advancing-hiv-treatment-and-science/our-approach-to-rd/",
      "status": "new",
      "txt": "Find out more about the Paediatric Innovation Seed Fund"
    },
    "https://www.viivhealthcare.com/supporting-the-community/positive-action-programmes/positive-action-challenges.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "status": "new",
      "txt": "Positive Action Challenges"
    },
    "https://www.viivhealthcare.com/supporting-the-community/positive-action-programmes/positive-action-for-adolescents.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "status": "new",
      "txt": "Positive Action for Adolescents"
    },
    "https://www.viivhealthcare.com/supporting-the-community/positive-action-programmes/positive-action-for-children-fund.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "status": "new",
      "txt": "Positive Action for Children Fund"
    },
    "https://www.viivhealthcare.com/supporting-the-community/positive-action-programmes/positive-action-for-girls-women.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "status": "new",
      "txt": "Positive Action for Girls & Women"
    },
    "https://www.viivhealthcare.com/supporting-the-community/positive-action-programmes/positive-action-for-msm-transgender-people.aspx": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/world-aids-day-2017-fighting-hiv-together/celebrating-the-25th-year-of-community-partnerships-and-collaborations-through-positive-action/",
      "status": "new",
      "txt": "Positive Action for MSM and Transgender People"
    },
    "https://www.viivhealthcare.com/umbraco/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2018/patienten-mit-hohen-cd4-zellzahlen-wer-profitiert-am-meisten-von/",
      "status": "new",
      "txt": "Save"
    },
    "https://www.w3.org/TR/WCAG20/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/accessibility/",
      "status": "new",
      "txt": "World Wide Web Consortium Web Accessibility Initiative (WCAG WAI) 2.0 guidelines"
    },
    "https://www.waset.org/conference/2018/05/london/ICHA/home": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/kalender/",
      "status": "new",
      "txt": "ICHA 2018: 20th International Conference on HIV and AIDS"
    },
    "https://www.welt-aids-tag.de/kampagne-2017/": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/de-de/aktuelles/2017/deutsche-aids-hilfe-startet-die-informationskampagne-zum-welt-ai/",
      "status": "new",
      "txt": "https://www.welt-aids-tag.de/kampagne-2017/"
    },
    "https://www.yesbroadway.com/archivefeed/asmuchasican": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/as-much-as-i-can-received-with-open-arms-in-new-york-city/",
      "status": "new",
      "txt": "As Much As I Can"
    },
    "https://www.youtube.com/channel/UCk2SxuZwTQswx6d1SZlj0hA/videos": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/",
      "status": "new",
      "txt": "ici"
    },
    "https://www.youtube.com/channel/UCVQ22WvF8uBYZiR-xu16gYg": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/fr-fr/france-articles/nos-engagements-nos-services-en-france/",
      "status": "new",
      "txt": "ici"
    },
    "https://www.youtube.com/playlist?list=PLGo14vcHL4DcK_1pUbkPOcrQtpao6dzGK": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/",
      "status": "new",
      "txt": "2016 Every Footstep Counts Playlist"
    },
    "https://www.youtube.com/playlist?list=PLMg9scXawOhQJMOJADZ_zvtuuKCS-2ceP": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/case-studies/kaiser-family-foundation/",
      "status": "new",
      "txt": "YouTube channel"
    },
    "https://www.youtube.com/user/viivhealthcare": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/contact-us/social-media-at-viiv-healthcare/",
      "status": "new",
      "txt": "Visit our YouTube channel"
    },
    "https://www.youtube.com/watch?v=4sJQ7RfQby0": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/partnerships-key-populations/young-britons-break-down-hiv-stigma-isolation-to-be-the-genendit/",
      "status": "new",
      "txt": "Listening to Charlize Theron’s speech"
    },
    "https://www.youtube.com/watch?v=88H5vyc_D3Y&list=PLGo14vcHL4Ddj5RZYvub_I_P26aY4e4Lh&index=3": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund/",
      "status": "new",
      "txt": "2014 Every Footstep Counts Playlist"
    },
    "https://www.youtube.com/watch?v=bIFHyjHOxSI": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund-french/",
      "status": "new",
      "txt": "Public Health Research Institute of India (PHRII) – Change Makers"
    },
    "https://www.youtube.com/watch?v=f4GLt7SersY&list=PLGo14vcHL4DcK_1pUbkPOcrQtpao6dzGK": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/our-stories/innovation-hiv-science/a-look-back-at-aids-2016/",
      "status": "new",
      "txt": "Every Footstep Counts video competition"
    },
    "https://www.youtube.com/watch?v=jRa2yo8rT2E": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund-french/",
      "status": "new",
      "txt": "Pro-Life Advancement and Education Partners (PLAEP) – Esther, A Beacon of Hope!"
    },
    "https://www.youtube.com/watch?v=lUuyAKoB3co&list=PLGo14vcHL4DcK_1pUbkPOcrQtpao6dzGK&index=8": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/announcing-the-2016-every-footsteps-counts-winners/",
      "status": "new",
      "txt": "Public Health Research Institute of India (PHRII) – Change Makers"
    },
    "https://www.youtube.com/watch?v=N7rKolYiDO0": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/announcing-the-2016-every-footsteps-counts-winners/",
      "status": "new",
      "txt": "India Health Action Trust (IHAT) – A Tale To Tell"
    },
    "https://www.youtube.com/watch?v=U2kfgRl1M0w": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/media/press-releases/2016/october/viiv-healthcare-s-positive-action-europe-invites-applications-for-2017-grants-scheme/",
      "status": "new",
      "txt": "PAE Video"
    },
    "https://www.youtube.com/watch?v=Vojhm9frrko": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-for-children-fund-french/",
      "status": "new",
      "txt": "World Vision Uganda – TTC Contribution in the Elimination of Mother to Child Transmission of HIV/AIDS"
    },
    "https://www.youtube.com/watch?v=vUgl_38YopA": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-gb/supporting-the-community/positive-action-programmes/positive-action-southern-initiative/",
      "status": "new",
      "txt": "https://www.youtube.com/watch?v=vUgl_38YopA"
    },
    "https://www.zincmapser.com/Jobs/JobView.aspx?Job.Id=877583": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-annuncia-i-risultati-positivi-di-fase-3-dello-st/",
      "status": "new",
      "txt": "ITA/HIVP/0005/18"
    },
    "https://www.zincmapser.com/Jobs/JobView.aspx?Job.Id=877588": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-presenta-i-dati-relativi-a-tre-anni-di-trattamen/",
      "status": "new",
      "txt": "ITA/HIVP/0006/18"
    },
    "https://www.zincmapser.com/Jobs/JobView.aspx?Job.Id=877594": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/it-it/sala-stampa/2018/ottobre/viiv-healthcare-presenta-i-risultati-positivi-a-48-settimane-del/",
      "status": "new",
      "txt": "ITA/HIVP/0007/18"
    },
    "https://www1.nyc.gov/site/doh/about/press/pr2017/pr003-17.page": {
      "firstFound": "https://viivhealthcare-com-preprod-cf5.gdsgsk.com/en-us/closing-the-gap-in-the-latinx-community/",
      "status": "new",
      "txt": "announced"
    }
  }
}